Page last updated: 2024-11-04

mitomycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID31728
CHEMBL ID1201160
CHEBI ID32102
SCHEMBL ID122631
MeSH IDM0013948
PubMed CID5746
CHEMBL ID105
CHEBI ID27504
SCHEMBL ID3760
MeSH IDM0013948

Synonyms (213)

Synonym
AC-3536
MLS002153782 ,
smr001233166
ritodrinium
PRESTWICK_763
D01263
yutopar (tn)
ritodrine hydrochloride (jp17/usp)
CHEMBL1201160
HMS1569E19
dtxsid8045438 ,
tox21_110603
CCG-220349
SCHEMBL122631
AKOS025117464
mfcd01657514
4-[2-[[(1r,2s)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol;hydrochloride
4-(2-(((1r,2s)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl)amino)ethyl)phenol hydrochloride
ritodrine hydrochloride, united states pharmacopeia (usp) reference standard
ritodrine hydrochloride, pharmaceutical secondary standard; certified reference material
CHEBI:32102
J-015046
ritodrin-hydrochloride
ritodrine hydrochloride, british pharmacopoeia (bp) reference standard
4-(2-((1r,2s)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-ylamino)ethyl)phenol hydrochloride
AS-12194
du21220 (hydrochloride)
T72119
BR164351
ritodrine hydrochloride- bio-x
AC-918
CBIOL_001927
HY-13316
AB00918689-03
BRD-K59670716-001-02-6
CHEBI:27504 ,
[(1as,8s,8ar,8bs)-6-amino-8a-methoxy-5-methyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazirino[2',3':3,4]pyrrolo[1,2-a]indol-8-yl]methyl carbamate
7-amino-9alpha-methoxymitosane
mls002702984 ,
ametycine
MMC ,
nci-c04706
wln: t d3 b556 bn em jv mvttt&j go1 h1ovz kz l1
mitocin-c
mitomycinum
NSC26980 ,
ametycin
7-amino-9.alpha.-methoxymitosane
azirino[2',4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b- hexahydro-8a-methoxy-5-methyl-, [1ar-(1a.alpha.,8.beta.,8a.alpha.,8b.alpha.)]-
azirino[2',4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a- methoxy-5-methyl-, carbamate (ester)
mito-c
mitozytrex (tn) (supergene)
mytomycin
mit-c
nsc-26980
mutamycin
mitomycin-c
[(1as,8s,8ar,8bs)-6-amino-8a-methoxy-5-methyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazireno[2',3':3,4]pyrrolo[1,2-a]indol-8-yl]methyl carbamate
mitomycinum c
hsdb 3239
azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 6-amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a-methoxy-5-methyl-, carbamate (ester)
ai3-26199
nsc 26980
azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 6-amino-8-(((aminocarbonyl)oxy)methyl)-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, (1as,8s,8ar,8bs)-
mitozytrex
rcra waste number u010
6-amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a-methoxy-5-methylazirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione carbamate (ester)
mitomycyna c [polish]
einecs 200-008-6
mytozytrex
ccris 414
rcra waste no. u010
azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 6-amino-8-(((aminocarbonyl)oxy)methyl)-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, (1as-(1aalpha,8beta,8aalpha,8balpha))-
mitomycin (tn)
mitomycin c (jp17)
mitomycin (usp/inn)
muamycin (tn)
D00208
jelmyto (tn)
BIO2_000464
BIO1_001191
BIO1_000213
BIO1_000702
BIO2_000944
IDI1_002219
SMP1_000307
BSPBIO_001267
50-07-7
C06681
mitomycin c ,
mitomycin
mitamycin
azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, (1as,8s,8ar,8bs)-
(amino-methoxy-methyl-dioxo-[?]yl)methyl carbamate
mitomycin c from streptomyces caespitosus, >=970 mug/mg (usp xxiv)
mitomycin c from streptomyces caespitosus, powder, bioreagent, suitable for cell culture
mitomycin c from streptomyces caespitosus, powder, contains nacl as solubilizer
DB00305
mitocin c
NCGC00095258-01
c15h18n4o5
KBIO2_005743
KBIO2_000607
KBIO2_003175
KBIO3_001073
KBIOGR_000607
KBIOSS_000607
KBIO3_001074
NCGC00163468-02
MLS001332654
smr000058401
HMS1990O09
HMS2089F16
CHEMBL105
ugn-101
ugn-102
muamycin
HMS1792O09
HMS1362O09
NCGC00163468-03
1404-00-8
cas-50-07-7
dtxsid2020898 ,
dtxcid00898
tox21_111493
BCP9000285
bdbm50428658
mitomycyna c
BCPP000410
ametycin pound notmitomycin c
BCP0726000181
unii-50sg953sk6
50sg953sk6 ,
mitomycin [usan:usp:inn:ban]
mitosol
NCGC00163468-06
CS-0564
AKOS015895703
S8146
gtpl7089
mitomycin [vandf]
mitomycin [inn]
mitomycin [hsdb]
jelmyto
mitomycin c [jan]
azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 6-amino-8-(((aminocarbonyl)oxy)methyl)-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, (1as-(1a.alpha.,8.beta.,8a.alpha.,8b.alpha.))-
mitomycin [ep monograph]
mitomycin [orange book]
mitomycin [usan]
mitomycin [who-dd]
mitomycin [usp monograph]
mitomycin [mart.]
mitomycin c [mi]
mitomycin [usp-rs]
mitomycin c [iarc]
CCG-208564
GR-311
M2320
SCHEMBL3760
NCGC00163468-05
tox21_111493_1
KS-5148
AB00918689-04
NWIBSHFKIJFRCO-WUDYKRTCSA-N
Q-201410
mitomycin c, antibiotic for culture media use only
[1as-(1a?,8?,8a?,8b?)]-6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione
((1as,8s,8ar,8bs)-6-amino-8a-methoxy-5-methyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazirino[2',3':3,4]pyrrolo[1,2-a]indol-8-yl)methyl carbamate
HMS3403O09
[1as-(1aalpha,8beta,8aalpha,8balpha)]-6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione
mfcd00078109
[(4s,6s,7r,8s)-11-amino-7-methoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.0^{2,7}.0^{4,6}]trideca-1(9),11-dien-8-yl]methyl carbamate
mitomycin c from streptomyces caespitosus
EX-A501
mitomycin c from streptomyces caespitosus, >=98% (hplc), potency: >=970 mug per mg (usp xxiv), gamma-irradiated, suitable for cell culture
mitomycin; [(1as,8s,8ar,8bs)-6-amino-8a-methoxy-5-methyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazirino[2'',3'':3,4]pyrrolo[1,2-a]indol-8-yl]methyl carbamate; mitomycin c
HB4458
Q19856779
AMY10316
BRD-K59670716-001-06-7
mitomycin 100 microg/ml in acetonitrile
D91590
BM164668
mitomycin c- bio-x
50-07-7 (non-salt)
mitomycin c (4% in nacl)
DTXSID00858942 ,
EN300-7405455
azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 6-amino-8-(((aminocarbonyl)oxy)methyl)-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, (1as-(1aalpha,8beta,8aalpha,8b.alpha)).-
mito-medac
((1as,8s,8ar,8bs)-6-amino-8a-methoxy-5-methyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazirino(2',3':3,4)pyrrolo(1,2-a)indol-8-yl)methyl carbamate
mitomycin (ep monograph)
(1ar)-6-amino-8-(((aminocarbonyl)oxy)methyl)-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione
mitolem
l01dc03
azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione,6-amino-8-(((aminocarbonyl)oxy) methyl)-1,1a,2,8,8a,8b-hexahydro-8-a-methoxy-5-methyl-, (1as-(1aalpha,8beta, 8aalpha,8balpha))-
mitomycin-x
7-amino-9-alpha-methoxymitosane
6-amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a-methoxy-5-methylazirino-(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, carbamate (ester)
mitomycin (usp monograph)
mito
mitomycin c (iarc)
mutamycin(mitomycin for injection)
mitomycin (usp-rs)
mitomycine c
azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 6-amino-8-(((aminocarbonyl)oxy)methyl)-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-,(1ar-(1aalpha,8beta,8aalpha,8balpha))-
mutamycine
mitomycin (mart.)
(1as,8s,8ar,8bs)-6-amino-8-(((aminocarbonyl)oxy)methyl)-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione
(1as,8s,8ar,8bs)-6-amino-4,7-dioxo-8a-methoxy-5-methyl-1,1a,2,8,8a,8b-hexahydroazirino(2',3':3,4)pyrrolo(1,2-a)indol-8-ylmethyl carbamate
mitomycin (usan:usp:inn:ban)
(1as-(1a alpha,8beta,8a alpha,8b alpha))-6-amino-8-(((aminocarbonyl)oxy)methyl)-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione
mitocin

Research Excerpts

Overview

Mitomycin 9 is a tetramer connected by the disulfide linker 11. Mitomycin C (MMC) is an effective TRAIL-resistant tumor sensitizer, which indicates a potential utility of combination therapy.

ExcerptReferenceRelevance
"Mitomycin 9 is a tetramer connected by the disulfide linker 11, and easily undergoes disulfide cleavage to provide two dimeric structures 9r that each contains a single thiol probe for activations."( Design, synthesis, and mode of action studies of a mitomycin tetramer inducing double activations with a single probe.
Kim, HR; Lee, SH; Park, YK, 2016
)
1.41
"Mitomycin C (MMC) is an excellent antifibrosis antigen that has been used in many fields, but its effect on a urethral stricture remains controversial."( Efficacy of Mitomycin C Combined with Direct Vision Internal Urethrotomy for Urethral Strictures: A Systematic Review and Meta-Analysis.
Cai, T; Lin, J; Lin, L; Lv, T; Xu, C; Zhu, Z, 2023
)
2.01
"Mitomycins are a family of naturally occurring, potent alkylating agents in which the C member has been clinically used for cancer chemotherapy for over 5 decades. "( Tracing of Acyl Carrier Protein-channeled Mitomycin Intermediates in
Cheng, Y; Liu, W; Wang, S; Wang, X; Yang, Q, 2022
)
2.43
"Mitomycin C (MMC) is an effective TRAIL-resistant tumor sensitizer, which indicates a potential utility of combination therapy."( Codelivery of TRAIL and Mitomycin C via Liposomes Shows Improved Antitumor Effect on TRAIL-Resistant Tumors.
Chang, R; Chu, X; Feng, C; Fu, R; Huang, Y; Jia, D; Li, G; Li, J; Wang, R; Yan, H; Yuan, F; Zhang, J, 2023
)
1.94
"Mitomycin C (MMC) is an alkylating chemotherapy drug that causes DNA crosslinking resulting in transcription arrest and apoptosis. "( Mitomycin C induced genotoxic stress in endothelial cells is associated with differential expression of proinflammatory cytokines.
Asanov, MA; Kutikhin, AG; Minina, VI; Ponasenko, AV; Shishkova, DK; Sinitsky, MY; Tsepokina, AV; Yuzhalin, AE,
)
3.02
"Mitomycin C (MMC) is an alkylating agent with extraordinary ability to crosslink DNA, preventing DNA synthesis. "( History, presence, and future of mitomycin C in glaucoma filtration surgery.
Al Majidi, R; Beckers, HJM; Gorgels, TGMF; Pinchuk, L; van Mechelen, RJS; Webers, CAB; Wolters, JEJ, 2021
)
2.35
"Mitomycin C (MyC) is a cytotoxic agent that is isolated from Streptomyces caespitosus and acts by inhibiting DNA and RNA synthesis through alkylation and cross-linkages."( Fiberoptic Bronchoscopic Submucosal Injection of Mitomycin C for Recurrent Bening Tracheal Stenosis: A Case Series.
Fomin, I; Kleinhendler, E; Man, A; Parluk, T; Schwarz, Y; Tiran, B, 2020
)
1.53
"Mitomycin C is a routinely used antimetabolite which effectively limits the scarring process. "( National survey of intraoperative mitomycin C use during trabeculectomy surgery in the UK.
Arain, UR; Khan, SA; Razzaq, MA; Whittaker, K, 2021
)
2.34
"Mitomycin C (MMC) is a genotoxic agent that induces DNA cross-links, DNA alkylation, and the production of reactive oxygen species (ROS). "( The SOS and RpoS Regulons Contribute to Bacterial Cell Robustness to Genotoxic Stress by Synergistically Regulating DNA Polymerase Pol II.
Bredeche, MF; Dapa, T; Fleurier, S; Matic, I, 2017
)
1.9
"Mitomycin C (MMC) is an antitumor agent that is often administered intravesically to treat bladder cancer. "( Solubilization and Stability of Mitomycin C Solutions Prepared for Intravesical Administration.
Dinney, CPN; Kamat, AM; Kawedia, JD; Kramer, MA; Metcalfe, MJ; Myers, AL; Sobocinski, SM; Zhang, YP; Zhou, X, 2017
)
2.18
"Mitomycin-C is a drug that is commonly used to suppress cell proliferation in this context."( Discrete and Continuum Approximations for Collective Cell Migration in a Scratch Assay with Cell Size Dynamics.
Baker, RE; Matsiaka, OM; Penington, CJ; Simpson, MJ, 2018
)
1.2
"Mitomycin C is an anticancer antibiotic agent that has the potential for broad-spectrum use against several cancers, including mammary cancers. "( Diminishing the side effect of mitomycin C by using pH-sensitive liposomes: in vitro characterization and in vivo pharmacokinetics.
Fang, YP; Hu, PY; Huang, YB, 2018
)
2.21
"Mitomycin C is an antitumor alkylating antibiotic agent that inhibits DNA synthesis extensively used as intravesical chemotherapy agent in the adjuvant treatment of urothelial carcinoma. "( [Immediate post TURBT MMC instillation.]
Domínguez-Escrig, JL, 2018
)
1.92
"Mitomycin C (MMC) is an anti-cancer drug used for the treatment of breast cancer with limited therapeutic index, extreme gastric adverse effects and bone marrow suppression. "( LHRH Targeted Chonderosomes of Mitomycin C in Breast Cancer: An
Aghaei, M; Aliomrani, M; Azizi, R; Sarrami, N; Varshosaz, J, 2019
)
2.24
"Mitomycin C (MMC) is an antineoplastic antibiotic that has been used off-label in the treatment of hypertrophic scars and keloids. "( Mitomycin C in the treatment of keloids: a case and review.
Chotzen, VA; Kilmer, SL; Kleinerman, R, 2013
)
3.28
"Mitomycin C (MMC) is a water-soluble anticancer drug extensively used in first-line chemotherapy but is limited by its poor aqueous stability in vitro, rapid elimination from the body, and lack of target specificity."( Mitomycin C-soybean phosphatidylcholine complex-loaded self-assembled PEG-lipid-PLA hybrid nanoparticles for targeted drug delivery and dual-controlled drug release.
Hou, Z; Huang, Y; Jia, M; Li, Y; Lin, J; Wu, H; Wu, S; Yang, X, 2014
)
2.57
"Mitomycin C (MMC) is an antineoplastic agent used for the treatment of several human malignancies. "( Effect of recombinant human erythropoietin on mitomycin C-induced oxidative stress and genotoxicity in rat kidney and heart tissues.
Abid-Essefi, S; Achour, A; Ayed-Boussema, I; Bacha, H; Guedri, Y; Rjiba-Touati, K, 2016
)
2.14
"Mitomycin C (MMC) is a powerful anti-bacterial, anti-fungal and anti-tumor antibiotic, often active against multidrug resistant cells. "( Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: Intracellular activation and enhanced cytotoxicity.
Amitay, Y; Gabizon, A; Ohana, P; Patil, Y; Shmeeda, H, 2016
)
2.16
"Mitomycin C (MC) is a cytotoxic and mutagenic antitumor agent that alkylates DNA upon reductive activation. "( Comparative Error-Free and Error-Prone Translesion Synthesis of N(2)-2'-Deoxyguanosine Adducts Formed by Mitomycin C and Its Metabolite, 2,7-Diaminomitosene, in Human Cells.
Basu, AK; Bose, A; Champeil, E; Pande, P; Surugihalli, C, 2016
)
2.09
"Mitomycin C (MMC) is an active antineoplastic agent and is suggested to induce apoptosis in a caspase- dependent manner in human gastric, bladder, and breast cancer cells. "( Apoptotic death mode of mitomycin C-treated HeLa cells and cellular localization of mitomycin C-induced P-glycoprotein.
Chen, SC; Cheng, HT; Cheng, MH; Chou, MY; Liao, PH; Lin, SS; Pai, CJ; Yang, CC; Yang, JJ; Young, SC, 2009
)
2.1
"Mitomycin C is an alkylating agent with cytotoxic and antiproliferative effects that reduces the myofibroblast repopulation after laser surface ablation and, therefore, reduces the risk of postoperative corneal haze."( Mitomycin C in corneal refractive surgery.
Alió, JL; de Benito-Llopis, L; Teus, MA,
)
2.3
"Mitomycin C (MMC) is an antineoplastic agent used to fight a number of different cancers including cancer of the stomach, colon, rectum, pancreas, breast, lung, uterus, cervix, bladder, head, neck, eye and oesophagus. "( Assessment of cell viability, lipid peroxidation and quantification of DNA fragmentation after the treatment of anticancerous drug mitomycin C and curcumin in cultured human blood lymphocytes.
Afzal, M; Ara, G; Beg, T; Gupta, J; Siddique, YH, 2010
)
2.01
"The Mitomycin C is a chemotherapeutic agent used in several types of carcinomas. "( [Pulmonary fibrosis and endovesical mitomycin C].
Casas Agudo, VP; González Dacal, J; González Martín, M; Janeiro Pais, JM; Lamas Meilán, C; López Garcia, D,
)
0.96
"Mitomycin C (MMC) is a widely used agent for the adjuvant treatment of bladder tumors."( Perivesical inflammation and necrosis due to mitomycin C instillation after transurethral resection of bladder tumor: we must be vigilant!
Cek, M; Fazlioglu, A; Kurtulus, FO; Parlakkilic, O; Tandogdu, Z, 2009
)
1.33
"Mitomycin C (MMC) is a commonly used and extensively studied chemotherapeutic agent requiring biological reduction for activity. "( Mitomycin C inhibits ribosomal RNA: a novel cytotoxic mechanism for bioreductive drugs.
Collier, AC; Coon, AE; Pritsos, CA; Snodgrass, RG, 2010
)
3.25
"Mitomycin C is an old drug that acts synergistically with capecitabine and irinotecan. "( Is there a role for mitomycin C in metastatic colorectal cancer?
Dimou, A; Saif, MW; Syrigos, KN, 2010
)
2.13
"Mitomycin C is a chemotherapeutic agent used in the treatment of peritoneal surface malignancies, administered as hyperthermic intraperitoneal chemotherapy after cytoreductive surgery. "( Validation and use of microdialysis for determination of pharmacokinetic properties of the chemotherapeutic agent mitomycin C - an experimental study.
Alexandr, K; Andersen, A; Ekstrøm, PO; Flatmark, K; Giercksky, KE; Olsen, H; Sørensen, O, 2010
)
2.01
"Mitomycin C (MMC) is an antimitotic drug that may, when applied topically, prevent postoperative stenosis. "( Evidence-based applications of mitomycin C in the nose.
Assimakopoulos, AD; Karkos, PD; Leong, SC; Sastry, A; Swift, AC,
)
1.86
"Mitomycin C is a drug often used in this clinical setting."( Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis.
Chang, D; Mahteme, H; Stuart, OA; Sugarbaker, PH; Van der Speeten, K, 2011
)
1.31
"Mitomycin C (MMC) is an effective cytostatic agent used in the treatment of patients with gynecological malignancies and breast carcinoma. "( Mitomycin C in patients with gynecological malignancies.
Beyer, U; Fasching, PA; Kahmann, L; Lux, MP; Mehlhorn, G; Strnad, V; Thiel, FC, 2010
)
3.25
"Mitomycin-C (MMC) is a first-line therapy for anal squamous cell carcinoma (ASCC), and it continues to be used for several other indications. "( Mitomycin--C-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: cumulative toxicity of an old drug in a new era.
Chu, E; El-Ghazal, R; Marks, P; Podoltsev, N; Saif, MW, 2011
)
3.25
"Mitomycin C (MMC) is a potent antitumour agent that forms a covalent bond with the 2-amino group of selected guanines in the minor groove of double-stranded DNA following intracellular reduction of its quinone ring and opening of its aziridine moiety. "( Rationale for the opposite stereochemistry of the major monoadducts and interstrand crosslinks formed by mitomycin C and its decarbamoylated analogue at CpG steps in DNA and the effect of cytosine modification on reactivity.
Bueren-Calabuig, JA; Gago, F; Morreale, A; Negri, A, 2012
)
2.04
"Mitomycin C (MMC) is an alkylating agent that suppresses allogeneic T-cell responses."( Mitomycin-C-treated peripheral blood mononuclear cells (PBMCs) prolong allograft survival in composite tissue allotransplantation.
Dittmar, L; Gebhard, MM; Germann, G; Horn, D; Kiefer, J; Kleist, C; Koellensperger, E; Lehnhardt, M; Radu, CA; Rebel, M; Ryssel, H; Sandra, F; Terness, P, 2012
)
2.54
"Mitomycin C (MMC) is a chemotherapeutic drug that requires an enzymatic bioreduction to exert its biological effects. "( A new mechanism of action for the anticancer drug mitomycin C: mechanism-based inhibition of thioredoxin reductase.
Holmgren, A; Lu, J; Paz, MM; Zhang, X, 2012
)
2.07
"Mitomycin 8 is a dimer connected by a 1,2-dithiolane (a five-membered cyclic disulfide) linker, and was specifically designed to undergo nucleophilic activation and double DNA alkylations leading to efficient production of DNA interstrand cross-link (DNA ISC) adducts."( Studies on synthesis and activation mechanism of mitomycin dimers connected by 1,2-dithiolane and diol linkers.
Kim, HR; Kim, JJ; Lee, SH; Park, JJ, 2012
)
1.35
"Mitomycin-C is an effective adjuvant treatment method in the management of BCAS. "( [Effect of topical application with mitomycin C in the management of benign cicatricial airway stenosis].
Cui, J; Pei, YH; Wang, J; Wang, T; Xu, M; Zhang, CY; Zhang, J, 2012
)
2.1
"Mitomycin C (MC) is a potent anticancer agent. "( Molecular basis of mitomycin C resistance in streptomyces: structure and function of the MRD protein.
Dauter, Z; Derewenda, U; Derewenda, ZS; Devedjiev, Y; He, M; Jelen, F; Martin, TW; Otlewski, J; Sheffield, P; Sherman, DH, 2002
)
2.09
"Mitomycin C appears to be a safe and effective adjunct therapy in correcting punctal stenosis."( Mitomycin C as adjunct therapy in correcting punctal stenosis.
Awwad, ST; Hamush, NG; Ma'luf, RN; Noureddin, BN, 2002
)
3.2
"Mitomycin C (MC) is a cytotoxic chemotherapeutic agent that causes DNA damage in the form of DNA cross-links as well as a variety of DNA monoadducts and is known to induce p53. "( Differential activation of p53 by the various adducts of mitomycin C.
Abbas, T; Bargonetti, J; Houser, S; Kumar, GS; Lopez, J; Olivier, M; Tomasz, M; Xiao, G, 2002
)
2
"Mitomycin C (MMC) is an anticancer drug that requires reductive activation to exert its toxicity. "( Role of GRP58 in mitomycin C-induced DNA cross-linking.
Celli, CM; Jaiswal, AK, 2003
)
2.1
"Mitomycin C is a DNA cross-linking agent that also causes replication fork arrest."( Correlation of sister chromatid exchange formation through homologous recombination with ribonucleotide reductase inhibition.
Fukuhara, K; Jenssen, D; Johansson, F; Lundin, C; Matsuoka, A; Onfelt, A; Sahlin, M; Sjöberg, BM, 2004
)
1.04
"Mitomycin C (MC) is a cytotoxic and mutagenic antitumor agent that alkylates and cross-links DNA. "( DNA adduct of the mitomycin C metabolite 2,7-diaminomitosene is a nontoxic and nonmutagenic DNA lesion in vitro and in vivo.
Basu, AK; Clement, CC; Das, A; Ramos, LA; Tomasz, M; Utzat, CD, 2005
)
2.1
"Mitomycin C (MC) is an anti-neoplastic agent with an anti-proliferative effect on fibroblasts. "( Use of mitomycin C for treatment of keloid: a preliminary report.
Kronenberg, J; Orenstein, A; Talmi, YP; Wolf, M, 2005
)
2.23
"Mitomycin C is a bioreductive agent that is used clinically for treatment of solid tumors."( Effect of NQO1 induction on the antitumor activity of RH1 in human tumors in vitro and in vivo.
Begleiter, A; Digby, T; Leith, MK; Thliveris, JA, 2005
)
1.05
"Mitomycin C (MMC) is a cytostatic agent topically used in conjunctival neoplasms, secondary to glaucoma filtering, pterygium, and strabismus surgery to increase the success rate. "( Evaluation of the stability of extemporaneously prepared ophthalmic formulation of mitomycin C.
Ghose, S; Kumari, SS; Mathur, R; Ranjan, N; Ravi, AK; Saluja, V; Velpandian, T, 2005
)
2
"Mitomycin-C is an antimetabolite that has seen increased use in ophthalmology over the past several decades. "( How and when to use mitomycin-C in refractive surgery.
Lacayo, GO; Majmudar, PA, 2005
)
2.09
"Mitomycin C (MMc) is an antibiotic that exerts a potent antiproliferative effect in tumor cells. "( Single perivascular delivery of mitomycin C stimulates p21 expression and inhibits neointima formation in rat arteries.
Azam, MA; Durante, W; Ensenat, D; Granada, JF; Kaluza, GL; Keswani, AN; Liu, XM; Peyton, KJ; Raizner, AE; Wang, H, 2005
)
2.05
"Mitomycin C (MMC) is an antimetabolite used during the initial stages of a trabeculectomy to prevent excessive postoperative scarring and thus reduce the risk of failure."( Intra-operative mitomycin C for glaucoma surgery.
Indar, A; Wilkins, M; Wormald, R, 2005
)
1.4
"Mitomycin C (MC) is an antitumor antibiotic previously demonstrated to reduce SOD1 expression in a reporter gene system."( Inhibition of SOD1 expression by mitomycin C is a non-specific consequence of cellular toxicity.
Ay, I; Broom, WJ; Brown, RH; Pasinelli, P, 2006
)
1.34
"Mitomycin C is an antibiotic that acts as an alkylating agent, inhibiting DNA synthesis."( Successful treatment of laryngeal stenosis in laryngo-onycho-cutaneous syndrome with topical mitomycin C.
Albert, DM; Amonoo-Kuofi, K; Atherton, DJ; Hore, ID; Phillips, PS,
)
1.07
"Mitomycin C is an antiproliferative agent that has been used successfully as an adjunct treatment in ophthalmological procedures, in the management of laryngeal and tracheal stenosis, and more recently to prevent the recurrence of caustic esophageal strictures in children. "( Mitomycin C: an alternative conservative treatment for refractory esophageal stricture in children?
Fayoux, P; Gottrand, F; Guimber, D; Michaud, L; Turck, D; Uhlen, S; Vachin, F, 2006
)
3.22
"Mitomycin C is an alkylating chemotherapeutic agent which is instilled intravesically to prevent recurrence of superficial bladder carcinomas. "( [Hematogenous contact dermatitis after intravesicular instillation of mitomycin C].
Bayerl, C; Goerdt, S; Klemke, CD; Michel, MS; Peitsch, WK, 2007
)
2.02
"Mitomycin C is a topically applied medication widely used in a variety of surgical procedures to prevent excessive scar tissue formation. "( Topical application of mitomycin C to the middle ear is ototoxic in the gerbil.
Lambert, PR; Lang, H; Moody, MW; Schmiedt, RA; Smythe, N; Spiess, AC, 2006
)
2.09
"Mitomycin C is an anti-fibroblast chemotherapeutic agent that has demonstrated promise in the treatment of head and neck cancer-related cervical stenosis. "( Role of mitomycin in upper digestive tract stricture.
Brodsky, MB; Day, TA; Gillespie, MB; Martin-Harris, B; Sharma, AK, 2007
)
2.22
"Mitomycin C (MMC) is an antibiotic-antineoplastic agent that decreases fibroblast proliferation and scar formation. "( Effect of mitomycin C on the size of antrostomy after endoscopic sinus surgery.
Cha, HE; Chung, YS; Gang, IG; Ha, JS; Kim, ST, 2006
)
2.18
"Mitomycin C (MMC) is a common anticancer drug used for the treatment of numerous types of tumors."( Genetic variation of human cytochrome p450 reductase as a potential biomarker for mitomycin C-induced cytotoxicity.
Han, JF; He, XY; Hong, JY; Wang, SL; Wang, XR, 2007
)
1.29
"Mitomycin-C is a chemotherapeutic agent that inhibits DNA synthesis and fibroblast proliferation."( Application of mitomycin-C for head and neck keloids.
Kim, JY; Stewart, CE, 2006
)
1.41
"Mitomycin C (MMC) is an alkylating agent which suppresses allogeneic T-cell responses. "( Ex vivo perfusion with mitomycin C containing solution prolongs heart graft survival in rats.
Ehser, S; Kleist, C; Opelz, G; Terness, P; Wang, D, 2006
)
2.09
"Mitomycin C is a chemotherapeutic agent that acts by inhibiting DNA synthesis. "( Uses and complications of mitomycin C in ophthalmology.
Aslanides, IM; Mearza, AA, 2007
)
2.08
"Mitomycin C is an antimetabolite agent that blocks DNA and RNA replication and protein synthesis. "( [Mitomycin C and excimer laser].
Campos, M; Leoratti, MC; Wallau, AD,
)
2.48
"Mitomycin C (MMC) acts as a potent fibroblastic inhibitor, and topical application of MMC is effective in preventing scar formation. "( Efficacy of mitomycin C irrigation after removal of an occluded nasolacrimal stent.
Choi, EK; Kim, JH; Kim, KR; Lee, YJ; Shin, JH; Song, HY, 2007
)
2.16
"Mitomycin C is a natural product with potent alkylating activity, and it is an important anticancer drug and antibiotic. "( Analysis of a parallel branch in the mitomycin biosynthetic pathway involving the mitN-encoded aziridine N-methyltransferase.
Lopanik, NB; Mao, Y; Sherman, DH; Sitachitta, N, 2007
)
2.06
"Mitomycin C (MMC) is a highly active anticancer drug commonly used alone and in combination with other chemotherapeutic agents for the treatment of different cancers. "( Protective effects of American ginseng (Panax quinquefolium) against mitomycin C induced micronuclei in mice.
Jena, G; Pawar, AA; Ramarao, P; Tripathi, DN, 2007
)
2.02
"Mitomycin C is a chemotherapeutic agent known to suppress fibroblast proliferation."( The effect of topical mitomycin C on full-thickness burns.
Dick, E; Helling, ER; Lyons, RC; Tennyson, H; Wiseman, J, 2007
)
1.38
"The Mitomycin are a family of antibiotics useful in the treatment of breast, lung, stomach, colorectal and other solid tumours. "( [Mitomycin C: current status of knowledge and use in laryngeal tumors].
Aragona, P; Bertelli, E; Giorgi, G; Salvini, M,
)
1.6
"Mitomycin C is an active drug in the treatment of superficial bladder cancer. "( Studies of mitomycin C absorption after intravesical treatment of superficial bladder tumors.
Block, A; Dhafir, RA; Dragone, N; MacDonald, S; Pfeffer, M; Pontes, JE; Wajsman, Z, 1984
)
2.1
"Mitomycin C (MC) is an N-heterocyclic quinone with chemotherapeutic action against solid tumors."( Effects of mitomycin C on metabolism in a rat liver preparation.
Kimpel, DL; Sagone, AL, 1984
)
1.38
"Mitomycin C (MMC) is a cytotoxic agent that may induce a hemolytic uremic syndrome (HUS) with severe renal insufficiency. "( Recovery from mitomycin C-induced hemolytic uremic syndrome. A case report.
Boven, E; Pinedo, HM; van der Meulen, J; Verwey, J, 1984
)
2.07
"Mitomycin C (MMC) is a bioreductive antitumor agent that is activated by NADPH:cytochrome P450 reductase (EC 1.6.2.4) and NAD(P)H:(quinone acceptor) oxidoreductase (EC 1.6.99.2) (DT-diaphorase). "( Induction of DT-diaphorase by doxorubicin and combination therapy with mitomycin C in vitro.
Begleiter, A; Leith, MK, 1995
)
1.97
"Mitomycin C (MC) is a potent antitumor antibiotic which alkylates DNA through covalent linkage of its C-1" position with the exocyclic N2 amino group of guanine to yield the [MC]dG adduct at the duplex level. "( Solution structure of the monoalkylated mitomycin C-DNA complex.
Fiala, R; Lipman, R; Patel, DJ; Sastry, M; Tomasz, M, 1995
)
2
"Mitomycin C is an antibiotic used for its alkylizing effect in the treatment of broncogenic cancer. "( [Interstitial pneumonia and mitomycin C. Apropos of a case with analysis of the bronchoalveolar lavage].
Bannier, M; Briens, E; Coëtmeur, D; Le Breton-Belleguic, C; Niel-Duriez, M, 1995
)
2.03
"Mitomycin C appears to be a viable alternative to 5-FU in patients with posterior chamber implants with uncontrolled glaucoma who require filtration surgery."( 5-Fluorouracil and mitomycin C in pseudophakic patients.
Belkin, JK; Lamping, KA, 1995
)
2.06
"Mitomycin C (MMC) is a bifunctional alkylating agent used in cancer chemotherapy. "( Toxicity of mitomycin C toward cultured pulmonary artery endothelium.
Hoorn, CM; Petry, TW; Roth, RA; Wagner, JG, 1995
)
2.11
"Mitomycin is an antibiotic with antineoplastic activity which inhibits fibroblast proliferation in the operative field in glaucoma filtering surgery. "( Filtering surgery with mitomycin-C in uncomplicated (primary open angle) glaucoma.
Doğan, H; Erkiliç, K; Karaküçük, S; Mirza, GE, 1994
)
2.04
"Mitomycin C is a promising substance which improves substantially the prognosis of complicated cases of glaucoma."( [Initial experience with the use of mitomycin C in anti-glaucoma filtering surgery].
Liehneová, I; Rozsíval, P, 1994
)
1.28
"Mitomycin C seems to be a better treatment than 5 fluorouracil."( [Mitomycin C in glaucoma surgery].
Collignon-Brach, J, 1993
)
1.92
"Mitomycin C (MMC) is an alkylating agent that has been recently associated with the hemolytic-uremic syndrome (HUS). "( Pulmonary hemorrhage as a clinical manifestation of hemolytic-uremic syndrome associated with mitomycin C therapy.
Bombí, JA; Poch, E; Revert, L; Torra, R; Torras, A,
)
1.79
"Mitomycin C (MC) is a powerful antitumor agent that targets the DNA sequence CpG. "( Cytosine methylation enhances mitomycin C cross-linking.
Beachy, TM; Millard, JT, 1993
)
2.02
"Mitomycin C (MMC) is an antineoplastic agent with activity against a wide variety of tumours. "( Disruption of normal cellular bioenergetics in Balb/c mice by mitomycin C.
Briggs, LA; Pritsos, CA, 1996
)
1.98
"Mitomycin C (MC) is a clinically used antitumor agent, which upon reductive activation activates and cross-links DNA. "( Structural and function modification of DNA by mitomycin C. Mechanism of the DNA sequence specificity of mitomycins.
Gargiulo, D; Kumar, GS; Musser, SS; Tomasz, M, 1995
)
1.99
"Mitomycin C (MMC) is a genotoxic cancer chemotherapeutic agent that reacts principally at the N2 position of guanine to form one of two predominant monoadducts, or a G-G interstrand cross-link at CpG sites, or a G-G intrastrand cross-link at GpG sites. "( Synthesis and structural characterization of the N2G-mitomycin C-N2G interstrand cross-link in a model synthetic 23 base pair oligonucleotide DNA duplex.
Hamilton, JW; Warren, AJ,
)
1.82
"Mitomycin C appears to be a safe adjunct to ONSD in a series of six patients followed between 20 and 37 months. "( Long-term results using adjunctive mitomycin C in optic nerve sheath decompression for pseudotumor cerebri.
McHenry, JG; Shin, DH; Spoor, TC, 1995
)
2.01
"Mitomycin C is a useful adjunct to glaucoma surgery. "( Low-dosage mitomycin C as an adjunct to trabeculectomy. A prospective controlled study.
Laffi, GL; Martini, E; Scorolli, L; Sprovieri, C,
)
1.96
"Mitomycin C (MMC) is an anticancer, antibiotic that is currently used clinically against a wide variety of tumors. "( A new cellular target for mitomycin C: a case for mitochondrial DNA.
Briggs, LA; Gustafson, DL; Pritsos, CA, 1997
)
2.04
"Mitomycin C (MC) is an antibiotic that affects DNA synthesis."( Spermatogenic cell apoptosis induced by mitomycin C in the mouse testis.
Fujioka, M; Mori, C; Nakagawa, S; Nakamura, N, 1997
)
1.29
"Mitomycin C (MMC) is a DNA cross-linking agent that has been used in cancer chemotherapy for over 20 years, yet little is known either qualitatively or quantitatively about MMC-induced DNA adduct formation and repair in vivo. "( Detection of mitomycin C-DNA adducts in vivo by 32P-postlabeling: time course for formation and removal of adducts and biochemical modulation.
Hamilton, JW; Maccubbin, AE; Warren, AJ, 1998
)
2.11
"Mitomycin C (MMC) is a DNA crosslinking agent that is used in cancer chemotherapy. "( Binding of nuclear proteins associated with mammalian DNA repair to the mitomycin C-DNA interstrand crosslink.
Hamilton, JW; Ihnat, MA; Ogdon, SE; Rowell, EE; Warren, AJ, 1998
)
1.98
"Mitomycin-C (MMC) is a useful adjunct to high risk glaucoma surgery. "( Intraoperative mitomycin C and the corneal endothelium.
Agarwal, HC; Sharma, T; Sihota, R, 1998
)
2.1
"Mitomycin C (MMC) is a bifunctional alkylating agent and a chemotherapeutic drug, covalently binds to the DNA of cells and produces monoadducts and DNA-DNA, DNA-protein crosslinks, induces damages at chromosomal level and slows down the rate of cell proliferation. "( Modulation of mitomycin C-induced sister chromatid exchanges and cell cycle delay by buthionine sulfoximine and reduced glutathione in mouse bone marrow cells in vivo.
Chatterjee, A; Giri, SD, 1998
)
2.1
"Mitomycine C appears to be an effective and safe adjunctive treatment for this cost-efficacy and this facility of use comparison."( [A comparative study of thio-tepa and mitomycin C in the treatment of pterygium. Preliminary results].
Kayembe, L; Ngoy, D, 1998
)
2.01
"Mitomycin-C is an anti metabolite known to inhibit fibroblast proliferation in vitro. "( Mitomycin-C in the treatment of tracheal cicatrix after tracheal reconstruction.
April, MM; Ward, RF, 1998
)
3.19
"Mitomycin C (MC) is an antitumor antibiotic derived biosynthetically from 3-amino-5-hydroxybenzoic acid (AHBA), D-glucosamine, and carbamoyl phosphate. "( Genetic localization and molecular characterization of two key genes (mitAB) required for biosynthesis of the antitumor antibiotic mitomycin C.
Mao, Y; Sherman, DH; Varoglu, M, 1999
)
1.95
"Mitomycin C is a vesicant chemotherapeutic agent used to treat solid tumors. "( Distant and delayed mitomycin C extravasation.
Krusa, M; Patel, JS, 1999
)
2.07
"Mitomycin C (MMC) is a clinically active anticancer drug that requires reductive activation to exert its toxicity. "( Relative contributions of mouse liver subcellular fractions to the bioactivation of mitomycin C at various pH levels.
Briggs, LA; Pritsos, CA, 1999
)
1.97
"Mitomycin C is an antineoplastic agent used to maintain a patent trabeculectomy site in patients with glaucoma."( Use of mitomycin C for maintaining myringotomy patency.
Estrem, SA; Vanleeuwen, RN, 2000
)
1.48
"Mitomycin C (MMC) is a prototype bioreductive drug employed to treat a variety of cancers including head and neck cancer. "( A unique cytosolic activity related but distinct from NQO1 catalyses metabolic activation of mitomycin C.
Jaiswal, AK; Joseph, P, 2000
)
1.97
"Mitomycin-C is an antineoplastic antibiotic that acts as an alkylating agent by inhibiting DNA and protein synthesis. "( Preliminary results of intraoperative mitomycin-C in the treatment and prevention of glottic and subglottic stenosis.
Rahbar, R; Shapshay, SM; Valdez, TA, 2000
)
2.02
"Mitomycin C (MMC) is a clinically useful anticancer drug which can cause severe dermatological problems upon injection. "( Approaches to reducing toxicity of parenteral anticancer drug formulations using cyclodextrins.
Bhardwaj, R; Blanchard, J; Dorr, RT,
)
1.57
"Mitomycin C (MMC) is a clinically used anticancer drug that is reduced to cytotoxic metabolites by cellular reductases via a process known as bioreductive drug activation. "( Predicting tumor responses to mitomycin C on the basis of DT-diaphorase activity or drug metabolism by tumor homogenates: implications for enzyme-directed bioreductive drug development.
Burger, AM; Fiebig, HH; Jarrett, CM; Loadman, PM; Phillips, RM; Swaine, DJ, 2000
)
2.04
"Mitomycin C is an antibiotic with a demonstrated antiproliferative capacity as an inhibitor of fibroblastic cells proliferation. "( [Effect of mitomycin C on corneal endothelium cells. In vitro study].
Barahona, JM; Guzmán, K; Hernández-Galilea, E; Moro, MJ; Sánchez, F; Vázquez, R, 2000
)
2.14
"Mitomycin-C is an antineoplastic antibiotic that acts as an alkylating agent by inhibiting DNA and protein synthesis."( Mitomycin: effects on laryngeal and tracheal stenosis, benefits, and complications.
Healy, GB; Rahbar, R; Shapshay, SM, 2001
)
2.47
"Mitomycin C (MMC) is a cytotoxic agent that alkylates and crosslinks DNA and also inhibits fibroblast proliferation up to a few weeks."( An experimental study evaluating the effect of Mitomycin C on the prevention of postoperative intraabdominal adhesions.
Alponat, A; Cubukçu, A; Erçin, C; Gönüllü, NN; Ozkan, S, 2001
)
1.29
"Mitomycin C is an antimetabolite applied between the sclera and conjunctiva during the initial stages of a trabeculectomy to prevent excessive post-operative scarring and thus reduce the risk of failure."( Intra-operative mitomycin C for glaucoma surgery.
Indar, A; Wilkins, M; Wormald, R, 2001
)
1.38
"Mitomycin C (MMC) is a DNA cross-linking agent that has been used in cancer chemotherapy for >20 years. "( Detection of mitomycin C-DNA adducts in human breast cancer cells grown in culture, as xenografted tumors in nude mice, and in biopsies of human breast cancer patient tumors as determined by (32)P-postlabeling.
Hamilton, JW; Mustra, DJ; Warren, AJ, 2001
)
2.12
"Mitomycin C (MC) is a bacterial product that must be enzymatically reduced to exert anticancer activity."( Reversal of mitomycin C resistance by overexpression of bioreductive enzymes in Chinese hamster ovary cells.
Baumann, RP; Belcourt, MF; Hodnick, WF; Rockwell, S; Sartorelli, AC; Seow, HA; Sherman, DH, 2001
)
1.41
"Mitomycin is an effective and reliable treatment for improving the surgical outcome for choanal atresia repair. "( Surgical management of choanal atresia: improved outcome using mitomycin.
Holland, BW; McGuirt, WF, 2001
)
1.99
"Mitomycin C (MMC) is an antineoplastic agent with an antiproliferative effect on fibroblasts. "( Mitomycin C in sinus surgery: preliminary results in a rabbit model.
Ahmarani, C; Péloquin, L; Rahal, A, 2001
)
3.2
"Mitomycin-C is an antineoplastic agent obtained from Streptomyces caesptosus and is used on the treatment of disseminated adenocarcinoma of the stomach or pancreas."( Effect of mitomycin-C on the bioavailability of the radiopharmaceutical (99m)technetium-phytic acid in mice: a model to evaluate the toxicological effect of a chemical drug.
Bernardo-Filho, M; Bezerra, RJ; de Mattos, DM; de Paula, EF; de Souza Braga, AC; de Souza Freitas, R; Gomes, ML,
)
1.26
"Mitomycin C is a powerful antineoplastic agent. "( Erythropoietin is beneficial in mitomycin-induced hemolytic-uremic syndrome.
Catalano, C; Fabbian, F; Gianesini, C, 2002
)
2.04
"Mitomycin C (MMC) is an antineoplastic agent that has been shown to decrease scar tissue after ophthalmologic surgery. "( Mitomycin C for the prevention of adhesion formation after endoscopic sinus surgery: a randomized, controlled study.
Chung, JH; Cosenza, MJ; Metson, RB; Rahbar, R, 2002
)
3.2
"mitomycin C (MMC), is a particularly important question."( Pharmacodynamics and pharmacokinetics of intravesical mitomycin C upon different dwelling times.
De Bruijn, EA; Maes, RA; Sleeboom, HP; Tjaden, UR; van Helsdingen, PJ; van Oosterom, AT, 1992
)
1.25
"Mitomycin C is an antineoplastic antibiotic requiring bioactivation to an alkylating species or to an intermediate capable of generating oxygen radicals for its toxic effect. "( Bioactivation of mitomycin C by xanthine dehydrogenase from EMT6 mouse mammary carcinoma tumors.
Gustafson, DL; Pritsos, CA, 1992
)
2.07
"The mitomycins are a group of antitumor antibiotics that covalently bind to DNA upon reductive activation. "( Reductive alkylation of DNA by mitomycin A, a mitomycin with high redox potential.
Goldstein, J; Lipman, R; McGuinness, BF; Nakanishi, K; Tomasz, M, 1991
)
1.13
"Mitomycin-C is a commonly used anticancer drug for patients with advanced anal, breast, colorectal, gastric, lung, or pancreatic cancers. "( Case report: topical DMSO for mitomycin-C-induced skin ulceration.
Alberts, DS; Dorr, RT,
)
1.86
"Mitomycin C (MMC) is a bioreductive alkylating agent that is capable of generating oxygen radicals. "( Inhibition of mitomycin C's aerobic toxicity by the seleno-organic antioxidant PZ-51.
Gustafson, DL; Pritsos, CA, 1991
)
2.08
"Mitomycin C is an alkylating agent used in cancer chemotherapy that shows some specificity towards hypoxic cells. "( Activation of mitomycin C by NADPH:cytochrome P-450 reductase.
Bartoszek, A; Beggs, JD; Bligh, HF; Hickson, ID; Kasper, CB; Robson, CN; Wolf, CR, 1990
)
2.08
"Mitomycin C (MMC) is an alkylating agent which has been associated with microangiopathic hemolytic anemia and acute renal failure, with an overall incidence between 2 and 10%. "( Silent renal microangiography after mitomycin C therapy.
Botey, A; Darnell, A; González-Clemente, JM; Poch, E; Revert, L; Torras, A, 1990
)
2
"Mitomycin C is an alkylating agent, used by intravesical instillation to treat carcinoma of the bladder. "( Dermatitis due to intravesical mitomycin C: a delayed-type hypersensitivity reaction?
Colver, GB; Hunter, JA; Inglis, JA; McVittie, E; Spencer, MJ; Tolley, DA, 1990
)
2.01
"Mitomycin-C (MMC) is an alkylating agent which has shown significant activity in gynecologic cancers, both in vivo and in vitro. "( Pharmacokinetics of mitomycin-C in plasma and tumor tissue of cervical cancer patients and in selected tissues of female rats.
Boike, G; Deppe, G; Gove, N; Malviya, VK; Young, JD, 1986
)
2.04
"Mitomycin C (1) is a clinically used antitumor antibiotic that binds covalently to deoxyribonucleic acid under reductive or acidic catalysis. "( Reassignment of the guanine-binding mode of reduced mitomycin C.
Lipman, R; Nakanishi, K; Tomasz, M; Verdine, GL, 1986
)
1.96
"Mitomycin C (MMC) is a clinically used drug with mutagenic and antitumor activities, presumably elicited through its covalent binding to DNA, however, little is known about MMC binding to DNA in vivo. "( 32P-analysis of DNA adducts in somatic and reproductive tissues of rats treated with the anticancer antibiotic, mitomycin C.
Randerath, K; Reddy, MV, 1987
)
1.93
"Mitomycin C is a chemotherapeutic agent active against breast cancer. "( Mitomycin C in the chemotherapy of advanced breast cancer.
Garewal, HS, 1988
)
3.16
"Mitomycin-C is an effective antitumor agent in breast cancer and should be carefully incorporated in the therapeutic strategy of this disease."( Mitomycin-C in breast cancer.
Hortobagyi, GN, 1985
)
2.43

Effects

Mitomycin has a unique chemical structure and contains densely assembled functionalities with extraordinary antitumor activity. Mitomycin C has a documented response rate of 20% to 30% when used as treatment in advanced breast cancer.

Mitomycin-C application has being shown useful adjunct to surgical technique in managing nasopharyngeal stenosis for surgeons. Mitomycin (MMC) has been frequently used as the compound for intravesical treatment.

ExcerptReferenceRelevance
"Mitomycin has a unique chemical structure and contains densely assembled functionalities with extraordinary antitumor activity. "( Determination of the Protein-Protein Interactions within Acyl Carrier Protein (MmcB)-Dependent Modifications in the Biosynthesis of Mitomycin.
Bai, L; Deng, Z; Kang, Q; Leng, D; Ou, Y; Sheng, Y; Wang, H; Wei, J, 2021
)
2.27
"Mitomycin C has an adjunct effect in laser myringotomy in prolonging the patency rate of myringotomy on rats. "( Topical use of mitomycin C in laser myringotomy: an experimental study in rats.
Yucel, OT, 2000
)
2.1
"Mitomycin C has a documented response rate of 20% to 30% when used as treatment in advanced breast cancer. "( Mitomycin C in advanced breast cancer: an update.
Godfrey, TE, 1988
)
3.16
"Mitomycin has a unique chemical structure and contains densely assembled functionalities with extraordinary antitumor activity. "( Determination of the Protein-Protein Interactions within Acyl Carrier Protein (MmcB)-Dependent Modifications in the Biosynthesis of Mitomycin.
Bai, L; Deng, Z; Kang, Q; Leng, D; Ou, Y; Sheng, Y; Wang, H; Wei, J, 2021
)
2.27
" Mitomycin C has been used adjunctively in various procedures, including pterygium excision. "( Inadvertent filtering bleb due to extracapsular cataract extraction wound reopening after mitomycin C use: a case report.
Chaidaroon, W; Pathanapitoon, K; Upaphong, P, 2023
)
2.04
"Mitomycin-C has been previously identified as a causal agent when administered intravenously at high doses."( Hepatic sinusoidal obstruction syndrome secondary to intravesical instillation of mitomycin-C.
Arroyo-López, M; Jiménez-Almonacid, J; Justo-Quintas, J; Marchán-López, Á; Pérez-Jacoiste Asín, MA, 2020
)
1.51
"Mitomycin C (MMC) has been using for the treatment of a variety of digestive tract cancers. "( Conjugating Aptamer and Mitomycin C with Reductant-Responsive Linker Leading to Synergistically Enhanced Anticancer Effect.
Deng, Z; He, J; Peng, T; Tan, W; Tan, Y; Wang, D; Wang, XQ; Yang, Q; Zhang, D, 2020
)
2.31
"Mitomycin C has been used in ophthalmic surgery to mitigate postoperative scarring. "( Topical mitomycin in endoscopic-assisted probing for the treatment of congenital nasolacrimal duct obstruction in older children.
Akaishi, PM; Cruz, AAV; Dolmetsch, A; Galindo-Ferreiro, A; Galvez-Ruiz, A; Khandekar, R; Schellini, SA, 2020
)
2.44
"Mitomycin (MMC) has been frequently used as the compound for intravesical treatment. "( Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trial.
Chen, K; Ding, Y; Dong, Z; Gao, K; Li, R; Li, W; Li, Y; Ma, X; Song, J; Wang, Y; Wang, Z; Yang, X, 2020
)
2.28
"Mitomycin C (MMC) has replaced 5-fluorouracil (5-FU) intraoperatively with comparable success rates and a decrease in postoperative antimetabolite administration."( Outcomes of Primary Trabeculectomy From Two Same-centre Cohorts 10 Years Apart.
Au, L; Cristian, C; Fenerty, CH; Mercieca, KJ; Naqvi, S; Shiwani, HA; Spencer, AF, 2021
)
1.34
"Mitomycin C (MMC) has been demonstrated to have significant inhibitory effects on epidural scar."( MMC controlled-release membranes attenuate epidural scar formation in rat models after laminectomy.
Cao, X; Geng, D; Jiang, L; Liu, J; Qin, J; Shen, X; Wang, B; Wu, T; Xie, H; Yu, C; Yuan, T, 2017
)
1.18
"Mitomycin has long been used, however, our previous phase I experience and European retrospective studies suggest oxaliplatin as an alternative."( A Multicenter Randomized Trial to Evaluate Hematologic Toxicities after Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin or Mitomycin in Patients with Appendiceal Tumors.
Bartlett, D; Fenstermaker, J; Levine, EA; Mansfield, P; Russell, G; Shen, P; Stewart, JH; Votanopoulos, KI, 2018
)
1.41
"Mitomycin C (MMC) has been utilized for its antifibrotic properties in nonmalignant tracheobronchial stenosis but its application is not well studied in post-lung transplant stenosis."( Management of Lung Transplant Bronchial Stenosis With Mitomycin C.
Cheng, GZ; Davidson, KR; Elmasri, M; Mahmood, K; Shofer, SL; Wahidi, MM, 2019
)
1.48
"Mitomycin C has recently been used to prevent nasal synechiae and sinus ostium stenosis after endoscopic sinus surgery."( Efficacy of Mitomycin C for postoperative endoscopic sinus surgery: a systematic review and meta-analysis.
Attia, J; McEvoy, M; Numthavaj, P; Roongpuvapaht, B; Tanjararak, K; Thakkinstian, A, 2013
)
2.21
"Mitomycin C has been shown in studies to be highly effective but has short-term and long-term side-effects that may be intolerable."( Topical chemotherapy for ocular surface squamous neoplasia.
Karp, CL; Nanji, AA; Sayyad, FE, 2013
)
1.11
"Mitomycin C (MMC) has shown potent efficacy against a wide spectrum of cancers and is clinical first choice in superficial bladder tumors. "( Cationic core-shell nanoparticles for intravesical chemotherapy in tumor-induced rat model: safety and efficacy.
Bilensoy, E; Erdogar, N; Eroglu, H; İskit, AB; Mungan, NA; Sargon, MF, 2014
)
1.85
"Mitomycin C has been used for the past 16 years to inhibit pediatric airway fibroblast proliferation. "( The use of mitomycin C in pediatric airway surgery: does it work?
Bent, JP; Gangar, M, 2014
)
2.23
"Mitomycin C (MMC) has previously been demonstrated to inhibit fibroblast proliferation and to induce fibroblast apoptosis."( Mitomycin C induces apoptosis in rheumatoid arthritis fibroblast-like synoviocytes via a mitochondrial-mediated pathway.
Cao, X; Ge, D; Kong, D; Su, C; Yan, C; Zhang, X; Zhang, Y, 2015
)
2.58
"Mitomycin C (MMC) has potent cytotoxicity but cumulative toxicity limits widespread use. "( Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients.
Amitay, Y; Berger, R; Gabizon, AA; Golan, T; Grenader, T; La-Beck, NM; Ohana, P; Shmeeda, H; Tahover, E, 2015
)
2.18
"Mitomycin C has been the most commonly used chemotherapeutic in HIPEC for the past several decades."( Pulmonary toxicity after intraperitoneal mitomycin C: a case report of a rare complication of HIPEC.
Abel, ML; Blazer, DG; Kokosis, G, 2017
)
1.44
"Mitomycin C has been used as a fibroblasts inhibitor, thus reducing the scaring process in surgical wounds."( Study of wound healing in rats treated with topical and injected mitomycin-C.
Borges, Jde P; Guaraldo, L; Quintanilha Ribeiro, Fde A; Vianna, MR,
)
1.81
"Mitomycin-C application has being shown useful adjunct to surgical technique in managing nasopharyngeal stenosis for surgeons."( Velopharyngeal stenosis, a late complication of radiotherapy.
Kumar, SS; Lee, SC; Singh, A; Singh, S; Tang, IP, 2009
)
1.07
"Mitomycin C has played a deciding role in the current revival of excimer laser surface ablation techniques. "( Mitomycin C in corneal refractive surgery.
Alió, JL; de Benito-Llopis, L; Teus, MA,
)
3.02
"Mitomycin C (MMC) has been shown to have a therapeutic effect against human pterygium fibroblasts (HPFs) by inducing apoptosis. "( Atomic force microscope-related study membrane-associated cytotoxicity in human pterygium fibroblasts induced by mitomycin C.
Cai, J; Cai, X; Chen, Q; Wu, S; Yang, X, 2010
)
2.01
"Mitomycin C has been suggested to have a useful role in reducing post-operative scarring after endonasal surgery. "( Safe application of mitomycin C within the nasal cavity.
Gutierrez, T; Hopkins, C, 2011
)
2.14
"Mitomycin C (MMC) has been widely used in this context, and despite good tolerability, there are doubts regarding its true benefit."( A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer.
Costa, FP; Ferrarotto, R; Hoff, PM; Kopetz, S; Machado, K; Mak, MP; Overman, MJ; Shah, N; Takahashi, TK, 2012
)
1.37
"Mitomycin-C has been in clinical use primarily as a chemotherapeutic agent and is well known for antifibrotic properties. "( The effect of mitomycin-C in reducing pericardial adhesion after cardiac surgery in rabbits.
Akkaya, IO; Aksoy, ON; Alpay, MF; Bayrak, R; Cakir, O; Colak, N; Nazli, Y; Tasoglu, I, 2013
)
2.19
"Mitomycin C has been reported to have some antitumor efficacy in this setting."( Treatment of peritoneal carcinomatosis in patients with digestive cancers with combination of intraperitoneal hyperthermia and mitomycin C.
Banssillon, V; Bienvenu, J; Francois, Y; Garbit, F; Gilly, FN; Glehen, O; Grandclément, E; Panteix, G; Sadeghi-Looyeh, B; Sayag-Beaujard, AC; Vignal, J, 2004
)
1.25
"Mitomycin C (MMC) has been used successfully in other fields to decrease postoperative scar formation."( The role of mitomycin C in preventing synechia and stenosis after endoscopic sinus surgery.
Anand, VK; Huang, C; Kacker, A; Newman, JG; Tabaee, A,
)
1.23
"Mitomycin C has been successfully used to prevent scar tissue formation at the site of subglottic stenosis in the field of pediatric otolaryngology."( Topical mitomycin C in the prevention of keloid scar recurrence.
Gage-White, L; Sanders, KW; Stucker, FJ,
)
1.29
"Mitomycin C (MMC) has been described as having a positive effect in different types of dacryocystorhinostomy (DCR) surgery such as external DCR, endonasal and transcanalicular DCR. "( [Use of mitomycin C (MMC) for dacryocystorhinostomy interventions].
Adenis, JP; Robert, PY; Sommer, U, 2005
)
2.21
"Mitomycin C has been successfully used in otolaryngology."( Effect of mitomycin C on the secretion of granulocyte macrophages colonies stimulating factor and interleukin-5 in eosinophilic nasal polyps stromal culture.
Becker, CG; Becker, HM; Crosara, PF; Crosara, SL; Guimarães, RE; Nascimento, E; Vasconcelos, AC,
)
1.26
"Mitomycin C has antifibroblast and anticollagen properties and in sporadic reports of animal and clinical studies it has increased the success rate of trabeculectomy and myringotomy."( Effect of mitomycin C on anterior urethral stricture recurrence after internal urethrotomy.
Ghassami, F; Mazdak, H; Meshki, I, 2007
)
1.46
"Mitomycin C has emerged as a major agent for an immediate post-resection intravesical instillation."( Risk of post-operative intravesical mitomycin C instillation following transurethral bladder tumor resection.
Haas, GP; Jones, K; Landas, S; Shapiro, O; Wang, C, 2006
)
1.33
"Mitomycin C has been used successfully in various ophthalmologic and, more recently, otolaryngologic procedures. "( Mitomycin C and endoscopic sinus surgery: where are we?
Anand, VK; Brown, SM; Tabaee, A, 2007
)
3.23
"Mitomycin C (MMC) has been evaluated in combination with several antitumor agents. "( Mitomycin C combination therapy against murine tumor systems. Effectiveness with cyclophosphamide and methotrexate.
Mabel, JA; Wodinsky, I, 1983
)
3.15
"Mitomycin C has proved to be useful as prophylaxis against superficial bladder tumor recurrences. "( Prostatic recurrences in the management of superficial bladder tumors.
Bondhus, MJ; Chaikin, L; Lockhart, JL; Politano, VA, 1983
)
1.71
"Mitomycin has proven to be among the most active drugs available for the single-agent treatment of non-small cell lung cancer (NSCLC). "( Experience with mitomycin in the treatment of non-small cell lung cancer.
Folman, RS, 1993
)
2.07
"Mitomycin has also demonstrated efficacy when given in combination with doxorubicin and in the three-drug regimen FAM (5-fluorouracil/doxorubicin/mitomycin)."( Mitomycin therapy in gastric cancer.
Macdonald, JS; Schnall, S, 1993
)
2.45
"Mitomycin-C (MMC) has proved to be the most effective drug to reduce myofibroblastic proliferation in experimental in vivo and in vitro models."( Morphometric study of wound healing in a model of filtering surgery with mitomycin-C.
Alvarez, R; González, I; Honrubia, FM; Larrosa, JM; Pablo, LE; Ramírez, T,
)
1.08
"Mitomycin C (MMC) has been used with encouraging results as an adjunct to standard treatment of hypertrophic conjunctival scars after strabismus surgery."( Evaluation of mitomycin to limit postoperative adhesions in strabismus surgery.
Cruz, OA,
)
1.21
"Mitomycin C has been found clinically useful in the treatment of colorectal cancer when administered via the hepatic artery. "( Superselective intra-arterial chemotherapy with mitomycin C in hepatic metastases from colorectal cancer.
Kairaluoma, M; Kantola, R; Kiviniemi, H; Laitinen, S; Leinonen, S; Mäkelä, J; Siniluoto, T; Tikkakoski, T, 1997
)
2
"Mitomycin-C has been shown to dramatically reduce pterygium recurrence rates; however, its use has been associated with serious complications, especially in higher cumulative doses. "( Topical mitomycin-C for pterygia: is single application appropriate?
Rubinfeld, RS; Stein, RM, 1997
)
2.17
"Mitomycin-C (MMC) has been shown to improve the surgical success of trabeculectomy; however, the advantages of MMC have been evaluated almost entirely as an adjunct to limbal-based trabeculectomy. "( Fornix-based trabeculectomy with mitomycin-C.
Goldenfeld, M; Levkovitch-verbin, H; Melamed, S, 1997
)
2.02
"Mitomycin C has limited systemic absorption when given intravesically because of its high molecular weight."( Adjuvant mitomycin C following endoscopic treatment of upper tract transitional cell carcinoma.
Bagley, DH; Keeley, FX, 1997
)
1.44
"Mitomycin-C has antiproliferative effects at concentrations below those cytotoxic to human keratocytes. "( In vitro effects of mitomycin-C on human keratocytes.
Hayashi, S; LaBree, L; McDonnell, PJ; Sadeghi, HM; Seitz, B,
)
1.9
"Mitomycin C has no beneficial effect when used in conjunction to orchiectomy in patients with newly diagnosed metastatic prostate cancer."( Mitomycin C for metastatic prostate cancer: final analysis of a randomized trial.
Baert, L; Billiet, I; Boel, K; Casselman, J; Derluyn, J; Goethuys, H; Paridaens, R; Popelier, G; Van Poppel, H; Vandenbroucke, F; Vanuytsel, L,
)
3.02
"Mitomycin-C has been reported to cause toxic effects on the ciliary body after episcleral application during glaucoma surgery. "( Intrascleral concentration vs depth profile of mitomycin-C after episcleral application: impact of irrigation.
El Menyawi, I; Georgopoulos, M; Menapace, R; Nimmerrichter, P; Radda, S; Vass, C, 2000
)
2.01
"Mitomycin C has improved the success rate of glaucoma filtering surgery in patients at high risk for surgical failure. "( Midterm follow-up of necrotic bleb excision and advancement of the fornical conjunctiva.
Ahn, DG; Hyung, SM, 1999
)
1.75
"Mitomycin C has some single-agent activity in advanced gastric cancer but no substantial efficacy was seen as in heavily pretreated colorectal carcinoma."( Phase II study of continuous 120-hour-infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent gastrointestinal adenocarcinoma.
Bokemeyer, C; Hartmann, JT; Kanz, L,
)
1.11
"Mitomycin C has an adjunct effect in laser myringotomy in prolonging the patency rate of myringotomy on rats. "( Topical use of mitomycin C in laser myringotomy: an experimental study in rats.
Yucel, OT, 2000
)
2.1
"The mitomycin-ILK procedure has shown obvious better results than the conventional SLS technique due to a considerable reduction in postoperative complications. "( Intrastromal holmium laser keratostomy: long-term results.
Boberg-Ans, J; Heegaard, S; Kessing, SV,
)
0.69
"Mitomycin C (MMC) has been used as a component of many chemotherapeutic regimens and some toxic effects of this substance have been reported. "( Study of the toxicological effect of mitomycin C in mice: alteration on the biodistribution of radiopharmaceuticals used for renal evaluations.
Bernardo-Filho, M; Bezerra, RJ; de Mattos, DM; de Souza Freitas, R; Gomes, ML, 2001
)
2.03
"Mitomycin-C has recently become an adjunct medication for inhibition of fibroblast proliferation in glaucoma filtering procedures. "( Toxic effects of mitomycin-C on cultured ciliary process cells and trabecular meshwork cells.
Hong, SJ; Lai, YH; Wang, HZ; Wu, KY, 2001
)
2.09
"Mitomycin C has antitumor activity against squamous cell lung carcinoma when used alone or in combination with MVP. "( A phase III trial of mitomycin C alone versus mitomycin C, vinblastine, and cisplatin for metastatic squamous cell lung carcinoma.
Dalton, RJ; Etzell, PS; Foley, JF; Jett, JR; Kardinal, CG; Mailliard, JA; Maksymiuk, AW; Marschke, RF; Su, JQ; Veeder, MH, 1992
)
2.05
"Mitomycin C, which has not been used in childhood malignant tumors, was effective against 2 out of 4 xenografts, TNB-9 and SK-N-AS, with 72.0% and 78.4% maximum inhibition rates, respectively."( [In vivo assessment on the therapeutic effects of etoposide, vincristine and mitomycin C against human neuroblastoma].
Kaneko, M; Kaneko, S; Ohkawa, H, 1991
)
1.23
"Mitomycin C has the latter activity, and was thus evaluated."( Synergism of cisplatin and mitomycin C in sensitive and resistant cell subpopulations of a tumor model.
Durand, RE, 1989
)
1.3
"Mitomycin C (MMC) has been known to be nephrotoxic since 1971. "( Mitomycin C-induced renal toxicity, a dose-dependent side effect?
de Vries, J; Pinedo, HM; Verwey, J, 1987
)
3.16
"Mitomycin C has a documented response rate of 20% to 30% when used as treatment in advanced breast cancer. "( Mitomycin C in advanced breast cancer: an update.
Godfrey, TE, 1988
)
3.16
"Mitomycin C has broad-spectrum activity, but clinical utility is limited by cumulative myelosuppression. "( The search for more active and less toxic mitomycin and etoposide analogs.
Schurig, JE; Stringfellow, DA, 1987
)
1.98

Actions

Mitomycin C is used because of its antiproliferative effect on fibroblasts in order to reduce scar tissue formation. Mitomycin can inhibit the proliferation of lens epithelial cells effectively. It does not increase the success rate of revision endoscopic DCR.

ExcerptReferenceRelevance
"Mitomycin C could inhibit proliferation of granulation tissue and attenuate the degree of airway stenosis caused by stent implantation."( Establishment of two canine models of benign airway stenosis and the effect of mitomycin C on airway stenosis.
Cai, Z; He, Y; Li, F; Li, H; Li, L; Li, P; Liu, X; Yan, X; Ye, L; Zhang, H, 2022
)
1.67
"Mitomycin C is used because of its antiproliferative effect on fibroblasts in order to reduce scar tissue formation."( [Adjuvants in operative laryngology: corticosteroids, fibrin adhesives, Mitomycin C].
Sittel, C, 2008
)
1.3
"Mitomycin C does not increase the success rate of revision endoscopic DCR."( Mitomycin C-enhanced revision endoscopic dacryocystorhinostomy: a prospective randomized controlled trial.
Elsherif, HS; Gamea, AM; Ragab, SM; Shehata, EM; Younes, A, 2012
)
2.54
"Mitomycin can inhibit fibroblast proliferation, induce fibroblast apoptosis, and regulate intracellular protein expression on mRNA levels. "( Effect of mitomycin on normal dermal fibroblast and HaCat cell: an in vitro study.
Li, LH; Ren, JH; Wang, SH; Wang, YW; Xia, K; Xie, DH; Yin, TF, 2012
)
2.22
"Mitomycin may inhibit wound healing by downregulating the gene expression for extracellular matrix proteins. "( The effect of mitomycin on extracellular matrix proteins in a rat wound model.
Gray, SD; Li, W; Tritle, N, 2003
)
2.12
"Mitomycin C could cause the degeneration of lens epithelial cells."( [The inhibitory effect of mitomycin C applied by intracapsular method on rabbit lens epithelial cells: an experimental study of after-cataract].
Huang, J; Liu, Y; Zheng, D; Zheng, H, 2001
)
1.33
"Mitomycin C can inhibit the proliferation of lens epithelial cells effectively. "( [The inhibitory effect of mitomycin C applied by intracapsular method on rabbit lens epithelial cells: an experimental study of after-cataract].
Huang, J; Liu, Y; Zheng, D; Zheng, H, 2001
)
2.05
"Mitomycin C appears to enhance ALA-mediated PDT when administered first. "( Investigation of sequential mitomycin C and photodynamic therapy in a mitomycin-resistant bladder cancer cell-line model.
Allman, R; Datta, SN; French, AJ; Matthews, PN, 2004
)
2.06
"Mitomycin C did not increase the short- or intermediate-term success rates of Ahmed Glaucoma Valve implantation."( Efficacy and safety of adjunctive mitomycin C during Ahmed Glaucoma Valve implantation: a prospective randomized clinical trial.
Arcieri, ES; Azuara-Blanco, A; Costa, VP; Lesk, MR; Netland, PA, 2004
)
2.05
"Mitomycin C can produce substantial sensorineural hearing loss when applied topically to the gerbil middle ear for even brief periods. "( Topical application of mitomycin C to the middle ear is ototoxic in the gerbil.
Lambert, PR; Lang, H; Moody, MW; Schmiedt, RA; Smythe, N; Spiess, AC, 2006
)
2.09
"Mitomycin C appears to inhibit the B-->Z transition, even in the presence of 3 mM MgCl2, while the Z-form of poly[d(G-m5C)] does not interact significantly with the drug under bifunctionally activating conditions; thus no reversion from the Z-form to the B-form of the polynucleotide can be observed under the salt conditions which are required for the Z-form to exist."( Mitomycin C binding to poly[d(G-m5C)].
Portugal, J; Sánchez-Baeza, FJ, 1995
)
2.46
"Mitomycin C did not produce inflammation in experimentally bypassed segments of small bowel despite the presence of colonic-type bacteria, suggesting that lack of intraluminal bacteria was not responsible for the absence of inflammation in the small intestine."( Mitomycin C-induced colitis in rats: a new animal model of acute colonic inflammation implicating reactive oxygen species.
Doria, MI; Gaginella, T; Hecht, D; Holmes, EW; Ibrahim, C; Kanofsky, JR; Keshavarzian, A; List, T; Sedghi, S; Urban, G, 1992
)
2.45
"Mitomycin-C can cause severe necrosis and ulceration when extravasated inadvertently into skin and soft tissues following IV drug administration."( Case report: topical DMSO for mitomycin-C-induced skin ulceration.
Alberts, DS; Dorr, RT,
)
1.14
"Mitomycin C did not cause the oxidation of NADPH by quinone reductase and there was no utilization of mitomycin C and no appearance of its metabolites."( Mitomycin C is not metabolized by but is an inhibitor of human kidney NAD(P)H: (quinone-acceptor)oxidoreductase.
Powis, G; Schlager, JJ, 1988
)
2.44

Treatment

Treatment with mitomycin C, hycanthone and gamma-radiation increased frequencies of SCE in DS lymphocytes and in those of their parents as compared to controls. MitomycinC treatment induced transcription of 737 genes and 28 ncRNAs at least 2 fold, while it repressed 231 genes and 17 nc RNAs.

ExcerptReferenceRelevance
"Mitomycin treatment induces pulmonary toxicity, and alveolar epithelial cell senescence is crucial in the pathogenesis of the latter. "( Mitomycin induces alveolar epithelial cell senescence by down-regulating GSK3β signaling.
Chen, X; Jiang, X; Sun, X; Wan, X; Xu, X, 2021
)
3.51
"Mitomycin C as a treatment for superficial bladder carcinomas and upper urinary tract tumours has been linked to local adverse events. "( Interstitial pneumonitis and myelosuppression associated to mitomycin C urinary tract instillations: A case report.
Castro-Rebollo, P; Marco-Hernandez, J; Rodriguez-Reyes, M; Soy-Muner, D, 2019
)
2.2
"Mitomycin C treatment induced transcription of 737 genes and 28 ncRNAs at least 2 fold, while it repressed 231 genes and 17 ncRNAs."( Expansion of the SOS regulon of Vibrio cholerae through extensive transcriptome analysis and experimental validation.
Campoy, S; Coppée, JY; Cruveiller, S; Dillies, MA; Irazoki, O; Jagla, B; Krin, E; Mazel, D; Médigue, C; Pierlé, SA; Rouy, Z; Sismeiro, O; Varet, H, 2018
)
1.2
"The mitomycin C-treated group showed a significant decrease in cell proliferation and DNA damage, but a considerable increase in DNA repair compared with the positive and experimental control groups."( Morphological effects of mitomycin C on urothelial responses to experimentally-induced urethral stricture in rats.
Chang, IY; Han, M; Huh, JS; Kim, JN; Kim, SO; Maeng, YH; Yoon, SP, 2015
)
1.2
"Mitomycin treatment of MEF induced similar epigenetic modification of p53 and its binding to the promoter chromatin."( Kinetics of repression by modified p53 on the PDGF beta-receptor promoter.
Funa, K; Matsumoto, Y; Wetterskog, D; Yang, W, 2008
)
1.07
"Mitomycin C treatment after 1 h and 7 d prolonged survival to more than 300 d in 40% and 50%, respectively; however, treatment turned out to be nephrotoxic."( Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice.
Autenrieth, M; Bruchertseifer, F; Morgenstern, A; Pfost, B; Saur, D; Schwaiger, M; Seidl, C; Senekowitsch-Schmidtke, R, 2009
)
1.07
"Mitomycin C treatments and siRNA knockdown of Bl-Piwi result in deficient cells incapable of expanding or differentiating and to subsequent regeneration arrest."( Piwi positive cells that line the vasculature epithelium, underlie whole body regeneration in a basal chordate.
Lapidot, Z; Moiseeva, E; Rabinowitz, C; Rinkevich, B; Rinkevich, Y; Rosner, A, 2010
)
1.08
"Mitomycin C treatment, selected on the basis of its robust preclinical activity in a personalized xenograft generated from the patient's tumor, resulted in long-lasting (36+ months) tumor response."( Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.
De Jesus-Acosta, A; Donehower, R; Eshleman, JR; Garrido-Laguna, I; Hidalgo, M; Hruban, RH; Jones, S; Klein, A; Laheru, D; Maitra, A; Rajeshkumar, NV; Villarroel, MC, 2011
)
1.09
"Mitomycin C treatment also protected GJIC from disruption after cytokine treatment."( Rapid changes in connexin-43 in response to genotoxic stress stabilize cell-cell communication in corneal endothelium.
Funderburgh, JL; Roh, DS, 2011
)
1.09
"Mitomycin C-treated HTFs were used for comparison."( In vitro analyses of the anti-fibrotic effect of SPARC silencing in human Tenon's fibroblasts: comparisons with mitomycin C.
Seet, LF; Su, R; Toh, LZ; Wong, TT, 2012
)
1.31
"Mitomycin C treatment protects islets from the progression of central damage during culture. "( Mitomycin C treatment significantly reduces central damage of islets in culture.
Anazawa, T; Gotoh, M; Haga, J; Ise, K; Oshibe, I; Saito, T; Sato, Y; Waguri, S; Yamamoto, M, 2012
)
3.26
"Mitomycin C treatment of Erwinia tasmaniensis strains from Australia induced prophages and the expression of bacteriocins. "( Tasmancin and lysogenic bacteriophages induced from Erwinia tasmaniensis strains.
Geider, K; Lurz, R; Müller, I, 2012
)
1.82
"The mitomycin C-treated Fancc(-/-) mouse provides a valuable model to address long-term efficacy of such treatment."( Short-term granulocyte colony-stimulating factor and erythropoietin treatment enhances hematopoiesis and survival in the mitomycin C-conditioned Fancc(-/-) mouse model, while long-term treatment is ineffective.
Buchwald, M; Carreau, M; Dick, JE; Gan, OI; Hitzler, JK; Liu, L, 2002
)
1
"Mitomycin C treatment of endothelial cells caused capping and microparticle release with a time course similar to TNF-alpha induction for 15 to 24 h, but assays for caspase 3 were positive, confirming the apoptotic action of mitomycin C."( Agonist-induced capping of adhesion proteins and microparticle shedding in cultures of human renal microvascular endothelial cells.
Ahn, YS; Arnold, PI; Jimenez, JJ; Jy, W; Mauro, LM; Mendez, AJ; Newton, KR; Schultz, DR, 2002
)
1.04
"Mitomycin C (MMC)-treated spleen cells as well as MMC-treated RL male symbol 1 cells partly released RL male symbol 1 cells from the inhibition of proliferation by PS gelatin."( Comparison between bovine bone and porcine skin gelatins in their effects on murine cell proliferation.
Hasegawa, M; Horikoshi, I; Ito, N; Koide, T; Kojima, T; Nagata, H; Sano, M; Sasanabe, R, 2002
)
1.04
"Mitomycin C treatment over the secondary plate alone permits removal of this plate if MMC-related complications occur without requiring removal of the whole implant."( Mitomycin C eliminates the short-term intraocular pressure rise found following Molteno tube implantation.
Ellingham, RB; House, PH; Morgan, WH; Westlake, W, 2003
)
2.48
"The mitomycin C-treated sites showed significantly decreased peridural fibrosis."( Topical mitomycin C-induced inhibition of postlaminectomy peridural fibrosis in rabbits.
Baykaner, K; Ceviker, N; Dogulu, F; Emmez, H; Erdem, O; Kurt, G; Memis, L, 2003
)
1.23
"Mitomycin C (MMC) treatment produces genotoxic stress and exerts various biologic effects on cell function. "( Permanent acceptance of mitomycin C-treated islet allograft.
Gotoh, M; Gunji, T; Ise, K; Matsuyama, S; Saito, T; Sato, Y, 2003
)
2.07
"Mitomycin C-treated nerves showed significantly less perineural adhesions than controls."( Topical application of mitomycin C prevents epineural scar formation in rats.
Ceylan, S; Etus, V; Ilbay, G; Ilbay, K; Yildiz, K, 2005
)
1.36
"Mitomycin was a primary treatment for residual epithelial disease in ten patients (eight with PAM with atypia and two with conjunctival melanoma) and as an adjuvant to excision and cryotherapy in six with conjunctival malignant melanoma."( Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: 12 years' experience.
Finger, PT; Kurli, M, 2005
)
1.48
"Mitomycin C treatment induces apoptosis of keratocytes and myofibroblasts, but the predominate effect in inhibiting or treating haze appears to be at the level of blocked replication of keratocytes or other progenitor cells of myofibroblasts. "( Effect of prophylactic and therapeutic mitomycin C on corneal apoptosis, cellular proliferation, haze, and long-term keratocyte density in rabbits.
Gupta, PC; Mohan, RR; Netto, MV; Sharma, A; Sinha, S; Wilson, SE, 2006
)
2.05
"Mitomycin C (MMC) treatment has been used to arrest cell proliferation but not much is known about the effect of MMC on human foreskin fibroblasts (HFF) used as feeders for human embryonic stem cells (hESC). "( Effect of mitomycin-C on human foreskin fibroblasts used as feeders in human embryonic stem cells: immunocytochemistry MIB1 score and DNA ploidy and apoptosis evaluated by flow cytometry.
Barnie, A; Barroso del Jesus, A; Cabrera, CM; Catalina, P; Cobo, F; Concha, A; Cortés, JL; Montes, R; Nieto, A, 2007
)
2.18
"Mitomycin C treatment resulted in malcoordinated swarming and abortive side branch formation and a strong tendency by a subpopulation of the cells to form minimal rotating aggregates of only a few cells."( Swarming and complex pattern formation in Paenibacillus vortex studied by imaging and tracking cells.
Ben Jacob, E; Ingham, CJ, 2008
)
1.07
"Mitomycin C treated tumor cell suspensions, when cocultured with normal human blood leukocytes, markedly depressed the expected blastogenic responses in vitro to concanavalin A, pokeweed mitogen, and phytohemagglutin."( Lymphoblastoid cell-induced suppression of human peripheral blood leukocyte mitogenic responses.
Friedman, F; Friedman, H; Hsu, KH; Nonoyama, M; Specter, S; Zhang, JL, 1984
)
0.99
"Mitomycin C-treated wild type E."( Survival and induction of recA protein in mitomycin C-treated Escherichia coli rec, lex, or uvr strains.
Giacomoni, PU, 1983
)
1.25
"Mitomycin C treatment diminished their inhibitory capacity."( Enrichment of MLR-activated human suppressor cells by discontinuous density-gradient centrifugation.
Aigrain, Y; Fink, U; Kabelitz, D; Reichert, A, 1981
)
0.98
"Mitomycin C-treated null cell ALL blasts from two of five children suppressed the proliferative responses of normal responder cells by 80% and 58% whereas those from two other children enhanced the responses by 118% and 31%."( Immunoregulation by blasts from null cell and T-cell leukemias: help and suppression of T-cell proliferative responses to mitogens.
Good, RA; Gupta, S; Kaur, P; Miller, DR; Schulof, RS; Steinherz, P, 1982
)
0.99
"Mitomycin C treatment of MNC from IDDM patients abolished insulin secretion inhibition in recipient mice."( Insulin secretion by pancreas of athymic mice injected with peripheral mononuclear cells from insulin-dependent diabetic patients.
Arata, M; Basabe, JC; Fabiano de Bruno, L; Gagliardi, G; Goncalvez Volpini, W; Quintans, CJ, 1995
)
1.01
"Mitomycin C treatment (MMC, 5 x 10(-6) M, 0.5 h) doubled the 'spontaneous' SCE frequency, maleic hydrazide treatment (MH, 5 x 10(-4) M, 0.5 h) increased it nearly 7-fold."( Sister-chromatid exchanges in Picea abies--a test for genotoxicity in forest trees.
Rieger, R; Schubert, I, 1994
)
1.01
"Mitomycin C-treated eyes received an average of 0.6 medications for IOP control, and 5-FU-treated eyes received an average of 1.05 medications (P = 0.03)."( 5-Fluorouracil and mitomycin C in pseudophakic patients.
Belkin, JK; Lamping, KA, 1995
)
1.34
"Mitomycin C-treated BMC were unable to inhibit SSC-induced accelerated rejection."( Abrogation of secondary skin allograft rejection by veto-like cells in donor bone marrow.
De Fazio, SR; Gozzo, JJ; Pourshadi, M, 1993
)
1.01
"mitomycin C after pretreatment with interferon alpha showed a dramatic decrease in cell proliferation (from 98.8 +/- 2.1% to 80.2 +/- 4.0% of control)."( Interferons modify in vitro proliferation of human bladder transitional cell carcinoma in the presence of doxorubicin and mitomycin C.
Kinne, RK; Okamoto, E; Sökeland, J, 1996
)
1.22
"Mitomycin C treatment of otherwise isogenic E."( Cloning, sequencing and complementation analysis of the recA gene from Prevotella ruminicola.
Aminov, RI; Benno, Y; Nagamine, T; Ogata, K; Sugiura, M; Tajima, K, 1996
)
1.02
"The mitomycin C-treated patients had 41% recurrence, 1.7 recurrence/100 patients-month, 17 months mean time to recurrence and 8.8% tumor progression. "( [Prevention of superficial bladder cancer with mitomycin C or interferon: final results of a prospective study].
Alonso Rodrigo, A; Barros Rodríguez, M; Benavente Delgado, J; Domínguez Freire, F; Nogueira March, YJ; Ojea Calvo, A; Rodríguez Iglesias, B; Vérez Vivero, M, 1996
)
1.11
"Mitomycin C pretreatment also significantly increased the sensitivity of cancer cells to subsequent killing by the P-glycoprotein substrate doxorubicin, decreasing the ED50 by 5- to 10-fold."( Suppression of P-glycoprotein expression and multidrug resistance by DNA cross-linking agents.
Blaxall, JR; Hamilton, JW; Ihnat, MA; La Ronde, N; Lariviere, JP; Pierre, KM; Turpie, BW; Warren, AJ, 1997
)
1.02
"As mitomycin-C treatment altered 99Tcm-MDP uptake in some organs, any hot spots should be evaluated carefully to avoid a misdiagnosis."( The effect of mitomycin-C on the biodistribution of 99Tcm-MDP in Balb/c mice.
Bernardo-Filho, M; Boasquevisque, EM; de Mattos, DM; de Souza Braga, AC; de Souza Freitas, R; Gomes, ML, 1998
)
1.17
"Mitomycin C (MMC) treatment or mutations in uvrD enhance the frequency of Tn10 precise excision. "( RecBC and RecF recombination pathways and the induced precise excision of Tn10 in Escherichia coli.
Chan, A; Nagel, R, 1999
)
1.75
"Mitomycin C treatment of strains carrying several lytA-hybridizing fragments caused the appearance of extrachromosomal DNA hybridizing to the lytA gene, followed by lysis of the bacteria."( A high incidence of prophage carriage among natural isolates of Streptococcus pneumoniae.
Ramirez, M; Severina, E; Tomasz, A, 1999
)
1.02
"The mitomycin-C treated larynges demonstrated improved cricoarytenoid joint mobility (P = .007), decreased granulation tissue development (P = .03), and complete prevention of secondary "vocal granuloma" formation (P = .0004) when compared with eight dogs with identical laser injuries allowed to heal untreated. "( Preservation of function and histologic appearance in the injured glottis with topical mitomycin-C.
Baranowski, B; Huang, S; Luther, M; McGehee, B; Page, RN; Reinisch, L; Spector, JE; Spector, NC; Werkhaven, JA, 1999
)
1.08
"The mitomycin C-treated eyes clearly had more conjunctival avascularity and a lower disinsertion force. "( Intraoperative sponge 5-fluorouracil to reduce postoperative scarring in strabismus surgery.
Evan, AP; Helveston, EM; Mora, JS; Sprunger, DT, 1997
)
0.86
"The mitomycin C treated ears had delayed closure time and healing rate (from day 0 to 25) compared to the control group. "( Creating a stable tympanic membrane perforation using mitomycin C.
Cass, SP; Goldman, SA; O'Reilly, RC; Widner, SA, 2001
)
1.12
"Mitomycin C treatment blocked this early expansion, suggesting that aberrant division of angioblasts and/or endothelial cells is a hallmark of the flt-1 mutant phenotype throughout vascular development."( Vascular endothelial growth factor receptor Flt-1 negatively regulates developmental blood vessel formation by modulating endothelial cell division.
Ambler, CA; Bautch, VL; Johnson, N; Kearney, JB; Monaco, KA; Rapoport, RG, 2002
)
1.04
"Mitomycin C treatment resulted in downregulation of p27(Kip1) and p21(WAF-1); no significant change in P-gp levels was observed."( Modulation of intrinsic P-glycoprotein expression in multicellular prostate tumor spheroids by cell cycle inhibitors.
Fischer, K; Hescheler, J; Sauer, H; Wartenberg, M, 2002
)
1.04
"Mitomycin C treatment of Escherichia coli K-12 cells containing the nonconjugative plasmid CloDF13 resulted in inhibition of host chromosome protein synthesis and a high rate of synthesis of two CloDF13-specified proteins whose molecular weights correspond to cloacin and immunity protein. "( Changes in protein synthesis on mitomycin C induction of wild-type and mutant CloDF13 plasmids.
Dougan, G; Sherratt, DJ, 1977
)
1.98
"Mitomycin C treatment had no effect on centriole reorientation, but caused a significant delay in golgi localization."( Influence of mitomycin C on endothelial monolayer regeneration in vitro.
Coomber, BL, 1992
)
1.37
"When mitomycin C-treated B cells were added to in vitro culture of responder B cells as a stimulator, Ig production of responder B cells was enhanced in a concentration-dependent manner."( B-B cell interactions in the spontaneous activation of B cells in autoimmune NZB mice.
Eto, S; Ota, T; Saito, K; Tanaka, Y; Yamashita, U, 1991
)
0.74
"Mitomycin-C-treated cultures were used as control for the micronucleus method, because it is known that mitomycin-C is a potent genotoxic agent, capable of inducing micronuclei."( Spontaneous and mitomycin-C-induced micronuclei in human lymphocytes exposed to extremely low frequency pulsed magnetic fields.
Bersani, F; Cadossi, R; Castellani, G; Cossarizza, A; Franceschetti, G; Franceschi, C; Monti, D; Scarfi, MR, 1991
)
1.35
"Mitomycin C treatment enhanced the proportion to 80%."( Production of bacteriocins and siderophore-like activity by Azospirillum brasilense.
Caballero-Mellado, J; Mascarúa-Esparza, MA; Tapia-Hernández, A, 1990
)
1
"Mitomycin treatment of the lymphocytes blunted their specific effects, suggesting that proliferation of T cells is required for maximal exertion of their regulatory activity."( T lymphocyte subset modulation of hepatic fibroblast function in murine schistosomiasis.
Dunn, MA; el-Ghorab, NM; Mansour, MM; Salah, LA; Woody, JN, 1989
)
1
"Mitomycin C treatment of fresh E rosetting cells or those exposed to BEBV for up to 10 days in culture abrogates growth regression and the subsequent appearance of LCLEBV killer cells."( Regulation of the growth of Epstein-Barr virus-infected B cells. I. Growth regression by E rosetting cells from VCA-positive donors is a combined effect of autologous mixed leukocyte reaction and activation of T8+ memory cells.
Bluestein, HG; Konttinen, YT; Zvaifler, NJ, 1985
)
0.99
"(3) Mitomycin C treated group (MMC: active control) and (4) plasma exchange + MMC treated group (combination therapy)."( [A basic study on plasma exchange therapy of malignant tumor in tumor bearing rats].
Suzuki, M, 1986
)
0.75
"Mitomycin C-pretreated proximal stumps were subsequently sutured to cellular or acellular autografts (0.5 cm long) and neurite growth into and within the grafts was examined during a 5-week post-operative period."( The effect of inhibiting Schwann cell mitosis on the re-innervation of acellular autografts in the peripheral nervous system of the mouse.
Hall, SM,
)
0.85
"Mitomycin C treatment does not induce permanent expression of the silent chromosome, so the activation seems to be temporary, perhaps reflecting the action of an SOS function under RecE control."( RecE-dependent lysogenic induction in the absence of repressor in Bacillus subtilis non-complementing diploids.
D'Ari, R; Guillén, N; Hirschbein, L; Zahraoui, A, 1986
)
0.99
"Mitomycin-C treated stocks showed as many as 46.99 +/- 2.48% aberrations compared with 7.5 +/- 0.80% in the controls."( Effect of mitomycin-C and cyclophosphamide on the polytene chromosomes of Anopheles stephensi (Culicidae:Diptera).
Chaudhry, A; Dhar, M; Sharma, GP; Sobti, RC, 1987
)
1.4
"When mitomycin-C treatment alone was performed on day 9.5 of pregnancy, only vertebral anomalies increased in incidence."( Teratogenic interactions between methylmercury and mitomycin-C in mice.
Inouye, M; Kajiwara, Y, 1988
)
0.98
"The mitomycin-treated blastocysts with only 70% of normal ICM cells developed to egg cylinders that were about half normal size, but by days 12-14 the body size of the surviving embryo was similar to that of the control embryo."( Postimplantation development of mitomycin C-treated mouse blastocysts.
Tam, PP, 1988
)
1.04
"Mitomycin C (MMC) treatment of lymphocyte cultures from 6 patients having a Robertsonian translocation showed that in cases 1 and 2, who were already mosaics, MMC induced a statistically significant increase of the number of cells with the dissociated translocation."( Mitomycin C effect on Robertsonian translocations.
Carnevale, A; Frias, S; Molina, B; Zavaleta, MJ, 1988
)
2.44
"Treatment of mitomycin C with pyrimidine nucleotides in acidic media produced derivatives of 2,7-diaminomitosene in which C-1 was covalently bound to the phosphate group of the nucleotides. "( Nucleotide derivatives of 2,7-diaminomitosene.
Dorr, RT; Iyengar, BS; Kowal, CD; Remers, WA, 1988
)
0.64
"treatment with Mitomycin-C dissolved in an alkaline wash plus rifampicin and control group: only treated with rifampicin and alkaline nasal wash. "( Topical Mitomycin-C can help as an adjunct to alkaline nasal wash and rifampicin in primary atrophic rhinitis.
Abdel-Naby Awad, OG; Hasan, MM,
)
0.92
"Treatment with mitomycin C increased TXNIP level in EAC solid tumors in mice."( Dorzolamide synergizes the antitumor activity of mitomycin C against Ehrlich's carcinoma grown in mice: role of thioredoxin-interacting protein.
Ali, BM; Moustafa, YM; Shouman, SA; Zaitone, SA, 2015
)
1.01
"When treated with mitomycin-C (MMC), miR-31-expressing UBC cells displayed lower survival and higher apoptotic rates, and deactivated Akt and ERK."( MicroRNA-31 functions as a tumor suppressor and increases sensitivity to mitomycin-C in urothelial bladder cancer by targeting integrin α5.
Fan, Y; Liu, Y; Qin, L; Shen, Z; Wang, X; Xia, L; Xu, C; Xu, T; Zhang, X; Zhong, S; Zhu, Z, 2016
)
0.99
"Upon treatment with mitomycin C, these variants lyse with production of a myovirus containing DNA of equal size to the plasmid but which cannot be recovered by alkaline extraction."( Enhancement of UV light sensitivity of a Vibrio parahaemolyticus O3:K6 pandemic strain due to natural lysogenization by a telomeric phage.
Espejo, RT; García, K; Zabala, B, 2009
)
0.67
"Treatment with mitomycin-C only showed median and mean survival times of 13.3 and 24 months, with gemcitabine only they were 11 and 22.3 months, and with a combination of mitomycin-C and gemcitabine 24.8 and 35.5 months."( Transarterial chemoembolization (TACE) with mitomycin C and gemcitabine for liver metastases in breast cancer.
Eichler, K; Gruber-Rouh, T; Naguib, NN; Nour-Eldin, NE; Vogl, TJ; Zangos, S, 2010
)
0.96
"When treated with mitomycin C, p53-deficient cells, but not p53-expressing cells, showed a marked increase in ceramide levels."( DNA damage induces down-regulation of UDP-glucose ceramide glucosyltransferase, increases ceramide levels and triggers apoptosis in p53-deficient cancer cells.
Duerksen-Hughes, PJ; Filippov, V; Filippova, M; Haynes, TA; Yang, J; Zhang, K, 2012
)
0.7
"Treatment with mitomycin C decreased MRP expression at high concentrations and hyperthermia intensified these effects."( The exposure of cancer cells to hyperthermia, iron oxide nanoparticles, and mitomycin C influences membrane multidrug resistance protein expression levels.
Franke, K; Hilger, I; Kaiser, WA; Kettering, M; Lange, K, 2013
)
0.96
"Treatment with mitomycin-C resulted in the increased expression of Fas, FasL, Bad, and phosphorylated p53 and a decreased level of phosphorylated AKT."( Mitomycin-C induces the apoptosis of human Tenon's capsule fibroblast by activation of c-Jun N-terminal kinase 1 and caspase-3 protease.
Hong, YJ; Kim, CY; Kim, SD; Park, C; Park, R; Seong, GJ; So, HS, 2005
)
2.11
"GES treated with mitomycin C can significantly inhibit neointimal formation in rabbit arteries due to the formation of granulation tissue. "( Granulation encapsulated stent: a new therapeutic approach for vascular implantation.
Chen, X; Gardin, JM; LaLonde, T; Tang, L; Tang, S, 2007
)
0.68
"Treated with mitomycin of the concentrations of 0.01, 0.1, and 1 microg/ml for 24 hours, the apoptotic rates of the RT4 cells were 12.7% +/- 2.9%, 31.3% +/- 4.4%, and 48.9% +/- 5.8% respectively, and the apoptotic rates of the RT4 cells were 7.2% +/- 3.3%, 15.5% +/- 5.2%, and 21.2% +/- 4.4% respectively, all significantly lower than those of the RT4 cells (all P < 0.05)."( [Adriamycin and mitomycin dose-dependently downregulate X-kinked inhibitor of apoptosis protein in human bladder cancer cells].
Chen, L; Gan, L; Lai, YQ; Li, M; Liu, G; Na, YQ; Yin, ZF; Yuan, YM, 2006
)
1.03
"Treatment with mitomycin C and hyperthermia resulted in additive tumor-cell killing, and minocycline administration further increased that effect.(ABSTRACT TRUNCATED AT 250 WORDS)"( Minocycline as a modulator of chemotherapy and hyperthermia in vitro and in vivo.
Ara, G; Herman, TS; Holden, SA; Liu, CJ; Teicher, BA, 1994
)
0.63
"Treatment with mitomycin C and menadione was well tolerated except for hematologic toxicity and cardiac events of unclear relationship to the study drugs."( Mitomycin C and menadione for the treatment of lung cancer: a phase II trial.
Ahn, C; Akman, S; Chow, W; Doroshow, JH; Leong, L; Margolin, K; Morgan, RJ; Raschko, J; Somlo, G; Tetef, M, 1995
)
2.07
"Treatment with mitomycin C resulted in a 5.5-fold increase in the expression of a chloramphenicol acetyltransferase construct containing 3 kb of DT-diaphorase promoter sequence."( Involvement of activator protein-1 and nuclear factor-kappaB transcription factors in the control of the DT-diaphorase expression induced by mitomycin C treatment.
Ford, P; Hageboutros, A; O'Dwyer, PJ; Yao, KS, 1997
)
0.84
"Cell treatment with mitomycin C completely eliminates the stimulating effect of EGF, without, however, affecting baseline level of cell migration, which is independent on growth stimulants."( [The action of epidermal growth factor on the migration of A-431 cells].
Samarova, AV; Terskikh, VV; Vasil'ev, AV; Voroteliak, EA,
)
0.45
"Treatment with mitomycin C or UV light also caused a substantial increase in the expression of PblA and PblB, as detected by Western blot analysis of proteins in the SF100 cell wall."( Proteins PblA and PblB of Streptococcus mitis, which promote binding to human platelets, are encoded within a lysogenic bacteriophage.
Bensing, BA; Siboo, IR; Sullam, PM, 2001
)
0.65
"Pretreatment with mitomycin-C (0.4 mg/mL) rendered fibroblasts susceptible to agonistic anti-Fas monoclonal IgM antibodies (50-500 ng/mL) and led to a further 50% reduction in viable fibroblasts at 48 hours, compared with mitomycin-C alone (P < 0.05)."( Apoptosis gene expression and death receptor signaling in mitomycin-C-treated human tenon capsule fibroblasts.
Akbar, AN; Chang, LH; Constable, PH; Crowston, JG; Daniels, JT; Khaw, PT, 2002
)
0.88
"Treatment with mitomycin C (0.05 micrograms/ml), hycanthone (0.1 micrograms/ml) and gamma-radiation (0.1 Gy) revealed a significant (P less than 0.01) increase in frequencies of SCE in DS lymphocytes and in those of their parents as compared to controls."( Sister-chromatid exchanges in lymphocytes from infants with Down's syndrome.
Allak, BM; Hamami, HA; Khaleel, AH; Shubber, EK, 1991
)
0.62
"Cell treatment with mitomycin C increases the level of the KIN protein."( KIN, a mammalian nuclear protein immunologically related to E. coli RecA protein.
Angulo, JF; Bertolotti, R; Devoret, R; Hill, AM; Laporte, J; Maunoury, R; Moreau, PL, 1989
)
0.59
"Treatment with mitomycin C of target cells did not change their NK sensitivity."( Enhancement by X-ray irradiation of target cell susceptibility to natural killer cells.
Fujimoto, T; Ikenaga, M; Mizutani, Y; Uchida, A; Yoshida, O, 1989
)
0.62
"Treatment with mitomycin/5-bromodeoxyuridine and PGE1/cAMP inhibited growth as seen by the growth curves and caused morphological differentiation as seen by the extension of long neurites."( Differentiation characteristics of human neuroblastoma cells in the presence of growth modulators and antimitotic drugs.
Felten, S; Gash, DM; Gupta, M; Notter, MF, 1985
)
0.61
"Treatment with mitomycin C of the ColD-carrying cells leads to induction of the synthesis both of colicin and of a 10 KD protein responsible for cell killing and lysis."( [Organization and gene expression of plasmid ColD-CA23 connected with colicin biosynthesis].
Khmel', IA; Kolot, MN; Lipasova, VA; Pshennikova, ES, 1986
)
0.61
"Treatment with mitomycin C at different times after dimethyl sulfoxide addition shows that cell sensitivity to inhibition is not homogeneous during the induction period; it is maximal between 18 and 24 h from the start of induction and is observed with a concentration of mitomycin C as low as 25 fM."( Inhibition of dimethyl sulfoxide induced erythropoietic differentiation of murine erythroleukemia cells in culture.
Foresti, M; Gaudio, L; Geraci, G; Manduca, P, 1986
)
0.61
"Treatment with mitomycin C did not result in an enhancement of microcin levels."( Factors affecting microcin E492 production.
de Lorenzo, V, 1985
)
0.61
"Treatment of mitomycin C with DCl in D2O gave predominantly cis product with about 45% deuterium exchange at C-1."( A comparison of mechanisms proposed for the conversion of mitomycins into mitosenes.
Iyengar, BS; Remers, WA, 1985
)
0.87

Toxicity

The ADP1_recA_lux was used to detect a variety of toxic or potentially toxic compounds including mitomycin C (MMC), methyl methanesulfonate, ethidium bromide, H2O2, toluene, single-wall nanocarbon tubes (SWNCT), nano Au colloids (20 nm), pyrene, beno[a]pyrene and UV light.

ExcerptReferenceRelevance
" The toxic activity of MMC in mouse bone marrow was significantly reduced or completely abolished after its inclusion in PBCN."( Diminished genotoxicity of mitomycin C and farmorubicin included in polybutylcyanoacrylate nanoparticles.
Balansky, RM; Blagoeva, PM; Mircheva, TJ; Simeonova, MI, 1992
)
0.58
" SOD-POE did not influence the antitumor effects of ADR and MMC either in vitro or in vivo, but prevented the toxic death of BALB/c, nu/nu male mice caused by overdoses of ADR or MMC."( Polyoxyethylene-modified superoxide dismutase reduces side effects of adriamycin and mitomycin C.
Akiyama, S; Dohmitsu, K; Ito, K; Kataoka, M; Kawasaki, S; Kondoh, K; Kurokawa, T; Sugiyama, S; Watanabe, T; Yamauchi, M, 1992
)
0.51
" None of the nonresponders responded to the addition of folinic acid, on the contrary toxicity was increased and 2 toxic deaths were reported."( Continuous 24-hour infusion of folinic acid does not increase the response rate of 5-fluorouracil but only the toxicity.
Karvounis, N; Kosmidis, P; Tsavaris, N; Tzannou, I, 1992
)
0.28
" It is based on the continuous monitoring of growth of Salmonella typhimurium TA 98 and TA 100 (strains that are also employed in the classical Ames test (1) for mutagenicity screening) under the influence of the toxic compounds."( [An automated in vitro toxicity test of 25 chemicals].
Jakob, R; Lindl, T, 1990
)
0.28
" We now demonstrate that DIC sensitizes EMT6 cells to two MC analogues, porfiromycin (POR) and the 7-N-dimethylaminomethylene analogue of mitomycin C (BMY-25282), in hypoxia and protects cells from these agents in air, despite the fact that POR is preferentially toxic to hypoxic cells and BMY-25282 is preferentially toxic to aerobic cells."( Modification of the metabolism and cytotoxicity of bioreductive alkylating agents by dicoumarol in aerobic and hypoxic murine tumor cells.
Keyes, SR; Rockwell, S; Sartorelli, AC, 1989
)
0.48
" All agents chosen for these experiments represented classes of compounds known to be more toxic towards hypoxic cells than they are to aerobic cells."( The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay.
Stephens, MA; Stratford, IJ, 1989
)
0.28
"Mitomycin C (MC) and its structural analogs porfiromycin (PM), BMY-25282 and BL-6783 are toxic to EMT6 cells under aerobic and hypoxic conditions."( Effect of the superoxide dismutase inhibitor, diethyldithiocarbamate, on the cytotoxicity of mitomycin antibiotics.
Keyes, SR; Pritsos, CA; Sartorelli, AC, 1989
)
1.94
" These findings suggested that dicoumarol might enhance the toxicity of MC to the hypoxic cells of solid tumors, without increasing the toxic side effects of the antibiotic to the host."( Enhancement of mitomycin C cytotoxicity to hypoxic tumor cells by dicoumarol in vivo and in vitro.
Keyes, SR; Rockwell, S; Sartorelli, AC, 1985
)
0.62
" This new testing system appears to be a sensitive method of measuring the direct effects of toxic chemicals which yields results in a short term."( Toxic effects of chemicals on mouse post-blastocyst development--a trial to establish a testing system for embryotoxicity.
Katayama, S; Matsumoto, N, 1985
)
0.27
" No significant side effect was noted in any case."( [Chemoembolization therapy of hepatocellular carcinoma-antitumor effect and side effect].
Ikami, I; Kanehira, J; Midorikawa, H; Saito, Y; Sasaki, T; Takekawa, SD; Tarusawa, K; Yodono, H, 1988
)
0.27
"Mitomycin C (MC) was more toxic to EMT6 mouse mammary tumor cells in vitro under hypoxia than under aerobic conditions."( Effect of some proliferative and environmental factors on the toxicity of mitomycin C to tumor cells in vitro.
Rockwell, S, 1986
)
1.94
" No serious adverse effects were observed in any of the groups."( [Cooperative study of surgical adjuvant chemotherapy of colorectal cancer (first report): Investigation of background factors and adverse effects. Cooperative Study Group of Surgical Adjuvant Chemotherapy of Colorectal Cancer in Japan].
Abe, O; Hattori, T; Inokuchi, K; Kasai, Y; Kikuchi, K; Komi, N; Kondo, T; Kunii, Y; Ogawa, N; Taguchi, T, 1987
)
0.27
" Whether this side effect was dose-dependent is unknown, while data on incidence are scanty."( Mitomycin C-induced renal toxicity, a dose-dependent side effect?
de Vries, J; Pinedo, HM; Verwey, J, 1987
)
1.72
"2 and 3 times the LD50 value in rats."( Pharmacokinetics and toxicity of mitomycin C in rodents, given alone, in combination, or after induction of microsomal drug metabolism.
Kanyár, B; Kerpel-Fronius, S; Lelieveld, P; Pinedo, HM; Stuurman, M; Verwey, J, 1988
)
0.56
" Data on dose dependency or incidence concerning this side effect were not known."( A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C.
Funke-Küpper, AJ; Pinedo, HM; Teule, GJ; Verweij, J, 1988
)
0.51
" The disease might be due to a direct toxic effect of mitomycin C on the vascular endothelium."( [Nephrotoxicity of mitomycin C (apropos of 25 case reports). Results of a multicenter survey organized by the Society of Nephrology].
Alix, JL; Bayle, F; Cordonnier, D; Couderc, P; Vert-Pré, FC, 1985
)
0.85
" Agents which are preferentially toxic to cells with low oxygen contents could therefore be useful as adjuncts to the regimens now used to treat these cancers."( Porfiromycin as a bioreductive alkylating agent with selective toxicity to hypoxic EMT6 tumor cells in vivo and in vitro.
Keyes, SR; Rockwell, S; Sartorelli, AC, 1985
)
0.27
" These results indicate that JTX enhances the anti-tumor activity of MMC and lessens the adverse effects of it."( Protective effects of juzentaihoto, dried decoctum of 10 Chinese herbs mixture, upon the adverse effects of mitomycin C in mice.
Aburada, M; Hosoya, E; Ito, E; Nakamura, M; Takeda, S, 1983
)
0.48
" administration of trioxane produced no chromosomal damage resulting in erythrocyte micronucleus formation, even at highly toxic doses."( Genotoxic effects of dioxolane and trioxane in mice evaluated by the micronucleus test.
Dziubałtowska, E; Kowalski, Z; Przybojewska, B, 1984
)
0.27
" BMS-181174 was more toxic to all five cell lines in air than in hypoxia; in contrast, MC is more toxic in hypoxia."( Cytotoxicity of BMS-181174. Effects of hypoxia, dicoumarol, and repair deficits.
Kelley, M; Kemple, B; Rockwell, S, 1995
)
0.29
" No toxic death occurred."( Symptomatic, stage IV, non-small-cell lung cancer (NSCLC): response, toxicity, performance status change and symptom relief in patients treated with cisplatin, vinblastine and mitomycin-C.
Cellerino, R; Graziano, F; Isidori, P; Tummarello, D, 1995
)
0.48
" Other CBR substrates such as menadione, phenanthrenequinone, and doxorubicin were equally toxic to both the CBR expresser cells and the control cells under the conditions tested."( Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells.
Akman, S; Doroshow, J; Forrest, GL; Gonzalez, B; Kaplan, WD; Rivera, H, 1995
)
0.29
" We conclude that there is greater risk of toxic anterior segment effects when mitomycin C is used as adjunctive therapy following filtration or pterygium surgery."( Ocular toxicity of mitomycin C and 5-fluorouracil in the rabbit.
Feldman, F; Heathcote, JG; Ikeda-Douglas, JV; Morrow, GL; Stein, RM, 1994
)
0.84
"Since prolonged postoperative hypotony has been a frequent complication of glaucomatous filtration surgery in which mitomycin C (MMC) was used, it is important to determine the intraocular toxic effects of the drug."( Extraocular application of mitomycin C in a rabbit model: cytotoxic effects on the ciliary body and epithelium.
Addicks, K; Diestelhorst, M; Krieglstein, GK; Mietz, H, 1994
)
0.8
" Thus 5-fluorouracil appears to be toxic to fibroblasts while sparing vascular endothelial cells, whereas mitomycin C is cytotoxic for both cell types."( Comparative toxicity of mitomycin C and 5-fluorouracil in vitro.
D'Amore, PA; Dreyer, EB; Smith, S, 1994
)
0.81
" The nerves within the ciliary body in areas adjacent to the region of treatment showed toxic effects related to the concentrations of Mitomycin C applied."( Intraocular toxicity to ciliary nerves after extraocular application of mitomycin C in rabbits.
Addicks, K; Diestelhorst, M; Krieglstein, GK; Mietz, H, 1995
)
0.73
" Specifically, T-lineage cells show a high degree of resistance to the toxic effects of exposure to chemotherapeutic drugs, whereas B-lineage cells show a high degree of sensitivity."( Involvement of gene-specific DNA damage and apoptosis in the differential toxicity of mitomycin C analogs towards B-lineage versus T-lineage lymphoma cells.
Bloom, SE; Muscarella, DE, 1997
)
0.52
" PMA was about 3- or 5-fold more effective in inducing endoreduplication than CH3HgCl or Hg2+ at equivalent toxic concentrations, respectively."( Distinct genotoxicity of phenylmercury acetate in human lymphocytes as compared with other mercury compounds.
Lee, CH; Lin, RH; Lin-Shiau, SY; Liu, SH, 1997
)
0.3
"04% MMC thus showed no evident toxic effects on the function of the ciliary body and other pathological changes were minor."( [The cytotoxic effect of topical mitomycin C on the ciliary body in rabbits].
Araie, M; Hara, T; Obata, H; Shirato, S, 1998
)
0.58
" Adverse events were similar between groups (P = ."( The efficacy and safety of diclofenac 0.1% versus prednisolone acetate 1% following trabeculectomy with adjunctive mitomycin-C.
Cate, EA; Dubiner, HB; Kent, AR; Mundorf, TK; Stewart, JA; Stewart, WC; Whitaker, R, 1998
)
0.51
" We show that Aag protects against the toxic and clastogenic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea and mitomycin C (MMC), as measured by cell killing, sister chromatid exchange, and chromosome aberrations."( Mammalian 3-methyladenine DNA glycosylase protects against the toxicity and clastogenicity of certain chemotherapeutic DNA cross-linking agents.
Allan, JM; Dreslin, AJ; Engelward, BP; Samson, LD; Tomasz, M; Wyatt, MD, 1998
)
0.51
" In the standard alkaline comet assay, only MMC induced a slight increase in DNA migration at high toxic concentrations."( Detection of crosslinks with the comet assay in relationship to genotoxicity and cytotoxicity.
Merk, O; Speit, G, 1999
)
0.3
" Upon administration of ifosfamide, the P450 enzyme converts the ifosfamide into antitumorigenic toxic metabolites at the site required, thereby significantly reducing tumor burden."( Characterization of a human cell clone expressing cytochrome P450 for safe use in human somatic cell therapy.
Günzburg, WH; Karle, P; Renner, M; Renz, R; Salmons, B, 1999
)
0.3
" The system's ability to monitor the possible upsets or accidental discharges of toxic chemicals was also evaluated with these step insults."( A two-stage minibioreactor system for continuous toxicity monitoring.
Gil, GC; Gu, MB; Kim, JH, 1999
)
0.3
" In this study, the toxic effects of mitomycin-C on cultured porcine keratocytes and endothelial cells were estimated by MTT, 3H-thymidine uptake and cellular counting assay methods."( Toxic effects of mitomycin-C on cultured corneal keratocytes and endothelial cells.
Chen, CW; Hong, SJ; Huang, HT; Lin, CP; Wu, KY, 1999
)
0.92
"Topical mitomycin C appears to be safe and effective at prolonging the duration of myringotomy patency in the guinea pig."( Safety and efficacy of topical mitomycin C in myringotomy patency.
Buchman, CA; Gomez-Marin, O; Jassir, D, 2001
)
1.03
" In order to characterize the hypotony mechanism, we compared the toxic effects of mitomycin-C on cultured rabbit ciliary process cells and trabecular meshwork cells."( Toxic effects of mitomycin-C on cultured ciliary process cells and trabecular meshwork cells.
Hong, SJ; Lai, YH; Wang, HZ; Wu, KY, 2001
)
0.88
" The sensitivity, however, for all the strains to step injections of the toxic chemicals was found to increase with an increase in the dilution rate up to a certain dilution rate and then decreased, mainly due to the rapid washing out of the injected chemicals."( Enhancing the sensitivity of a two-stage continuous toxicity monitoring system through the manipulation of the dilution rate.
Gil, GC; Gu, MB; Kim, JH, 2002
)
0.31
"These findings suggest a toxic effect of MMC on the NECs of ciliary body, possibly that can decrease the aqueous production and intraocular pressure, even causing persistent hypotony."( [Cytotoxic effect of mitomycin C on the nonpigmented epithelium of ciliary body in rabbit eyes].
Huang, P; Jiang, Y; Wen, J; Wu, Z; Xia, X; Zeng, Q, 1998
)
0.62
" Changes in laboratory data and frequency of the occurrence of the adverse effects were compared between patients aged 75 (n = 5) or more and those aged 74 or less (n = 14)."( [Audit of the safety of hepatic arterial infusion of degradable starch microspheres (DSM). Adriamycin (ADM).mitomycin C (MMC) on aged patients with liver metastases of colorectal cancer].
Hashimoto, D; Ishida, H; Kashimada, A; Kuwabara, K; Matumoto, Y; Miura, T; Osada, H; Takeuchi, I, 2002
)
0.53
"It was found that the toxic effect of MMC on the cells was in a dose-dependent mode."( A study of toxic effect of mitomycin C on cultured bovine trabecular meshwork cells.
Jiang, F; Lu, Y; Wei, H; Zhang, Y; Zhou, Y, 2000
)
0.6
" The use of topical azelastine did not cause any adverse event."( Efficacy and safety of topical azelastine compared with topical mitomycin C in patients with allergic conjunctivitis.
Pandey, RM; Ratan, SK; Sodhi, PK, 2003
)
0.56
" The use of topical MMC in low doses does not cause any significant adverse effect."( Efficacy and safety of topical azelastine compared with topical mitomycin C in patients with allergic conjunctivitis.
Pandey, RM; Ratan, SK; Sodhi, PK, 2003
)
0.56
"The 3 concentrations of viscoanesthetic solutions appeared to be safe to rabbit corneal endothelium."( Viscoanesthesia. Part I: toxicity to corneal endothelial cells in a rabbit model.
Apple, DJ; Izak, AM; Macky, TA; Pandey, SK; Trivedi, RH; Werner, L, 2003
)
0.32
"Electron microscopy revealed toxic effects in the epithelium of the ciliary body of all treatment groups."( Toxic effects of subconjunctival 5-fluorouracil and mitomycin C on ciliary body of rats.
Kachko, L; Klemperer, I; Levy, J; Lifshitz, T; Rosenthal, G; Tessler, Z; Zirkin, HJ, 2001
)
0.56
"This study demonstrates that subconjunctival antimetabolites mitomycin C and 5-fluorouracil can penetrate the sclera and exert toxic effects on the epithelium of the ciliary body, even in low doses."( Toxic effects of subconjunctival 5-fluorouracil and mitomycin C on ciliary body of rats.
Kachko, L; Klemperer, I; Levy, J; Lifshitz, T; Rosenthal, G; Tessler, Z; Zirkin, HJ, 2001
)
0.8
" This increase in bioluminescence followed a dose dependent response to the toxic chemicals within a specific concentration range."( A bioluminescent sensor for high throughput toxicity classification.
Gu, MB; Kim, BC, 2003
)
0.32
"The antitumor and toxic side effects of mitomycin C-estradiol conjugates (EB-glu-MMC and E-glu-MMC) were evaluated in detail for solutions in propylene glycol and suspensions in 10% (v/v) propylene glycol."( Evaluation of antitumor and toxic side effects of mitomycin C-estradiol conjugates.
Ishiki, N; Machida, Y; Onishi, H, 2004
)
0.84
" One pneumothorax occurred and was treated by chest tube placement, without any adverse sequelae."( Feasibility and safety of airway bypass stent placement and influence of topical mitomycin C on stent patency.
Choong, CK; Cooper, JD; Gee, EY; Haddad, FJ, 2005
)
0.55
"The results of this study indicate that topical mitomycin C on Gelfoam applied in the middle ear appears safe when low concentrations are used, even in the rat, which has a higher susceptibility to gentamycin toxicity than humans."( Otologic effects of topical mitomycin C: phase I-evaluation of ototoxicity.
Babu, SC; Kartush, JM; Patni, A, 2005
)
0.88
"These findings suggest that complete removal of all Tenon's membrane in the affected quadrant combined with topical MMC in the aforementioned dose is a safe method of pterygium excision with a low rate of recurrence and pyogenic granuloma formation."( Safety and efficacy of the technique of complete tenon's membrane excision and mitomycin C in pterygium surgery.
Jacobson, L; Levy, RL; Naidu, S, 2005
)
0.56
", without system interruption due to highly toxic samples."( A multi-channel continuous water toxicity monitoring system: its evaluation and application to water discharged from a power plant.
Gu, MB; Kim, BC, 2005
)
0.33
" Several lines of evidence argue that mutant SOD1 causes ALS by a toxic gain of function."( Inhibition of SOD1 expression by mitomycin C is a non-specific consequence of cellular toxicity.
Ay, I; Broom, WJ; Brown, RH; Pasinelli, P, 2006
)
0.62
"This large series contributes to literature that MMC is a safe adjunct to laryngotracheal surgery."( Mitomycin-c application in airway stenosis surgery: analysis of safety and costs.
Ettema, SL; Merati, AL; Simpson, CB; Toohill, RJ; Ubell, ML, 2006
)
1.78
"Mitomycin-c seems to be safe and cost-effective in endoscopic airway surgery."( Mitomycin-c application in airway stenosis surgery: analysis of safety and costs.
Ettema, SL; Merati, AL; Simpson, CB; Toohill, RJ; Ubell, ML, 2006
)
3.22
" The postoperative mortality rate was 0%; adverse events occurred in 18 (51%) patients."( Toxicity and quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy.
Greeno, E; Knutsen, A; Tuttle, TM; Zhang, Y, 2006
)
0.33
"Intra-arterial chemotherapy is an effective and safe treatment for locally advanced breast cancer in the elderly."( Intra-arterial chemotherapy: a safe treatment for elderly patients with locally advanced breast cancer.
Cantore, M; Della Seta, R; Fiorentini, G; Mambrini, A; Muttini, MP; Pacetti, P; Palmieri, B; Paolucci, R; Sanguinetti, F,
)
0.13
" Results can be achieved within 1 day and are less susceptible to possible toxic effects than phage generation or other methods that require DNA synthesis."( New method for evaluation of genotoxicity, based on the use of real-time PCR and lysogenic gram-positive and gram-negative bacteria.
Martín, R; Soberón, N; Suárez, JE, 2007
)
0.34
" These specific ocular side effects are described, caution being taken to precise the strength of the association between each side effect and the related drug by using the classification of World Health Organisation (WHO) (certain, probable, possible or unlikely)."( [Ocular side effects of glaucoma treatment agents].
Bremer, F; Ehongo, A, 2007
)
0.34
" Regions of the Krasnodar Krai where sea and fresh waters exerted toxic action on luminescence were determined by the microbioluminescent method."( [Microbioluminescent study of the general toxicity and mutagenicity of pollutants].
Goliasnaia, NV; Maslennikova, IL,
)
0.13
" Mitomycin-C is cytotoxic, and a safe endoluminal delivery system that avoids inadvertent application to adjacent mucosa has not yet been described."( Topical mitomycin-C for recalcitrant esophageal strictures: a novel endoscopic/fluoroscopic technique for safe endoluminal delivery.
Baird, R; Blair, GK; Heran, MK; Skarsgard, ED, 2008
)
1.69
"Trabeculectomy with mitomycin is safe and effective for short-term or long-term treatment of congenital or developmental glaucoma."( Efficacy and safety of trabeculectomy with mitomycin C for childhood glaucoma: a study of results with long-term follow-up.
Borges-Giampani, AS; Carani, JC; Giampani, J; Oltrogge, EW; Susanna, R, 2008
)
0.93
"The primary objective of this study was to determine if intraoperative application of mitomycin C (MMC) is safe as an adjunct for pterygium surgery."( Efficacy and safety of intraoperative mitomycin C as adjunct therapy for pterygium surgery.
Díaz, L; Emanuelli, A; Izquierdo, NJ; Villegas, VM, 2008
)
0.84
"Findings in our study suggest that MMC is efficacious in preventing recurrences and a safe adjunct therapy during pterygium surgery."( Efficacy and safety of intraoperative mitomycin C as adjunct therapy for pterygium surgery.
Díaz, L; Emanuelli, A; Izquierdo, NJ; Villegas, VM, 2008
)
0.62
"The scleral punch provides a safe and effective method for constructing and revising full-thickness sclerectomies in the nanophthalmic eye, minimizing the risk of choroidal trauma."( Scleral punch method with topical mitomycin C for safe revision of failed deep sclerectomy in nanophthalmic uveal effusion syndrome.
MacLaren, RE; Sabrosa, NA; Smith, HB, 2009
)
0.63
" Although injection remained as a cosmetic concern, it was a safe alternative to limbal-conjunctival autograft in cases where mobilizing autologous conjunctival tissue would not be feasible."( Prospective study on the safety and efficacy of combined conjunctival rotational autograft with intraoperative 0.02% mitomycin C in primary pterygium excision.
Cheng, LL; Lam, DS; Lam, PT; Leung, GY; Tam, PM; Young, AL, 2009
)
0.56
"In this large pooled analysis, we found MMC, when capped at a cumulative dose of 36 mg/m(2), to be safe and tolerable in combination with capecitabine or irinotecan with no reportable cases of TTP/HUS."( Capped-dose mitomycin C: a pooled safety analysis from three prospective clinical trials.
Arce-Lara, C; Bekaii-Saab, T; Cataland, S; Kraut, E; Ntukidem, N; Otterson, GA, 2010
)
0.74
" The results of this study demonstrate that Cd has both toxic and genotoxic potential in bone marrow and only genotoxic potential in peripheral blood."( Assessment of cadmium genotoxicity in peripheral blood and bone marrow tissues of male Wistar rats.
Büyükakilli, B; Celik, A; Cimen, B; Eke, D; Oztürk, MI; Taşdelen, B, 2009
)
0.35
" The ADP1_recA_lux was used to detect a variety of toxic or potentially toxic compounds including mitomycin C (MMC), methyl methanesulfonate, ethidium bromide, H2O2, toluene, single-wall nanocarbon tubes (SWNCT), nano Au colloids (20 nm), pyrene, beno[a]pyrene, and UV light."( Optimization of bacterial whole cell bioreporters for toxicity assay of environmental samples.
Banwart, SA; Huang, WE; Lerner, DN; Li, G; Song, Y; Thompson, IP; Thornton, SF, 2009
)
0.57
" We examined the administration sequence of combining 5FU with MMC to maximize toxicity against a human gastric cancer cell line, and then investigated the possible molecular mechanisms underlying the observed toxic effects."( Toxicity against gastric cancer cells by combined treatment with 5-fluorouracil and mitomycin c: implication in oxidative stress.
Alpers, DH; Hara, A; Hirayama, R; Kaai, K; Kohno, S; Komoda, T; Matsunaga, T; Tsuji, Y, 2010
)
0.59
"Pretreatment for 24 h with 5FU augmented the toxic effect of MMC in MKN45 cells."( Toxicity against gastric cancer cells by combined treatment with 5-fluorouracil and mitomycin c: implication in oxidative stress.
Alpers, DH; Hara, A; Hirayama, R; Kaai, K; Kohno, S; Komoda, T; Matsunaga, T; Tsuji, Y, 2010
)
0.59
" Main adverse events grades 2/3/4 were (n): leukocytopenia 3/2/2, anemia 13/4/0, thrombocytopenia 3/1/0, nausea/vomiting 2/1/0, diarrhea 5/1/0, hand-foot-skin reaction 7/0/0."( Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma.
Ernst, T; Hochhaus, A; Hofheinz, RD; Hofmann, WK; Kripp, M; Kruth, J; Lukan, N; Merx, K; Nissen, J, 2010
)
0.59
"PRK with MMC was safe after one year of follow-up for the reduction of hyperopia after radial keratotomy."( [Safety of photorefractive keratectomy with mitomycin-C for the treatment of hyperopia after radial keratotomy].
Ghanem, EA; Ghanem, RC; Kara-José, N,
)
0.39
" In contrast, 2-aromatic ring substituted (benzimidazole-4,7-diones) analogues, benzimidazolequinone with a pyridine ring and mitomycin C were more toxic than the highly conjugated naphthyl fused benzimidazolequinone towards the normal cell line."( Synthesis and toxicity towards normal and cancer cell lines of benzimidazolequinones containing fused aromatic rings and 2-aromatic ring substituents.
Aldabbagh, F; Bonham, S; Carr, M; Carty, MP; Moriarty, E, 2010
)
0.57
"Needling revision with adjunctive MMC is effective for reviving flat filtering blebs and controlling IOP, even several years after the original trabeculectomy, and seems to be safe for the corneal endothelium."( Late needling of flat filtering blebs with adjunctive mitomycin C: efficacy and safety for the corneal endothelium.
Cronemberger, S; Diniz, AF; Ferreira, GA; Filho, AD; Maestrini, HA; Matoso, HD; Mérula, RV; Reis, JR; Sakurai, E, 2011
)
0.62
"One of the key obstacles against the success in cancer chemotherapy is the toxic and side effects of the chemotherapeutic agents."( Using activated carbon nanoparticles to decrease the genotoxicity and teratogenicity of anticancer therapeutic agents.
Shuzheng, M; Yingge, Z; Zhong, Y, 2010
)
0.36
" These hematologic adverse events persisted for 9 months and resolved after discontinuation of chemotherapy followed by multiple courses of oral corticosteroids."( Mitomycin--C-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: cumulative toxicity of an old drug in a new era.
Chu, E; El-Ghazal, R; Marks, P; Podoltsev, N; Saif, MW, 2011
)
1.81
" The time of reccurrence and adverse effects were recorded."( [Evaluation of the efficacy and safety of intravesical instillation with gemcitabine after first-line intravesical chemotherapy failure in the treatment of non-muscle-invasive bladder cancer].
Cao, M; Chen, HG; Ma, CK; Ma, J; Xue, W, 2011
)
0.37
"Nephrotoxicity is an inherent adverse effect of certain anticancer drugs and may result in a variety of functional consequences that include any combination of glomerular or tubular dysfunction, hypertension and disturbance of the renal endocrine function."( Nephrotoxicity of anticancer drugs--an underestimated problem?
Kruse, V; Lameire, N; Rottey, S,
)
0.13
"The morbidity of abdominal and pelvic SFP performed on a miscellaneous group of patients in our institute was analyzed and potential risk factors for adverse events were evaluated."( Complications and toxicity after abdominal and pelvic hypoxic stop-flow perfusion chemotherapy: incidence and assessment of risk factors.
Askoxylakis, J; de Bree, E; Melissas, J; Metaxari, M; Michalakis, J; Romanos, J; Tsiftsis, DD; Tsogkas, J; Volakakis, E, 2012
)
0.38
" In total, 28 adverse effects were observed after 30% of the procedures."( Complications and toxicity after abdominal and pelvic hypoxic stop-flow perfusion chemotherapy: incidence and assessment of risk factors.
Askoxylakis, J; de Bree, E; Melissas, J; Metaxari, M; Michalakis, J; Romanos, J; Tsiftsis, DD; Tsogkas, J; Volakakis, E, 2012
)
0.38
"Still there is no consensus on the choice of the most efficient and the least toxic chemotherapy regimen in the treatment of advanced gastric cancer."( [Evaluation of the efficacy and toxicity of protocol cisplatin, 5-fluorouracil, leucovorin compared to protocol fluorouracil, doxorubicin and mitomycin C in locally advanced and metastatic gastric cancer].
Andrić, Z; Crevar, S; Gutović, J; Kostić, S; Kovčin, V; Murtezani, Z; Randjelović, T,
)
0.33
" These features of the pluripotent stem cells are the major issue for development of safe cell therapy technologies based on pluripotent stem cells."( [Antiproliferative and cytotoxic effects of different type cytostatics on mouse pluripotent stem and teratocarcinoma cells].
Gordeeva, OF,
)
0.13
" Additional postoperative treatments, such as bleb needling, and adverse events were secondary outcomes."( Efficacy and safety of collagen matrix implants in phacotrabeculectomy and comparison with mitomycin C augmented phacotrabeculectomy at 1 year.
Aung, T; Hoh, ST; Htoon, HM; Narayanaswamy, A; Perera, SA; Seah, SK; Wong, TT, 2013
)
0.61
" There was similar frequency (<10%) of adverse events in both groups, and there were no complications directly related to the Ologen implant."( Efficacy and safety of collagen matrix implants in phacotrabeculectomy and comparison with mitomycin C augmented phacotrabeculectomy at 1 year.
Aung, T; Hoh, ST; Htoon, HM; Narayanaswamy, A; Perera, SA; Seah, SK; Wong, TT, 2013
)
0.61
" The 90-day subchronic study (500, 1000 and 2000mg/kg body weight, delivered by gavage) in rats reported no significant adverse effects in food consumption, body weight, mortality, urinalysis, hematology, biochemistry, necropsy, organ weight and histopathology."( Toxicological assessment of enzyme-treated asparagus extract in rat acute and subchronic oral toxicity studies and genotoxicity tests.
Goto, K; Ito, T; Maeda, T; Miura, T; Nishioka, H; Ono, T; Sato, A; Wakame, K, 2014
)
0.4
" In conclusion, even after particle therapy, PIHP is a safe treatment and is associated with a good local control rate for remnant HCCs."( [Analysis of the safety and efficacy of percutaneous isolated hepatic perfusion after particle therapy for advanced hepatocellular carcinoma].
Ajiki, T; Demizu, Y; Fujii, O; Fukumoto, T; Fukushima, K; Fuwa, N; Kido, M; Kinoshita, H; Komatsu, S; Ku, Y; Kuramitsu, K; Matsumoto, I; Shinzeki, M; So, S; Takebe, A; Tanaka, M; Terashima, K; Urade, T, 2013
)
0.39
"COS-MMC is a safe and effective adjunctive modality in DCR."( Circumostial injection of mitomycin C (COS-MMC) in external and endoscopic dacryocystorhinostomy: efficacy, safety profile, and outcomes.
Ali, MJ; Kamal, S; Naik, MN,
)
0.43
" The concurrent administration of LP with AFM1 strongly reduced the adverse effects of AFM1 on each parameter."( Potential preventive role of lactic acid bacteria against aflatoxin M₁ immunotoxicity and genotoxicity in mice.
Abbès, S; Ben Salah-Abbès, J; Haous, Z; Jebali, R; Oueslati, R,
)
0.13
"MMC-augmented revision appears to be a safe and useful tool in reducing intraocular pressure after trabeculectomy failure."( Efficacy and safety of mitomycin C--augmented revisions of non-functioning filtering blebs after trabeculectomy--7 year results.
Kosior-Jarecka, E; Tomaszewska, J; Tulidowicz-Bielak, M; Zarnowski, T, 2013
)
0.7
" Nanocarriers may be a promising alternative for prolonged, effective and safe intravesical drug delivery due to their favorable size, surface properties and optimum interaction with mucosal layer of the bladder wall."( Cationic core-shell nanoparticles for intravesical chemotherapy in tumor-induced rat model: safety and efficacy.
Bilensoy, E; Erdogar, N; Eroglu, H; İskit, AB; Mungan, NA; Sargon, MF, 2014
)
0.4
"The severity of the toxic side effects of chemotherapy shows a great deal of interindividual variability, and much of this variation is likely genetically based."( Using Drosophila melanogaster to identify chemotherapy toxicity genes.
King, EG; Kislukhin, G; Long, AD; Walters, KN, 2014
)
0.4
"Trabeculectomy is a safe and effective method for achieving single-digit IOP targets in NTG eyes with progression at low IOP."( Safety And Efficacy Of Achieving Single-Digit Intraocular Pressure Targets With Filtration Surgery In Eyes With Progressive Normal-Tension Glaucoma.
Greenfield, DS; Iverson, SM; Schultz, SK; Shi, W, 2016
)
0.43
"Postoperative EMDA with mitomycin is a safe procedure."( [Non-muscle invasive bladder cancer: safety of postoperative EMDA-assisted instillation of mitomycin].
Niedworok, C; Rehme, C; Rübben, H; Vom Dorp, F, 2015
)
0.94
" Adverse effects on the gastrointestinal tract also were lower than in controls (p<0."( Safety of Brucea javanica and cantharidin combined with chemotherapy for treatment of NSCLC patients.
Huang, XE; Ji, ZQ; Liu, J; Tang, JH; Wang, L; Wu, XY, 2014
)
0.4
"Bevacizumab could be a safe and effective anti-scarring agent; however IOP reduction appears to be greater with MMC, and also less antiglaucoma medications are needed with this anti-scarring agent."( [Comparison study on the efficacy and safety of bevacizumab versus mitomycin C as adjuvants in trabeculectomy].
Martín Giral, E; Perucho Martínez, S; Rivera Zori, M; Toledano Fernández, N, 2015
)
0.65
"To determine the efficacy of safe surgery system trabeculectomy combined with manual small incision cataract surgery/phacoemulsification in primary glaucoma coexistent with cataract."( Surgical outcome of safe surgery system trabeculectomy combined with cataract extraction.
Agashe, A; Khandelwal, R; Khandelwal, RR; Majumdar, M; Raje, D; Rathi, A, 2015
)
0.42
" Safe surgery system trabeculectomy with diffuse and posterior application of mitomycin C was performed in all cases."( Surgical outcome of safe surgery system trabeculectomy combined with cataract extraction.
Agashe, A; Khandelwal, R; Khandelwal, RR; Majumdar, M; Raje, D; Rathi, A, 2015
)
0.65
" The overall success rates (with or without medication) when safe surgery system trabeculectomy was combined with MSICS were 91, 70, and 51% for IOP ≤18, ≤15, and ≤12 mm Hg, respectively, and target IOP was achieved in 72% cases."( Surgical outcome of safe surgery system trabeculectomy combined with cataract extraction.
Agashe, A; Khandelwal, R; Khandelwal, RR; Majumdar, M; Raje, D; Rathi, A, 2015
)
0.42
"The Safe Surgery System Trabeculectomy combined with cataract surgery offers excellent IOP control with minimal postoperative complications."( Surgical outcome of safe surgery system trabeculectomy combined with cataract extraction.
Agashe, A; Khandelwal, R; Khandelwal, RR; Majumdar, M; Raje, D; Rathi, A, 2015
)
0.42
" EE-DCR with adjunctive MMC and TA is a safe and successful procedure for the treatment of NLDO."( Safety and efficacy of adjunctive intranasal mitomycin C and triamcinolone in endonasal endoscopic dacryocystorhinostomy.
Cheng, AC; Li, EY; Sze, AM; Wong, AC; Yuen, HK, 2016
)
0.69
" There were no sight-threatening long-term adverse events."( [One-year results on the safety and efficacy of the InnFocus MicroShunt™ depending on placement and concentration of mitomycin C].
Batlle, J; Kato, YP; Parel, JM; Pinchuk, L; Riss, I; Weber, BA, 2015
)
0.63
"The purpose of this study is to evaluate the fluctuations of coagulation parameters during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) and confirm beyond doubt that epidural anaesthesia is safe with this type of operations."( Lack of significant intraoperative coagulopathy in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) indicates that epidural anaesthesia is a safe option.
Alevizos, L; Daskalou, T; Eleftheriadis, S; Iatrou, C; Korakianitis, O; Mavroudis, C; Stamou, K; Tentes, AA; Vogiatzaki, T, 2015
)
0.42
"Our results support the belief that epidural analgesia is a safe option in cytoreductive surgery and HIPEC despite certain intraoperative fluctuations in coagulation parameters."( Lack of significant intraoperative coagulopathy in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) indicates that epidural anaesthesia is a safe option.
Alevizos, L; Daskalou, T; Eleftheriadis, S; Iatrou, C; Korakianitis, O; Mavroudis, C; Stamou, K; Tentes, AA; Vogiatzaki, T, 2015
)
0.42
"Contact dermatitis of non-allergic origin is a common side effect described in many instances in the literature, on the other hand exists dermatitis secondary to delayed hypersensitivity type IV much less common, requiring treatment with corticosteroids."( Dermatological side effects of intravesical Mitomycin C: Delayed hypersensitivity.
Castillo Pacheco, C; Colomer Gallardo, A; González Satue, C; Ibarz Servio, L; Martínez Rodríguez, R, 2016
)
0.7
" Conclusions HT with daily IGRT is efficacious and safe in the treatment of anal canal cancer patients, and is considered in our department standard of care in this clinical setting."( Efficacy and safety of helical tomotherapy with daily image guidance in anal canal cancer patients.
Bouchaab, H; Bourhis, J; De Bari, B; Hanhloser, D; Jumeau, R; Matzinger, O; Mirimanoff, RO; Ozsahin, EM; Troussier, I; Vallet, V; Wagner, AD, 2016
)
0.43
" The primary endpoint was recurrence-free survival, and secondary endpoints were progression-free survival and adverse events."( Randomized controlled study of the efficacy and safety of continuous saline bladder irrigation after transurethral resection for the treatment of non-muscle-invasive bladder cancer.
Masui, S; Onishi, T; Sasaki, T; Shibahara, T; Sugino, Y; Yabana, T, 2017
)
0.46
" The incidence of adverse events was significantly lower in the CSBI group."( Randomized controlled study of the efficacy and safety of continuous saline bladder irrigation after transurethral resection for the treatment of non-muscle-invasive bladder cancer.
Masui, S; Onishi, T; Sasaki, T; Shibahara, T; Sugino, Y; Yabana, T, 2017
)
0.46
" Management of these adverse effects is reviewed, as are future directions in anal cancer treatment and their impact on toxicity."( Evolution and Management of Treatment-Related Toxicity in Anal Cancer.
Czito, BG; Kachnic, LA; Ludmir, EB, 2017
)
0.46
" Herein, we fabricated a safe delivery system of iPS cells treated with MMC loading with gold nanorods (AuNRs) for the targeted photothermal treatment of gastric cancer."( Mitomycin C-treated human-induced pluripotent stem cells as a safe delivery system of gold nanorods for targeted photothermal therapy of gastric cancer.
Cui, D; Hou, W; Jiang, X; Liu, Y; Ni, J; Pan, F; Yang, M; Yang, Y; Zhang, C; Zhi, X, 2017
)
1.9
" No mortality, clinical adverse events, or meaningful changes in hematology, chemistry, coagulation, or urinalysis were attributable to MitoGel, RTGel alone, or water instillations."( Serial retrograde instillations of sustained release formulation of mitomycin C to the upper urinary tract of the Yorkshire swine using a thermosensitive polymer: Safety and feasibility.
Agmon-Gerstein, Y; Belldegrun, AS; Chamie, K; Donin, NM; Holden, S; Lenis, AT; Malchi, N; Pantuck, AJ; Strauss-Ayali, D, 2017
)
0.69
"Serial retrograde instillations of MitoGel to the pyelocaliceal system were technically feasible, and produced no observable adverse clinical, laboratory, or histologic effects."( Serial retrograde instillations of sustained release formulation of mitomycin C to the upper urinary tract of the Yorkshire swine using a thermosensitive polymer: Safety and feasibility.
Agmon-Gerstein, Y; Belldegrun, AS; Chamie, K; Donin, NM; Holden, S; Lenis, AT; Malchi, N; Pantuck, AJ; Strauss-Ayali, D, 2017
)
0.69
" Nausea and vomiting occurred as adverse event (AE) in eight out of 25 treatments (32%), with seven of eight events (87."( Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in Intrahepatic Cholangiocellular Carcinoma (ICC): Results from a National Multi-Center Study on Safety and Efficacy.
Albrecht, T; Michalik, K; Nolte-Ernsting, C; Pereira, PL; Pützler, M; Schicho, A; Stroszczynski, C; Wiggermann, P, 2017
)
0.46
" A single subconjunctival injection of MMP inhibitor during the experimental trabeculectomy showed a less toxic affect in the rabbit cornea, conjunctiva, and ciliary body compared to MMC."( Safety of Using Matrix Metalloproteinase Inhibitor in Experimental Glaucoma Filtration Surgery.
Han, JR; Han, KE; Suh, W, 2017
)
0.46
" This secondary analysis was performed to identify patient and treatment factors associated with acute and late gastrointestinal (GI) adverse events (AEs)."( Predictors of Radiation Therapy-Related Gastrointestinal Toxicity From Anal Cancer Dose-Painted Intensity Modulated Radiation Therapy: Secondary Analysis of NRG Oncology RTOG 0529.
Abitbol, A; Chang, A; Chen, Y; Crane, CH; Doncals, DE; Fisher, B; Johnson, D; Kachnic, L; Michalski, J; Moughan, J; Myerson, R; Narayan, S; Olsen, JR; Schefter, TE, 2017
)
0.46
"HAIC offers a safe and effective salvage treatment strategy in heavily pretreated patients with LMBC and no further treatment options."( Hepatic arterial infusion chemotherapy for extensive liver metastases of breast cancer: efficacy, safety and prognostic parameters.
Bogner, S; Peis, MW; Reinboldt, MP; Schuler, M; Tewes, M; Theysohn, JM; Welt, A, 2017
)
0.46
" Four patients experienced grade 1 or 2 adverse events."( Feasibility and safety of hyperthermic intraperitoneal chemotherapy using 5-fluorouracil combined with cisplatin and mitomycin C in patients undergoing gastrectomy for advanced gastric cancer.
Kaida, S; Murata, S; Naitoh, H; Naka, S; Shimizu, T; Shiomi, H; Tani, M; Tani, T; Yamaguchi, T; Yamamoto, H, 2017
)
0.66
" No adverse events were reported."( Mitomycin-C and urethral dilatation: A safe, effective, and minimally invasive procedure for recurrent vesicourethral anastomotic stenoses.
Bettez, M; Jundi, M; Richard, PO; Sourial, MW; Tu, LM, 2017
)
1.9
"A major problem with cancer chemotherapy is its severe toxic effects on non-target tissues."( Heated naringin mitigate the genotoxicity effect of Mitomycin C in BALB/c mice through enhancing the antioxidant status.
Chaaban, H; Chekir-Ghedira, L; Ghedira, K; Ghoul, M; Ioannou, I; Maatouk, M; Mokdad-Bzeouich, I; Mustapha, N, 2018
)
0.73
" The aim of this study was to investigate the possibility of diminishing the side effect of mitomycin C by using pH-sensitive liposomes."( Diminishing the side effect of mitomycin C by using pH-sensitive liposomes: in vitro characterization and in vivo pharmacokinetics.
Fang, YP; Hu, PY; Huang, YB, 2018
)
0.99
"For Taiwanese children, the combined trabeculotomy-trabeculectomy using the modified Safer Surgery System offered an efficient and safe surgical option for treating glaucoma with long-term satisfactory control of IOP."( Combined trabeculotomy-trabeculectomy using the modified Safer Surgery System augmented with MMC: its long-term outcomes of glaucoma treatment in Asian children.
Chen, YH; Hsu, CR; Lu, DW; Tai, MC, 2018
)
0.48
" Patient acute gastrointestinal toxicity was recorded using Common Terminology Criteria of Adverse Events (CTCAE) diarrhoea grading."( Intensity-modulated Radiotherapy for Anal Cancer: Dose-Volume Relationship of Acute Gastrointestinal Toxicity and Disease Outcomes.
Amor, H; Blakey, D; Chao, M; Guerrieri, M; Guiney, M; Ho, H; Macleod, C; Melven, L; Ng, M; Skelton, J; Subramanian, B, 2018
)
0.48
"Our results suggest that the use of IMRT decreases acute and chronic adverse effects although reduced QoL also occurred in the IMRT group."( Chemoradiation in female patients with anal cancer: Patient-reported outcome of acute and chronic side effects.
Adeberg, S; Debus, J; Haefner, MF; Herfarth, K; Koerber, SA; Krug, D; Liermann, J; Seither, B; Slynko, A; Sterzing, F, 2019
)
0.51
"Using Ologen as drug depot for bevacizumab in a trabeculectomy (TE) with MMC is a safe and active surgical method without an increased risk of complications in comparison to pure TE with MMC or TE with MMC and Ologen implant."( [Trabeculectomy with Collagen Matrix Implant as Bevacizumab Depot: Clinical Results on Efficacy and Safety].
Heinz, C; Koch, JM; Lommatzsch, C; Rothaus, K, 2020
)
0.56
" Adverse events grade 3 and 4 were reported in 17."( Intra-arterial Mitomycin C infusion in a large cohort of advanced liver metastatic breast cancer patients: safety, efficacy and factors influencing survival.
Aarts, BM; Beets-Tan, RGH; Dresen, RC; Klompenhouwer, EG; Laenen, A; Maleux, G; Neven, P; Punie, K; Wildiers, H, 2019
)
0.87
"MMC infusion is safe and effective in advanced LMBC patients."( Intra-arterial Mitomycin C infusion in a large cohort of advanced liver metastatic breast cancer patients: safety, efficacy and factors influencing survival.
Aarts, BM; Beets-Tan, RGH; Dresen, RC; Klompenhouwer, EG; Laenen, A; Maleux, G; Neven, P; Punie, K; Wildiers, H, 2019
)
0.87
"The TC-coated silicone plate was more effective in inhibiting inflammation and fibrosis versus the MMC-coated silicone plate and was associated with fewer adverse effects in the rabbit model."( Safety and efficacy of tacrolimus-coated silicone plates as an alternative to mitomycin C in a rabbit model of conjunctival fibrosis.
Han, GS; Jung, HS; Kim, ES; Kim, JY; Suh, LH; Tchah, H; Yoon, SY, 2019
)
0.74
"CRS/HIPEC performed is a safe method with low perioperative mortality."( Evaluation and management of toxicity of cytoreductive surgery/hyperthermic intraperitoneal chemotherapy: the initial experience of a single centre study.
Flasarova, D; Havlik, R; Klos, D; Lemstrova, R; Lovecek, M; Melichar, B; Mohelnikova-Duchonova, B; Neoral, C; Spisarova, M, 2020
)
0.56
"This study is the largest series reported showing that topical application of MC is an efficient and safe treatment for recurrent esophageal stenosis in children."( Efficacy and Safety of the Local Application of Mitomycin C to Recurrent Esophageal Strictures in Children.
Bridenne, M; Fayoux, P; Gottrand, F; Hauser, B; Lachaux, A; Lemale, J; Ley, D; Michaud, L; Rebouissoux, L; Viala, J, 2019
)
0.77
"Hyperthermic Mitomycin using the HIVEC® device is a rather safe and well tolerated treatment."( [Safety of Hyperthermic IntraVEsical Chemotherapy (HIVEC) for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients].
Branger, N; Dermeche, S; Fakhfakh, S; Gravis, G; Marquette, T; Maubon, T; Pignot, G; Rybikowski, S; Verde, KL; Walz, J, 2020
)
0.93
" The study is to analyze the incidence of perioperative serious adverse events (SAEs) of CRS + HIPEC to treat PMP patients, and identify the risk factors, for guiding the prevention of SAEs."( Perioperative safety after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal origin: Experience on 254 patients from a single center.
Chen, LF; Ji, ZH; Li, XB; Li, Y; Lin, YL; Ma, R; Yan, FC; Yang, ZR; Zhang, J, 2020
)
0.56
" Patient demographics, the timing of MMC instillation, adverse events (surgical and potentially MMC-related) and length of stay (LOS) were assessed according to the Clavien-Dindo classification."( Safety and feasibility of early single-dose mitomycin C bladder instillation after robot-assisted radical nephroureterectomy.
Barod, R; Bex, A; Cullen, D; Gulamhusein, A; Mumtaz, F; Patki, P; Silva, P; Tran, M, 2020
)
0.82
" No adverse events potentially related to MMC instillation were noted within 30 days postoperatively."( Safety and feasibility of early single-dose mitomycin C bladder instillation after robot-assisted radical nephroureterectomy.
Barod, R; Bex, A; Cullen, D; Gulamhusein, A; Mumtaz, F; Patki, P; Silva, P; Tran, M, 2020
)
0.82
"The use of intravesical MMC instillation given in the immediate postoperative period appears feasible and safe in patients undergoing RARNU with intraoperative confirmation of a water-tight closure ensuring early catheter-free discharge, with no significant adverse events."( Safety and feasibility of early single-dose mitomycin C bladder instillation after robot-assisted radical nephroureterectomy.
Barod, R; Bex, A; Cullen, D; Gulamhusein, A; Mumtaz, F; Patki, P; Silva, P; Tran, M, 2020
)
0.82
"Convective bladder hyperthermia using the Combat BRS device is safe and the temperature can be maintained at 43 °C."( Safety and efficacy of intravesical chemotherapy and hyperthermia in the bladder: results of a porcine study.
Brousell, SC; Chang, A; Etienne, W; Fantony, JJ; Grimberg, DC; Inman, BA; Longo, TA; Maccarini, P; Spasojevic, I; Tan, WP, 2020
)
0.56
" We evaluated QoL and adverse events (AE) in this 3-arm observational study."( Quality of life and adverse events in patients with nonmuscle invasive bladder cancer receiving adjuvant treatment with BCG, MMC, or chemohyperthermia.
Corona-laPuerta, M; García-Jarabo, E; González-Díaz, A; González-Padilla, DA; Guerrero-Ramos, F; Rodríguez-Antolín, A; Rodríguez-Serrano, A; Villacampa-Aubá, F, 2021
)
0.62
"IVC injection of conbercept combined with trabeculectomy is effective and safe for the treatment of NVG."( The efficacy and safety of intravitreal conbercept combined with mitomycin C augmented trabeculectomy for treating neovascular glaucoma.
Gao, Z; Jia, Y; Jiang, S; Xue, S,
)
0.37
" Suberanilohydroxamic acid (SAHA) however has been proposed to prevent corneal haze without any adverse effects."( Safety and efficacy of combination of suberoylamilide hydroxyamic acid and mitomycin C in reducing pro-fibrotic changes in human corneal epithelial cells.
Dadachanji, ZV; Das, D; Ghosh, A; Khamar, P; Krishna, L; Kumar, NR; Matalia, H; Mohan, RR; Murugeswari, P; Shetty, R; Subramani, M, 2021
)
0.85
"Sub-Tenon injection of MMC during trabeculectomy seems to be as safe and as efficacious as conventional application of MMC with sponges at 1 year after surgery."( One-Year Randomized Comparison of Safety and Efficacy of Trabeculectomy with Mitomycin C Sub-Tenon Injection versus Mitomycin C-Infused Sponges.
Diagourtas, A; Georgalas, I; Ifantides, C; Kandarakis, SA; Papakonstantinou, E; Petrou, P; Serle, J,
)
0.36
" Additional end points at year 2 included IOP reduction, success, glaucoma medications, adverse events (AEs), and reoperations."( Safety and Effectiveness of the PRESERFLO® MicroShunt in Primary Open-Angle Glaucoma: Results from a 2-Year Multicenter Study.
Angeles, R; Aptel, F; Beckers, HJM; Bluwol, E; García-Feijoó, J; Lachkar, Y; Martínez-de-la-Casa, JM; Méndez-Hernández, CD; Pinchuk, L; Riss, I; Sadruddin, O; Shaarawy, TM; Shao, H; Webers, CAB,
)
0.13
"Studies suggest that transepithelial photorefractive keratectomy (TransPRK) with the all-surface laser ablation (ASLA)-SCHWIND platform is effective and safe for both low-moderate myopia and high myopia."( Efficacy and safety of single-step transepithelial photorefractive keratectomy with the all-surface laser ablation SCHWIND platform without mitomycin-C for high myopia: A retrospective study of 69 eyes.
Bloch, F; El Nar, A; Giral, JB; Goetz, C; Lhuillier, L; Perone, JM; Sot, M; Vermion, JC; Zevering, Y, 2021
)
0.82
"ASLA-SCHWIND TransPRK without mitomycin-C appears to be safe as well as effective and accurate for high myopia."( Efficacy and safety of single-step transepithelial photorefractive keratectomy with the all-surface laser ablation SCHWIND platform without mitomycin-C for high myopia: A retrospective study of 69 eyes.
Bloch, F; El Nar, A; Giral, JB; Goetz, C; Lhuillier, L; Perone, JM; Sot, M; Vermion, JC; Zevering, Y, 2021
)
1.11
"Our results suggest IMRT-based CRT with concurrent fluoropyrimidine and cisplatin is a safe and feasible option for patient with SCCA and may cause less acute toxicity."( Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution.
Bednarski, BK; Chang, GJ; Das, P; Delclos, ME; Eng, C; Holliday, EB; Jennings, K; Johnson, B; Koay, EJ; Koong, AC; Ludmir, EB; Messick, CA; Minsky, BD; Morris, VK; Rodriguez-Bigas, MA; Skibber, JM; Smith, GL; Taniguchi, C; Tillman, MM; You, YN, 2022
)
0.72
"The Preserflo Microshunt (PSM) is a safe and effective glaucoma microfiltering implant that significantly reduces the intraocular pressure (IOP), either alone or in combination with phacoemulsification, during the first year after surgery."( Efficacy and Safety of the Preserflo Microshunt With Mitomycin C for the Treatment of Open Angle Glaucoma.
Caballero-Magro, E; Ibarz Barberá, M; Martínez-Galdón, F; Rodríguez-Piñero, M; Tañá-Rivero, P, 2022
)
0.97
" Safety was assessed by the incidence of adverse events."( Efficacy and Safety of the Preserflo Microshunt With Mitomycin C for the Treatment of Open Angle Glaucoma.
Caballero-Magro, E; Ibarz Barberá, M; Martínez-Galdón, F; Rodríguez-Piñero, M; Tañá-Rivero, P, 2022
)
0.97
" The most common adverse event was clinical hypotony (7."( Efficacy and Safety of the Preserflo Microshunt With Mitomycin C for the Treatment of Open Angle Glaucoma.
Caballero-Magro, E; Ibarz Barberá, M; Martínez-Galdón, F; Rodríguez-Piñero, M; Tañá-Rivero, P, 2022
)
0.97
"Glaucoma surgery with the PSM and mitomycin C was efficacious and safe in the short term, either alone or in combination with cataract surgery, and may be considered a surgical option for lowering IOP in primary open angle glaucoma."( Efficacy and Safety of the Preserflo Microshunt With Mitomycin C for the Treatment of Open Angle Glaucoma.
Caballero-Magro, E; Ibarz Barberá, M; Martínez-Galdón, F; Rodríguez-Piñero, M; Tañá-Rivero, P, 2022
)
1.25
"High-concentration MMC was considered safe in the pediatric and adult populations."( Safety profile and efficacy of high-dose topical mitomycin-C for choanal atresia repair: A prospective cohort study.
Alammar, A; Aldriweesh, B; Aljasser, A; Alshareef, W; Alsini, A, 2022
)
0.98
" Outcome measures included IOP reduction from baseline, mean IOP change from baseline at month 6, medication use at 6 months, complications, adverse events, and need for further procedures."( Efficacy and safety of the PreserFlo implant with mitomycin C in childhood glaucoma after previous failed glaucoma surgeries.
Burgos-Blasco, B; Fernandez-Vigo, JI; García-Feijóo, J; Gines-Gallego, C; Martinez de la Casa, JM; Mendez-Hernandez, CD; Morales-Fernandez, L; Perucho-Gonzalez, L; Saenz-Frances, F, 2023
)
1.16
" No adverse events were noted."( Efficacy and safety of the PreserFlo implant with mitomycin C in childhood glaucoma after previous failed glaucoma surgeries.
Burgos-Blasco, B; Fernandez-Vigo, JI; García-Feijóo, J; Gines-Gallego, C; Martinez de la Casa, JM; Mendez-Hernandez, CD; Morales-Fernandez, L; Perucho-Gonzalez, L; Saenz-Frances, F, 2023
)
1.16
" Ureteral stenosis and other adverse events were abstracted from the medical records."( Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy After Complete Endoscopic Management of Upper Tract Urothelial Carcinoma.
Bjurlin, M; Dickstein, R; Eisner, B; Feldman, A; Ghodoussipour, S; Humphreys, M; Jacob, J; Kaimakliotis, H; Labbate, C; Linehan, J; Lotan, Y; Matin, SF; Murray, K; Nieder, A; O'Donnell, M; Quek, M; Rose, K; Sexton, W; Tachibana, I; Woldu, S, 2023
)
1.22
"In patients being considered for UGN-101, maximal endoscopic ablation prior to UGN-101 treatment may result in fewer patients with disease at first endoscopy and possibly fewer adverse events than primary chemoablative therapy."( Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy After Complete Endoscopic Management of Upper Tract Urothelial Carcinoma.
Bjurlin, M; Dickstein, R; Eisner, B; Feldman, A; Ghodoussipour, S; Humphreys, M; Jacob, J; Kaimakliotis, H; Labbate, C; Linehan, J; Lotan, Y; Matin, SF; Murray, K; Nieder, A; O'Donnell, M; Quek, M; Rose, K; Sexton, W; Tachibana, I; Woldu, S, 2023
)
1.22
" There was no significant difference in the incidence of all adverse events between the two groups after PSM."( Comparative Study of Short-Term Efficacy and Safety of Mitomycin versus Lobaplatin for Hyperthermic Intraperitoneal Chemotherapy after Radical Surgery in Colorectal Cancer with High-Risk Factors for Peritoneal Carcinomatosis: A Propensity Score Matching A
Guo, X; Li, Y; Lin, Y; Lv, J; Ruan, T; Shen, C; Tao, K; Wu, C; Xiang, F; Zeng, X, 2023
)
1.16
" Acute toxicity was assessed (Common Terminology Criteria for Adverse Events) weekly during radiotherapy and at 10 weeks after the start of treatment."( Acute Toxicity of Hypofractionated and Conventionally Fractionated (Chemo)Radiotherapy Regimens for Bladder Cancer: An Exploratory Analysis from the RAIDER Trial.
Alonzi, R; Birtle, A; Cheung, KC; Choudhury, A; Foroudi, F; Gribble, H; Griffin, C; Hafeez, S; Hall, E; Henry, A; Hilman, S; Hindson, B; Huddart, R; Lewis, R; McLaren, DB; McNair, H; Muthukumar, D; Nikapota, A; Olorunfemi, A; Omar, A; Parikh, O; Philipps, L; Rimmer, Y; Syndikus, I; Tolentino, A; Varughese, M; Vassallo-Bonner, C; Webster, A, 2023
)
0.91
"Grade 2+ acute adverse events are common."( Acute Toxicity of Hypofractionated and Conventionally Fractionated (Chemo)Radiotherapy Regimens for Bladder Cancer: An Exploratory Analysis from the RAIDER Trial.
Alonzi, R; Birtle, A; Cheung, KC; Choudhury, A; Foroudi, F; Gribble, H; Griffin, C; Hafeez, S; Hall, E; Henry, A; Hilman, S; Hindson, B; Huddart, R; Lewis, R; McLaren, DB; McNair, H; Muthukumar, D; Nikapota, A; Olorunfemi, A; Omar, A; Parikh, O; Philipps, L; Rimmer, Y; Syndikus, I; Tolentino, A; Varughese, M; Vassallo-Bonner, C; Webster, A, 2023
)
0.91
" Time of resolution and frequency of adverse effects were analyzed to determine the pharmacological efficacy and safety of both medications."( Safety and efficacy of topical interferon alpha 2B and mitomycin C for localized conjunctival intraepithelial neoplasia: long-term report of their pharmacological safety and efficacy.
Alvarado-Castillo, B; Garcia-Benavides, L; Gonzalez-Castillo, C; Navarro-Partida, J; Rosales-Gradilla, ME; Santa Cruz-Pavlovich, FJ; Vidal-Paredes, IA, 2023
)
1.16
" Regarding adverse effects, one or more mild adverse reaction occurred in 77% of patients managed with MMC and in 50% of patients managed with IFNα2b (p > 0."( Safety and efficacy of topical interferon alpha 2B and mitomycin C for localized conjunctival intraepithelial neoplasia: long-term report of their pharmacological safety and efficacy.
Alvarado-Castillo, B; Garcia-Benavides, L; Gonzalez-Castillo, C; Navarro-Partida, J; Rosales-Gradilla, ME; Santa Cruz-Pavlovich, FJ; Vidal-Paredes, IA, 2023
)
1.16

Pharmacokinetics

Conjugates of mitomycin C (MMC) with estradiol benzoate and estradio via glutaric acid were examined. Study looked at their pharmacokinetic behaviors and antitumor effects against P388 leukemia and Sarcoma 180.

ExcerptReferenceRelevance
" A marked pharmacokinetic advantage was observed when 5-FU and CDDP were administered."( [Large volume intraperitoneal chemotherapy as treatment for the peritoneal carcinomatosis from gastric cancer].
Ito, A; Ito, K; Kodera, Y; Kondo, K; Kuzuya, T; Nagai, S; Nakahara, H; Satta, T; Takagi, H; Yamauchi, M, 1992
)
0.28
" In this study, the pharmacokinetic profile of intrahepatic arterial mitomycin C microcapsules is reported."( Mitomycin C-loaded microcapsules in the treatment of colorectal liver metastases. Pharmacokinetics of regionally administered particulate chemotherapy.
Blackie, R; Goldberg, JA; Kato, T; Kerr, DJ; McArdle, CS; Pettit, L; Whately, TL, 1991
)
1.96
" Pharmacokinetic studies were performed at the time of the first, fourth, and sixth or first, second, and fourth treatments with MMC for a total of 28 treatments."( Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients.
Au, JL; Badalament, RA; Dalton, JT; Drago, JR; Wientjes, MG, 1991
)
0.56
"Isolated perfusion of organs or anatomic sites with chemotherapeutic agents offers a pharmacokinetic advantage of increasing drug bioavailability to target tissues which may result in a greater magnitude of biologic effect (pharmacologic or toxic) without systemic toxicity."( Pharmacokinetics and tissue uptake of mitomycin C in isolated perfusion of pancreas.
Arredondo, MA; Chaudhuri, B; Chaudhuri, PK; Thomford, NR, 1989
)
0.55
" In all patients, the area under the concentration time curve (AUC) was significantly lower when the drug was co-administrated with DSM, but the terminal half-life (t1/2) of mitomycin C was unchanged."( Pharmacokinetics of intra-arterial mitomycin C with or without degradable starch microspheres (DSM) in the treatment of non-resectable liver cancer.
Andersson, M; Aronsen, KF; Balch, C; Domellöf, L; Eksborg, S; Hafström, LO; Howell, SB; Kåresen, R; Midander, J; Teder, H, 1989
)
0.75
" In patients, the mean terminal half-life and total body clearance rates of MMC were 40 min and 275 ml/min/m2, respectively."( Pharmacokinetics of mitomycin-C in plasma and tumor tissue of cervical cancer patients and in selected tissues of female rats.
Boike, G; Deppe, G; Gove, N; Malviya, VK; Young, JD, 1986
)
0.59
"A series of toxicologic and pharmacokinetic studies were performed in BALB/c mice administered intradermal (ID) mitomycin C (MMC) at doses of ."( Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide.
Dorr, RT; Keller, JH; Liddil, JD; Soble, MJ, 1986
)
1.92
" Pharmacokinetic studies using HPLC technique were done in nine patients."( High-dose mitomycin-C with autologous bone marrow transplantation in patients with refractory malignancies. Influence of dose schedule on pharmacokinetics and nonhematopoietic toxicities.
Baker, LH; Emmer, D; Hoschner, JA; Karanes, C; Leichman, L; Ratanatharathorn, V; Schilcher, RB; Young, JD, 1986
)
0.67
" Infusion time, cholestasis, and urinary pH did not influence the pharmacokinetic data."( Relationship between clinical parameters and pharmacokinetics of mitomycin C.
de Vries, J; den Hartigh, J; Pinedo, HM; Stuurman, M; Verweij, J, 1987
)
0.51
" A dual-phase attenuation curve was obtained after the completion of infusion and the half-life period of the beta-phase was around 200 hours."( [The pharmacokinetics of cisplatin and its influence on renal functions based on different infusion methods].
Amano, H; Hishida, H; Ogura, Y; Saji, E; Takagi, M; Takagi, N; Takahashi, A, 1987
)
0.27
"The pharmacokinetic plasma profile of mitomycin C (MMC) was studied during sequential courses in man."( The pharmacokinetic plasma profile of mitomycin C, measured after sequential intermittent intravenous administration.
Lankelma, J; Pinedo, HM; Stuurman, M; van Bochove, A; van Hoogenhuijze, J; Vermorken, JB; Verweij, J, 1988
)
0.82
" Thus, we attempted to find the dose of a given drug that can reproduce in the nude mouse a plasma level similar to that seen in human patients treated with an effective dose of the drug based on comparative pharmacokinetic studies between man and nude mouse."( Pharmacokinetic approach to rational therapeutic doses for human tumor-bearing nude mice.
Inaba, M; Kobayashi, T; Sakurai, Y; Tashiro, T, 1988
)
0.27
" These studies demonstrate a rapid, biphasic elimination pattern for the drug: alpha half-life of 8 minutes and beta, or terminal, half-life of 48 minutes."( New findings in the pharmacokinetic, metabolic, and drug-resistance aspects of mitomycin C.
Dorr, RT, 1988
)
0.5
" Inoculation of MMC together with 5-fluorouracil and doxorubicin did not change the terminal half-life of MMC but decreased the total body clearance and the volume of distribution."( Pharmacokinetics and toxicity of mitomycin C in rodents, given alone, in combination, or after induction of microsomal drug metabolism.
Kanyár, B; Kerpel-Fronius, S; Lelieveld, P; Pinedo, HM; Stuurman, M; Verwey, J, 1988
)
0.56
" The serum level of M-83 detected by bioassay was biphasic, elimination half-life T1/2 beta was 10."( Antitumor activity and pharmacokinetics of 7-N-(p-hydroxyphenyl)mitomycin C in human tumor xenografts transplanted into nude mice.
Asanuma, F, 1985
)
0.51
"This paper describes an investigation into the pharmacokinetic behavior of mitomycin C (MMC) in 36 patients receiving either single-agent chemotherapy (10 to 20 mg/sq m), or a combination regimen including MMC (5 to 10 mg/sq m)."( Pharmacokinetics of mitomycin C in humans.
den Hartigh, J; McVie, JG; Pinedo, HM; van Oort, WJ, 1983
)
0.82
" By considering these pharmacokinetic behaviors, a suitable method of administration should be established."( [Chemical modification of anticancer agents from viewpoints of their pharmacokinetics].
Fujita, H, 1984
)
0.27
" Pharmacokinetic analysis of data by the CSTRIP and NONLIN digital computer programs generated parameters which suggested extensive distribution (V area = 656."( Pharmacokinetics of mitomycin C in non-oat cell carcinoma of the lung.
Buice, RG; Gurley, BJ; Niell, HB; Sidhu, P, 1984
)
0.59
" Total body clearance averaged 112 mL/min, and the mean terminal plasma half-life was 53 min."( Pharmacokinetics of mitomycin C in dogs: application of a high-performance liquid chromatographic assay.
Barbhaiya, RH; Papp, EA; Smyth, RD; Van Harken, DR, 1984
)
0.59
" These pharmacokinetic behaviours of KW-2083 might be related to the lower toxicity and higher therapeutic ratio in experimental animals."( [Pharmacokinetics of mitomycin C and its derivative (KW-2083)].
Fujita, H, 1982
)
0.58
"This pharmacokinetic study attempted to improve the exposure of gastrointestinal tract tissues to chemotherapy by increasing the transit time of a first pass of a drug through the vascular system."( Pharmacokinetic studies of intraaortic stop-flow infusion with 14C-labeled mitomycin C.
Averbach, AM; Fernandez-Trigo, V; Shamsa, F; Stephens, AD; Stuart, OA; Sugarbaker, PH; Sugarbaker, TA, 1995
)
0.52
" Microspheres produced a tumour pharmacokinetic profile of steady state drug levels, avoiding the much higher early peak (20."( Encapsulation of mitomycin C in albumin microspheres markedly alters pharmacokinetics, drug quinone reduction in tumour tissue and antitumour activity. Implications for the drugs' in vivo mechanism of action.
Allan, L; Cummings, J; Smyth, JF, 1994
)
0.63
"A pharmacokinetic comparison was made between nude mice and human gastric cancer patients."( Similarity of serum-tumor pharmacokinetics of antitumor agents in man and nude mice.
Furukawa, T; Hoffman, RM; Inoue, S; Ishibiki, K; Kawamura, E; Kitajima, M; Kubota, T,
)
0.13
" Pharmacokinetic analysis of each plasma concentration indicated that for each conjugate, the in vitro drug release reported previously was useful for the approximate estimation of the in vivo regeneration of MMC."( Pharmacokinetic characteristics and antitumor activity of the N-succinyl-chitosan-mitomycin C conjugate and the carboxymethyl-chitin-mitomycin C conjugate.
Nagai, T; Onishi, H; Song, Y, 1993
)
0.51
" Pharmacokinetic data from these patients showed very low plasma levels both for KW-2149, as for both known metabolites M-16 and M-18."( Phase I and pharmacokinetic study of KW-2149 given by 24 hours continuous infusion.
Ardiet, C; Catimel, G; De Bruijn, E; Dirix, L; Tranchand, B; Van Oosterom, A; Verdonk, R, 1995
)
0.29
" Pharmacokinetic parameters were computed assuming an open two-compartment model."( Pharmacokinetics of intraarterial mitomycin C in the chemoembolisation treatment of liver metastases.
Biederbick, W; Botvinik-Helling, S; Fischbach, R; Heindel, W; Klaus, W; Lackner, K; Rump, AF; Schierholz, JM; Stemmler, M; Theisohn, M, 1996
)
0.57
" Pharmacokinetic examination after intravenous injection of low-dose MMC (0."( A case of advanced gastric cancer complicated by severe toxicity induced by a combination of tegafur, uracil and mitomycin C, and associated with abnormal pharmacokinetics.
Boku, N; Ishii, H; Kaneko, K; Kusada, O; Muro, K; Muto, M; Ohkuwa, M; Ohtsu, A; Sasaki, Y; Tajiri, H; Yoshida, S, 1996
)
0.5
" By the use of 3 % gelatin solution, mean residence time (MRT) and Tmax values were significantly prolonged, and Cmax was decreased as compared with the administration of MMC solution."( Pharmacokinetics of mitomycin C (MMC) after intraperitoneal administration of MMC-gelatin gel and its anti-tumor effects against sarcoma-180 bearing mice.
Fujita, T; Muranishi, S; Tamura, T; Yamada, H; Yamamoto, A, 1997
)
0.62
" Three pharmacokinetic analyses were performed: (1) pharmacokinetics of heated intraoperative intraperitoneal MMC was determined for 18 patients by sampling peritoneal fluid, plasma, and urine during the 2-h procedure; (2) impact of peritoneal resections on MMC pharmacokinetics was assessed by comparing a group of patients who underwent < or = 1 peritonectomy procedure (minimal surgery) to a group of patients who underwent > or = 2 peritonectomy procedures (extensive surgery), and (3) effects of heated intraoperative intraperitoneal chemotherapy on the pharmacokinetics of early postoperative intraperitoneal 5-FU by comparing a group of patients treated with heated intraoperative intraperitoneal MMC to a control group who did not receive heated intraoperative intraperitoneal chemotherapy."( Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies.
Averbach, A; Chang, D; Jacquet, P; Stephens, AD; Stuart, OA; Sugarbaker, PH,
)
0.4
" Pharmacokinetic studies of early postoperative intraperitoneal 5-FU showed no significant difference in plasma AUC, perfusate AUC and AUC ratio between patients who received and those who did not receive heated intraoperative intraperitoneal MMC."( Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies.
Averbach, A; Chang, D; Jacquet, P; Stephens, AD; Stuart, OA; Sugarbaker, PH,
)
0.4
" The pharmacokinetic analysis revealed that macromolecular conjugation reduced elimination of MMC from the poorly-perfused region rather than well-perfused region."( Pharmacokinetic characteristics and therapeutic effects of mitomycin C-dextran conjugates after intratumoural injection.
Hashida, M; Honda, K; Morita, S; Nomura, T; Saikawa, A; Sakaeda Kakutani, T; Takakura, Y; Yamashita, F, 1998
)
0.54
" thymidine or TdR, and bromodeoxyuridine or BrdU) and expression of proliferating cell nuclear antigen (PCNA), as molecular pharmacodynamic endpoints in evaluation of anticancer drug effect in human solid tumors."( Proliferation indices as molecular pharmacodynamic endpoints in evaluation of anticancer drug effect in human solid tumors.
Au, JL; Gan, Y; Weaver, JR, 1998
)
0.3
" For this research, the pharmacokinetic advantages of mitomycin C delivery by four different methods were compared: intraaortic infusion with aortic stopflow; intraaortic infusion with inferior vena cava stopflow; intraaortic infusion with aortic and inferior caval vein stopflow (hypoxic pelvic perfusion); and hypoxic pelvic perfusion with hemofiltration."( Pharmacokinetics of mitomycin C in pelvic stopflow infusion and hypoxic pelvic perfusion with and without hemofiltration: a pilot study of patients with recurrent unresectable rectal cancer.
Aigner, KR; Cantore, M; Chaudhuri, PK; Clerico, M; Deraco, M; Fiorentini, G; Guadagni, S; Palumbo, G; Pozone, T, 1998
)
0.87
"Conjugates of mitomycin C (MMC) with estradiol benzoate and estradiol via glutaric acid, abbreviated to EB-glu-MMC and E-glu-MMC, respectively, as previously reported, were examined concerning their pharmacokinetic behaviors and antitumor effects against two kinds of general and popular tumors, P388 leukemia and Sarcoma 180."( In vivo properties of the conjugates of mitomycin C with estradiol benzoate and estradiol: pharmacokinetics and antitumor characteristics against P388 leukemia and sarcoma 180.
Ishiki, N; Machida, Y; Onishi, H, 1998
)
0.93
" An empirical, four-compartment pharmacokinetic model was developed to establish drug distribution curves for the pelvic and systemic circulations and to yield valid estimates of the pharmacokinetic parameters."( A pharmacokinetic model and the clinical pharmacology of cis-platinum, 5-fluorouracil and mitomycin-C in isolated pelvic perfusion.
Belliveau, JF; Wanebo, HJ, 1999
)
0.52
"These pharmacokinetic results indicate that this isolation technique has the potential to provide increased therapeutic indices and is a suitable system for evaluating fast-acting highly toxic experimental drugs to human pelvic cancers which are poorly responsive to conventional clinical protocols."( A pharmacokinetic model and the clinical pharmacology of cis-platinum, 5-fluorouracil and mitomycin-C in isolated pelvic perfusion.
Belliveau, JF; Wanebo, HJ, 1999
)
0.52
"Human solid tumor histocultures represent a clinically relevant experimental system for pharmacodynamic study."( Regional heterogeneity and pharmacodynamics in human solid tumor histoculture.
Au, JL; Weaver, JR; Wientjes, MG, 1999
)
0.3
" Pharmacokinetic models of drug absorption from the bladder have been developed, both in animals and humans."( Intravesical drug delivery. Pharmacokinetic and clinical considerations.
De Bruijn, EA; Highley, MS; Maes, RA; van Oosterom, AT, 1999
)
0.3
"A study has been performed in 15 patients with liver metastases from colorectal cancer to evaluate the pharmacokinetic of mitomycin C and the effectiveness of drug removal techniques during high-dose locoregional chemotherapy."( Pharmacokinetic of intraarterial mitomycin C with extra corporeal detoxification in humans.
Guadagni, S; Palumbo, G; Pantaleoni, GC,
)
0.62
" The resulting mean mitomycin C plasmatic half-life was 40."( Pharmacokinetic of intraarterial mitomycin C with extra corporeal detoxification in humans.
Guadagni, S; Palumbo, G; Pantaleoni, GC,
)
0.74
"First, we obtained experimental data on the relationship between drug concentration, treatment time and effect, and analyzed the data with a three-dimensional surface response method to obtain the pharmacodynamic model parameters and the magnitude of data variability."( A pharmacodynamic analysis method to determine the relative importance of drug concentration and treatment time on effect.
Au, JL; Millenbaugh, NJ; Wientjes, MG, 2000
)
0.31
"In summary, the three-step pharmacodynamic study design and analysis method can be used to define the relative importance of drug concentration and treatment time on drug effect."( A pharmacodynamic analysis method to determine the relative importance of drug concentration and treatment time on effect.
Au, JL; Millenbaugh, NJ; Wientjes, MG, 2000
)
0.31
" The pharmacokinetic parameters were computed assuming an open two-compartment model and linear kinetics."( Pharmacokinetics of intra-arterial mitomycin C in the chemoembolization treatment of liver metastases with polyvinylalcohol or degradable starch microspheres.
Fischbach, R; Heindel, W; Klaus, W; Lackner, K; Rump, AF; Theisohn, M; Woschée, U, 2002
)
0.59
" The pharmacokinetic parameters calculated for IHPL vs."( Application of cisplatin as intraoperative hyperthermic peritoneal lavage (IHPL) in patients with locally advanced gastric cancer: analysis of pharmacokinetics and of nephrotoxicity.
Becker, H; Braess, J; Hiddemann, W; Kern, W; Kotschofsky, M; Samel, S; Schleyer, E,
)
0.13
" MMC was assayed by high-pressure liquid chromatography (HPLC), and pharmacokinetic parameters were determined using an open, two-compartment model and linear kinetics."( Pharmacokinetics of intraarterial mitomycin C in hypoxic hepatic infusion with embolization in the treatment of liver metastases.
Cerretani, D; Civeli, L; Correale, P; De Manzoni, G; Francini, G; Giorgi, G; Marrelli, D; Pieraccini, M; Pinto, E; Roviello, F, 2002
)
0.59
" The observed concentration-time profiles were used to develop a population pharmacokinetic model using nonlinear mixed-effect modelling (NONMEM)."( Population pharmacokinetics and pharmacodynamics of mitomycin during intraoperative hyperthermic intraperitoneal chemotherapy.
Beijnen, JH; Mathôt, RA; Sparidans, RW; van Ruth, S; Verwaal, VJ; Zoetmulder, FA, 2004
)
0.57
" Pharmacokinetic analysis revealed an AUC value of 85."( Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: oxaliplatin pharmacokinetics and feasibility.
Ehrsson, H; Fester, C; Guthoff, I; Kornmann, M; Lotspeich, E; Schatz, M; Wallin, I,
)
0.35
" Despite its pharmacokinetic advantages, the aortic stop flow technique is currently not recommendable for routine use."( Pharmacokinetics of the antineoplastic drug mitomycin C in regional chemotherapy using the aortic stop flow technique in advanced pancreatic carcinoma.
Gebauer, T; Grote, R; Lippert, H; Martens-Lobenhoffer, J; Meyer, F; Ridwelski, K, 2005
)
0.59
" Pharmacokinetic assays were carried out at different time points (0."( [Pharmacokinetic study of intraperitoneal chemotherapy with mitomycin C bound to activated carbon particles].
Hao, XS; Li, W; Liang, H; Sun, H; Tang, HW, 2005
)
0.57
" The mean area under the curve (AUC) and terminal half-life (t1/2) were 15."( Pharmacokinetics of mitomycin C after resection of peritoneal carcinomatosis and intraperitoneal chemohyperthermic perfusion.
Cerretani, D; Cioppa, T; De Stefano, A; Giorgi, G; Marrelli, D; Nastri, G; Nencini, C; Pinto, E; Roviello, F; Urso, R, 2005
)
0.65
" Following treatment with an intraperitoneal injection, fibres were excised and cells retrieved for pharmacodynamic analysis using the comet assay/fluorescence microscopy."( The hollow fibre model--facilitating anti-cancer pre-clinical pharmacodynamics and improving animal welfare.
Bibby, MC; Cooper, PA; Shnyder, SD; Suggitt, M, 2006
)
0.33
" Potential pharmacokinetic interactions and Topo-1 and DT-diaphorase (NQ01) gene expressions in peripheral-mononuclear cells were evaluated."( Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies.
Drengler, R; Duan, W; Kolesar, JM; Kuhn, J; Otterson, G; Schaaf, LJ; Shapiro, C; Villalona-Calero, MA; Xu, Y, 2009
)
0.63
" No relevant pharmacokinetic interactions occurred between irinotecan and MMC, and mean increases in Topo-1, were observed."( Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies.
Drengler, R; Duan, W; Kolesar, JM; Kuhn, J; Otterson, G; Schaaf, LJ; Shapiro, C; Villalona-Calero, MA; Xu, Y, 2009
)
0.63
" Peritoneal and blood concentrations of cisplatinum were used to develop a pharmacokinetic model of the peritoneal and plasma compartments using NONMEM software."( Population pharmacokinetics and pharmacodynamics of cisplatinum during hyperthermic intraperitoneal chemotherapy using a closed abdominal procedure.
Bakrin, N; Colomban, O; Cotte, E; Gilly, FN; Glehen, O; Guitton, J; Tod, M; Tranchand, B, 2011
)
0.37
", undetectable at low dose or a peak concentration that was 6,000× lower than urine concentrations), and (c) disproportionally higher drug penetration and concentrations in bladder tissues at the higher dose."( Bladder tissue pharmacokinetics of intravesical mitomycin C and suramin in dogs.
Au, JL; Hu, L; Li, J; Wientjes, MG, 2010
)
0.62
" Pharmacokinetic studies have been based on analyses of blood, urine and abdominal perfusate, but actual tissue concentrations of the drug have never been determined."( Validation and use of microdialysis for determination of pharmacokinetic properties of the chemotherapeutic agent mitomycin C - an experimental study.
Alexandr, K; Andersen, A; Ekstrøm, PO; Flatmark, K; Giercksky, KE; Olsen, H; Sørensen, O, 2010
)
0.57
" Subsequently, intravenous and intraperitoneal bolus infusion experiments were performed and pharmacokinetic parameters were calculated."( Validation and use of microdialysis for determination of pharmacokinetic properties of the chemotherapeutic agent mitomycin C - an experimental study.
Alexandr, K; Andersen, A; Ekstrøm, PO; Flatmark, K; Giercksky, KE; Olsen, H; Sørensen, O, 2010
)
0.57
" The half-life of mitomycin C calculated after intravenous infusion was 40 minutes."( Validation and use of microdialysis for determination of pharmacokinetic properties of the chemotherapeutic agent mitomycin C - an experimental study.
Alexandr, K; Andersen, A; Ekstrøm, PO; Flatmark, K; Giercksky, KE; Olsen, H; Sørensen, O, 2010
)
0.9
"Mitomycin C concentration can be reliable monitored in vivo using microdialysis, suggesting that this technique can be used in pharmacokinetic studies of this drug during hyperthermic intraperitoneal chemotherapy."( Validation and use of microdialysis for determination of pharmacokinetic properties of the chemotherapeutic agent mitomycin C - an experimental study.
Alexandr, K; Andersen, A; Ekstrøm, PO; Flatmark, K; Giercksky, KE; Olsen, H; Sørensen, O, 2010
)
2.01
" A pharmacokinetic study was performed in 18 patients."( Mitomycin C hypoxic pelvic perfusion for unresectable recurrent rectal cancer: pharmacokinetic comparison of surgical and percutaneous techniques.
Clementi, M; Fiorentini, G; Guadagni, S; Mambrini, A; Masedu, F; Palumbo, P, 2017
)
1.9
" Because its half-life is 17 min after a 30 mg intravenous bolus administration, the suitability of mitomycin C for wide use in the clinical setting is limited."( Diminishing the side effect of mitomycin C by using pH-sensitive liposomes: in vitro characterization and in vivo pharmacokinetics.
Fang, YP; Hu, PY; Huang, YB, 2018
)
0.98
" The nature of the conjugated lipid and linker, as well as the composition of the liposomal bilayer were found to have a profound impact on the pharmacokinetic properties and biodistribution of the encapsulated drugs as well as on their biological activity."( Pharmacokinetics of lipid-drug conjugates loaded into liposomes.
Brambilla, D; Leroux, JC; Luciani, P; Signorell, RD, 2018
)
0.48
" A serum pharmacokinetic study was performed."( Development of a high-precision bladder hyperthermic intracavitary chemotherapy device for bladder cancer and pharmacokinetic study.
Ba, M; Cui, S; Gong, Y; Lin, K; Long, H; Tu, Y; Wu, W; Wu, Y; Zhang, B, 2019
)
0.51
" The correlation between clinical and pharmacokinetic parameters was statistically analyzed."( Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patients.
Amitay, Y; Gabizon, AA; Geva, R; Golan, T; Ohana, P; Perets, R; Shmeeda, H; Tahover, E, 2020
)
0.88

Compound-Compound Interactions

calcium gluconate in combination with mitomycin C and 5-fluorouracil was examined against subcutaneously implanted Lewis lung carcinoma-bearing C57BL/6 mice.

ExcerptReferenceRelevance
"Dibutyryl cyclic AMP was administered to 7 cases with hepatocellular carcinoma and its tumor thrombosis in portal vein, combined with intraarterial infusion of Mitomycin C or Adriamycin with implanted reservoir."( [Effect of dibutyryl cyclic AMP in the treatment of hepatocellular carcinoma--intraarterial infusion therapy combined with anticancer agent for hepatocellular carcinoma with portal vein thrombosis].
Fukui, H; Kitagami, K; Matsumoto, M; Nakano, H; Nakayama, M; Okamoto, Y; Tsujii, T, 1992
)
0.48
"Repeated hepatic dearterialization combined with intra-arterial infusion chemotherapy was performed in 29 patients with unresectable primary or secondary cancer of the liver."( [Evaluation of repeated hepatic dearterialization combined with intra-arterial infusion chemotherapy of unresectable primary or secondary cancer of the liver].
Hayashi, T; Kimoto, T; Kohno, H; Makino, Y; Nagasue, N; Ohiwa, K; Ono, T; Takemoto, Y; Taniura, H; Uchida, M, 1992
)
0.28
" PDT combined with either adriamycin, MMC or BCG, produced a greater retardation in the growth of the MBT-2 tumor than monotherapy with adriamycin, MMC, BCG or PDT."( Effects of photodynamic therapy in combination with intravesical drugs in a murine bladder tumor model.
Cho, YH; Smith, JA; Straight, RC, 1992
)
0.28
" Combination with mitomycin C or interferon-alpha-2b potentiated the cytostatic effect."( Cytostatic effect of different strains of Bacillus Calmette-Guérin on human bladder cancer cells in vitro alone and in combination with mitomycin C and interferon-alpha.
Alfthan, O; Jauhiainen, K; Kaasinen, E; Lähde, M; Nurmi, M; Rajala, P; Rintala, E, 1992
)
0.82
" These findings suggested that arterial infusion chemotherapy in combination with biochemical modulation was a safe and effective method for treating cancer patients."( [Arterial infusion chemotherapy combined with biochemical modulation in cancer patients].
Mai, M; Ogino, T; Suga, T; Takahashi, Y, 1991
)
0.28
"In order to prevent local recurrence, intra-operative pelvic hyperthermochemotherapy (IOPHC) combined with surgery for rectal cancer has been performed."( [Clinical evaluation of intra-operative pelvic hyperthermochemotherapy combined with operation for rectal cancer].
Endoh, F; Fujimoto, S; Kobayashi, K; Kokubun, M; Masuda, Y; Obata, G; Ohno, K; Takahashi, M; Takai, M, 1991
)
0.28
"Six patients with peritoneal recurrence after radical operation for gastric cancer were treated by an intraperitoneal hyperthermic perfusion (IPHP) combined with surgery (IPHP group)."( [Clinical results of intraperitoneal hyperthermic perfusion combined with surgery in patients with peritoneal recurrence from gastric cancer].
Fujimoto, S; Kiuchi, S; Kobayashi, K; Kokubun, M; Konno, C; Okui, K; Shrestha, RD, 1990
)
0.28
" These results indicated that rIL 2 in combination with MMC might be effective against advanced carcinoma without causing severe toxicity when these drugs are used in an appropriate combination."( The effect of recombinant interleukin 2 in combination with mitomycin C on advanced cancer.
Abe, R; Akiyoshi, T; Arinaga, S; Inoue, H; Karimine, N; Matsuoka, H; Nagamatsu, M; Nanbara, S; Takamuku, K; Watanabe, D, 1990
)
0.52
" On the other hand, the increase of the solid tumor weight in the every day treatment and in the every 7th day treatment of hEGF, in combination with the every 7th day administration of MMC, were as follows; from 282 +/- 41 mg to 1522 +/- 357 mg (71."( Response of A431 experimental human solid xenograft to mitomycin C in combination with human epidermal growth factor in mice.
Amagase, H; Fuwa, T; Hashimoto, K; Murakami, T; Tamura, K; Yata, N, 1990
)
0.53
"In order to prevent local recurrence after curative surgery for rectal cancer, intra-operative pelvic hyperthermochemotherapy (IOPHC) was performed, combined with surgery."( [Intra-operative pelvic hyperthermochemotherapy combined with surgery in rectal cancer].
Endoh, F; Fujimoto, S; Kobayashi, N; Masuda, Y; Obata, G; Oohno, K; Takahashi, M; Takai, M; Tanaka, H, 1990
)
0.28
" Thus, both intraarterial and intraportal chemotherapy combined with decollateralization by silicone rubber sheeting seems to be effective for advanced cholangiocarcinoma and metastatic carcinoma."( [Intraarterial and intraportal chemotherapy combined with decollateralization for cholangiocellular carcinoma and metastatic liver cancer].
Fukuda, I; Furukawa, H; Imaoka, S; Ishikawa, O; Masutani, S; Nagano, H; Ohashi, I; Oohigashi, H; Sasaki, Y; Yasuda, T, 1990
)
0.28
"This study observed the effect of chemotherapy combined with Chinese herbs and western drugs on white blood cell count in 31 patients with gastric cancer."( [Clinical effect of chemotherapy combined with Chinese herbs and western drugs on leukocytes of gastric cancer patients].
Chen, JZ, 1990
)
0.28
"Fourty eight patients with cancer of head of pancreas have been treated by the intra-arterial infusion of 5-FU and Mitomycin C alone or in combination with regional hyperthermia, employing microwave machine operating at a frequency of 2450 MHz."( [Hyperthermia: microwave hyperthermia in combination with intra-arterial infusion chemotherapy of cancer of the pancreas].
Endo, Y; Funatomi, H; Hatta, Y; Hirose, N; Miura, T; Sassa, T; Taguchi, S; Yoshikawa, N, 1985
)
0.48
"A clinical trial was performed to investigate the efficacy of hyperthermia in combination with chemotherapy for gynecological malignancies."( Therapeutic effect of hyperthermia combined with chemotherapy on vulvar and vaginal carcinoma.
Fujiwara, K; Kohno, I; Sekiba, K, 1987
)
0.27
"Human fibroblast interferon (IFN)-beta was administered in combination with the free radical-generating antiproliferative agents bleomycin (BLM), neocarzinostatin (NCS), adriamycin (ADM), and mitomycin C (MMC) to HeLa cells in culture."( Synergistic antiproliferative effect of interferon-beta in combination with bleomycin or neocarzinostatin on HeLa cells in culture: additive effect when combined with adriamycin or mitomycin C.
Hayashi, Y; Ito, M; Kawade, Y; Shigeta, S; Tanabe, F, 1987
)
0.65
"The effects of interferon alone and in combination with either adriamycin, mitomycin C or thiotepa were evaluated for antiproliferative activity for the mouse bladder tumor, MBT-2."( Effects of interferon in combination with cytotoxic drugs on mouse bladder tumor (MBT-2) growth in vitro and in vivo.
Bahnson, R; Ratliff, TL, 1988
)
0.51
"A new immunotherapy for hepatocellular carcinoma (HCC) using Freund's adjuvant and recombinant interleukin-2 (IL-2) combined with conventional transarterial chemoembolization therapy was performed."( Immunotherapy using Freund's adjuvant and recombinant interleukin-2 combined with transarterial chemoembolization for hepatocellular carcinoma.
Higashi, T; Ikeda, N; Ito, T; Nouso, K; Ohsawa, T; Okamoto, T; Sue, K; Tsuji, T; Ukida, M; Watanabe, A, 1989
)
0.28
"The antitumor activity of calcium gluconate in combination with mitomycin C and 5-fluorouracil was examined against subcutaneously implanted Lewis lung carcinoma-bearing C57BL/6 mice."( Antitumor activity of calcium in combination with antitumor agents against Lewis lung carcinoma.
Fujimoto, S; Nakano, K; Tokita, H,
)
0.37
" Four cycles of the regimen I drug combination failed to prolong life due to toxic side effects in every cancer line."( [Effects of alternating chemotherapy with 2 non-cross-resistant drug combinations on human alimentary and breast cancer xenografts in nude mice].
Fujita, F; Fujita, M; Inaba, H; Sakamoto, Y; Shimozuma, K; Taguchi, T; Yamauchi, T, 1987
)
0.27
"Antitumor activity of ascorbic acid in combination with antitumor agents (mitomycin C and 5-fluorouracil) was examined against subcutaneously implanted Lewis lung carcinoma-bearing C57BL/6 mice by feeding them an ascorbic acid-deficient diet."( Antitumor activity of ascorbic acid in combination with antitumor agents against Lewis lung carcinoma.
Fujimoto, S; Nakano, K; Tokita, H,
)
0.36
" During the past eleven years, we have used postoperative chemotherapy in three ways over three different periods: in the earliest period, short-term combined chemotherapy (STCC) was used, in the middle period, intermittent long-term combined chemotherapy (ILTCC) was used in combination with immunotherapy for a randomized group, and in the latest period, when continuous long-term combined chemotherapy (CLTCC) with immunotherapy was employed."( [Clinical value of postoperative chemotherapy for non-small cell lung cancer--with special reference to long-term combined chemotherapy combined with immunotherapy].
Hashizume, Y; Ichihashi, T; Iida, S; Kimoto, H; Kobayashi, H; Sato, H; Shimizu, J; Tsunamura, Y; Watanabe, Y; Yamada, T, 1985
)
0.27
" the same therapy in combination with UFT as a maintenance therapy (group B; 8 patients)."( [Clinical evaluation of MMC-mc-chemoembolization therapy and its combination with UFT in hepatocellular carcinoma].
Matsuo, SK; Ohmura, K; Ohtsuka, Y; Suzuki, M, 1987
)
0.27
"Fifty-seven patients with advanced squamous carcinoma of the larynx and hypopharynx were entered on a pilot study of initial therapy using split course radiation therapy combined with simultaneous chemotherapy using mitomycin-C and 5-fluorouracil."( A pilot study of mitomycin-C/5-fluorouracil infusion combined with split course radiation therapy for carcinomas of the larynx and hypopharynx.
Beale, FA; Cummings, BJ; Elhakim, T; Harwood, AR; Keane, TJ; Payne, DG; Rawlinson, E, 1986
)
0.8
" Based on the observed objective tumor response rate and median patient survival, further studies of these drugs in combination for the treatment of advanced gastric cancer are indicated."( Phase II clinical trial of triazinate in combination with mitomycin C for patients with advanced gastric cancer.
Hahn, RG; Moertel, CG; O'Connell, MJ; Schutt, AJ, 1987
)
0.52
"The effectiveness of arterial embolization using DSM (Degradable Starch Microspheres, Spherex, Sweden) combined with hyperthermia were investigated in the treatment of VX2 carcinoma in rabbits and also in human hepatic tumors."( [Enhancement of anti-tumor effects by arterial embolization combined with hyperthermia in the treatment of hepatic tumors].
Kawa, S; Murata, T; Sawada, S; Tanaka, Y; Yoshida, M, 1987
)
0.27
" This extensive surgery combined with IPHP using MMC and MIS was well tolerated and is a safe antitumor treatment for gastric cancer with peritoneal dissemination."( Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding.
Arimizu, N; Fujimoto, S; Kiuchi, S; Kobayashi, K; Kokubun, M; Miyoshi, T; Ohta, M; Okui, K; Shrestha, RD; Takahashi, M, 1988
)
0.27
" Intra-arterial chemotherapy combined with MMC and DSM was performed on eight cases of unresectable metastatic liver carcinoma."( [Intra-arterial chemotherapy combined with mitomycin C and degradable starch microspheres in unresectable metastatic liver carcinoma].
Arai, K; Awane, Y; Kitamura, M; Mori, T; Takahashi, T; Yoshikawa, T, 1988
)
0.54
"Intra-arterial chemotherapy combined with mitomycin C (MMC) and degradable starch microspheres (DSM) was prescribed repeatedly for 14 patients with inoperable hepatic metastasis."( [Repeated intra-arterial chemotherapy combined with mitomycin C and degradable starch microspheres in inoperable metastatic hepatic cancer].
Endoh, F; Fujimoto, S; Guhji, M; Kiuchi, S; Kobayashi, K; Koike, S; Kokubun, M; Okui, K; Ooi, T; Shrestha, RD, 1988
)
0.79
" Since the usefulness of DSM combined with anticancer agents had been indicated by the experimental results mentioned above, we carried out a clinical study (phage II)."( [Fundamental and clinical studies of intra-arterial chemotherapy combined with degradable starch microspheres (DSM)].
Hattori, T; Jinushi, K; Kodama, H; Niimoto, M; Saeki, T; Toge, T; Yoshinaka, K, 1988
)
0.27
"For many years surgery has been the treatment of choice for squamous cell carcinoma of the anus, but it is now becoming apparent that well-planned definitive radiation therapy combined with chemotherapy may obviate the need for an abdomino-perineal resection."( The use of radiation therapy combined with chemotherapy in the management of squamous cell carcinoma of the anus and marginally resectable adenocarcinoma of the rectum.
Sischy, B, 1985
)
0.27
"The effects of reduction surgery combined with chemotherapy used by MMC and ADM for DAB induced hepatoma were investigated."( [Experimental and clinical study of reduction surgery combined with chemotherapy of primary liver cancer].
Nakanishi, Y; Sano, H, 1985
)
0.27
"At present hyperthermia shows great promise when combined with other modalities."( [Clinical application of local hyperthermia combined with antineoplastic agents].
Ishiwata, J; Iwamoto, S; Koike, M; Maeda, Y; Masuda, T; Sasaki, T; Takeshita, Y; Tanaka, Y, 1985
)
0.27
" In this study we have examined the cytokinetic effects of this drug combination in vitro and in human bone marrow in vivo."( Cytokinetic evaluation of the four-drug combination of bleomycin, vincristine, mitomycin C, and methotrexate (BOMM) in cultured Burkitt's lymphoma cells and human bone marrow.
Clauw, DJ; Ensminger, WD; O'Toole, TE; Wheeler, RH, 1982
)
0.49
"Augmentation of antitumor activity of Lactobacillus casei YIT 9018 (LC 9018), which strongly inhibits the growth of transplantable allogeneic and syngeneic mouse tumors, in combination with antitumor drugs was investigated."( [Augmentation of antitumor activity of Lactobacillus casei YIT 8018 (LC 9018) in combination with various antitumor drugs].
Kato, I; Matsuzaki, T; Mutai, M; Yokokura, T, 1984
)
0.27
" At this time the ITC therapy is used in combination with induced-hypertension-chemotherapy (IHC therapy)."( [The clinical effect of hyperthermia combined with induced hypertension chemotherapy].
Hayashida, S; Kobayashi, T; Sugimoto, K, 1984
)
0.27
" The retinoids given in combination with MMC produced additive effects."( [Inhibitory effects of aromatic retinoic acid analog, administered alone or in combination with mitomycin C, on the in vitro growth of rat bladder carcinoma cells].
Fujita, J; Yoshida, O, 1984
)
0.49
"An aromatic retinoic acid analog (Ro 10-9359) was given orally in combination with intraperitoneal administration of mitomycin C (MMC), in an attempt to reduce the toxicity and enhance the therapeutic effect."( Therapeutic effect of an aromatic retinoic acid analog on rats with bladder carcinoma upon administration alone or in combination with mitomycin C.
Fujita, J; Miyakawa, M; Tokuda, H; Yoshida, O, 1982
)
0.68
"The sensitivity of two human pancreatic adenocarcinomas (Capan-1 and Capan-2) to heat and heat combined with chemotherapy was studied using xenografts of the tumors in the foot of athymic nude mice."( Sensitivity of xenografts of human pancreatic adenocarcinoma in nude mice to heat and heat combined with chemotherapy.
Cahan, A; Fogh, J; Fortner, JG; Shiu, MH, 1983
)
0.27
" In the TBHT combined with anticancer chemotherapy, a partial remission was observed in 4 (25."( [Application of heat combined with antineoplastic agent administration in the treatment of cancer (with special reference to malignancy of the digestive system)].
Hamazoe, R; Izumi, A; Koga, S; Maeta, M; Shimizu, N, 1983
)
0.27
"The effect of 5-fluorouracil (5-FU) in combination with herb medicine on the prolongation of survival rate in tumor bearing mice was studied."( [An approach to prolongation of survival rate in tumor bearing mice using 5-fluorouracil in combination with various kinds of herb medicine].
Abe, H; Odashima, S; Ohta, T; Tatsuka, M; Tawara, M, 1983
)
0.27
"The effects of mitomycin C alone and in combination with radiation on the cells of EMT6 mouse mammary tumors in BALB/cKaRw mice were examined."( Effects of mitomycin C alone and in combination with X-rays on EMT6 mouse mammary tumors in vivo.
Rockwell, S, 1983
)
1.01
"A short-term intensive chemotherapy (STIC) consisting of large dose of mitomycin C (MMC), tegafur (FT-207), streptococcus preparation picibanil (OK-432) and Krestin (PSK), combined with IVH was performed in 72 patients with advanced gastric cancer."( [Short-term intensive chemotherapy (STIC) combined with intravenous hyperalimentation in advanced stomach cancer].
Hamazoe, R; Kanayama, H; Karino, T; Koga, S; Maeta, M; Oda, M; Osaki, Y; Shimizu, N; Yamane, T, 1983
)
0.5
" The difference between the effect of MMC alone and that of MMC given in combination with Ro 10-9359 was not statistically significant."( Therapeutic effect of a retinoid (Ro 10-9359) on rats with bladder tumours induced by N-butyl-N-(4-hydroxybutyl)-nitrosamine upon administration alone or in combination with mitomycin C.
Fujita, J; Ito, Y; Tokuda, H; Yoshida, O, 1983
)
0.46
"The FAM combination with the simultaneous administration of 5-fluorouracil, doxorubicin, and mitomycin C is considered standard chemotherapy for gastric adenocarcinoma."( Drug combinations in the treatment of gastric adenocarcinoma: a randomized Southwest Oncology Group study.
Athens, J; Chen, TT; Costanzi, JJ; Haas, C; Heilbrun, LK; McDonald, B; Oishi, N; Panettiere, FJ; Talley, RW, 1984
)
0.49
"Intracarotid CDDP infusion in combination with angiotensin II was performed in two patients with metastatic brain tumor, lung carcinoma (LC) and ovarian carcinoma (OC)."( [Intracarotid arterial infusion with CDDP in combination with angiotensin II].
Hino, N; Mitsuhata, N; Nishigaki, S; Suga, K; Tagusagawa, Y, 1984
)
0.27
"The anti-tumor effect of twice a week instillation of 30 mg mitomycin C combined with 200 mg cytosine arabinoside dissolved in 30 ml saline was studied in 37 bladder tumor patients."( [Anti-tumor effect of intravesical instillation of mitomycin C combined with cytosine arabinoside].
Fujioka, H; Matsuda, M; Matsumiya, K; Nakano, E; Osafune, M; Sonoda, T; Tada, Y; Takaha, M, 1984
)
0.76
"The effect of fibrinolytic agents, Tissue Culture Urokinase (TCUK) and Urinary Urokinase (UUK), was investigated in a total of 146 patients with gastric cancer, pulmonary cancer or breast cancer who received various anti-cancer agents, mainly MMC, in combination with the fibrinolytic agents."( [Clinical evaluation of various antineoplastic agents combined with urokinase--a comparison between urokinase from tissue culture (TCUK) and urine-derived urokinase (UUK)].
Yamamoto, M, 1982
)
0.26
"The levels of anticancer drugs in tissue were measured by bioassay method in 28 patients with gastrointestinal cancer, who were treated with intravenous administration of 500 mg of 5-FU combined with ANG-II during surgery."( [Clinical studies of cancer chemotherapy combined with angiotensin-II (ANG-II)].
Kanno, H; Kikuchi, K; Kunii, Y; Takahashi, N, 1982
)
0.26
"In a prospective randomized study, 53 patients with advanced gastric cancer previously untreated by chemotherapy were randomly assigned to treatment with 5-FU alone or combined with mitomycin and cytarabine (MFC)."( Randomized comparison of 5-FU alone or combined with mitomycin and cytarabine (MFC) in the treatment of advanced gastric cancer.
Cocconi, G; DeLisi, V; Di Blasio, B, 1982
)
0.71
" This study assesses prospectively the results of liver resection as compared to liver resection combined with pre- and post-operative locoregional chemotherapy-immunotherapy in 40 patients suffering from hepatocellular carcinoma."( Hepatocellular carcinoma: surgical resection versus surgical resection combined with pre- and post-operative locoregional immunotherapy-chemotherapy. A prospective randomized study.
Konstantinidou, AE; Lygidakis, NJ; Pothoulakis, J; Spanos, H,
)
0.13
"Between March 1991 and October 1993, 49 patients with inoperable head and neck carcinoma were randomly assigned to receive either radiation therapy alone (group A) or radiotherapy combined with simultaneous application of Mitomycin C and Bleomycin (group B)."( Radiotherapy, combined with simultaneous chemotherapy with mitomycin C and bleomycin for inoperable head and neck cancer--preliminary report.
Budihna, M; Furlan, L; Lesnicar, H; Rudolf, Z; Smid, L; Soba, E; Zakotnik, B; Zargi, M, 1995
)
0.72
"In the present study, repeated hepatic dearterialization combined with intra-arterial infusion chemotherapy was performed in patients with unresectable tumors of the liver."( [Efficacy of repeated hepatic dearterialization combined with intra-arterial infusion chemotherapy for unresectable tumors of the liver].
Hashimoto, N; Hayashi, T; Kohno, H; Kubota, H; Nagasue, N; Ono, T; Uchida, M; Yamanoi, A, 1995
)
0.29
"To evaluate the efficacy of intra-arterial chemotherapy combined with hyperthermia for metastatic liver cancer, our cooperative study group carried out a randomized clinical trial comparing intra-arterial chemotherapy alone and intra-arterial chemotherapy combined with hyperthermia."( [A prospective randomized clinical trial comparing intra-arterial chemotherapy alone and when combined with hyperthermia for metastatic liver cancer].
Hiraoka, M; Itani, K; Kondo, M; Miura, K; Noguchi, M; Tanaka, Y; Watanabe, N; Yoshikawa, T, 1995
)
0.29
" When m-THPC PDT was combined with mitomycin C (MMC), light doses could be decreased by a factor of 2 for equal tumour effects."( Mechanisms for optimising photodynamic therapy: second-generation photosensitisers in combination with mitomycin C.
Oppelaar, H; Oussoren, YG; Schuitmaker, JJ; Stewart, FA; van Geel, IP, 1995
)
0.78
"61 cases of the gastric cancers have been treated with Replenishing Qi and Invigorating Spleen (RQIS) combined with chemotherapy."( [Clinical and experimental study in treating gastric cancer with replenishing qi and invigorating spleen oral liquid combined with chemotherapy].
Chen, CH; Sun, GZ; Wang, GM, 1994
)
0.29
" The synergistic effect was especially prominent when PDT was used in combination with a low dose of MMC (1 mg kg-1), since treatment of 1 mg kg-1 MMC alone had no effect on the tumour."( Anti-tumour activity of photodynamic therapy in combination with mitomycin C in nude mice with human colon adenocarcinoma.
Iani, V; Ma, LW; Moan, J; Steen, HB, 1995
)
0.53
" Interim analysis did not demonstrate a favorable effect of the combination with this chemotherapeutic agent compared to orchidectomy alone (P = ."( Interim results on a randomized trial of mitomycin C in combination with orchidectomy for newly diagnosed metastatic prostate cancer.
Baert, L; Billiet, I; Casselman, J; Derluyn, J; Paridaens, R; Popelier, G; Van Poppel, H; Vandenbroucke, F; Vanuytsel, L, 1995
)
0.56
" These results show that AO-90 in combination with MF therapy is efficacious in the treatment of patients with gastric cancer."( [A controlled study of AO-90, a methionine-free intravenous amino acid solution, in combination with 5-fluorouracil and mitomycin C in advanced gastric cancer patients (internal medicine group evaluation)].
Akazawa, S; Kitamura, S; Kosaki, G; Kurihara, M; Nakano, S; Ohtani, T; Sasaki, T; Takahashi, H; Tokunaga, K, 1995
)
0.5
" When the BFA HC-1 was used to be combined with MMC for the targeting treatment of human HCC implanted in nude mice, the highly significant suppression of tumor growth was achieved."( [Targeting treatment of human HCC xenografts implanted in nude mice using bifunctional antibody HC-1 combined with mitomycin C].
Liu, KD; Tang, ZY; Wei, C, 1994
)
0.5
"In an attempt to prevent local recurrence, intraoperative pelvic hyperthermochemotherapy (IOPHC) was performed in combination with curative surgery for rectal cancer."( [Pelvic hyperthermochemotherapy combined with surgery for rectal cancer].
Fujimoto, S; Ito, M; Kobayashi, K; Masaoka, H; Mutou, T; Takahashi, M, 1994
)
0.29
" QDBS syndrome is somehow related to immuno-deficiency and blood hypercoagulability, the method of Yiqi Huoxue (YQHX) which used to be combined with chemotherapy could not only reduce the toxic-side effects of chemotherapy, but also improve the cellular immune function and hemorheology."( [Studies of guben quyu No I combined with chemotherapy in treating cancer].
Peng, XM; Rao, XQ; Yu, RC, 1994
)
0.29
"7% tumor growth inhibition, and these conditions for hyperthermia were subsequently used as a criterion for evaluating the effects of its combination with various anticancer agents."( Studies of effects of anticancer agents in combination with/without hyperthermia on metastasized human bladder cancer cells in chick embryos using the polymerase chain reaction technique.
Endo, Y; Kunimi, K; Lee, SW; Noguchi, M; Ohkawa, M; Sasaki, T; Uchibayashi, T, 1994
)
0.29
" These results provide a rationale for using short duration of FUdR in combination with other drugs."( Short-term intrahepatic FUdR infusion combined with bolus mitomycin C: reduced risk for developing drug resistance.
Arisawa, Y; Dalton, RR; Sigurdson, ER; Sutanto-Ward, E, 1994
)
0.53
" The seven agents combined with CI-973 were mitomycin C, cyclophosphamide, doxorubicin, vinblastine, etoposide, ifosfamide, and methotrexate."( Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
Elliott, WL; Howard, CT; Leopold, WR; Roberts, BJ, 1994
)
0.55
"This study was conducted to investigate the activity and toxicity of 5fluorouracil folinic acid+mitomycin C combined with alpha 2b interferon in advanced colorectal cancer based upon recent studies suggesting a possible biochemical modulation of 5fluorouracil by interferon."( Mitomycin C, 5fluorouracil and folinic acid in combination with alpha 2b interferon for advanced colorectal cancer.
Bascioni, R; Battelli, N; Battelli, T; Delprete, S; Manocchi, P; Mattioli, R; Mazzanti, P; Pilone, A; Rossini, S; Silva, RR, 1993
)
1.95
"Between June 1990 and April 1991 25 previously untreated patients with advanced colorectal carcinoma were treated with mitomycin C 10 mg/m2 iv bolus on day 1, 5fluorouracil 375 mg/m2 on days 1 to 4 and folinic acid 200 mg/m2 on days 1 to 4 every 4 weeks, combined with alpha 2b interferon 3 million U day continuously."( Mitomycin C, 5fluorouracil and folinic acid in combination with alpha 2b interferon for advanced colorectal cancer.
Bascioni, R; Battelli, N; Battelli, T; Delprete, S; Manocchi, P; Mattioli, R; Mazzanti, P; Pilone, A; Rossini, S; Silva, RR, 1993
)
1.94
" No therapeutic efficacy was observed with CGP 19835A alone or in combination with any of a series of cytotoxic or biological agents, including cis-platinurn (cis-Pt), mitomycin C (MMC), adriamycin (ADR), cyclophosphamide (CP), interferon gamma (IFN gamma), and interleukin 2 (IL-2)."( Analysis of the antimetastatic effects of synthetic muramyl tripeptide (CGP 19835A) encapsulated in liposomes in combination with other immunomodulatory agents and chemotherapeutic drugs.
Bezault, J; Frost, H; Furmanski, P; Liebes, L; Tarcsay, L; Walsh, C,
)
0.33
"To compare the effect on the RIF-1 murine sarcoma of nine bioreductive agents from five different classes when used in combination with either photodynamic therapy or clamping."( Comparing the anti-tumor effect of several bioreductive drugs when used in combination with photodynamic therapy (PDT).
Adams, GE; Bradley, JK; Bremner, JC; Naylor, MA; Sansom, JM; Stratford, IJ, 1994
)
0.29
"RIF-1 tumors implanted intradermally in C3H mice were treated with either 50J photodynamic therapy or with 120 min clamping in combination with either misonidazole, pimonidazole, metronidazole, nimorazole, RB6145, RSU1069, SR4233, mitomycin-C, or RB90740."( Comparing the anti-tumor effect of several bioreductive drugs when used in combination with photodynamic therapy (PDT).
Adams, GE; Bradley, JK; Bremner, JC; Naylor, MA; Sansom, JM; Stratford, IJ, 1994
)
0.47
"RSU1069 produced the greatest anti-tumor activity in combination with both photodynamic therapy and clamping."( Comparing the anti-tumor effect of several bioreductive drugs when used in combination with photodynamic therapy (PDT).
Adams, GE; Bradley, JK; Bremner, JC; Naylor, MA; Sansom, JM; Stratford, IJ, 1994
)
0.29
"Of the bioreductive agents studied RSU1069, RB6145 and mitomycin-C showed the greatest anti-tumor response in combination with photodynamic therapy."( Comparing the anti-tumor effect of several bioreductive drugs when used in combination with photodynamic therapy (PDT).
Adams, GE; Bradley, JK; Bremner, JC; Naylor, MA; Sansom, JM; Stratford, IJ, 1994
)
0.54
"In the present comparative study, we examined an intra-arterial chemotherapy combined with PJ-203 in 60 patients with liver cancer metastasized from gastrointestinal cancer, using an intra-arterial chemotherapy alone as the control."( [Comparative clinical study in metastatic liver cancer between intra-arterial infusion of mitomycin C alone and intra-arterial infusion of mitomycin C combined with PJ-203 (degradable starch microspheres)].
Kondo, M; Nakamura, H; Ogawa, N; Okawa, T; Taguchi, T; Tanikawa, K, 1993
)
0.51
" This trial was undertaken to investigate the value of mitomycin C given with low dose suramin."( Suramin in combination with mitomycin C in hormone-resistant prostate cancer. A phase II clinical study.
de Wet, M; Falkson, G; Lotz, BP; Potgieter, HC; Raats, JI; Rapoport, BL, 1993
)
0.83
"2 mg/kg) given intra-arterially in combination with a temporary embolizing material, degradable starch microspheres (DSM, 5 mg/kg), to rabbits in which VX2 tumors had been implanted into the liver."( [Effect of intra-arterial chemotherapy combined with degradable starch microspheres against liver cancer--a study by experimental VX2 liver tumor model].
Itani, K; Kokura, S; Kondo, M; Oyamada, H; Yoshikawa, T, 1993
)
0.29
"We have investigated the therapeutic effect of CH-271 fusion polypeptide containing both cell-binding domain (C-274) and heparin-binding domain (H-271) of fibronectin in combination with anticancer drugs such as doxorubicin (DOX) or mitomycin C (MMC) on tumor metastasis of different types of tumors."( Antimetastatic effect by anti-adhesion therapy with cell-adhesive peptide of fibronectin in combination with anticancer drugs.
Azuma, I; Igarashi, Y; Ishizaki, Y; Kato, I; Kobayashi, H; Komazawa, H; Saiki, I; Yoneda, J, 1993
)
0.47
" Taking advantage of this pharmacodynamic effect, we have previously shown that FAA in combination with hyperthermia (HT) can produce a marked improvement in antitumor response in mice."( Flavone acetic acid increases the cytotoxicity of mitomycin C when combined with hyperthermia.
Baba, H; Maehara, Y; Newman, RA; Sugimachi, K; Takeuchi, H, 1996
)
0.55
" Experimental data suggest a synergistic cytotoxic activity of alpha-interferon (alpha-IFN) when combined with cisplatin, mitomycin C and vinca alkaloids."( A phase II study of mitomycin C, vindesine and cisplatin combined with alpha interferon in advanced non-small cell lung cancer.
Bascioni, R; Battelli, N; Battelli, T; Delprete, S; Gasparini, S; Mattioli, R; Pilone, A; Rossini, S; Silva, RR; Zuccatosta, L,
)
0.66
" Larger randomized trials are needed to assess the role of alpha-IFN combined with chemotherapy in advanced NSCLC."( A phase II study of mitomycin C, vindesine and cisplatin combined with alpha interferon in advanced non-small cell lung cancer.
Bascioni, R; Battelli, N; Battelli, T; Delprete, S; Gasparini, S; Mattioli, R; Pilone, A; Rossini, S; Silva, RR; Zuccatosta, L,
)
0.45
"The in vitro predictive chemosensitivity of a HeLa-S3 human cervical cancer cell line to a new series of Cu(II) complexes as well as their combination with several chemotherapeutic drugs was determined."( In vitro synergistic effects of some novel Cu(II) complexes in combination with epirubicin and mitomycin C against HeLa-S3 cervical cancer cell line.
Geromichalos, GD; Hadjikostas, CC; Katsoulos, GA; Kortsaris, AH; Kyriakidis, DA, 1996
)
0.51
"In an attempt to prevent postoperative intraperitoneal recurrence in patients with advanced gastric cancer and consequently to improve survival time, we treated patients with intraperitoneal hyperthermic perfusion (IPHP) using mitomycin C (MMC) combined with surgery."( Survival time and prevention of side effects of intraperitoneal hyperthermic perfusion with mitomycin C combined with surgery for patients with advanced gastric cancer.
Fujimoto, S; Kobayashi, K; Kondoh, K; Mutou, T; Ohkubo, H; Takahashi, M; Toyosawa, T, 1996
)
0.7
" In the present study we have evaluated the therapeutic efficacy of pamidronate (3-amino-1-hydroxypropylidene-1,1-bisphosphonic acid) combined with mitomycin C (MMC) on bone metastasis of breast cancer using an animal model."( Therapeutic efficacy of pamidronate in combination with chemotherapy to bone metastasis of breast cancer in a rat model.
Enomoto, K; Ikeda, T; Ishii, S; Kitajima, M; Tamura, H; Wada, N, 1996
)
0.49
"IHCP combined with aggressive surgery was performed in 48 gastric carcinoma patients with peritoneal carcinomatosis; 18 gastric carcinoma patients with peritoneal carcinomatosis serving as controls were treated with surgery alone."( Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery.
Fujimoto, S; Isawa, E; Kobayashi, K; Mutou, T; Ohkubo, H; Sumida, M; Takahashi, M; Toyosawa, T, 1997
)
0.3
" IHCP treatment combined with extensive surgery provides an effective and practical method of treating this disease entity."( Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery.
Fujimoto, S; Isawa, E; Kobayashi, K; Mutou, T; Ohkubo, H; Sumida, M; Takahashi, M; Toyosawa, T, 1997
)
0.3
"For the purpose of local control and breast conservation, intraarterial infusion chemotherapy combined with radiotherapy has been indicated in patients with locally advanced breast cancer both in primary and recurrent cases."( [Experience in treatment of patients with locally advanced or recurrent breast cancer: intraarterial infusion chemotherapy combined with radiotherapy].
Kazawa, N; Kobayashi, K; Kono, K; Kuroda, Y; Maetani, Y; Murakami, M; Okamoto, Y; Sai, H; Sano, A; Sasaki, R; Yoden, E, 1997
)
0.3
" In this pilot study, we tested the feasibility of MMC/VBL administration in combination with amifostine and we monitored the hematologic toxicity closely."( Mitomycin C and vinblastine in combination with amifostine in metastatic breast cancer. A feasibility study of the EORTC--Investigational Drug Branch for Breast Cancer (IDBBC).
Awada, A; Geurs, F; Habboubi, N; Kerger, J; Kusenda, Z; Piccart, MJ; Van Vreckem, A, 1997
)
1.74
"2 MHz) alone and in combination with a chemical DNA-damaging agent (mitomycin C)."( Cytogenetic effects of 935.2-MHz (GSM) microwaves alone and in combination with mitomycin C.
Collier, M; Maes, A; Van Gorp, U; Vandoninck, S; Verschaeve, L, 1997
)
0.76
"Porfiromycin (methyl mitomycin C) has been shown in laboratory studies to have increased preferential cytotoxicity to hypoxic cells and therefore may provide enhanced therapeutic efficacy over mitomycin C when used in combination with radiation therapy (RT)."( Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck.
Fischer, D; Fischer, JJ; Haffty, BG; Papac, R; Rockwell, S; Ross, D; Sartorelli, AC; Sasaki, CT; Son, YH; Wilson, LD, 1997
)
0.62
" CGP 69846A, in combination with cisplatin, showed superadditive antitumor effects against PC3 human prostate carcinomas with tumor cures, and in combination with mitomycin C, superadditive antitumor effects of CGP 69846A with tumor cures against NCI-H460 large cell lung carcinoma were found."( Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice.
Fabbro, D; Geiger, T; Monia, BP; Müller, M, 1997
)
0.49
" 1), a new cisplatin-derived compound, in combination with five conventional anticancer drugs: the antimetabolites 5-fluorouracil (5FU) and methotrexate (MTX), the alkylating agent mitomycin C (MMC), the antimicrotubule agent taxol (TAX) and the intercalating agent of the antracycline group doxorubicin (DOX), against murine P388 leukemic cells."( Effect of the cisplatin-procaine complex DPR in combination with several anticancer agents on murine P388 leukemic cells in vitro and in vivo.
Cafaggi, S; Esposito, M; Mariggiò, MA; Parodi, A; Pastrone, I; Viale, M,
)
0.32
"To evaluate the feasibility and the tolerance of Peritonectomy Procedure (PP) combined with Intraperitoneal Chemohyperthermia (IPCH) in patients with peritoneal carcinomatosis, a phase I-II study has been realised from January 1997 to September 1998."( Peritonectomy combined with intraperitoneal chemohyperthermia in abdominal cancer with peritoneal carcinomatosis: phase I-II study.
Beaujard, A; Benoit, M; Bienvenu, J; Caillot, JL; Francois, Y; Garbit, F; Gilly, FN; Glehen, O; Grandclement, E; Gueugniaud, PY; Sadeghi-Looyeh, B; Vignal, J,
)
0.13
" In order to promote the clinical response of chemotherapy for colorectal cancer using CPT-11, one of the most effective strategies is to use it in combination with other anticancer agents."( In vitro augmentation of antitumor effect in combination with CPT-11 and CDDP for human colorectal cancer.
Hotta, T; Ishimoto, K; Iwahashi, M; Matsuda, K; Tanaka, H; Tani, M; Tanimura, H; Tsunoda, T; Yamaue, H, 2000
)
0.31
" The augmentation of the antitumor effectiveness of 7-ethyl-10-hydroxy-CPT (SN-38) was analyzed in combination with other anticancer agents."( In vitro augmentation of antitumor effect in combination with CPT-11 and CDDP for human colorectal cancer.
Hotta, T; Ishimoto, K; Iwahashi, M; Matsuda, K; Tanaka, H; Tani, M; Tanimura, H; Tsunoda, T; Yamaue, H, 2000
)
0.31
"The percent inhibition of SN-38 in combination with cisplatin (CDDP) and mitomycin revealed a high anticancer effect compared with each anticancer agent alone for freshly isolated rectal cancer."( In vitro augmentation of antitumor effect in combination with CPT-11 and CDDP for human colorectal cancer.
Hotta, T; Ishimoto, K; Iwahashi, M; Matsuda, K; Tanaka, H; Tani, M; Tanimura, H; Tsunoda, T; Yamaue, H, 2000
)
0.54
" However, BW12C in combination with MMC for 5-FU-resistant colorectal cancer is not an effective regimen."( Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer.
Braybrooke, JP; Dixon, RM; Ganesan, TS; Harris, AL; Levitt, NC; Littlewood, TJ; O'Byrne, K; Propper, DJ; Rajagopalan, B; Talbot, DC; Thompson, CH, 2000
)
0.52
"The results revealed synergistic cytotoxicity when vinflunine was combined with cisplatin, mitomycin C, doxorubicin or 5-fluorouracil."( In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloid, in combination with other anticancer drugs.
Barret, JM; Etiévant, C; Hill, BT, 2000
)
0.53
"This study was performed to investigate the activity and safety of high dose 5-fluorouracil (5-FU) given as a weekly 24-hour infusion in combination with folinic acid plus mitomycin C in patients with advanced gastric cancer."( Weekly 24-hour infusion of high-dose 5-fluorouracil plus folinic acid in combination with mitomycin C for the treatment of advanced gastric cancer.
Benter, T; Dörken, B; Hohenberger, P; Köhne, CH; Kretzschmar, A; Reichardt, P; Thuss-Patience, PC, 2000
)
0.72
" 28 evaluable patients with previously untreated symptomatic NSCLC and mesothelioma were randomized to receive either 3 weekly intravenous combination chemotherapy alone, or chemotherapy given with monthly intra-dermal injections of SRL172."( A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma.
Bromelow, KV; Gregory, K; Kennard, DA; Mendes, R; O'Brien, ME; Palmer, RD; Priest, K; Ryan, C; Saini, A; Smith, IE; Souberbielle, BE; Tuckwell, N; Webb, A, 2000
)
0.31
"Our experience of arterial infusion chemotherapy combined with regional hyperthermia in the treatment of non-resectable pancreatic cancer was presented."( [Intra-arterial infusion chemotherapy in combination with microwave hyperthermia for cancer of head of pancreas and liver metastasis--a case of 16 years survival].
Endo, Y; Ikeda, H; Matumoto, Y; Miura, T, 2000
)
0.31
" We describe the design of a phase II study to investigate the safety and efficacy of UFT/leucovorin combined with mitomycin-C in a larger group of previously untreated patients with metastatic colorectal cancer."( UFT/leucovorin combined with mitomycin-C in metastatic colorectal Ca.
Jakobsen, A, 2000
)
0.81
"Main portal branch transection combined with major liver resection and neoadjuvant and adjuvant locoregional immunochemotherapy fulfilled our expectations firstly for increasing the resectability rate and secondly for increasing the overall survival and the disease-free survival."( Preoperative main portal branch transection combined with liver locoregional transarterial neo and adjuvant immunochemotherapy for patients with hepatocellular carcinoma.
Dedemadi, G; Kontis, A; Lygidakis, NJ; Nestoridis, J; Sgourakis, G; Spentzouris, N,
)
0.13
" Four cohorts of patients were recruited with MMC given at 8 mg/m2 for the first 3 levels together with irinotecan at 300 mg/m2, 325 mg/m2, and 350 mg/m2; the fourth dose level was given with MMC at 10 mg/m2 and irinotecan at 325 mg/m2."( Phase I-II study of irinotecan in combination with mitomycin C in patients with advanced gastrointestinal cancer.
Adam, R; Antoine, EC; Bassot, V; Benhammonda, A; Bismuth, H; Castaing, D; Gil-Delgado, MA; Grapin, JP; Guinet, F; Khayat, D, 2001
)
0.56
"To assess the clinical effect and safety of Shenqi Fuzheng Injection (SQFZI) combined with chemotherapy in treating malignant tumor of digestive tract."( [Clinical study on Shenqi Fuzheng injection combined with chemotherapy in treating malignant tumor of digestive tract].
Wang, J; Xin, M; Zhou, C, 1998
)
0.3
"SQFZI combined with chemotherapy has certain effect of remitting and stablizing on digestive tract tumor, the clinical effect is significant to patients with Qi-Deficiency, and is safe and reliable."( [Clinical study on Shenqi Fuzheng injection combined with chemotherapy in treating malignant tumor of digestive tract].
Wang, J; Xin, M; Zhou, C, 1998
)
0.3
"This communication represents the definitive report of a randomized phase III study comparing cisplatin and carboplatin, in combination with vindesine and mitomycin C in stage IIIB and IV squamous-cell bronchogenic carcinoma."( Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study.
Babović, N; Elezar, E; Gavrilović, D; Jelić, S; Kovacević, S; Kovcin, V; Mitrović, L; Radosavljević, D; Radulović, S; Tomasević, Z, 2001
)
0.73
" Thirty-one patients with superficial oesophageal or gastric cardiac carcinomas, who refused or were unsuitable for surgery, received endoscopic Nd:YAG laser therapy combined with local injection of chemotherapeutic drugs 5-fluorouracil and mitomycin."( Endoscopic Nd:YAG laser therapy combined with local chemotherapy of superficial carcinomas of the oesophagus and gastric cardia.
Huang, T; Jia, J; Wang, Y; Zhou, C, 2001
)
0.49
"The aim of this study was to evaluate the clinical effectiveness of intra-arterial chemotherapy combined with degradable starch microspheres (DSM) for liver metastases and the possibility of predicting the effectiveness of the chemotherapy by pretreatment diagnostic imaging."( [Clinical effectiveness of intra-arterial chemotherapy combined with degradable starch microspheres (DSM) for liver metastases and prediction of effectiveness by diagnostic imaging].
Majima, T; Nakajima, T; Nozu, S; Okayasu, K; Saitou, AY; Yagi, A, 2001
)
0.31
"To assess the effect and mechanism of composite Xiansu Capsule (CXSC) combined with chemotherapy in treating gastric carcinoma of mid-late stage."( [Clinical study on treatment of mid-late stage gastric carcinoma by composite xiansu capsule combined with chemotherapy].
Hua, B; Wang, A, 1999
)
0.3
"The 61 patients of the test group were treated by CXSC combined with chemotherapy and 30 patients of the control group treated with chemotherapy alone."( [Clinical study on treatment of mid-late stage gastric carcinoma by composite xiansu capsule combined with chemotherapy].
Hua, B; Wang, A, 1999
)
0.3
"To assess the clinical effect of Shenqi Fuzheng Injection (SQFZI) combined with chemotherapy in treating gastric cancer."( [Clinical study on effect of shenqi fuzheng injection combined with chemotherapy in treating gastric cancer].
Liu, B; Wang, J; Zhou, K, 1999
)
0.3
"SQFZI combined with chemotherapy has certain effect of remission and stabilization on gastric cancer, the clinical effect is significant to patients with Qi-Deficiency, and is reliable and safe."( [Clinical study on effect of shenqi fuzheng injection combined with chemotherapy in treating gastric cancer].
Liu, B; Wang, J; Zhou, K, 1999
)
0.3
"The potential of Mitomycin C in combination with fractionated irradiation to inhibit tumour cell repopulation of a fast growing squamous cell carcinoma after fractionated radiotherapy was investigated in vivo."( Mitomycin C in combination with radiotherapy as a potent inhibitor of tumour cell repopulation in a human squamous cell carcinoma.
Bamberg, M; Belka, C; Budach, W; Classen, J; Marini, P; Paulsen, F; Scheithauer, H; Welz, S, 2002
)
2.1
" The potential application of administering irofulven in combination with aziridine-containing chemotherapeutic agents was evaluated in this study."( Enhanced antitumor activity of irofulven in combination with thiotepa or mitomycin C.
Estes, L; Kelner, MJ; McMorris, TC; Rojas, RJ; Trani, NA, 2002
)
0.55
"Human lung carcinoma MV522 cells and BALB/c athymic mice bearing the human lung carcinoma MV522 xenograft were used to evaluate the activity of irofulven in combination with aziridine-containing drugs."( Enhanced antitumor activity of irofulven in combination with thiotepa or mitomycin C.
Estes, L; Kelner, MJ; McMorris, TC; Rojas, RJ; Trani, NA, 2002
)
0.55
"Irofulven in combination with either thiotepa or mitomycin C demonstrated a strong synergistic (supraadditive) activity both in vitro and in vivo, that exceeded results obtained with monotherapy at the same or higher doses of these agents."( Enhanced antitumor activity of irofulven in combination with thiotepa or mitomycin C.
Estes, L; Kelner, MJ; McMorris, TC; Rojas, RJ; Trani, NA, 2002
)
0.8
"These results indicate that the therapeutic activity of irofulven is enhanced when combined with mitomycin C or thiotepa, and further evaluation of these combinations is therefore warranted."( Enhanced antitumor activity of irofulven in combination with thiotepa or mitomycin C.
Estes, L; Kelner, MJ; McMorris, TC; Rojas, RJ; Trani, NA, 2002
)
0.76
" For advanced gastric cancer, although gastric cancer cells are generally not very sensitive to most of the currently available chemotherapeutic agents, it has been reported that biochemical modulation with treatments including low-dose cisplatin + 5-FU (fluorouracil) have high response rates and exert an immunomodulatory effect especially when used in combination with BRMs."( Clinical potential of biological response modifiers combined with chemotherapy for gastric cancer. Japanese experience.
Andou, K; Fujisaki, S; Fukuzawa, M; Nezu, T; Shibata, M; Tomita, R, 2002
)
0.31
" In addition, oral administration of CWSP concurrently with 5-fluorouracil (5-FU) or mitomycin C (MMC), significantly increased tumor regression as compared with the respective chemotherapy alone, illustrating the adjuvant effect of orally administered CWSP for tumor regression when combined with chemotherapeutic agents."( Antitumor and anticytopenic effects of aqueous extracts of propolis in combination with chemotherapeutic agents.
Fujimiya, Y; Groveman, DS; Hayashi, I; Suzuki, I; Takaki, T, 2002
)
0.54
"To observe the effects of chemotherapy combined with Chinese herbal medicine (Spleen-Kidney tonifying) in treating advanced tumor patients and on immune parameters."( [Clinical observation on effect of chemotherapy combined with Chinese medicine in treating advanced tumor patients and on immunologic parameters].
Gong, LY; Jiang, CM; Pang, MR, 2001
)
0.31
"One hundred and one advanced tumor patients were randomly divided into the treated group (54 patients) treated by Chinese medicine combined with chemotherapy, and the control group (47 patients) treated by chemotherapy alone."( [Clinical observation on effect of chemotherapy combined with Chinese medicine in treating advanced tumor patients and on immunologic parameters].
Gong, LY; Jiang, CM; Pang, MR, 2001
)
0.31
"Chemotherapy combined with Chinese Spleen-Kidney tonifying drugs could improve the immunologic functions in the advanced tumor patients."( [Clinical observation on effect of chemotherapy combined with Chinese medicine in treating advanced tumor patients and on immunologic parameters].
Gong, LY; Jiang, CM; Pang, MR, 2001
)
0.31
"To evaluate the tolerance of peritonectomy procedures (PP) combined with intraperitoneal chemohyperthermia (IPCH) in patients with peritoneal carcinomatosis (PC), a phase II study was carried out from January 1998 to September 2001."( Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study.
Beaujard, AC; Francois, Y; Freyer, G; Gilly, FN; Glehen, O; Guertsch, P; Mithieux, F; Osinsky, D; Panteix, G; Peyrat, P; Vignal, J, 2003
)
0.32
" In this paper, we report a case in which a patient with a single very large liver cancer has been successfully treated by chemoembolization combined with radiotherapy."( Large primary liver cancer treated by chemoembolization combined with radiotherapy successfully.
Guo, WJ; Yu, EX,
)
0.13
" Sixty-five eyes were combined with MMC (0."( [Long-term follow-up study on Hunan aqueous drainage implantation combined with mitomycin C for refractory glaucoma].
Duan, X; Jiang, Y; Qing, G, 2003
)
0.55
"This study suggests that HAD implantation is an effective method in the management of refractory glaucoma in spite of its unneligible complications and combined with MMC can improve the prognosis."( [Long-term follow-up study on Hunan aqueous drainage implantation combined with mitomycin C for refractory glaucoma].
Duan, X; Jiang, Y; Qing, G, 2003
)
0.55
"To study the clinical effect of trabeculectomy combined with Mitomycin C and removed suture."( [Trabeculectomy combined with mitomycin C and removed suture in glaucoma].
Feng, Y, 2003
)
0.85
"To evaluate the effect of tamoxifen (TAM) combined with a somatostatin analogue, octretide (OCT) on advanced liver cancer and whether tamoxifen combined with OCT is superior to regular chemotherapeutic agents 5-Fu and mitomycin C (MMC)."( Tamoxifen combined with octreotide or regular chemotherapeutic agents in treatment of primary liver cancer: a randomized controlled trial.
Chen, JW; Huo, YC; Pan, DY; Qiao, JG; Shi, HA; Zhou, YK, 2003
)
0.5
"The aim of this study was to define the maximum tolerated dose (MTD) of bolus mitomycin C (MMC) in combination with 24 h-continuous infusion of 5-flourouracil (FU) plus folinic acid, and to assess the toxicity and activity in patients with previously treated colorectal and gastric cancer."( Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study.
Bokemeyer, C; Hartmann, JT; Hofheinz, RD; Honecker, F; Käfer, G; Kanz, L; Köhne, CH; Nehls, O; Oechsle, K; Quietzsch, D; Wein, A, 2003
)
0.77
"To study the therapeutic effect and synergistic inhibition effect of high intensity focused ultrasound in combination with mitomycin on T739 mice bladder tumor."( [An experimental study on high intensity focused ultrasound combined with mitomycin treatment of bladder tumor].
Sun, LA; Wang, GM; Xu, YQ; Xu, ZB; Yang, YF, 2003
)
0.76
"HIFU group, HIFU combined chemotherapy group can distinctively inhibit tumor growth; HIFU combined with mitomycin has notable synergistic inhibitory effect."( [An experimental study on high intensity focused ultrasound combined with mitomycin treatment of bladder tumor].
Sun, LA; Wang, GM; Xu, YQ; Xu, ZB; Yang, YF, 2003
)
0.76
"Several studies have demonstrated the efficacy of systemic oxaliplatin (Oxa) in combination with 5-fluorouracil (5-FU) and folinic acid (FA) for the treatment of colorectal liver metastases (CRLM)."( Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: oxaliplatin pharmacokinetics and feasibility.
Ehrsson, H; Fester, C; Guthoff, I; Kornmann, M; Lotspeich, E; Schatz, M; Wallin, I,
)
0.35
"We designed a phase II trial using Oxa in combination with 5-FU/FA and mitomycin C (MMC) for HAI treatment of patients with isolated non-resectable CRLM."( Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: oxaliplatin pharmacokinetics and feasibility.
Ehrsson, H; Fester, C; Guthoff, I; Kornmann, M; Lotspeich, E; Schatz, M; Wallin, I,
)
0.58
"We conclude from our results that Oxa in combination with 5-FU/FA and MMC may be a feasible protocol for HAI treatment without major toxicity, especially avoiding higher grade neurotoxicity."( Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: oxaliplatin pharmacokinetics and feasibility.
Ehrsson, H; Fester, C; Guthoff, I; Kornmann, M; Lotspeich, E; Schatz, M; Wallin, I,
)
0.35
" The aim was to investigate the therapeutic efficacy and tolerance of mitomycin C (MMC) in combination with gemcitabine (GEM) or capecitabine (CAPE) in previously untreated patients with advanced biliary tract cancer."( Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial.
Depisch, D; Gruenberger, T; Karall, K; Kornek, GV; Laengle, F; Lang, F; Penz, M; Scheithauer, W; Schuell, B, 2004
)
2
"A total of 51 patients were entered in this study and randomly allocated to treatment with MMC 8 mg/m2 on day 1 in combination with GEM 2000 mg/m2 on days 1 and 15 every 4 weeks, or MMC 8 mg/m2 on day 1 plus CAPE 2000 mg/m2/day on days 1-14, every 4 weeks."( Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial.
Depisch, D; Gruenberger, T; Karall, K; Kornek, GV; Laengle, F; Lang, F; Penz, M; Scheithauer, W; Schuell, B, 2004
)
1.77
"Mitomycin C (MMC) in combination with infusional 5-fluorouracil (FU) plus folinic acid (FA) is an effective treatment for metastatic gastrointestinal cancer."( Pegylated liposomal doxorubicin in combination with mitomycin C, infusional 5-fluorouracil and sodium folinic acid. A phase-I-study in patients with upper gastrointestinal cancer.
Gnad, U; Hartmann, JT; Hehlmann, R; Hochhaus, A; Hofheinz, RD; Kreil, S; Saussele, S; Weisser, A; Willer, A, 2004
)
2.02
" The current study was performed to evaluate the outcome of patients with advanced hepatic hilar duct carcinoma who received external beam radiotherapy (EBRT) combined with transarterial chemotherapy and infusion of a vasoconstrictor."( Radiotherapy combined with transarterial infusion chemotherapy and concurrent infusion of a vasoconstrictor agent for nonresectable advanced hepatic hilar duct carcinoma.
Hori, Y; Kiyosue, H; Komatsu, E; Matsumoto, A; Matsumoto, S; Mori, H; Tomonari, K; Wakisaka, M, 2004
)
0.32
" In 10 of 19 patients who had not responded (SD, PD), three additional courses of chemotherapy were combined with sCMT (with 25 sCMT applications)."( Whole-body hyperthermia in the scope of von Ardenne's systemic cancer multistep therapy (sCMT) combined with chemotherapy in patients with metastatic colorectal cancer: a phase I/II study.
Ahlers, O; Deja, M; Dräger, J; Felix, R; Hildebrandt, B; Kerner, T; Löffel, J; Riess, H; Stroszczynski, C; Wust, P, 2004
)
0.32
"CPT-11 combined with MMC can be effective against advanced or recurrent SCC of the uterine cervix."( Phase II study of irinotecan combined with mitomycin-C for advanced or recurrent squamous cell carcinoma of the uterine cervix: the JGOG study.
Fujii, T; Fushiki, H; Hasegawa, K; Izumi, R; Nishida, M; Nishimura, R; Takizawa, K; Tanaka, T; Umesaki, N; Yamamoto, K, 2004
)
0.59
"The purpose of this study was to determine whether systemic glucocorticoid application, in combination with topical mitomycin or dexamethasone, prolongs the patency of a tympanic membrane perforation."( [Systemic corticoid application in combination with topical mitomycin or dexamethasone. Inhibition of wound healing after tympanic membrane perforation].
Hosemann, W; Kaftan, H, 2005
)
0.78
"This study evaluated the effect of transcatheter arterial chem-oembolization combined with external beam radiotherapy on the response rates and sur vival of patients with unresectable hepato-cellular carcinoma."( A comparison of chemoembolization combination with and without radiotherapy for unresectable hepatocellular carcinoma.
Fan, J; Guo, W; Qin, LX; Sun, HC; Tang, ZY; Wang, BL; Wang, JH; Ye, SL; Yu, Y; Zeng, ZC; Zhou, J,
)
0.13
"To explore the change of T cell subsets in patients suffered from hepatocellular carcinoma (HCC) before and after hepatectomy, and study the value of Roferon-A (interferon alpha-2a) combined with hepatic artery chemoembolization (HACE) and portal vein chemotherapy (PVC) after radical resection of HCC for preventing recurrence."( [The value of Roferon-A combined with hepatic artery chemoembolization and portal vein chemotherapy after radical resection in hepatocellular carcinoma for preventing recurrence].
Chen, JS; Duan, ZH; Li, HH; Wang, J; Zhang, HW, 2004
)
0.32
" Effect of Roferon-A combined with HACE and PVC on postoperative recurrence rate was compared with that of HACE and PVC."( [The value of Roferon-A combined with hepatic artery chemoembolization and portal vein chemotherapy after radical resection in hepatocellular carcinoma for preventing recurrence].
Chen, JS; Duan, ZH; Li, HH; Wang, J; Zhang, HW, 2004
)
0.32
"To evaluate the clinical efficacy of capecitabine combined with transcatheter arterial chemoembolization (TACE) for advanced liver cancer."( [Capecitabine combined with TACE for advanced liver cancer].
Chen, AJ; Hu, MD; Li, L; Li, XY; Ran, JH; Sun, F; Tang, JH, 2004
)
0.32
"Capecitabine combined with TACE is safe and effective for advanced liver cancer."( [Capecitabine combined with TACE for advanced liver cancer].
Chen, AJ; Hu, MD; Li, L; Li, XY; Ran, JH; Sun, F; Tang, JH, 2004
)
0.32
" We, therefore, undertook a phase I/II study of ONYX-015, days 1-5 every month administered intratumorally under radiographic guidance, in combination with MAP (mitomycin-C, doxorubicin, cisplatin) chemotherapy in patients with advanced sarcoma."( Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas.
Atherton, P; Edmonson, JH; Erlichman, C; Freeman, S; Galanis, E; Lee, RA; Lewis, BD; Nascimento, AG; Okuno, SH; Oliveira, AM; Randlev, B; Rubin, J; Sloan, JA; Wang, Q, 2005
)
0.52
"A multicenter randomized study comparing high dose of mitomycin and epirubicin given as hepatic intra-arterial chemotherapy (HIAC) combined with caval chemofiltration (CF) versus low doses of the same drugs in unresectable liver metastases from colorectal cancer showed a significant improvement in the survival rate of the 20 patients treated with high dose compared to the 22 patients treated with low doses with a 1 year survival of 69% vs 39%."( Hepatic intra-arterial chemotherapy (HIAC) of high dose mitomycin and epirubicin combined with caval chemofiltration versus prolonged low doses in liver metastases from colorectal cancer: a prospective randomized clinical study.
Bernardeschi, P; Cantore, M; De Simone, M; Dentico, P; Fiorentini, G; Guadagni, S; Poddie, DB; Rossi, G; Rossi, S; Tumolo, S; Valori, VM, 2004
)
0.82
"Patients were randomly assigned to undergo chemotherapy with 5-fluorouracil (5-FU) and mitomycin-C combined with radiotherapy with (arm A: 24 patients) or without ICHT (arm B: 25 patients)."( Chemoradiotherapy combined with intracavitary hyperthermia for anal cancer: feasibility and long-term results from a phase II randomized trial.
Dardoufas, C; Gennatas, C; Kouloulias, V; Kouvaris, J; Papavasiliou, C; Plataniotis, G; Uzunoglu, N; Vlahos, L, 2005
)
0.55
" In an effort to determine a way to better reduce the recurrence of pterygia, we compared the efficacy and safety of amniotic membrane graft (AMG) alone and AMG combined with intraoperative mitomycin C after excision of recurrent pterygia."( Comparison of amniotic membrane graft alone or combined with intraoperative mitomycin C to prevent recurrence after excision of recurrent pterygia.
Hwang, YS; Ma, DH; See, LC; Wang, SF, 2005
)
0.75
"Mitomycin C (MMC) in combination with infusional 5-fluorouracil (5-FU) is a well-tolerated active combination therapy for advanced gastric cancer."( Pegylated liposomal doxorubicin and mitomycin C in combination with infusional 5-fluorouracil and sodium folinic acid in the treatment of advanced gastric cancer: results of a phase II trial.
Gnad-Vogt, SU; Hehlmann, R; Hochhaus, A; Hofheinz, RD; Kreil, S; Pilz, L; Saussele, S; Willeke, F; Willer, A, 2005
)
2.05
"To investigate the effects of mitomycin (MMC) combined with sulindac on cell viability, apoptotic induction and expression of apoptosis-related gene Bcl-2 and cyclooxygenase-2 (COX-2) in gastric cancer SGC-7901 cells."( Apoptosis of human gastric cancer SGC-7901 cells induced by mitomycin combined with sulindac.
Ma, L; Xie, YL; Yu, Y; Zhang, QN, 2005
)
0.86
" MMC combined with sulindac can suppress the growth of gastric cancer cells through induction of apoptosis mediated by down-regulation of apoptosis-related Bcl-2 and COX-2 gene."( Apoptosis of human gastric cancer SGC-7901 cells induced by mitomycin combined with sulindac.
Ma, L; Xie, YL; Yu, Y; Zhang, QN, 2005
)
0.57
" Low-output RFA combined with TACE is a safe, effective therapy for HCC."( [Low-output radiofrequency ablation combined with transcatheter arterial oily-chemoembolization for hepatocellular carcinoma].
Higashi, K; Kimura, M; Maeda, M; Nakai, M; Sahara, S; Sato, M; Shiraki, T; Takeuchi, N; Terada, M, 2005
)
0.33
"The purpose of this pilot study was to evaluate the feasibility and toxicity of concurrent chemotherapy with vinorelbine and mitomycin C in combination with accelerated radiotherapy (RT) in patients with locally advanced cancer of the head and neck."( A new concurrent chemotherapy with vinorelbine and mitomycin C in combination with radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck.
Dellian, M; Dühmke, E; Pachmann, S; Schalhorn, A; Schymura, B; Wilkowski, R, 2005
)
0.79
"To assess the effect of transcatheter arterial chemoembolization (TACE) combined with laser-induced thermotherapy (LITT) for treatment of liver metastases in an animal model."( Liver metastases in rats: chemoembolization combined with interstitial laser ablation for treatment.
Bechstein, WO; Khan, MF; Maataoui, A; Mack, MG; Oppermann, E; Qian, J; Roozru, M; Schmidt, S; Vogl, TJ, 2005
)
0.33
"The object of this study was to investigate the efficacy of topical mitomycin C (MMC) in combination with subsequent topical dexamethasone to prolong the patency of myringotomies."( Topical application of mitomycin C in combination with dexamethasone: effective delay of myringotomy closure.
Hosemann, W; Kaftan, H, 2006
)
0.88
" After 33 months, a high dose of CDDP was administered twice in combination with TS-1, because elevation of serum CEA levels and paraortic lymphnode swelling were observed for the first time."( [A case of gastric cancer with peritoneal dissemination who achieved five-year survival by successive treatments with TS-1 alone and in combination with other drugs].
Aiko, S; Ishizuka, T; Kumano, I; Maehara, T; Sakano, T; Sugiura, Y; Yoshizumi, Y, 2006
)
0.33
"This study indicates that pterygium excision with a free conjunctival autograft combined with intraoperative low-dose MMC is a safe and effective technique in pterygium surgery."( Conjunctival autografting combined with low-dose mitomycin C for prevention of primary pterygium recurrence.
Frucht-Pery, J; Ilsar, M; Landau, D; Orucov, F; Raiskup, F; Solomon, A, 2006
)
0.59
" Anterior glottic web combined with epiglottic hypoplasia was found in a middle-aged man presenting with hoarseness and dyspnea on exertion."( Application of mitomycin C after endoscopic lysis of congenital laryngeal web combined with epiglottic hypoplasia in a middle-aged man.
Roh, JL, 2006
)
0.69
"Complete PRP combined with trabeculectomy with MMC can effectively reduce the elevated IOP in eyes with NVG."( Pars plana vitrectomy and panretinal photocoagulation combined with trabeculectomy for successful treatment of neovascular glaucoma.
Ito, N; Ito, S; Kiuchi, Y; Nakae, K; Saito, Y, 2006
)
0.33
"Bladder cancer cells were exposed to MeEPA in combination with epirubicin or mitomycin."( Meglumine Eicosapentaenoic acid (MeEPA) a new soluble omega-3 fatty acid formulation: in vitro bladder cancer cytotoxicity tests in combination with epirubicin and mitomycin.
Cooper, AJ; Harris, NM; Lwaleed, BA; Mackie, SJ; Sharma, DM, 2006
)
0.76
"To determine the outcomes of trabeculectomy with mitomycin C (MMC) combined with direct cauterization of peripheral iris before iridectomy in the management of neovascular glaucoma (NVG), and to demonstrate the effect of this surgical technique on decreasing the incidence of intraoperative bleeding and early postoperative hyphema."( Trabeculectomy with mitomycin C combined with direct cauterization of peripheral iris in the management of neovascular glaucoma.
Batman, A; Berker, N; Cankaya, B; Elgin, U; Simsek, T, 2006
)
0.91
"This prospective study was based on 72 eyes of 72 patients with NVG who underwent primary trabeculectomy with MMC combined with direct cauterization of peripheral iris before iridectomy."( Trabeculectomy with mitomycin C combined with direct cauterization of peripheral iris in the management of neovascular glaucoma.
Batman, A; Berker, N; Cankaya, B; Elgin, U; Simsek, T, 2006
)
0.66
"Trabeculectomy with MMC combined with direct cauterization of peripheral iris decreases the incidence of both intraoperative bleeding, and early postoperative hyphema, and provides reduction of IOP and the number of antiglaucomatous medications in cases with NVG in a 6-month follow-up period."( Trabeculectomy with mitomycin C combined with direct cauterization of peripheral iris in the management of neovascular glaucoma.
Batman, A; Berker, N; Cankaya, B; Elgin, U; Simsek, T, 2006
)
0.66
"To determine the efficiency of topical cyclosporine-A (CSA) combined with mitomycin C (MMC) as an adjunctive treatment in diffuse conjunctival and corneal squamous cell carcinoma (CCSC)."( Topical cyclosporine-a combined with mitomycin C for conjunctival and corneal squamous cell carcinoma.
Erbilen, E; Tunc, M, 2006
)
0.84
"01%) four times a day was combined with CSA at the second, fourth, and sixth weeks of the treatment."( Topical cyclosporine-a combined with mitomycin C for conjunctival and corneal squamous cell carcinoma.
Erbilen, E; Tunc, M, 2006
)
0.61
"05%) combined with MMC (0."( Topical cyclosporine-a combined with mitomycin C for conjunctival and corneal squamous cell carcinoma.
Erbilen, E; Tunc, M, 2006
)
0.61
"To evaluate the effect of pirarubicin (THP) in combination with hyperthermia on gastric cancer tissues in vitro and explore the underlying mechanisms."( [Effects of pirarubicin chemotherapy combined with hyperthermia on gastric cancer in vitro].
Fu, J; Li, GX; Luo, RC; Wang, XG; Zheng, H, 2006
)
0.33
" Hyperthermia has been shown to enhance the cytotoxic effect of some anticancer drugs and has been combined with intraperitoneal chemotherapy for the treatment of colorectal peritoneal carcinomatosis."( In vitro thermochemotherapy of colon cancer cell lines with irinotecan alone and combined with mitomycin C.
Benhamed, M; Chipponi, J; Gilly, FN; Glehen, O; Kwiatkowski, F; Le Page, S; Mohamed, F; Paulin, C; Pezet, D,
)
0.35
"ONYX-015 combined with MMC can produce significant cytotoxicity against T-24 cells and enhance therapeutic efficacy against bladder carcinoma."( [Cytotoxic effect of oncolytic virus combined with mitomycin against human bladder cancer cells in vitro and in vivo].
Tan, WL; Wu, YD; Xie, Y; Zhao, GZ; Zheng, SB; Zhu, WH, 2006
)
0.59
"To evaluate the enhancing effects of ginsenoside Rg3 combined with mitomycin C and tegafur (MF) on postoperative chemotherapy in advanced gastric cancer."( [Effect of adjuvant chemotherapy of ginsenoside Rg3 combined with mitomycin C and tegafur in advanced gastric cancer].
Chen, ZJ; Cheng, J; Han, SL; Huang, YP; Liu, NX; Yao, JG; Zhu, GB, 2007
)
0.81
" In conclusion, capecitabine can safely be combined with docetaxel (40 mg m(-2)) and mitomycin C (4 mg m(-2))."( Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial.
Ernst, T; Gnad-Vogt, U; Hochhaus, A; Hofheinz, RD; Kripp, M; Lukan, N; Merx, K; Schultheis, B, 2007
)
0.82
" During each treatment session, 40 mg of mitomycin C (MMC) was instilled into the bladder in combination with bladder wall hyperthermia of 42 ± 2 °C for 60 minutes."( Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder.
Colombo, R; Conti, G; Halachmi, S; Kedar, D; Maffezzini, M; Moskovitz, B; Nativ, O; Sandri, SD; Verweij, F,
)
0.77
"Hyperfractionated accelerated radiotherapy (HART) has been combined with chemotherapy (CC) for locally advanced head and neck cancer, but no data from randomized trials are available for a comparison with conventionally fractionated radiotherapy (CFRT) and CC."( Hyperfractionated accelerated radiotherapy versus conventional fractionation both combined with chemotherapy in patients with locally advanced head and neck carcinomas: a retrospective analysis of a monoinstitutional series.
Abu Jawad, J; Budach, V; Jahnke, K; Lehnerdt, G; Pöttgen, C; Sack, H; Stüben, G; Stuschke, M; Welz, H; Wierlemann, A; Wittig, A, 2009
)
0.35
"In combination with CC, there was no trend towards an improved efficacy of HART in comparison with CFRT."( Hyperfractionated accelerated radiotherapy versus conventional fractionation both combined with chemotherapy in patients with locally advanced head and neck carcinomas: a retrospective analysis of a monoinstitutional series.
Abu Jawad, J; Budach, V; Jahnke, K; Lehnerdt, G; Pöttgen, C; Sack, H; Stüben, G; Stuschke, M; Welz, H; Wierlemann, A; Wittig, A, 2009
)
0.35
" Based on preclinical and clinical data, combination with standard chemotherapy has the potential to further increase the antitumor activity of oncolytic virotherapy in a synergistic manner."( Phase I clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas.
Aderca, I; Galanis, E; Opyrchal, M, 2009
)
0.56
"To assess the feasibility and activity of radio-chemotherapy with mitomycin C (MMC) and cisplatin (CDDP) in locally advanced squamous cell anal carcinoma with reference to radiotherapy (RT) combined with MMC and fluorouracil (5-FU)."( Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014).
Bosset, JF; Collette, L; Haustermans, K; Koswig, S; Maingon, P; Matzinger, O; Mineur, L; Mueller, RP; Radosevic-Jelic, L; Roelofsen, F; Van Der Steen-Banasik, EM; Van Houtte, P, 2009
)
2.03
"To evaluate the outcomes of patients with unresectable massive primary liver cancer (PLC) receiving three-dimensional conformal radiotherapy (3-DCRT) combined with transcatheter arterial chemoembolization (TACE)."( [Three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for massive primary liver cancer].
Chen, LH; Guan, J; Li, QS; Sun, HW; Wei, CJ; Zheng, XK, 2009
)
0.35
"From January 2001 to December 2004, 84 patients with unresectable massive PLC (tumor size> or =10 cm) received 3-DCRT combined with TACE, including 49 cases in UICC/AJCC T(3) stage and 35 cases in T(4) stages."( [Three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for massive primary liver cancer].
Chen, LH; Guan, J; Li, QS; Sun, HW; Wei, CJ; Zheng, XK, 2009
)
0.35
"3-DCRT combined with TACE has definite therapeutic effect on advanced massive PLC, and Child-Pugh grade is an independent prognostic factor in such cases."( [Three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for massive primary liver cancer].
Chen, LH; Guan, J; Li, QS; Sun, HW; Wei, CJ; Zheng, XK, 2009
)
0.35
" Treatment consisted of capecitabine (2,000 mg/m(2) days 1-14) in combination with docetaxel (40 mg/m(2) day 1) and mitomycin C (4 mg/m(2) day 1)."( Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma.
Ernst, T; Hochhaus, A; Hofheinz, RD; Hofmann, WK; Kripp, M; Kruth, J; Lukan, N; Merx, K; Nissen, J, 2010
)
0.8
"We retrospectively assessed the benefits of 5-fluorouracil (5-FU)- and heparin-based portal infusion chemotherapy combined with systemic administration of mitomycin C (MMC) and cisplatin (CDDP) for 4 weeks following surgery (PI4W)."( Beneficial effects of 5-Fluorouracil and heparin-based portal infusion chemotherapy combined with mitomycin C and cisplatin after curative resection of pancreatic cancer.
Aiura, K; Kitagawa, Y; Matsui, J; Takahashi, S; Ueda, M, 2010
)
0.78
" EPO used in combination with MMC significantly decreased SCE levels and increased PRI and MI values induced by MMC alone both in vitro and in vivo."( In vitro and in vivo cytogenetic effects of recombinant human erythropoietin on the frequency of sister chromatid exchanges alone or in combination with mitomycin C.
Chrisafi, S; Digkas, EN; Hatzimichail, A; Lialiaris, TS; Passadaki, T; Tsalkidis, A; Vargemezis, V, 2010
)
0.56
"It is unknown whether sorafenib can be combined with transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma."( Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study.
Borner, M; Candinas, D; Dufour, JF; Heim, MH; Helbling, B; Hoppe, H; Kickuth, R; Maurhofer, O; Saar, B; Szucs-Farkas, Z, 2010
)
0.36
"Twenty-one patients were screened and 14 received sorafenib combined with TACE."( Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study.
Borner, M; Candinas, D; Dufour, JF; Heim, MH; Helbling, B; Hoppe, H; Kickuth, R; Maurhofer, O; Saar, B; Szucs-Farkas, Z, 2010
)
0.36
"Continuous administration of sorafenib at a dose of 400 mg bid combined with TACE was tolerable."( Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study.
Borner, M; Candinas, D; Dufour, JF; Heim, MH; Helbling, B; Hoppe, H; Kickuth, R; Maurhofer, O; Saar, B; Szucs-Farkas, Z, 2010
)
0.36
"We report three cases of anal canal squamous cell carcinoma treated with radiotherapy combined with S-1 and mitomycin C(MMC)."( [Three cases of radiotherapy combined with S-1 and mitomycin C for anal canal squamous cell carcinomas].
Akaike, M; Motohashi, O; Nakayama, N; Nakayama, Y; Nishimura, K; Nonaka, T; Shiozawa, M; Takagi, S; Yoshii, T, 2010
)
0.83
"To retrospectively evaluate the efficacy and tolerability of mitomycin-C (MMC) in combination with fluoropyrimidines as salvage 3rd -or 4th-line therapy in metastatic colorectal cancer (MCRC) patients."( Mitomycin-C in combination with fluoropyrimidines in the treatment of metastatic colorectal cancer after oxaliplatin and irinotecan failure.
Alkis, N; Benekli, M; Demirci, U; Gumus, M; Isikdogan, A; Kaplan, MA; Koca, D; Ozdemir, NY; Sevinc, A; Uncu, D; Unek, T; Yetisyigit, T; Yilmaz, U,
)
1.82
"MMC in combination with fluoropyrimidines is safe and active in heavily-pretreated MCRC patients."( Mitomycin-C in combination with fluoropyrimidines in the treatment of metastatic colorectal cancer after oxaliplatin and irinotecan failure.
Alkis, N; Benekli, M; Demirci, U; Gumus, M; Isikdogan, A; Kaplan, MA; Koca, D; Ozdemir, NY; Sevinc, A; Uncu, D; Unek, T; Yetisyigit, T; Yilmaz, U,
)
1.57
"To study the effect of the sphingosine kinase 1 (SphK1) inhibitor N,N-dimethylsphingosine (DMS) in combination with chemotherapeutic drugs (DDP, 5-Fu, MMC) on the proliferation of gastric cancer cells (SGC7901) in vitro, and to evaluate whether SphK1 inhibitors could be used as synergetic agents in chemotherapy."( [Antitumor effect of sphingosine kinase 1 inhibitor in combination with chemotherapy on SGC7901 gastric cancer cells in vitro].
Hu, CY; Lan, KH; Lu, Q; Tang, W; Wang, SF; Yin, GJ, 2012
)
0.38
" When 1 micromol/L DMS was used in combination with 5-Fu (1, 5, and 25 microg/ml) for 24 h, the growth inhibition rates of the cancer cells were (16."( [Antitumor effect of sphingosine kinase 1 inhibitor in combination with chemotherapy on SGC7901 gastric cancer cells in vitro].
Hu, CY; Lan, KH; Lu, Q; Tang, W; Wang, SF; Yin, GJ, 2012
)
0.38
"DMS can suppress the proliferation of SGC7901 cells in vitro, and there are evident synergetic effects when it is used in combination with chemotherapeutic drugs."( [Antitumor effect of sphingosine kinase 1 inhibitor in combination with chemotherapy on SGC7901 gastric cancer cells in vitro].
Hu, CY; Lan, KH; Lu, Q; Tang, W; Wang, SF; Yin, GJ, 2012
)
0.38
" Maintenance chemotherapy started 4-8 weeks later, three courses repeated every 21 days, using 5-FU/CDDP doses above, with MMC reduced to 7 mg/m(2) and administered with the first and third cycles."( Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin.
Cunningham, D; Davidson, N; Glynne-Jones, R; Grieve, R; Hurman, DC; Levine, E; Meadows, HM; Plowman, PN; Sebag-Montefiore, D, 2012
)
0.56
"To evaluate the anti-tumor effect of intra-arterial IL-12 gene delivery alone and in combination with transcatheter arterial chemoembolization (TACE) in rabbit VX2 liver cancer model."( Intra-arterial interleukin-12 gene delivery combined with chemoembolization: anti-tumor effect in a rabbit hepatocellular carcinoma (HCC) model.
Feng, G; Li, X; Liang, H; Xia, X; Zheng, C; Zhou, G, 2013
)
0.39
"9% saline solution (group A, control), TACE (group B, TACE alone, lipiodol + mitomycin), intra-arterial interleukin-12 gene infusion (group C, IL-12 alone), and intra-arterial interleukin-12 gene infusion in combination with TACE (group D, IL-12 plus TACE)."( Intra-arterial interleukin-12 gene delivery combined with chemoembolization: anti-tumor effect in a rabbit hepatocellular carcinoma (HCC) model.
Feng, G; Li, X; Liang, H; Xia, X; Zheng, C; Zhou, G, 2013
)
0.62
"Intra-arterial interleukin-12 gene therapy combined with TACE has a potent anti-tumor effect in rabbit VX2 liver cancer in comparison with TACE alone."( Intra-arterial interleukin-12 gene delivery combined with chemoembolization: anti-tumor effect in a rabbit hepatocellular carcinoma (HCC) model.
Feng, G; Li, X; Liang, H; Xia, X; Zheng, C; Zhou, G, 2013
)
0.39
" This pilot study demonstrates the utility of using yeast for screening large matrices of drug combinations, and it provides a means to prioritize drug combination tests in human cells."( A high-throughput yeast assay identifies synergistic drug combinations.
Brown, GW; Giaever, G; Lee, AY; Nislow, C; Torres, NP, 2013
)
0.39
"The effect of chemotherapy drug Mitomycin C (MMC) in combination with recombinant adeno-associated virus II (rAAV2) in cancer therapy was investigated, and the mechanism of MMC affecting rAAV2's bioactivity was also studied."( Effect and mechanism of Mitomycin C combined with recombinant adeno-associated virus type II against glioma.
Deng, Y; Han, C; Lei, R; Ma, H; Qing, H; Rao, L; Wang, H; Xiang, J; Yang, Z; Zhang, L; Zhang, Y, 2013
)
0.98
"In this case-control study, a chart review identified 37 eyes with Fuchs dystrophy and anterior corneal changes evident on preoperative slit lamp examination and that underwent DMEK combined with epithelial removal plus mitomycin-C application."( Descemet membrane endothelial keratoplasty combined with epithelial debridement and mitomycin-C application for fuchs dystrophy with preoperative subepithelial fibrosis or anterior basement membrane dystrophy.
Chaurasia, S; McKee, Y; Price, FW; Price, MO, 2014
)
0.81
"To compare the results of amniotic membrane transplantation (AMT) combined with mitomycin C (MMC) to the results of free conjunctival autograft (CA) combined with MMC for the treatment of patients with recurrent pterygium."( Comparison of Two Techniques for the Treatment of Recurrent Pterygium: Amniotic Membrane vs Conjunctival Autograft Combined with Mitomycin C.
Altiparmak, U; Cakir, B; Engur Goktas, S; Katırcıoglu, YA; Ornek, F; Singar, E, 2015
)
0.85
"In this prospective study, 60 eyes of 55 patients with recurrent pterygium were included and randomly assigned into group I (n = 30) who underwent AMT combined with MMC (AMT-MMC) and group II (n = 30) who underwent CA combined with MMC (CA-MMC)."( Comparison of Two Techniques for the Treatment of Recurrent Pterygium: Amniotic Membrane vs Conjunctival Autograft Combined with Mitomycin C.
Altiparmak, U; Cakir, B; Engur Goktas, S; Katırcıoglu, YA; Ornek, F; Singar, E, 2015
)
0.62
"Amniotic membrane combined with MMC has similar recurrence rate to CA combined with MMC, in patients with recurrent pterygium."( Comparison of Two Techniques for the Treatment of Recurrent Pterygium: Amniotic Membrane vs Conjunctival Autograft Combined with Mitomycin C.
Altiparmak, U; Cakir, B; Engur Goktas, S; Katırcıoglu, YA; Ornek, F; Singar, E, 2015
)
0.62
"Mitochondrial Bcl-2, Bax, cytochrome c and cytoplasmic caspase-3 expression, as well as toxic effect patterns, mitosis and cellular reactions due to α-tocopherol alone or combined with paclitaxel, mitomycin C and 5-flurouracil (5-FU), was studied in series obtained from human endothelial and primary Tenon's fibroblast cell cultures."( The evaluation of human tenon's fibroblasts and endothelial cell responses to antifibrotics alone and in combination with α-tocopherol.
Akgün-Dar, K; Arslan, M; Bilgiç, S; Çetin, B; Engin, KN; Erdem-Kuruca, S; Gürel, E; Karadenizli, S; Yemisci, B, 2015
)
0.61
"To assess the safety of Brucea javanica and Cantharidin combined with chemotherapy in treating patients with non-small-cell lung carcinoma."( Safety of Brucea javanica and cantharidin combined with chemotherapy for treatment of NSCLC patients.
Huang, XE; Ji, ZQ; Liu, J; Tang, JH; Wang, L; Wu, XY, 2014
)
0.4
"A consecutive cohort of patients with NSCLC were divided into four groups: experimental group A treated with Brucea javanica injection combined with chemotherapy; experimental group B with Cantharidin injection combined with chemotherapy; experimental group C treated with Brucea javanica and Cantharidin injection combined with chemotherapy; and the control group receiving only chemotherapy."( Safety of Brucea javanica and cantharidin combined with chemotherapy for treatment of NSCLC patients.
Huang, XE; Ji, ZQ; Liu, J; Tang, JH; Wang, L; Wu, XY, 2014
)
0.4
"Brucea javanica or Cantharidin combined with chemotherapy could in both cases improve quality of life in our cohort of NSCLC patients without any increase in toxicity."( Safety of Brucea javanica and cantharidin combined with chemotherapy for treatment of NSCLC patients.
Huang, XE; Ji, ZQ; Liu, J; Tang, JH; Wang, L; Wu, XY, 2014
)
0.4
"To determine the efficacy of safe surgery system trabeculectomy combined with manual small incision cataract surgery/phacoemulsification in primary glaucoma coexistent with cataract."( Surgical outcome of safe surgery system trabeculectomy combined with cataract extraction.
Agashe, A; Khandelwal, R; Khandelwal, RR; Majumdar, M; Raje, D; Rathi, A, 2015
)
0.42
" The overall success rates (with or without medication) when safe surgery system trabeculectomy was combined with MSICS were 91, 70, and 51% for IOP ≤18, ≤15, and ≤12 mm Hg, respectively, and target IOP was achieved in 72% cases."( Surgical outcome of safe surgery system trabeculectomy combined with cataract extraction.
Agashe, A; Khandelwal, R; Khandelwal, RR; Majumdar, M; Raje, D; Rathi, A, 2015
)
0.42
"The Safe Surgery System Trabeculectomy combined with cataract surgery offers excellent IOP control with minimal postoperative complications."( Surgical outcome of safe surgery system trabeculectomy combined with cataract extraction.
Agashe, A; Khandelwal, R; Khandelwal, RR; Majumdar, M; Raje, D; Rathi, A, 2015
)
0.42
" The objective of our study was to compare the clinical effects of transcatheter arterial chemoembolization (TACE) combined with interferon-alpha (IFN-α) therapy on recurrence after hepatic resection in patients with HBV-related HCC with that of TACE chemotherapy alone."( Transcatheter arterial chemoembolization combined with interferon-α is safe and effective for patients with hepatocellular carcinoma after curative resection.
Burns, M; Hong, Y; Lei, X; Li, JL; Li, QL; Li, YG; Liu, C; Liu, HC; Liu, JS; Qiu, XX; Wang, XH; Wu, QF; Xia, M; Xiao, H; Xu, RC; Zhu, HZ; Zuo, CH, 2015
)
0.42
" We describe here a procedure for definitive endoderm differentiation from human ESCs, in which human ESCs are subject to 10 days (d) differentiation combined with methionine deprivation between differentiation day (d) 8 to d10."( Definitive Endoderm Differentiation of Human Embryonic Stem Cells Combined with Selective Elimination of Undifferentiated Cells by Methionine Deprivation.
Kume, S; Shiraki, N; Tsuyama, T, 2016
)
0.43
"The MTDs were determined as 5FU 800 mg/m(2) on RT days 1-4 and 29-32 and MMC 8 mg/m(2) on days 1 and 29 when combined with IMRT/VMAT with SIB and cetuximab in locally advanced anal cancer."( Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer.
Gunnlaugsson, A; Guren, MG; Johnsson, A; Leon, O; Radu, C, 2015
)
0.66
" We screened cancer patients' tumors for FA functional defects then aimed to establish the safety/feasibility of administering PARP inhibitors as monotherapy and combined with a DNA-breaking agent."( Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair.
Bekaii-Saab, T; Chen, A; Duan, W; Ji, J; Lustberg, M; Marshall, J; Rose, J; Schaaf, LJ; Shilo, K; Thurmond, J; Timmers, C; Villalona-Calero, MA; Westman, JA; Xiaobai, L; Zhao, W, 2016
)
0.7
"The aim of this study was to assess the risk of HCs after CRS combined with HIPEC-Ox versus other drugs, and to determine predictive factors for HCs after HIPEC-Ox."( Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin Increases the Risk of Postoperative Hemorrhagic Complications: Analysis of Predictive Factors.
Charrier, T; Cotte, E; Elias, D; Eveno, C; Glehen, O; Gocevska, S; Goere, D; Maurice, C; Ortega-Deballon, P; Passot, G; Peron, J; Pocard, M; Quénet, F; Vaudoyer, D, 2016
)
0.43
" This study evaluated the efficacy and safety of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of PPSC."( Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for the treatment of primary peritoneal serous carcinoma: Results of a Chinese retrospective study.
Ji, ZH; Li, Y; Peng, KW; Sun, JH; Wu, HT; Yonemura, Y; Zhang, Q, 2016
)
0.43
"The aim of the study is to evaluate the long-term clinical results of amniotic membrane transplantation (AMT) combined with mitomycin C (MMC) for reconstruction of conjunctival defects created during the excision of ocular surface squamous neoplasia (OSSN)."( Long-term outcome of amniotic membrane transplantation combined with mitomycin C for conjunctival reconstruction after ocular surface squamous neoplasia excision.
Hanada, K; Miyokawa, N; Nishikawa, N; Yoshida, A, 2017
)
0.9
"This phase II prospective study investigates possible benefits of radiofrequency ablation (RFA) combined with hepatic arterial chemoembolization using degradable starch microsphere (DSM) mixed with mitomycin C (MMC) in non-surgical candidates with colorectal liver metastases."( Radiofrequency Ablation Combined with Hepatic Arterial Chemoembolization Using Degradable Starch Microsphere Mixed with Mitomycin C for the Treatment of Liver Metastasis from Colorectal Cancer: A Prospective Multicenter Study.
Hayashi, S; Inaba, Y; Nakatsuka, A; Nobata, K; Sato, Y; Takaki, H; Yamakado, K; Yamanaka, T; Yasumoto, T, 2017
)
0.85
"To determine the long-term outcomes of 2-site phacoemulsification combined with fornix-based trabeculectomy using mitomycin C (MMC) for primary angle-closure glaucoma (PACG) and primary open-angle glaucoma (POAG) in an Asian population."( Success rates of 2-site phacoemulsification combined with fornix-based trabeculectomy using mitomycin C for primary angle-closure glaucoma and primary open-angle glaucoma in an Asian population.
Aduan, J; Aquino, CM; Chee, LS; Chen, D; Chew, P; Koh, V; Sng, C, 2017
)
0.89
"Two-site phacoemulsification combined with fornix-based trabeculectomy using MMC is a good surgical approach for Asian eyes with concomitant mild-to-moderate primary glaucoma and cataracts."( Success rates of 2-site phacoemulsification combined with fornix-based trabeculectomy using mitomycin C for primary angle-closure glaucoma and primary open-angle glaucoma in an Asian population.
Aduan, J; Aquino, CM; Chee, LS; Chen, D; Chew, P; Koh, V; Sng, C, 2017
)
0.68
"In this phase 1 dose-escalation trial in patients with unresectable PDAC, we determined the maximum tolerated dose (MTD) of olaparib (tablet formulation) in combination with irinotecan 70 mg/m2 on days 1 and 8 and cisplatin 25 mg/m2 on days 1 and 8 of a 28-day cycle (olaparib plus IC)."( Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer.
Azad, NS; De Jesus-Acosta, A; Donehower, RC; Fine, RL; Goggins, M; Jaffee, EM; Johnson, BA; Laheru, DA; Le, DT; Myzak, MC; Oberstein, PE; Yarchoan, M; Zheng, L, 2017
)
0.7
"Olaparib had substantial toxicity when combined with IC or ICM in patients with PDAC, and this treatment combination did not have an acceptable risk/benefit profile for further study."( Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer.
Azad, NS; De Jesus-Acosta, A; Donehower, RC; Fine, RL; Goggins, M; Jaffee, EM; Johnson, BA; Laheru, DA; Le, DT; Myzak, MC; Oberstein, PE; Yarchoan, M; Zheng, L, 2017
)
0.7
"We conducted a dose-finding study for 5-fluorouracil (5-FU) administered with cisplatin (CDDP) and mitomycin C (MMC) to find an improved regimen for hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced gastric cancer (GC)."( Feasibility and safety of hyperthermic intraperitoneal chemotherapy using 5-fluorouracil combined with cisplatin and mitomycin C in patients undergoing gastrectomy for advanced gastric cancer.
Kaida, S; Murata, S; Naitoh, H; Naka, S; Shimizu, T; Shiomi, H; Tani, M; Tani, T; Yamaguchi, T; Yamamoto, H, 2017
)
0.88
" This was a clinical study to determine the recommended dose of 5-FU in combination with MMC and CDDP at 42°C for 30 min and to evaluate HIPEC safety in patients at high risk of developing peritoneal metastases following GC surgery."( Feasibility and safety of hyperthermic intraperitoneal chemotherapy using 5-fluorouracil combined with cisplatin and mitomycin C in patients undergoing gastrectomy for advanced gastric cancer.
Kaida, S; Murata, S; Naitoh, H; Naka, S; Shimizu, T; Shiomi, H; Tani, M; Tani, T; Yamaguchi, T; Yamamoto, H, 2017
)
0.66
"Twelve patients were treated with surgery plus HIPEC using 5-FU at 0, 500, 750, and 1000 mg combined with MMC (10 mg) and CDDP (50 mg) in the perfusate (5 L)."( Feasibility and safety of hyperthermic intraperitoneal chemotherapy using 5-fluorouracil combined with cisplatin and mitomycin C in patients undergoing gastrectomy for advanced gastric cancer.
Kaida, S; Murata, S; Naitoh, H; Naka, S; Shimizu, T; Shiomi, H; Tani, M; Tani, T; Yamaguchi, T; Yamamoto, H, 2017
)
0.66
" Nanoparticle-based drug combination has been shown to mitigate the problems encountered by free drug combination therapy."( Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice.
Chen, K; Cheng, J; Lai, P; Pang, KS; Rauth, AM; Wu, XY; Zhang, RX; Zhang, T, 2017
)
0.68
" We evaluated an optimized anti-tumor protocol comprising 5-fluorouracil (5-FU) combined with cisplatin (CDDP) and mitomycin C (MMC) in vitro for clinical use of HIPEC."( 5-fluorouracil combined with cisplatin and mitomycin C as an optimized regimen for hyperthermic intraperitoneal chemotherapy in gastric cancer.
Kaida, S; Miyake, T; Murata, S; Naitoh, H; Shimizu, T; Takebayashi, K; Tani, M; Tani, T; Yamaguchi, T; Yamamoto, H, 2018
)
0.95
"To evaluate and compare the recurrence rate and complications of conjunctival autograft (CAG) combined with preoperative mitomycin C (MMC) injection versus CAG with intraoperative local MMC over the medial rectus muscle tendon in primary pterygium."( Conjunctival Autograft Combined With Either Preoperative Mitomycin C Injection or Intraoperative Local Mitomycin C Over the Medial Rectus Muscle Tendon in Primary Pterygium Surgery.
Abdelrahman, A; Abdulhalim, BH; Gad, AAM; Lotfy, A; Samir, A, 2018
)
0.93
"The objective of this study was to evaluate the efficacy and safety of bevacizumab combined with antimetabolite as an adjunctive therapy in primary trabeculectomy for glaucoma."( Efficacy and Safety of Bevacizumab Combined with Mitomycin C or 5-Fluorouracil in Primary Trabeculectomy: A Meta-Analysis of Randomized Clinical Trials.
Chen, HJ; Chen, YH; Lee, CH; Lin, C, 2018
)
0.74
" Further randomized controlled trials are needed to evaluate the efficacy and safety of bevacizumab combined with lower concentrations and a shorter application time of antimetabolite."( Efficacy and Safety of Bevacizumab Combined with Mitomycin C or 5-Fluorouracil in Primary Trabeculectomy: A Meta-Analysis of Randomized Clinical Trials.
Chen, HJ; Chen, YH; Lee, CH; Lin, C, 2018
)
0.74
"In a retrospective clinical study, 806 patients with advanced glaucoma were treated with trabeculectomy combined with mitomycin C0."( [Long-Term Results after Trabeculectomy Combined with Mitomycin C and Ologen Implant].
Fili, S; Kohlhaas, M; Seddig, S, 2019
)
0.97
" Trabeculectomy combined with mitomycin C0."( [Long-Term Results after Trabeculectomy Combined with Mitomycin C and Ologen Implant].
Fili, S; Kohlhaas, M; Seddig, S, 2019
)
1.05
"to study the efficacy and safety of the use of subconjunctival triamcinolone acetate alone or in combination with mitomycin C as a modulator of trabeculectomy healing in rabbits."( Healing modulation in glaucoma surgery after application of subconjunctival triamcinolone acetate alone or combined with mitomycin C: an experimetal study.
Araújo, ID; Cronemberger, S; Rangel, HMDA; Rolim, HT; Vidigal, P, 2018
)
0.9
" Patients with primary or secondary open-angle glaucoma who underwent XEN implantation combined with phacoemulsification between January 2015 and June 2016 were retrospectively enrolled."( Impact of Phacoemulsification Combined with XEN Gel Stent Implantation on Corneal Endothelial Cell Density: 2-Year Results.
Bravetti, GE; Gillmann, K; Mansouri, K; Mermoud, A; Rao, HL, 2020
)
0.56
"The present study demonstrated that the XEN gel implant combined with phacoemulsification produces 24-month ECD loss of a similar magnitude to that observed following standalone phacoemulsification."( Impact of Phacoemulsification Combined with XEN Gel Stent Implantation on Corneal Endothelial Cell Density: 2-Year Results.
Bravetti, GE; Gillmann, K; Mansouri, K; Mermoud, A; Rao, HL, 2020
)
0.56
" All patients received preoperative IVC combined with mitomycin C (MMC) augmented trabeculectomy with a 12-month follow-up."( The efficacy and safety of intravitreal conbercept combined with mitomycin C augmented trabeculectomy for treating neovascular glaucoma.
Gao, Z; Jia, Y; Jiang, S; Xue, S,
)
0.62
"IVC injection of conbercept combined with trabeculectomy is effective and safe for the treatment of NVG."( The efficacy and safety of intravitreal conbercept combined with mitomycin C augmented trabeculectomy for treating neovascular glaucoma.
Gao, Z; Jia, Y; Jiang, S; Xue, S,
)
0.37
"Treatment of leakage with ocular hypotony after trabeculectomy with mitomycin C (MMC) can be safely achieved through conjunctival patch alone or combined with donor scleral graft in cases of melted underlying sclera."( Outcome of Bleb Revision With Autologous Conjunctival Graft Alone or Combined With Donor Scleral Graft for Late-onset Bleb Leakage With Hypotony After Standard Trabeculectomy With Mitomycin C.
Chronopoulos, P; Grehn, F; Hoffmann, EM; Laspas, P; Peters, H; Pfeiffer, N; Prokosch-Willing, V; Wahl, J, 2021
)
1.05
" Here we propose and describe modified bare sclera technique combined with the intraoperative application of MMC for pterygium excision."( Pterygium excision with modified bare sclera technique combined with mitomycin C.
Aziza, Y; Inatomi, T; Kinoshita, S; Sotozono, C, 2021
)
0.86
"The modified bare sclera technique combined with MMC application was found to be safe, effective, and presents good cosmetic appearance for the treatment of primary pterygium when safety points are strictly applied."( Pterygium excision with modified bare sclera technique combined with mitomycin C.
Aziza, Y; Inatomi, T; Kinoshita, S; Sotozono, C, 2021
)
0.86
"To evaluate the effectiveness of repeat trabeculectomy with Mitomycin C (MMC) in isolation or combined with phacoemulsification, and to identify risk factors for failure over 1 year."( Outcome of repeat trabeculectomy with mitomycin C in isolation or combined with phacoemulsification.
George, R; Jagannathan, J; Shantha, B; Vijaya, L, 2021
)
1.13
" It was the aim of this study to investigate the therapeutic success of Xen45 gel stents as a stand-alone technique (Xen) and combined with cataract surgery (XenPhaco), and with antimetabolites (mitomycin C, MMC) in open-angle glaucoma patients."( Influence of Mitomycin C on the Therapeutic Success of Stand-Alone Xen45 Gel Stents and Its Combination with Cataract Surgery in Open-Angle Glaucoma Patients.
Denkel, L; Hohberger, B; Lämmer, R, 2021
)
1.18
"The use of MMC seemed to increase the therapeutic success rate after stand-alone Xen45 gel stent implantation and combined with cataract surgery, yet statistical significant was not reached."( Influence of Mitomycin C on the Therapeutic Success of Stand-Alone Xen45 Gel Stents and Its Combination with Cataract Surgery in Open-Angle Glaucoma Patients.
Denkel, L; Hohberger, B; Lämmer, R, 2021
)
0.99
"MMC combined with DVIU is a promising way to reduce the long-term recurrence rate of a short-segment anterior urethral stricture."( Efficacy of Mitomycin C Combined with Direct Vision Internal Urethrotomy for Urethral Strictures: A Systematic Review and Meta-Analysis.
Cai, T; Lin, J; Lin, L; Lv, T; Xu, C; Zhu, Z, 2023
)
1.29
"To compare the therapeutic effects of locoregional deep hyperthermia combined with intravesical chemotherapy with those of intravesical chemotherapy alone in patients with intermediate-/high-risk non-muscle invasive bladder cancer (NMIBC)."( Loco-regional deep hyperthermia combined with intravesical Mitomycin instillation reduces the recurrence of non-muscle invasive papillary bladder cancer.
Fan, YC; Lai, BCH; Lee, HL; Lee, LM; Lin, KH; Lin, YW; Shih, HJ; Syu, SH; Wen, YC, 2021
)
0.86
"We analyzed data retrieved from the medical records of patients with intermediate-/high-risk NMIBC treated with intravesical mitomycin (IM group) or locoregional deep hyperthermia combined with intravesical mitomycin (CHT group) at a single tertiary care hospital between May 2016 and June 2019."( Loco-regional deep hyperthermia combined with intravesical Mitomycin instillation reduces the recurrence of non-muscle invasive papillary bladder cancer.
Fan, YC; Lai, BCH; Lee, HL; Lee, LM; Lin, KH; Lin, YW; Shih, HJ; Syu, SH; Wen, YC, 2021
)
1.07
"Intravesical chemotherapy combined with locoregional deep hyperthermia for intermediate-/high-risk papillary NMIBC can significantly decrease the recurrence rate relative to that observed after intravesical chemotherapy alone."( Loco-regional deep hyperthermia combined with intravesical Mitomycin instillation reduces the recurrence of non-muscle invasive papillary bladder cancer.
Fan, YC; Lai, BCH; Lee, HL; Lee, LM; Lin, KH; Lin, YW; Shih, HJ; Syu, SH; Wen, YC, 2021
)
0.86
"To evaluate the clinical results of amniotic membrane transplantation alone or in combination with adjuvant therapies in conjunctival fornix reconstruction."( Clinical Results of the Use of Amniotic Membrane Transplantation Alone or in Combination with Adjuvant Therapies in Conjunctival Fornix Reconstruction.
Aslan Katırcıoğlu, Y; Kaderli, A; Örnek, F; Şingar Özdemir, E, 2022
)
0.72
"The clinical results of patients who presented to our clinic between 2002 and 2016 due to conjunctival fornix obliteration and underwent amniotic membrane transplantation alone or in combination with additional treatments were retrospectively analyzed."( Clinical Results of the Use of Amniotic Membrane Transplantation Alone or in Combination with Adjuvant Therapies in Conjunctival Fornix Reconstruction.
Aslan Katırcıoğlu, Y; Kaderli, A; Örnek, F; Şingar Özdemir, E, 2022
)
0.72
"8 mg/kg in combination with RT treatment is safe, with a high rate of tumor control."( Pegylated Liposomal Mitomycin C Lipidic Prodrug in Combination With External Beam Radiation Therapy in Patients With Advanced Cancer: A Phase 1B Study.
Amitay, Y; Corn, B; Gabizon, A; Levy, A; Ohana, P; Pfeffer, R; Purim, O; Sapir, E; Wygoda, M, 2023
)
1.23
"To assess the clinical and oncological outcomes of sequential treatment with Bacillus Calmette-Guerin (BCG) and Mitomycin C (MMC) administered with Electromotive Drug Administration (EMDA) in patients with high-risk NMIBC who fail BCG immunotherapy."( Sequential Treatment With Bacillus Calmette-Güerin (BCG) and Mitomycin C Administered With Electromotive Drug Administration (EMDA) in Patients With High-Risk Nonmuscle Invasive Bladder Cancer After BCG Failure.
Bravo, A; Breda, A; Gaya, JM; Huguet, J; Palou, J; Robalino, J; Rodríguez Faba, Ó; Sanz Gómez, I; Territo, Á, 2023
)
1.36

Bioavailability

The mean reduction of mitomycin C bioavailability in the extracorporeal circuit blood was 42.8 GHz microwave (MW) specific absorption rate (SAR, 3 W/kg) on human lymphocytes.

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"h without Spherex), thus leading to a lower systemic bioavailability of the drug and a higher local bioavailability in the tumor region."( Pharmacokinetics of mitomycin C in patients after bolus injection and chemobolisation of the hepatic artery with Spherex starch particles.
Czejka, MJ; Jäger, W; Schüller, J,
)
0.45
"Isolated perfusion of organs or anatomic sites with chemotherapeutic agents offers a pharmacokinetic advantage of increasing drug bioavailability to target tissues which may result in a greater magnitude of biologic effect (pharmacologic or toxic) without systemic toxicity."( Pharmacokinetics and tissue uptake of mitomycin C in isolated perfusion of pancreas.
Arredondo, MA; Chaudhuri, B; Chaudhuri, PK; Thomford, NR, 1989
)
0.55
"8 mW/cm2 and the measured specific absorption rate (SAR) in this system was 30 W/kg (600 W forward power), which is well above current safety guidelines."( Absence of mutagenic interaction between microwaves and mitomycin C in mammalian cells.
Eagan, P; Erwin, DN; Meltz, ML, 1989
)
0.52
" The increase in absorption of poorly absorbed drugs could be ascribed to the increased permeability of the blood-gastric epithelium barrier as was evidenced by leakage of Evans Blue."( Characterization of mitomycin C-induced gastrointestinal damage: changes in the gastric absorption of drugs in rats.
Hashida, M; Kawabata, S; Mizuno, M; Sezaki, H, 1986
)
0.59
" The repetition rate of 25,000 pulses per sec (pps), pulse width of 10 microseconds, and exposure geometry used, resulted in a specific absorption rate (SAR) of 33."( Effects of radiofrequency radiation and simultaneous exposure with mitomycin C on the frequency of sister chromatid exchanges in Chinese hamster ovary cells.
Ciaravino, V; Erwin, DN; Meltz, ML, 1987
)
0.51
"Neither doxorubicin (ADM) nor mitomycin C (MMC) were well absorbed through the intact or damaged rabbit bladder wall into the blood stream."( The absorption of doxorubicin and mitomycin C in perioperative instillation. An experimental and clinical study.
Alfthan, O; Eksborg, S; Jauhiainen, K; Kangas, L; Perilä, M, 1985
)
0.84
" The 65% reduction in MMC-mc bioavailability observed for this patient indicates a quantitative local improvement in exposure to the drug and correlates well with the low incidence of systemic side effects noted in preliminary clinical studies."( Systemic blood levels after intra-arterial administration of microencapsulated mitomycin C in cancer patients.
Boublil, JL; Bourry, J; Bruneton, JN; Milano, G; Namer, M; Renee, N; Roux, P; Thyss, A,
)
0.36
"The mean reduction of mitomycin C bioavailability in the extracorporeal circuit blood was 42."( Pharmacokinetic of intraarterial mitomycin C with extra corporeal detoxification in humans.
Guadagni, S; Palumbo, G; Pantaleoni, GC,
)
0.73
" Since patients on chemotherapeutic treatment can be submitted to nuclear medicine procedures, we studied the mitomycin-C effect on the bioavailability of the technetium-99m-labelled sodium pyrophosphate (9mTc-PYP) using an animal model."( Evaluation of the effect of mitomycin-C on the bioavailability of technetium-99m-labelled sodium pyrophosphate in mice.
Bernardo-Filho, M; de Mattos, DM; Diré, GF; Freitas, RS; Gomes, ML; Lima, EA; Souza, SM, 2002
)
0.82
" This is probably attributable to the low systemic bioavailability of Oxa."( Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: oxaliplatin pharmacokinetics and feasibility.
Ehrsson, H; Fester, C; Guthoff, I; Kornmann, M; Lotspeich, E; Schatz, M; Wallin, I,
)
0.35
"8 GHz microwave (MW) specific absorption rate (SAR, 3 W/kg) on human lymphocytes DNA damage induced by 4 chemical mutagens [mitomycin C (MMC), bleomycin (BLM), methyl methanesulfonate (MMS), and 4-nitroquinoline 1-oxide (4NQO)]."( [Influence of 1.8 GHz microwave on DNA damage induced by 4 chemical mutagens].
Deng, HP; He, JL; Jin, LF; Li, QY; Lou, JL; Lu, DQ; Wang, BH; Zheng, W, 2005
)
0.54
" Mitomycin C exhibited fast and even distribution in rat tissues, and equal bioavailability was achieved by intravenous and intraperitoneal infusion."( Validation and use of microdialysis for determination of pharmacokinetic properties of the chemotherapeutic agent mitomycin C - an experimental study.
Alexandr, K; Andersen, A; Ekstrøm, PO; Flatmark, K; Giercksky, KE; Olsen, H; Sørensen, O, 2010
)
1.48
" The early absorption rate depends on TURBT extension."( Systemic absorption and pharmacokinetics of single-dose early intravesical mitomycin C after transurethral resection of non-muscle-invasive bladder cancer.
Campodonico, F; Maffezzini, M; Manuputty, EE; Marini, V; Martelli, A; Mattioli, F; Puntoni, M; Tamagno, S, 2013
)
0.62
"IPEC provides high intraperitoneal MMC concentration and increased bioavailability in extraperitoneal tissue, combined with low systemic absorption."( Impact of hyperthermia on pharmacokinetics of intraperitoneal mitomycin C in rats investigated by microdialysis.
Andersen, AM; Flatmark, K; Giercksky, KE; Kristian, A; Sørensen, O, 2014
)
0.64
"5 times higher than that of MTC injection, and these micelles can enhance the bioavailability of MTC."( Deoxycholic acid-grafted PEGylated chitosan micelles for the delivery of mitomycin C.
Guan, J; Jin, Y; Shi, NQ; Zhang, XR; Zhao, Y; Zhu, HY, 2015
)
0.65
" At the start of treatments, temperature rise measurements were performed with 3 different antenna settings optimized for each patient, from which the absorbed power (specific absorption rate [SAR]) was derived."( Toward online adaptive hyperthermia treatment planning: correlation between measured and simulated specific absorption rate changes caused by phase steering in patients.
Bardati, F; Bel, A; Ciampa, S; Crezee, J; de Kroon-Oldenhof, R; Geijsen, ED; Kok, HP; Stalpers, LJ; Steggerda-Carvalho, EJ; van Stam, G; Zum Vörde Sive Vörding, PJ, 2014
)
0.4
" Mechanical wounding reduced fibroblast aromatase activity but increased keratinocyte activity, amplifying the bioavailability of intracellular estrogen."( Intracrine sex steroid synthesis and signaling in human epidermal keratinocytes and dermal fibroblasts.
Colombo, L; Dalla Valle, L; Pertile, P; Pomari, E; Thornton, MJ, 2015
)
0.42
" Herein we investigated whether coencapsulation of doxorubicin and mitomycin C within polymer-lipid hybrid nanoparticles (DMPLN) achieved this goal via ratiometric drugs in an orthotopic murine breast tumor model with nanocarrier-modified biodistribution, pharmacokinetics, local bioavailability and toxicity."( Polymer-lipid hybrid nanoparticles synchronize pharmacokinetics of co-encapsulated doxorubicin-mitomycin C and enable their spatiotemporal co-delivery and local bioavailability in breast tumor.
Adissu, HA; Cai, P; Chen, K; Cheng, J; Li, J; Pang, KS; Rauth, AM; Wu, XY; Zhang, RX; Zhang, T, 2016
)
0.89
" Compared to conventional solution forms, such superior efficacy of DMPLN was attributed to the synchronized pharmacokinetics of DOX and MMC and increased intracellular drug bioavailability within tumor cells enabled by the nanocarrier PLN."( Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice.
Chen, K; Cheng, J; Lai, P; Pang, KS; Rauth, AM; Wu, XY; Zhang, RX; Zhang, T, 2017
)
0.68
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" These observations demonstrate the bioavailability of liposomal MLP in human tumors, and its pharmacologic potential in cancer therapy."( Ex-vivo activation of a liposomal prodrug of mitomycin C by human tumors.
Amitay, Y; Ben-Haim, M; Dagan, A; Dorot, S; Doviner, V; Gabizon, A; Ohana, P; Reissman, P; Shmeeda, H; Tankel, J, 2022
)
0.98

Dosage Studied

Nine lipophilic la-N-substituted prodrugs of mitomycin C were formulated in lipid dispersion dosage forms and their fundamental antitumor activities were evaluated. The dose-response relations and the kinetics of recA protein induction following treatment of the cells with ultra-violet light, nalidixic acid, mitomyin C, and cisplatin were studied.

ExcerptRelevanceReference
" The portal concentration of MMC increased rapidly to the maximum concentration of 826 +/- 364 ng/ml at 5 minutes after administration, when the dosage was 20 mg (four cases)."( [Portal blood levels of mitomycin C after intraperitoneal administration].
Kakizaki, K; Yamada, Y; Yamauchi, H, 1992
)
0.59
" At the dosage level used in the present study (5 micrograms/mouse x 6), 3H11-DEX-ADM showed an inhibition rate of 51."( [The antitumor effect of adriamycin conjugated with monoclonal antibody against gastric cancer in vitro and in vivo].
Dong, ZW; Li, N; Liu, T; Wang, NQ; Zhang, YT, 1992
)
0.28
" Haematologic toxicity is greater in the CMF group, requiring more frequent dosage reductions."( Randomized trial of adjuvant chemotherapy for operable breast cancer comparing i.v. CMF to an epirubicin-containing regimen [see comment].
Bonichon, F; Chauvergne, J; Dilhuydy, JM; Durand, M; Mauriac, L, 1992
)
0.28
" Since part of these agents may gain access to the anterior chamber and cause cytotoxicity to the corneal endothelium we set up an in vitro system to establish a dose-response effect."( The effects of 5-fluorouracil and mitomycin C on the corneal endothelium.
Greve, EL; Nuyts, RM; Pels, E, 1992
)
0.56
" The success of treatment seems out of question on dosage but with the continuation of the instillation program."( Endovesical instillation of mitomycin-C in preventing recurrence of superficial bladder carcinoma.
Wu, JJ; Yin, ZL; Zhu, JN, 1992
)
0.58
" Pharmaceutical dosage was set at approximately 30% of the increased life span (ILS) for Meth-A."( [Experimental study of the treatment of carcinomatous peritonitis in gastric cancer].
Arai, K; Kitamura, M; Miyashita, K, 1992
)
0.28
"The schedule in dosing of intravesical chemotherapy has thus far received little attention."( Pharmacodynamics and pharmacokinetics of intravesical mitomycin C upon different dwelling times.
De Bruijn, EA; Maes, RA; Sleeboom, HP; Tjaden, UR; van Helsdingen, PJ; van Oosterom, AT, 1992
)
0.53
" Different dosage schedules and methods require further study."( Intravesical chemotherapy. Treatment selection, techniques, and results.
Richie, JP, 1992
)
0.28
" At a tolerable dosage level, bleomycin A6 exerted remarkable growth inhibition on human colon cancer HT-29 and cecum cancer Hce-8693 xenografts (approximately 90% inhibition)."( [Inhibitory effect of bleomycin A6 on human colon cancer xenografts in nude mice].
Deng, Y, 1990
)
0.28
"There are few reports about the methods, amounts, and kinds of dosage about intermittent intra-arterial chemotherapy of liver metastases from primal pathological type's squamous cell carcinoma."( [Study of intermittent intra-arterial infusion chemotherapy in liver metastases from squamous cell carcinoma].
Aoki, T; Kasuya, K; Kimura, K; Koyanagi, Y; Ozawa, T; Sato, S; Tsuchida, A; Yasuda, D; Yoshimatsu, A, 1991
)
0.28
" The beta-GA, reflecting the SOS-inducing activity, of GE94 and KY946 treated with these compounds increased significantly with a clear dose-response relationship, and reached a maximum level within 60 min, while no response was seen in KY945 and KY943."( 'Rec-lac test' for detecting SOS-inducing activity of environmental genotoxic substance.
Nishioka, H; Nunoshiba, T, 1991
)
0.28
" In the dose-response study, a dose-related inhibition of the mitomycin C (MMC)-induced MPCE frequency by estradiol (E2) treatment was observed."( Effect of estrogen on induction of micronuclei by mutagens in male mice.
Miyamoto, H; Nagae, Y; Shimizu, H; Suzuki, Y, 1991
)
0.52
"01) lower blood levels of 1 in contrast to bolus injection of 1 without 2 under identical dosage regimens."( [The effect of the vasoconstrictor glycylpressin on the bioavailability of mitomycin C].
Czejka, M; Jäger, W; Schüller, J, 1991
)
0.51
" The case history reported here is discussed in relation to dose and scheduling of mitomycin C, and a safe maximum dosage is suggested."( Cancer-associated hemolytic-uremic syndrome with spontaneous resolution. A case report.
Abdolrahimzadeh, S; Barone, C; Franchi, F; Gozzer, M; Seminara, P, 1991
)
0.51
" Although the sensitivity of the serum-treated group to MMC was slightly higher than that of the untreated group, the dose-response curves of the tumor cells to MMC were similar to each other."( The influence of stromal cells on the MTT assay (II)--Study on the nude mouse system.
Suto, A, 1991
)
0.28
" The dose-response relationships were the same with or without concomitant treatment with MMC (10(-6) M)."( Quantitative analyses of the induction of chromosome aberrations and sister-chromatid exchanges in human lymphocytes exposed to gamma-rays and mitomycin-C in combination.
Iijima, K; Morimoto, K, 1991
)
0.48
"When chemotherapeutic drugs with low liver extraction are used for hepatic arterial infusion (HAI), dosage limits are usually determined by systemic rather than hepatic toxicity."( Hepatic arterial infusion chemotherapy with complete hepatic venous isolation and extracorporeal chemofiltration: a feasibility study of a novel system.
Bodden, W; Byrd, DR; Carrasco, CH; Chase, J; Cromeens, D; Curley, SA; Dougherty, T; Ellis, HJ; Newman, RA; Wright, K, 1991
)
0.28
" Then the adequate dosage of each anticancer drug for this assay system was investigated so that the body weights of mice do not decrease more than 20%, and the following doses were determined; Mitomycin C: 5mg/kg; Cisplatinum: 4mg/kg; Cyclophosphamide: 100mg/kg and 5FU: 90 mg/kg."( [Subrenal capsule assay in normal mice immunosuppressed by cyclosporin A].
Takagi, H; Yamamoto, K; Yamauchi, M, 1990
)
0.47
" At a dosage range in mice of 50-12."( Antimutagens from Momordica charantia.
Dayrit, F; Finch, P; Guevara, AP; Lim-Sylianco, C, 1990
)
0.28
" In the present study, the combined therapy by hEGF and mitomycin C (MMC) as an antitumor agent was studied in A431 solid tumor-bearing mice to determine the dosage schedule of hEGF."( Response of A431 experimental human solid xenograft to mitomycin C in combination with human epidermal growth factor in mice.
Amagase, H; Fuwa, T; Hashimoto, K; Murakami, T; Tamura, K; Yata, N, 1990
)
0.77
" Up to now, most of the chemicals tested have shown additive effects when combined with doses of the ascending part of the dose-response curve and potentiating effects when combined with doses of its descending part."( The induction of reciprocal translocations in mouse germ cells by chemicals and ionizing radiations. II. Combined effects of mitomycin C or thio-tepa with two doses of gamma-rays.
Andrieu, JM; De Luca, JC; Dulout, FN; Furnus, CC; Ulrich, MA, 1990
)
0.49
" It is expected that the dose intensity may clear dose-response relationships which are sometimes obscure in cancer chemotherapy because dose reduction or treatment delay caused by adverse effects."( [Dose intensity in cancer chemotherapy in gastric cancer].
Ishibiki, K; Kumai, K, 1990
)
0.28
" In view of the steep dose-response curve of this alkylating agent this opens new perspectives for the treatment of liver metastasis."( A comparative study of isolated liver perfusion versus hepatic artery infusion with mitomycin C in rats.
Eggermont, AM; Franken, HC; Kuppen, PJ; Marinelli, A; Souverijn, JH; van de Velde, CJ, 1990
)
0.5
"Increasing the number of antigen-specific T cell clones in a T cell proliferation assay resulted in a shift in the antigen dose-response curves toward higher amounts of antigen (i."( Functional analysis of the interaction of the antigen-specific T cell receptor with its ligands.
Ashwell, JD; Fox, BS; Schwartz, RH, 1986
)
0.27
"A new dosage form consisting of small activated carbon particles which adsorb Aclacinomycin A, Adriamycin, Mitomycin C or Pepleomycin was prepared in order to deliver larger amounts of anticancer agents to the lymph nodes through the high ability of lymphatics to adsorb particles."( Anticancer agents adsorbed by activated carbon particles, a new form of dosage enhancing efficacy on lymphnodal metastases.
Ahn, T; Hagiwara, A; Iwamoto, A; Takahashi, T; Torii, T; Ueda, T,
)
0.34
"The effect of a new dosage form for anti-cancer agents was studied on tissue distribution and compared with the aqueous solution form."( Activated carbon particles as anti-cancer drug carrier into regional lymph nodes.
Hagiwara, A; Iwamoto, A; Takahashi, T; Torii, T; Ueda, T, 1987
)
0.27
" The data revealed a distinct dose-response effect."( A simplified method for micronucleus preparation from hepatic cells.
Das, RK; Roy, B, 1988
)
0.27
" Hypoxic fractions (HF) were calculated by an indirect technique using the horizontal displacement of the TCD50 value from the dose-response curves of tumors irradiated under normal or clamped conditions."( Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay.
Grau, C; Overgaard, J, 1988
)
0.27
"For prevention and therapy of peritoneal dissemination, a new dosage from (MMC-CH) comprising carbon particles adsorbing mitomycin C was given to 44 patients (the MMC-CH group) undergoing gastrectomy for gastric cancer, of which advancing stage was classified into the category of H0, and S2 or S3, and P0, P1, P2 or P3 according to the General Rules for the Gastric Cancer Study."( [Intraoperative chemotherapy against peritoneal dissemination of gastric cancer with intraperitoneal activated carbon particles adsorbing mitomycin C].
Hagiwara, A; Iwamoto, A; Sawai, K; Takahashi, T; Yamaguchi, T; Yoneyama, C, 1989
)
0.69
" IV group underwent identical dosing through the jugular vein."( Pharmacokinetics and tissue uptake of mitomycin C in isolated perfusion of pancreas.
Arredondo, MA; Chaudhuri, B; Chaudhuri, PK; Thomford, NR, 1989
)
0.55
" In both strains, a clear positive dose-response relation was shown by both routes."( A comparison of intraperitoneal injection and oral gavage in the micronucleus test with mitomycin C in mice.
Hiraga, Y; Ikeda, Y; Inui, N; Sato, S, 1989
)
0.5
" Significant pregnancy-specific alterations in drug disposition, including higher plasma concentrations and decreased clearances in pregnant animals, highlight the need for drug-level monitoring and possible dosage modification when these agents are used in pregnancy."( Chemotherapy in a pregnant rat model. 1. Mitomycin-C: pregnancy-specific kinetics and placental transfer.
Boike, GM; Bottoms, SF; Deppe, G; Gove, NL; Malone, JM; Malviya, VK; Sokol, RJ; Young, JD, 1989
)
0.54
"A 58-year-old woman who was inoperable because of S3 (pancreas and colon) and P1 at the initial operation was treated with UFT, ADM and MMC at a dosage of 242."( [An unresectable gastric cancer radically resectable following UFT, ADM, MMC therapy].
Hayashi, S; Kamejima, N; Kasugai, T; Kataoka, M; Kureyama, Y; Masaoka, A; Mitsui, T; Taniwaki, S; Tsuji, H; Watarai, N, 1989
)
0.28
" The dosage was 250 mg/day for 5-FU continuously, 10 mg/week for MMC and 5 KE/week for OK-432, respectively."( [Three cases of effective hepatic arterial infusion with OK-432, mitomycin C and 5-fluorouracil in liver metastasis from gastric cancer].
Hamada, H; Mori, N; Nakajima, I; Nakamura, T; Nakamura, Y; Tanaka, A; Wada, T; Yasutomi, M, 1989
)
0.51
" Dosage was based on investigators' estimate of patients' bone marrow reserve."( Vindesine and mitomycin C in metastatic breast cancer. A Southeastern Cancer Study Group Trial.
Einhorn, L; Luedke, DW; Luedke, SL; Lyss, AP; Raney, M, 1989
)
0.64
" On the other hand, results from isolated limb perfusion for satellitosis and in-transit metastasis suggest distinct dose-response correlations with tumoricidal properties of appropriate antineoplastic agents."( [Systemically administered regional tumor therapy. Regional hemi-body chemotherapy of metastatic malignant melanoma--an experimental therapy concept].
Aigner, KR; Link, KH; Müller, H; Voigt, H; Walther, H, 1989
)
0.28
" The UV dose-response curve of mus-26 showed a characteristic plateau in the range of 100-200 J/m2."( Epistasis, photoreactivation and mutagen sensitivity of DNA repair mutants upr-1 and mus-26 in Neurospora crassa.
Inoue, H; Ishii, C, 1989
)
0.28
" The same dosing regimen of DDTC ameliorated Adriamycin-induced toxicity to bone marrow stem cells at the two higher doses tested."( Myeloprotective effect of diethyldithiocarbamate treatment following 1,3-bis(2-chloroethyl)-1-nitrosourea, adriamycin, or mitomycin C in mice.
Borch, RF; Schmalbach, TK, 1989
)
0.48
" The median dosage of FAM agents delivered to nonresponders was reduced."( 5-Fluorouracil, doxorubicin (adriamycin) and mitomycin-C (FAM) in advanced gastric cancer: observations on response, patient characteristics, myelosuppression and delivered dosage.
Biran, H; Biran, S; Sulkes, A, 1989
)
0.54
" After injection into the rat thigh muscle, MMC was rapidly absorbed regardless of the dosage form."( Absorption characteristics of the lipophilic prodrug of mitomycin C from injected liposomes or an emulsion.
Hashida, M; Kakutani, T; Sasaki, H; Sezaki, H, 1985
)
0.52
" From these results, it was suggested that the release speed of anti-cancer agents can be controlled by modifying the drug dosage and form."( [Basic study of anti-cancer agents suspended in lipiodol].
Takahashi, T; Taniguchi, H; Yamaguchi, T, 1986
)
0.27
" Both dosage and releasing time can be adjusted."( [Treatment of malignant brain tumors with slowly releasing anticancer drug-polymer composites].
Himuro, H; Inoue, N; Kaetsu, I; Kitamura, K; Kubo, O; Sakairi, M; Tajika, T; Tajika, Y; Tohyama, T; Yoshida, M, 1986
)
0.27
" For treatments resulting in fewer than 2 lethal hits, MNU, ENU, and MC gave rise to apparently linear dose-response curves for gene mutations (hgprt and tk genes) as well as for chromosomal aberrations."( Spontaneous and induced chromosomal aberrations and gene mutations in human lymphoblasts: mitomycin C, methylnitrosourea, and ethylnitrosourea.
Jensen, JC; Thilly, WG, 1986
)
0.49
"5 mg/kg) reduced the semiconservative DNA synthesis of the hepatocytes, but simultaneous dosing of fumaric acid (40 mg/kg) enhanced the recovery of the DNA synthesis."( Fumaric acid enhances DNA synthesis of rat hepatocytes by counteracting the toxicities of mitomycin C and aflatoxin B1.
Akao, M; Kuroda, K; Terao, K, 1986
)
0.49
" The consistent dose-response relations were obtained in cultures treated with mitomycin C, caffeine and colcemid."( Measurement of micronuclei by cytokinesis-block method in cultured Chinese hamster cells: comparison with types and rates of chromosome aberrations.
Sasaki, MS; Wakata, A, 1987
)
0.5
"Selective delivery of a high level of Mitomycin C (MMC) in intraperitoneal disseminated lesions was studied using a new dosage form of MMC, called MMC-CH."( Selective delivery of high levels of mitomycin C to peritoneal carcinomatosis using a new dosage form.
Hagiwara, A; Itoh, T; Lee, R; Takahashi, T; Takeda, M; Ueda, T,
)
0.68
"A new drug dosage form comprising activated carbon particles adsorbing mitomycin C (MMC-CH) is designed to slowly release its components, and has affinity for the tumor surface and lymph nodes and a tendency to stay long in the local portion."( Chemotherapy for carcinomatous peritonitis and pleuritis with MMC-CH, mitomycin C adsorbed on activated carbon particles. Clinical trials.
Hagiwara, A; Itoh, T; Lee, R; Takahashi, T; Takeda, M; Ueda, T, 1987
)
0.74
" Anticancer agents (ADM, CDDP, CHA3, CQ, MMC) at 1/3 LD50 dosage for mice were administered intraperitoneally on a schedule of 3 doses for every 4 days."( Efficacy of anticancer agents in vitro and in vivo using cultured human endometrial carcinoma cells--study of therapeutic index.
Yasui, Y, 1987
)
0.27
" Dose-response curves and kinetic profiles for the IgSC responses induced by pokeweed mitogen (PWM), a polyclonal B cell activator, were similar for CSF cells (CSFC) and peripheral blood mononuclear cells (PBMC)."( B cell activation in multiple sclerosis.
Levinson, AI; Lisak, RP; Sandberg, M; Zweiman, B, 1986
)
0.27
"A new dosage form (MMC-CH) of mitomycin C (in a suspension of activated carbon adsorbing mitomycin C in saline), designed for intracavitary use in carcinomatous peritonitis, was studied for its toxicity and pathological effects in rats."( Toxicity and pathological effects of a new dosage form of mitomycin C for carcinomatous peritonitis.
Hagiwara, A; Itoh, T; Lee, R; Takahashi, T; Takeda, M; Ueda, T,
)
0.66
" An apparent chemical hepatic arteritis developed in five patients after multiple courses, however, its relationship to prior hepatic arterial infusion therapies, Mitomycin, starch microspheres, and repeated dosing of the drug-microsphere mixture remains unclear."( Phase II study of hepatic arterial degradable starch microspheres and mitomycin.
Ensminger, WD; Smith, JE; Walker-Andrews, SC; Wollner, IS, 1986
)
0.7
"A new dosage form of mitomycin C (MMC-CH) was tested for toxicity and therapeutic efficacy against intraperitoneally inoculated cancer cells in mice."( Enhanced anticancer efficacy by use of mitomycin C adsorbed on small activated carbon particles in mice.
Hagiwara, A; Nakagawa, Y; Takahashi, T; Ueda, T, 1987
)
0.86
"A new dosage form, comprising Mitomycin C adsorbed on activated carbon particles (MMC-CH) was studied for its local therapeutic effects on carcinomatous peritonitis."( Enhanced chemotherapeutic efficacy on carcinomatous peritonitis using a new dosage form in animal experiments.
Hagiwara, A; Itoh, T; Lee, R; Takahashi, T; Takeda, M; Ueda, T,
)
0.42
" Changes in some of these parameters, as a function of drug concentration, resulted in dose-response curves which were bell-like shaped, hence paradoxical similarities between non-drug-treated cells and cells treated with higher drug concentrations were observed."( Induction, by adriamycin and mitomycin C, of modifications in lipid composition, size distribution, membrane fluidity and permeability of cultured RDM4 lymphoma cells.
Bégin, M; Bischoff, P; Bruneau, C; Leroux, JY; Mercier, G; Oth, D, 1987
)
0.56
" During the first week of radiotherapy, 5-fluorouracil (1000 mg/m2 daily for four days by continuous infusion), and mitomycin (10 mg/m2 on day 1) were administered; four weeks later, a second cycle at the same dosage followed."( [Function-preserving treatment of anal cancer using simultaneous radio- and chemotherapy].
Dunst, J; Reichard, U; Sauer, R; Wolf, N, 1987
)
0.48
" With respect to non-protein-bound Pt concentrations, the 5-division dosage showed the highest value, which was considered to be a temporary phenomenon, while with continuous infusion, the shorter the infusion period, the higher the value became."( [The pharmacokinetics of cisplatin and its influence on renal functions based on different infusion methods].
Amano, H; Hishida, H; Ogura, Y; Saji, E; Takagi, M; Takagi, N; Takahashi, A, 1987
)
0.27
" The clinical course of this case had decided for us which route would be the most effective and would have the least side effect, also, how much of a dosage can be administered as a maximum adoptive dose of an anti-cancer agent, and what kind of a second-line chemotherapy is effective against resistant cancer cells."( [A case report of an advanced ovarian cancer (stage T4) treated with a total amount of 1815 mg of CDDP].
Hino, K; Ibaraki, T; Katou, Y; Kiyozuka, Y; Maruyama, M; Nabuchi, K; Ninomiya, Y; Noda, T; Okamura, Y; Oku, M, 1987
)
0.27
" Dosing with 5-FU via both routes caused the largest but almost equal suppression of L-tryptophan absorption."( Effects of mitomycin C, 5-fluorouracil and cyclophosphamide on drug absorption, enzyme activities and mucosal lipid composition of intestine.
Hashida, M; Mizuno, M; Sezaki, H; Tamura, M, 1987
)
0.66
"6% at the lowest dosage (0."( Spontaneous expulsion of micronuclei by enucleation in the micronucleus assay.
Ariyuki, F; Nito, S; Okaniwa, A,
)
0.13
" Compared to a group treated in 1970 bis 1982 with the same dosage of irradiation without the combination of chemotherapy the median survival could be raized from nine to 24 months, the two year survival rate improved from 18% to 42%."( [Simultaneous radio- and chemotherapy of squamous cell carcinoma of the esophagus].
Rohloff, R; Tosch, U; Wendt, TG; Willich, N, 1988
)
0.27
" The trophectoderm population was reduced only at the highest dosage (0."( Postimplantation development of mitomycin C-treated mouse blastocysts.
Tam, PP, 1988
)
0.56
" The reduced dosage does not appear to have compromised the treatment results."( Mitomycin C in advanced breast cancer: an update.
Godfrey, TE, 1988
)
1.72
" The degree of blockade of arterial blood flow was correlated with the dosage of DSM, and estimated by the angiographic change."( [Experimental and clinical studies on degradable starch microspheres (DSM) in the treatment of hepatic neoplasms].
Kaminou, T; Manabe, T; Matsuo, R; Murata, K; Nakamura, K; Nakatsuka, H; Takashima, S; Tsubakimoto, M; Usuki, N; Yamada, T, 1988
)
0.27
"A new dosage form of activated carbon particles adsorbing mitomycin C (MMC-CH) was studied for its therapeutic effects on peritoneal dissemination in both animal experiments and preliminary clinical trials."( Intraoperative chemotherapy with carbon particles adsorbing mitomycin C for gastric cancer with peritoneal dissemination in rabbits.
Hagiwara, A; Itoh, T; Lee, R; Takahashi, T; Takeda, M; Ueda, T, 1988
)
0.76
" The microencapsulated dosage form of mitomycin C was found to enhance the drug's activity through sustained drug release."( Preparation and in vitro evaluation of polylactic acid-mitomycin C microcapsules.
Hogan, TF; Howard, SA; Kandzari, SJ; Ma, JK; Malanga, CJ; Tsai, DC,
)
0.65
" As a criterion of genotoxic effects of the compound, adopted is a significant and reproducible difference of results at least once or a significant increase in the percentage of polychromatic erythrocytes with micronuclei and dose-response relationship."( [Methods used for evaluating mutagenic and genotoxic properties of chemical compounds. I. The micronucleus test in vivo (an abridged version)].
Przybojewska, B, 1988
)
0.27
" Highly enriched OKT4+ and OKT8+ T cell subsets co-cultured with adherent cells in the presence of OKT3 mab both produced GM-CSF and IFN-gamma and showed similar dose-response curves to OKT3 mab."( OKT3 monoclonal antibody induces production of colony-stimulating factor(s) for granulocytes and macrophages in cultures of human T lymphocytes and adherent cells.
Broxmeyer, HE; Lu, L; Moore, MA; Platzer, E; Rubin, BY; Welte, K, 1985
)
0.27
" Drug dose-response and time-response curves were plotted, and the IC50 ratio was calculated, for each test compound in order to investigate the mechanism of anticancer action."( [In vitro sensitivity test of a cultured human ovarian cancer cell line to anticancer agents].
Fujiya, S; Hatiya, S; Nakabayashi, Y; Tahira, K; Terashima, Y; Yasuda, M; Yoshioka, M, 1985
)
0.27
" There was a good correlation between ISCs and cytotoxicity in dose-response studies in each cell line."( Interactions of mitomycin C with mammalian DNA detected by alkaline elution.
Alberts, DS; Bowden, GT; Dorr, RT; Liddil, JD, 1985
)
0.62
" The severity of the glomerular, vascular, and tubular lesions correlated with the total dosage of MMC received."( Mitomycin-C nephrotoxicity: a clinico-pathologic study of 17 cases.
Bettez, P; Giroux, L, 1985
)
1.71
" Eleven additional patients were evaluated for tolerance to repeated 6-ml dosing of DSM."( Phase I study of hepatic arterial degradable starch microspheres and mitomycin.
Ensminger, WD; Gyves, JW; Stetson, P; Walker-Andrews, S, 1985
)
0.5
" This three-drug combination appears to be an active regimen in the treatment of non-small-cell bronchogenic carcinoma; however, altered dosage schedules should be examined in order to decrease drug-related toxicity."( Combination chemotherapy with mitomycin-C, cisplatin, and vinblastine in the treatment of non-small-cell lung cancer.
Griffin, JP; Niell, HB, 1985
)
0.56
" As systemic cancer chemotherapy was not so effective, targeted cancer chemotherapy for lymph node metastasis and carcinomatous peritonitis was carried out by modification of drug dosage form as fat emulsion and activated carbon incorporating anticancer agent."( [Combined therapy of gastric cancer].
Takahashi, T, 1985
)
0.27
" The anticancer effects were more enhanced when TBHT was combined with dosage of cis-DDP."( [Total-body hyperthermia and combined anticancer chemotherapy].
Koga, S; Maeta, M, 1985
)
0.27
" When the dosage of halogenated nucleosides reached 500 mg/kg, satisfactory differential sister chromatid staining of bone marrow cells was obtained."( An improved method for the analysis of sister-chromatid exchange in vivo.
Long, JB; Ou, BX, 1985
)
0.27
" Results showed that the optimal treatment times at which the agents could most efficiently produce SCEs were different for MMC and 4NQO, and that the dose-response curves tended to 'bend down' at very high doses; that is, treatments with very high doses induced smaller than expected numbers of SCEs."( Sister-chromatid exchanges and cell-cycle kinetics in human lymphocyte cultures exposed to alkylating mutagens: apparent deformity in dose-response relationships.
Koizumi, A; Morimoto, K; Sato-Mizuno, M,
)
0.13
" There was no serious life-threatening toxicity, and with appropriate dosage adjustment, the drug was administered to patients with mild hepatic insufficiency."( 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract.
Harvey, JH; Schein, PS; Smith, FP, 1984
)
0.61
" The toxicities in the case of intra-arterial infusion were less prominent than in the case of intravenous administration of the same dosage of the oncostatics."( [Intra-arterial infusion of oncostatics in recurrent cervical carcinoma].
Iijima, S; Inaba, J; Kawagoe, K; Sasaki, J; Tsunoda, H, 1983
)
0.27
" By comparing dose-response curves obtained with three protocols which overcome the optical and cytochemical difficulties of sperm measurement in different ways we conclude the response is due to X-ray-induced DNA content variability."( Radiation-induced DNA content variability in mouse sperm.
Gledhill, BL; Lake, S; Pinkel, D; Van Dilla, MA; Wyrobek, AJ, 1983
)
0.27
" Time-response and dose-response were studied for chromosomal aberrations induced by transplacental treatment of mouse embryos."( New approaches to mutagenicity studies in animals for carcinogenic and mutagenic agents. II. Clastogenic effects determined in transplacentally treated mouse embryos.
Adler, ID, 1983
)
0.27
" It has become evident that DES at a dosage of 3 mg/day carries a significantly higher risk of overall cardiovascular toxicity than does cyproterone acetate, but severe cardiovascular complications did not differ between treatment groups."( Treatment of prostatic cancer: the EORTC experience--preliminary results of prostatic carcinoma trials.
Schroeder, FH, 1984
)
0.27
" After a sublethal dosage of mitomycin C, single- and double-stranded cuts of cross-linked DNA were observed in the wild-type cells during postincubation."( DNA double-strand breakage and removal of cross-links in Deinococcus radiodurans.
Asaka, S; Kitayama, S; Totsuka, K, 1983
)
0.56
" Mitomycin C and radiation in combination produced an additive cytotoxicity; neither agent was found to alter significantly the shape of the dose-response curve for the other agent."( Effects of mitomycin C alone and in combination with X-rays on EMT6 mouse mammary tumors in vivo.
Rockwell, S, 1983
)
1.57
" The killing ability of macrophages and polymorphonuclear leukocytes of the immunosuppressed mice was also markedly enhanced by dosing with FK-156."( Immunoactive peptides, FK-156 and FK-565. II. Restoration of host resistance to microbial infection in immunosuppressed mice.
Goto, S; Kuwahara, S; Mine, Y; Nishida, M; Wakai, Y; Watanabe, Y; Yokota, Y, 1983
)
0.27
" After determination of dose-response relationships and toxicity, treated tumours were biopsied at different times and cell cycle distribution pattern, 3HTdR incorporation into DNA, histology and tumour volume were recorded."( Cell cycle perturbations in heterotransplanted squamous-cell carcinoma of the head and neck after mitomycin C and cisplatin treatment.
Alm, P; Biörklund, A; Killander, D; Långström, E; Tropé, C; Wennerberg, J, 1984
)
0.48
"Nine lipophilic la-N-substituted prodrugs of mitomycin C were formulated in lipid dispersion dosage forms and their fundamental antitumor activities were evaluated."( Antitumor activity of lipophilic prodrugs of mitomycin C entrapped in liposome or O/W emulsion.
Hashida, M; Kimura, T; Sasaki, H; Sezaki, H; Takakura, Y, 1984
)
0.79
"Three main aspects involved in the chemical induction of anaphase-telophase aberrations in the first mitosis after treatment were analyzed: 1) the relationship between the frequency of anaphase-telophase aberrations and the time of fixation after treatment; 2) the dose-response relationships; and 3) the proliferative rate of cells exposed to chemicals which interact with DNA by different mechanisms."( Anaphase-telophase analysis of chromosomal damage induced by chemicals.
Dulout, FN; Olivero, OA, 1984
)
0.27
" A clear curvilinear dose-response relationship was found."( [Evaluation of the mutagenic properties of mitomycin C by the sister chromatid exchange test in human blood lymphocytes in vitro].
Bajerska, A; Wyszyńska, K, 1984
)
0.53
" Both preparations provided a sustained-release property and a sensitive response to conventional magnetic force, although certain differences in the release rate of drug, magnetic responsiveness, and particle size were found between the two dosage forms."( Magnetic microcapsules for targeted delivery of anticancer drugs.
Abe, R; Goto, A; Harada, M; Homma, M; Kato, T; Mori, H; Murota, H; Nemoto, R; Unno, K, 1984
)
0.27
" However, with a fixed experimental regimen, treatments with relatively higher doses cause a deformity of the dose-response relationship."( Proliferative kinetics and chemical-induced sister chromatid exchanges in human lymphocyte cultures.
Morimoto, K, 1984
)
0.27
" Two dosage levels were prepared for each combination."( [Clinical evaluation of adriamycin for advanced breast cancer (3)--a joint study by 26 institutes on the CAF and CMcF treatment].
Abe, O; Enomoto, K; Izuo, M; Koyama, H; Kubo, K; Nomura, Y; Sakai, K; Terasawa, T; Tominaga, T, 1983
)
0.27
" Although the dosage of the anticancer chemotherapy was quite small, this treatment may have promoted the regression of the tumor in conjunction with activated antitumor immunity of the host."( [A case of advanced gastric cancer which disappeared histopathologically after short-time chemotherapy].
Furuta, K; Hara, K; Kiyomitsu, Y; Nakazaki, S; Shinoda, M; Watanabe, K; Yajima, K; Yasuda, S; Yokoyama, T, 1984
)
0.27
" The cytotoxicities of the two agents were found to be additive as judged by comparing dose-response curves for each agent alone with survival curves after combination therapy and by isobologram analysis."( Cytotoxicities of mitomycin C and x rays to aerobic and hypoxic cells in vitro.
Rockwell, S, 1982
)
0.6
" A dose-response effect was also evident."( Induction of chromosomal aberrations in fish Boleophthalmus dissumieri after exposure in vivo to mitomycin C and heavy metals mercury, selenium and chromium.
Krishnaja, AP; Rege, MS,
)
0.35
" Furthermore, the survival was elevated in proportion to the increase of total dosage of futraful."( [Effect of postoperative long-term chemotherapy of stomach cancer using mitomycin C and futraful--the secondary study (1)].
Abe, O; Akiyama, H; Hattori, T; Hayasaka, A; Inokuchi, K; Inoue, K; Ito, I; Kasai, Y; Kikuchi, K; Kondo, T; Muto, T; Nakajima, T; Sugie, S; Taguchi, T, 1982
)
0.5
"Double dosing and single sampling seems to be the simplest and most reliable method for detecting clastogens in the mouse peripheral blood micronucleus test."( An optimal, generalized sampling time of 30 +/- 6 h after double dosing in the mouse peripheral blood micronucleus test.
Higashikuni, N; Sutou, S, 1995
)
0.29
" The dose-response curve for the induction of Robertsonian translocations both in G1 and S peaked at 2 Gy and slightly declined at higher doses."( The induction of Robertsonian translocations by X-rays and mitomycin C in mouse cells.
Durante, M; Gialanella, G; Grossi, GF; Nappo, M; Pugliese, M, 1994
)
0.53
" The highest frequency of micronuclei and dose-response relationship between PGE2 doses and micronucleus frequency were observed 30 h after injection of MMC to mice administered PGE2 24 h previously."( Effects of prostaglandin E2 on the micronucleus formation in mouse bone marrow cells by various mutagens.
Fukumoto, M; Ishikawa, T; Kadokura, M; Okonogi, H; Sakaba, H; Shimizu, H; Suzuki, Y, 1994
)
0.29
" Mitomycin-C was given as a bolus intravenous at a dosage of 10 mg/m2, the first day."( Adjuvant treatment in operable stage II and III rectal cancer.
Aurelio, P; Claudio, C; Domenico, D; Fabrizio, AI; Maurizio, C; Numa, C; Paolo, M; Pierluigi, G; Santina, C; Vincenzo, V,
)
1.04
" Relative resistance was not significantly changed by co-incubation with a non-cytotoxic dosage of these inhibitors."( Role of sodium pump systems to determine sensitivity to mitomycin C in non-small cell lung cancer cell lines.
Bando, T; Fujimura, M; Kasahara, K; Matsuda, T; Nakatsumi, Y; Numata, Y; Shibata, K,
)
0.38
" The aim of this phase I study was to determine the toxicity profile and the optimal dosage of KW-2149."( Phase I and pharmacokinetic study of a novel mitomycin C analog KW-2149.
Ardiet, C; Catimel, G; De Bruijn, E; Dirix, L; Dumortier, A; Evene, E; Joossens, E; Koier, I; Provè, A; Schrijvers, D, 1995
)
0.55
" coli strains and does not involve a gene dosage mechanism but a strain-dependent stimulation of gene expression unrelated to the RecA protease activity."( Mitomycin C stimulates thermally induced recombinant gene expression in Escherichia coli MC strains.
Benito, A; Carbonell, X; Corchero, JL; Villaverde, A, 1995
)
1.73
" No statistically or biologically significant increases in the incidence of micronucleated polychromatic erythrocytes compared with the solvent control dosed animals were observed in either sex at the 6 h sampling time or in the females at the 24 h sampling time."( Trichloroacetic acid: investigation into the mechanism of chromosomal damage in the in vitro human lymphocyte cytogenetic assay and the mouse bone marrow micronucleus test.
Coutts, C; Fox, DA; Fox, V; Griffiths, K; Howard, CA; Mackay, JM; Styles, JA; Wyatt, I, 1995
)
0.29
") doses for dose-response and sub-acute (0."( Use of chick, Gallus domesticus, as an in vivo model for the study of chromosome aberration: a study with mitomycin C and probable location of a 'hot spot'.
Bhunya, SP; Jena, GB, 1995
)
0.5
" The slope of the X-ray dose-response curve of Allium roots derived from the meristematic regions was lower than that derived from cells in the F1 region."( The improved Allium/Vicia root tip micronucleus assay for clastogenicity of environmental pollutants.
Arreola, GA; Ma, TH; McConnell, H; Rabago, EV; Xu, C; Xu, Z; Zhang, H, 1995
)
0.29
"A new drug dosage form comprising activated carbon particles absorbing mitomycin C (MMC-CH) has the advantage of being retained in the peritoneal cavity and distributes a larger amount of mitomycin C for a long time."( [The prevention of peritoneal dissemination of gastric cancer with intraperitoneal activated carbon particles absorbing mitomycin C].
Chohei, S; Hagiwara, A; Imanishi, T; Ohgaki, M; Ohyama, T; Ozaki, K; Shimotsuma, M; Takahashi, T; Tsujimoto, H, 1994
)
0.73
" The issues under investigation include best chemotherapy dosage and duration, identification of risk factors and the role of preoperative chemotherapy."( ["State of the art" of adjuvant chemo-endocrine therapy for breast cancer in Japan].
Ikeda, T, 1994
)
0.29
"We studied the recurrence rate of pterygium after administration of a single dosage of topical mitomycin C at the completion of pterygium surgery."( Single dosage of mitomycin C for prevention of recurrent pterygium: preliminary report.
Frucht-Pery, J; Hemo, I; Ilsar, M, 1994
)
0.85
" Next, the overall system was compared to human visual scoring in a dose-response experiment by analyzing the effect of mitomycin C on human chromosomes scored visually by two observers and by the fully automatic scoring."( Automatic scoring of sister chromatid exchanges by image analysis in a dose response experiment.
García-Sagredo, JM; Piper, J; Rutovitz, D; Vaquero, JJ; Vázquez-Mazariego, Y, 1994
)
0.5
" A dose-response relation was also observed between the dosage of DAT and the enhancement of induction of UDS."( [Modulation of mutagenic drug-induced unscheduled DNA synthesis (UDS) in primary rat hepatocytes by diallyl trisulfide].
Deng, DJ, 1993
)
0.29
" Dosing schedules were based on those commonly used in the clinic, and bladder function was assessed from changes in urination frequency."( Bladder damage in mice after single and repeated intravesical instillations of mitomycin C or doxorubicin.
Oussoren, Y; Post, JG; Stewart, FA; te Poele, JA, 1993
)
0.51
" Although MMC is simple to use, it is a potent adjunct to glaucoma filtration surgery, more work should follow to determine the mechanism of action, indications, dosage and optimal exposure time of MMC."( Effects of topical mitomycin C on glaucoma filtration surgery.
Hong, C; Hyung, SM; Kim, DM; Song, KY; Youn, DH, 1993
)
0.61
" 5-Fluorouracil is given in a dosage of 1000 mg/m2/day as a continuous 24-hour infusion for 4 days."( Concomitant preoperative radiochemotherapy in operable locally advanced rectal cancer.
Cellini, N; Coco, C; De Franco, A; Magistrelli, P; Mattana, C; Netri, G; Picciocchi, A; Roncolini, G; Valentini, V; Vecchio, FM, 1994
)
0.29
" The appropriate dosage of six well-known antitumor drugs [mitomycin C (MMC), cyclophosphamide (CPA), nimustine hydrochloride 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU), cis-platinum (II) diaminodichloride (CDDP), adriamycin (ADM) and 5-fluorouracil (5-FU)] in human tumor-bearing nude mice was determined based on the maximum tolerance dose of the drug."( A standardized method of using nude mice for the in vivo screening of antitumor drugs for human tumors.
Abe, O; Hattori, T; Imaizumi, M; Kitano, M; Kondo, T; Taguchi, T; Wakui, A, 1993
)
0.53
" The simulations predicted that changes in treatment parameters would affect the therapeutic outcome in the following rank order: dose > residual volume > urine production > dosing volume > urine pH > dwell time."( Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer.
Au, JL; Badalament, RA; Wientjes, MG, 1993
)
0.5
" We administered the usual therapeutic dosage of various chemotherapeutic agents to 8-week female C57BL/6 mice, and 3 days after these administrations all mice were sacrificed and splenectomised."( [Host immunological status modification by various chemotherapeutic drugs].
Hata, Y; Hosokawa, M; Uchino, J; Wakizaka, Y; Yang, ZB, 1993
)
0.29
" The dosage was 14 mg/m2 (7 mg/m2 at second and following administrations) of MMC and 35 mg/m2 of CDDP and they were repeatedly administered in the abdominal cavity via the drug delivery system."( [Intraperitoneal repeated chemotherapy using CDDP combined with MMC for carcinomatous peritonitis].
Arai, K; Kitamura, M; Miyashita, K, 1993
)
0.29
"A new dosage format (MMC-CH) of mitomycin C, which is composed of mitomycin C on activated carbon particles, was efficacious for prevention of peritoneal recurrence of gastric cancer."( [Four long-surviving cases of gastric cancer with peritoneal dissemination treated by intraperitoneal administration of mitomycin C adsorbed on activated carbon particles].
Hagiwara, A; Oyama, T; Ozaki, K; Sakakibara, T; Sakakura, C; Sasaki, S; Shimotsuma, M; Takahashi, T; Tsujimoto, H, 1993
)
0.78
"In collaboration with 428 institutions nation-wide, comparative studies on the optimal daily dosage of UFT were carried out for non-curative resection cases of colorectal cancer for two years from January 1984 to December 1985."( [Cooperative Study of Surgical Adjuvant Chemotherapy for Colorectal Cancer (fourth report): five-year results after surgery].
Abe, O; Hattori, T; Inokuchi, K; Kikuchi, K; Komi, N; Kondo, T; Maehara, Y; Sugimachi, K; Taguchi, T; Uchino, J, 1993
)
0.29
"025 micrograms/ml, the cytotoxic effects of the two treatments changed from additivity to supra-additivity as judged by comparing dose-response curves for each treatment alone with survival curves after combination therapy and by isobologram analysis."( Potentiation of photodynamic therapy by mitomycin C in cultured human colon adenocarcinoma cells.
Berg, K; Ma, LW; Moan, J; Peng, Q; Steen, HB, 1993
)
0.55
" Pelvic irradiation was administered by external beams (6 Mv), for a 50-Gy dosage (200 cGy/day for 5 weeks); in 4 cases treatment was completed by means of brachytherapy (192 Ir), with 20-25 Gy dosage."( [Loco-regional intra-arterial chemotherapy combined with radiotherapy in cervical carcinoma].
Raffetto, N; Salvatori, F; Trinci, C; Trinci, M, 1993
)
0.29
" The dosing solution (40 mg/20 ml) was instilled just prior to the start of surgery and maintained for 60-115 min until just prior to bladder excision."( Penetration of intravesical doxorubicin in human bladders.
Au, JL; Badalament, RA; Wientjes, MG, 1996
)
0.29
" The authors studied the recurrence rate of pterygium after administration of a single intraoperative dosage of topcial mitomycin C at the completion of pterygium excision."( Intraoperative application of topical mitomycin C for pterygium surgery.
Frucht-Pery, J; Ilsar, M; Siganos, CS, 1996
)
0.77
") were injected with MMC at a dosage of 3 to 5 mg/kg to inhibit the bone marrow, thus creating a mouse model with reduced immunopotential."( [The effect of herbal medicines on the immunodeficient animals by injecting cancer chemotherapeutic agent-special reference to age related recovery of the function].
Komatsu, Y; Li, AL; Nakashima, K; Nakatani, F; Ono, Y; Yamaguchi, N, 1996
)
0.29
"A combined phase I/II study (UFTM) of tegafururacil (UFT) and mitomycin C (MMC) was performed to find the optimal dosage for advanced colorectal cancer."( [Optimal dosage of UFT + MMC combination chemotherapy for advanced colorectal cancer--phase I/II study of combination chemotherapy of MMC with 2-week intervals and intermittent UFT administration--Study Group of UFTM Therapy for Advanced Colorectal Cancer
Ikeda, E; Isomoto, H; Kato, T; Kodaira, S; Okuda, M; Takahashi, T; Teramoto, T; Yamamoto, Y, 1996
)
0.53
"Objective methods to quantify the microscopic effects of MMC can be useful to improve our knowledge about the action on this antimetabolite and to enable us to adjust more accurately the timing and dosage when applying the drug in glaucoma filtering surgery."( Morphometric study of wound healing in a model of filtering surgery with mitomycin-C.
Alvarez, R; González, I; Honrubia, FM; Larrosa, JM; Pablo, LE; Ramírez, T,
)
0.36
" The method was found to be safe when flow was observed and dosage decisions were made during perfusion according to flow."( Peritoneal carcinomatosis and radioimmunoguided surgery.
Arnold, MW; Martin, EW; Schneebaum, S; Staubus, AE, 1996
)
0.29
"The purposes of this study are to examine the complications and results of a novel approach to the use of mitomycin-C in pterygium surgery; to identify the lowest effective dosage required to prevent recurrence; and to select those high-risk pterygia that could benefit from mitomycin-C use."( Indications for and complications of mitomycin-C in pterygium surgery.
Anduze, AL; Burnett, JM, 1996
)
0.78
"The persistence and intensity of discomfort noted at the higher dosage has prompted these authors to suggest that only high-risk pterygia should receive mitomycin-C."( Indications for and complications of mitomycin-C in pterygium surgery.
Anduze, AL; Burnett, JM, 1996
)
0.77
" Although topical mitomycin-C is effective as an adjunct to pterygium surgery and may reduce recurrence, the safety and efficacy of various concentrations and dosing schedules need further definition."( Corneoscleral melt after pterygium surgery using a single intraoperative application of mitomycin-C.
Dougherty, PJ; Hardten, DR; Lindstrom, RL, 1996
)
0.85
" The goal of the present study was to determine if the efficacy of intravesical MMC therapy in patients treated for superficial bladder cancer can be enhanced by using acidified dosing solutions."( Different pH dependency of mitomycin C activity in monolayer and three-dimensional cultures.
Au, JL; Schmittgen, T; Yen, WC, 1996
)
0.59
" The time lag for pHi to equilibrate with pHe in the multilayer systems and the instability of MMC at low pHe imply that the efficacy of intravesical MMC therapy is unlikely to be enhanced by using acidic dosing solution."( Different pH dependency of mitomycin C activity in monolayer and three-dimensional cultures.
Au, JL; Schmittgen, T; Yen, WC, 1996
)
0.59
" From the dose-response curves, the 50% growth inhibition (IC50) level for each drug was estimated."( In vitro chemosensitivity of human pancreatic cancer cell lines.
Oka, T; Sawabe, Y; Yamagishi, H; Yamaguchi, N; Yamamura, Y, 1996
)
0.29
" New anti-glaucoma drugs, latanoprost and nipradilol, have been shown to effect a reduction in IOP equal to that achieved with the equivalent dosage of timolol, with no adverse systemic side effects."( [Current topics in glaucoma].
Masuda, K, 1996
)
0.29
" Based on these findings, the author established a consecutive low-dose CDDP dosing method, which possibly could deliver a higher therapeutic index compared with the bolus-dosing method."( [Consecutive low-dose cisplatin-based chemotherapy for gynecologic malignancies].
Shimizu, Y, 1997
)
0.3
" Adverse effects at the dosage used are mainly due to hypotony and are preventable with two-layer suture."( Low-dosage mitomycin C as an adjunct to trabeculectomy. A prospective controlled study.
Laffi, GL; Martini, E; Scorolli, L; Sprovieri, C,
)
0.52
" The preferential repression of EPX on the cell proliferation of 212 and T24 cells was further demonstrated by decreasing Ha-ras oncogene expression levels while EPX dosage increased."( Antitumor effect of 2,6-di(2,3-epoxypropoxy)xanthone on tumor cell lines.
Lin, CN; Liu, HS; Won, SJ,
)
0.13
" Thus, at low doses of MMC, FA-C cells exhibit a unique cyclin B1/cdc2 response that is not observed in wild-type cells treated with an equitoxic high dosage of cross-linker."( Involvement of the Fanconi's anemia protein FAC in a pathway that signals to the cyclin B/cdc2 kinase.
Arwert, F; Dijkmans, LM; Joenje, H; Kruyt, FA, 1997
)
0.3
"To establish the long-term, dose-response relationship between the concentration of and duration of exposure to mitomycin to a decrease in intraocular pressure (IOP) and fewer complications."( A long-term dose-response study of mitomycin in glaucoma filtration surgery.
Bhatnagar, R; Katz, JD; Krishnadas, R; Ramakrishnan, R; Robin, AL; Selvaraj, S; Skuta, GL; Smith, SD, 1997
)
0.79
" The number of eyes achieving strict IOP control and the development of cataract suggest a possible dose-response effect for concentration and time of exposure."( A long-term dose-response study of mitomycin in glaucoma filtration surgery.
Bhatnagar, R; Katz, JD; Krishnadas, R; Ramakrishnan, R; Robin, AL; Selvaraj, S; Skuta, GL; Smith, SD, 1997
)
0.57
"A possible dose-response relationship seemed to exist between the concentration of and duration of exposure to mitomycin."( A long-term dose-response study of mitomycin in glaucoma filtration surgery.
Bhatnagar, R; Katz, JD; Krishnadas, R; Ramakrishnan, R; Robin, AL; Selvaraj, S; Skuta, GL; Smith, SD, 1997
)
0.79
" Chemotherapy consisted of three dosage regimens: (1) vindesine and cisplatin (VP); (2) mitomycin, vindesine and cisplatin (MVP); or (3) etoposide and cisplatin alternating with vindesine and mitomycin (EP/VM)."( Cisplatin-based combination chemotherapy for elderly patients with non-small-cell lung cancer.
Fukuoka, M; Furuse, K; Kawahara, M; Kodama, N; Kubota, K; Kudoh, S; Kusunoki, Y; Masuda, N; Matsui, K; Negoro, S; Ogawara, M; Takada, M; Takifuji, N, 1997
)
0.52
" The results showed a distinct dose-response relationship in the induction of chromosomal aberrations."( [Chromosomal aberrations induced in human spermatozoa by mitomycin C].
Cai, M; Huang, J; Huang, T; Liu, X, 1997
)
0.54
"Single or multiple subconjunctival injections of mitomycin-C (MMC) may offer one way of establishing the total dosage of MMC more accurately."( Long-term effects of postoperative subconjunctival injections of mitomycin-C in the rabbit eye.
Honrubia, FM; Larrosa, JM; Pablo, LE; Polo, V; Pueyo, M; Ramirez, T,
)
0.62
" Furthermore, the effectiveness of this therapy is greatly anticipated for the unresectable abdominal cancer, evaluating the selection of anti-cancer drugs and their administration dosage etc."( [Aortic stop flow and hypoxic perfusion chemotherapy for unresectable gallbladder cancer].
Aoki, T; Asami, K; Inoue, K; Kasuya, K; Koyanagi, Y; Masuhara, S; Ozawa, T; Tsuchida, A; Uda, O, 1998
)
0.3
" Because alkylating agents generally have steep dose-response curves, mitomycin C (MMC) and melphalan (L-PAM) entered phase I/II studies on IHP."( Delivery of anticancer drugs via isolated hepatic perfusion: a promising strategy in the treatment of irresectable liver metastases?
Kuppen, PJ; Vahrmeijer, AL; Van De Velde, CJ; Van Der Eb, MM; Van Dierendonck, JH,
)
0.37
" There was no significant nausea or vomiting, nephrotoxicity, or pulmonary toxicity, which was attributable to the CLD-cisplatin and the adequate dosing schedule of bleomycin."( Combination of consecutive low-dose cisplatin with bleomycin, vincristine, and mitomycin for recurrent cervical carcinoma.
Akiyama, F; Hasumi, K; Ishiya, T; Shimizu, Y; Umezawa, S; Utsugi, K, 1998
)
0.53
"In an attempt to improve tumor response and survival among patients with colorectal cancer metastases confined to the liver, we developed an experimental (rats and pigs) and clinical isolated hepatic perfusion (IHP) technique to exploit maximally the steep dose-response relation of may anticancer drugs."( Phase I/II studies of isolated hepatic perfusion with mitomycin C or melphalan in patients with colorectal cancer hepatic metastases.
Marinelli, A; Vahrmeijer, AL; van de Velde, CJ, 1998
)
0.55
" A dose-response effect of the concentration of MMC and IOP levels is present, suggesting that the higher concentration leads to lower IOP values."( Three-year follow-up of trabeculectomies performed with different concentrations of mitomycin-C.
Krieglstein, GK; Mietz, H, 1998
)
0.52
" To explain this tumor selectivity, the distribution of FK317 was investigated after dosing tumor-bearing mice with the 14C-labelled compound."( FK317, a novel substituted dihydrobenzoxazine, exhibits potent antitumor activity against human tumor xenografts in nude mice.
Fujiwara, T; Inami, M; Kawamura, I; Manda, T; Matsumoto, S; Naoe, Y; Nishigaki, F; Shimomura, K; Takagaki, S; Tsujimoto, S; Yamazaki, S, 1998
)
0.3
"The aim of this study was to determine how the in vitro dose-response effects of chemotherapeutic agents should be analyzed and reported."( Sigmoid model versus median-effect analysis for obtaining dose-response curves for in vitro chemosensitivity testing.
Petru, E; Pöch, G; Vychodil-Kahr, S, 1999
)
0.3
" Dose-response curves (DRCs) were calculated by non-linear (sigmoid model: SigmaPlot) and linear curve fitting (median-effect analysis: CalcuSyn)."( Sigmoid model versus median-effect analysis for obtaining dose-response curves for in vitro chemosensitivity testing.
Petru, E; Pöch, G; Vychodil-Kahr, S, 1999
)
0.3
" The authors designed a prospective, randomized study to explore the recurrence rate of pterygium after a single dosage of mitomycin C at the completion of pterygium excision, comparing it to postoperative mitomycin C therapy."( Intraoperative application versus postoperative mitomycin C eye drops in pterygium surgery.
Basar, E; Gurler, B; Oguz, H, 1999
)
0.77
" Combining the use of MMC with conjunctival autograft allows for decreased dosage and time of intraoperative exposure of mitomycin, thereby making it safer for application."( Use of mitomycin C with conjunctival autograft in pterygium surgery in Asian-Canadians.
Law, FC; Wong, VA, 1999
)
0.97
"Combination chemotherapy with multiple drugs (FLMP therapy), in which the drugs were determined based on biochemical modulation and the dosing schedule was established in accordance with the circadian rhythms of the human body, was performed in cases of advanced recurrent gastric cancer."( [Effect of combination chemotherapy with multiple drugs (FLMP therapy) based on the circadian rhythms of the human body in advanced recurrent gastric cancer].
Iesato, H; Kamoshita, N; Kato, Y; Nagaoka, H; Okabe, T; Yokomori, T, 1999
)
0.3
" On the other hand, bacillus Calmette-Guerin (BCG) currently appears to be the most effective agent for intravesical use, especially in patients with high grade and stage neoplasms but the optimum strain, dosage and duration schedule have not been determined."( Intravesical therapy of superficial bladder cancer.
Melekos, MD; Moutzouris, GD, 2000
)
0.31
" The dose-response to 5-fluorouracil (5FU) and mitomycin C (MMC) was determined."( Collagen type I and III synthesis by Tenon's capsule fibroblasts in culture: individual patient characteristics and response to mitomycin C, 5-fluorouracil, and ascorbic acid.
Gross, RL, 1999
)
0.77
" A dose-response relationship was observed after exposing RTG-2 cells to vincristine sulfate and benzo(a)pyrene."( Flow cytometric detection of micronuclei and cell cycle alterations in fish-derived cells after exposure to three model genotoxic agents: mitomycin C, vincristine sulfate and benzo(a)pyrene.
Castaño, A; Llorente, MT; Sánchez, P, 2000
)
0.51
" Dose-response effect was noted with the lower concentrations and shorter exposure times where the inhibition rates were lower (but not significantly so)."( Effect of brief exposure to mitomycin C on cultured human nasal mucosa fibroblasts.
Hu, D; Oda, D; Royack, GA; Sires, BS; Tong, DC, 2000
)
0.6
"A new dosage formulation consisting of an anti-cancer drug bound to activated carbon particles was developed for a local injection against early gastric cancer so that the dosage formulation yields chemotherapeutic effects selectively to the lymph node metastases as well as to the primary lesion."( Local injection of anti-cancer drugs bound to carbon particles for early gastric cancer--a pilot study.
Hagiwara, A; Imanishi, T; Ohgaki, M; Sakakura, C; Sawai, K; Shirasu, M; Takahashi, T; Torii, T; Yamasaki, J,
)
0.13
"As a pilot study, the new dosage formulation, total of 50-200 mg of methotrexate only or total of 200 mg of methotrexate plus 8 mg of mitomycin C, was injected into the primary lesions and the adjacent gastric wall of 8 patients with early gastric cancer, guided by a gastrofiberscope before gastrectomy."( Local injection of anti-cancer drugs bound to carbon particles for early gastric cancer--a pilot study.
Hagiwara, A; Imanishi, T; Ohgaki, M; Sakakura, C; Sawai, K; Shirasu, M; Takahashi, T; Torii, T; Yamasaki, J,
)
0.33
"Preoperative local injection of the new dosage formulation will be useful to give chemotherapeutic effects on the potential metastases in the regional nodes as well as to the primary lesion."( Local injection of anti-cancer drugs bound to carbon particles for early gastric cancer--a pilot study.
Hagiwara, A; Imanishi, T; Ohgaki, M; Sakakura, C; Sawai, K; Shirasu, M; Takahashi, T; Torii, T; Yamasaki, J,
)
0.13
" The 'treatment protocol adherence' was evaluated by recalculation of the ideal protocol dose and its comparison with the actual delivered dosage at each cycle of chemotherapy."( Quality control in multicentric clinical trials. An experience of the EORTC Gynecological Cancer Cooperative Group.
Favalli, G; Pecorelli, S; Renard, J; Van Oosterom, AT; Vantongelen, K; Vermorken, JB, 2000
)
0.31
" However, the degree of toxicity was limited in our trial and therefore attempts to increase the dosage and/or revise the administration schedule for cancer of the pharynx and T1 to T3 tumor disease appear warranted."( Survival results of neoadjuvant chemotherapy for advanced squamous cell carcinoma of the head and neck.
Ikari, T; Kano, S; Kawaida, M; Kawaura, M; Kohno, N; Nakamizo, M; Tanaka, K, 2000
)
0.31
" A dose-response relationship was observed between the radiation dose and the tumor downstaging and local control."( Preoperative chemotherapy and pelvic radiation for tethered or fixed rectal cancer: a phase II dose escalation study.
Buie, D; Chan, AK; Heine, J; Jenken, D; Johnson, DR; Langevin, J; Wong, AO, 2000
)
0.31
" Our trial failed to demonstrate a significant improvement in response or survival when patients with metastatic NSCLC were treated, in addition to ifosfamide and mitomycin, by combination of moderate dosages of cisplatin and carboplatin instead of moderate dosage of cisplatin alone."( Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer.
Alexopoulos, CG; Baumöhl, J; Berghmans, T; Florin, MC; Klastersky, J; Koumakis, G; Lafitte, JJ; Mommen, P; Ninane, V; Paesmans, M; Schmerber, J; Sculier, JP; Thiriaux, J; Zacharias, C, 2000
)
0.71
" To help us understand this resistance phenotype, genes whose expression was altered by increased sdiA dosage were identified using a DNA microarray-based, comprehensive transcript profiling method."( Global impact of sdiA amplification revealed by comprehensive gene expression profiling of Escherichia coli.
LaRossa, RA; Lee, JM; Smulski, DR; Wei, Y, 2001
)
0.31
" The optimal biocompatible dosage must be carefully determined by further investigation."( Prevention of posterior capsule opacification by retinoic acid and mitomycin.
Güler, C; Ilker, SS; Inan, UU; Kaynak, S; Ozer, E; Oztürk, F, 2001
)
0.55
" All dosing was achieved using a dosing volume of 90% (900 microl/ml), and the vehicle control cultures were treated with 900 microl/ml of fully supplemented RPMI culture medium with 1% Pluronic F68."( p-Aramid RFP do not induce chromosomal aberrations in a standardized in vitro genotoxicity assay using human lymphocytes.
Donner, M; Murli, H; Warheit, DB, 2001
)
0.31
" If Mitomycin is used in that low dosage and in that special application as shown, it could be a very efficient therapy with less complications."( [The treatment of a primary acquired melanosis of the conjunctiva with atypia by low dose of Mitomycin C 0.02 % - case report with follow up of 2 years].
Klaehsen, D; Maier, M; Merté, RL; Schmidt, M; Schmidt, T, 2001
)
1.09
"The authors in a retrospective study assess the recurrence rate of pterygium after the application of a single intraoperative dosage of topical Mitomycin C during the pterygium excision."( [Peroperative use of mitomycin C in excision of primary pterygia].
Furdová, A; Hlavácková, K; Pesko, K, 2001
)
0.83
" An alternative approach can be proposed as to design a pharmacotherapeutic agent delivery system, which will supply the suitable dosage of the agent for a certain time period to solve those problems."( Design and evaluation of a mucoadhesive therapeutic agent delivery system for postoperative chemotherapy in superficial bladder cancer.
Acar, A; Denkbaş, EB; Eroğlu, M; Irmak, S, 2002
)
0.31
" Different cell types might present a different sensitivity to MMC and therefore a dose-response curve to MMC has to be obtained for each cell type of interest."( Mitomycin C as an alternative to irradiation to inhibit the feeder layer growth in long-term culture assays.
Duma, L; Gibelli, N; Oliviero, B; Pedrazzoli, P; Ponchio, L; Robustelli della Cuna, G, 2000
)
1.75
"MMC was found to be safe to use during sinus surgery, and it may reduce the incidence of postoperative adhesions at the dosage used in this study."( Mitomycin C for the prevention of adhesion formation after endoscopic sinus surgery: a randomized, controlled study.
Chung, JH; Cosenza, MJ; Metson, RB; Rahbar, R, 2002
)
1.76
" rendalli at the maximum tolerated dose only, while roundup induced MN at three dosed levels."( A comparison between mouse and fish micronucleus test using cyclophosphamide, mitomycin C and various pesticides.
Grisolia, CK, 2002
)
0.54
"Amiloride, which blocks the Na(+)/H(+) antiport, shifted the CHS 828 dose-response curve to the left in a synergistic manner according to the additive interaction model."( Interactions between the new cytotoxic drug CHS 828 and amiloride and mitomycin C in a human tumour cell line and in tumour cells from patients.
Ekelund, S; Larsson, R; Nygren, P; Persson, I, 2002
)
0.55
"To investigate the effects of the dosage of anticancer agents during transcatheter arterial chemoembolization (TACE) on the T cell subsets in patients with hepatocellular carcinoma (HCC)."( Effect of dosage of anticancer agents during transcatheter arterial chemoembolization on T cell subsets in patients with hepatocellular carcinoma.
Chen, Y; He, XF; Li, YH; Lu, W; Qiu, YR; Zeng, QL, 2002
)
0.31
" Numerical solutions of the resulting system of partial differential equations for the multicell spheroid case are compared with closed form solutions of the monolayer case, particularly with respect to the effects on the cell kill of the drug dosage and of the duration of its application."( Mathematical modelling of drug transport in tumour multicell spheroids and monolayer cultures.
King, JR; Ward, JP, 2003
)
0.32
" However, no significant dose-response correlation could be found for either of the pesticides."( Induction of sister chromatid exchanges by cypermethrin and carbosulfan in bone marrow cells of mice in vivo.
Giri, A; Giri, S; Prasad, SB; Sharma, GD, 2003
)
0.32
" Four patients received intratumoral injection of the dosage formulation (total dose 100-400 mg of methotrexate or 8-32 mg of mitomycin C) under colonofiberscope."( [Endoscopic local injection of anticancer drugs bound to carbon particles for treatment of advanced rectal cancer, when surgical treatment was contraindicated].
Fujiyama, J; Fukuda, K; Hagiwara, A; Ito, T; Itoi, H; Kin, S; Kitamura, K; Nakase, Y; Okamoto, K; Otsuji, E; Sakakura, C; Shimomura, K; Takagi, T; Toma, A; Yamagishi, H, 2002
)
0.52
"To evaluate the effect of different dosing regimens of mitomycin on skin wound contraction."( Effect of topical mitomycin on skin wound contraction.
Connor, NP; Hartig, GK; Heisey, DM; Robertson, KM; Sewall, GK,
)
0.71
"Full-thickness skin wounds were created in 5 groups of hairless mice, which represented different dosing regimens or a sterile water control: A, control; B, mitomycin (0."( Effect of topical mitomycin on skin wound contraction.
Connor, NP; Hartig, GK; Heisey, DM; Robertson, KM; Sewall, GK,
)
0.66
"All dosing regimens of mitomycin application resulted in an initially exponential rate of wound contraction that was significantly slower than in the sterile water control group, with a significantly larger wound surface area on day 29."( Effect of topical mitomycin on skin wound contraction.
Connor, NP; Hartig, GK; Heisey, DM; Robertson, KM; Sewall, GK,
)
0.78
" Compared with the cell necrosis, the dosage of drugs was less and the time was shorter for inducing apoptosis."( [Apoptosis of human pancreatic carcinoma cell lines induced by combinations of chemotherapeutic drugs].
Cai, L; Liao, Q; Wu, Y; Zhao, Y; Zhu, Y, 1999
)
0.3
" In addition, a time course study with constant dosage of drugs was performed."( The cell cycle distribution of cultured human retinal pigmented epithelial cells under exposure of anti-proliferative drugs.
Kao, YH; Tseng, HY; Wu, WC, 2003
)
0.32
" Chitosan is used as an excipient in oral dosage form."( Application of chitin and chitosan derivatives in the pharmaceutical field.
Kato, Y; Machida, Y; Onishi, H, 2003
)
0.32
" Our data indicate that dosing based on body surface area is rational and reliable."( Pharmacokinetics of intraperitoneal mitomycin C.
van Ruth, S; Verwaal, VJ; Zoetmulder, FA, 2003
)
0.59
"We sought to determine a dose-response curve for topical mitomycin C when used to prolong the patency of laser-assisted myringotomies."( Dose-response relationship of topically applied mitomycin C for the prevention of laser myringotomy closure.
Buchman, CA; Gomez-Marin, O; Jassir, D; Odabasi, O, 2003
)
0.82
" The developed pharmacokinetic-pharmacodynamic model can be used to simulate different dosage schemes in order to optimise mitomycin administration during HIPEC."( Population pharmacokinetics and pharmacodynamics of mitomycin during intraoperative hyperthermic intraperitoneal chemotherapy.
Beijnen, JH; Mathôt, RA; Sparidans, RW; van Ruth, S; Verwaal, VJ; Zoetmulder, FA, 2004
)
0.78
" Haematological toxicity and dosage reductions were higher with SuperMIP, which was nevertheless associated with a significantly increased absolute dose intensity."( A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancer.
Berghmans, T; Corhay, JL; Efremidis, A; Giner, V; Koumakis, G; Lafitte, JJ; Lecomte, J; Lothaire, P; Mommen, P; Ninane, V; Paesmans, M; Richez, M; Sculier, JP; Thiriaux, J; Van Houtte, P; Wackenier, P, 2004
)
0.32
" As cytostatics for hyperthermic peritoneal perfusion, we have used Mitomycin in a dosage of 18 mg/m2 plus Melphalan in a dosage of 25 mg/m2."( Cytoreductive surgery plus intraperitoneal hyperthermic perfusion is an effective treatment for metastasized malignant mixed mesodermal tumours (MMMT)--report of six cases.
Müller, H; Nakchbandi, V, 2004
)
0.56
" Dose-response curves for several genotoxins were obtained."( Living bacterial cell array for genotoxin monitoring.
Biran, I; Kuang, Y; Walt, DR, 2004
)
0.32
" Pathological findings diagnosed undifferentiated carcinoma (large cell type) of thymus, the patient underwent radiation therapy of the mediastinum at a total dosage of 50 Gy and chemotherapy [cisplatin (CDDP) + vinorelbine ditartrate + mitomycin C (MMC)]."( [Thymic carcinoma incidentally detected on routine chest computed tomography; report of a case].
Ida, M; Kita, Y; Neyatani, H; Nogimura, H; Shundo, Y, 2004
)
0.51
" Furthermore, blocking proliferation by incubation with mitomycin C caused a dose-response inhibition of monolayer formation."( Endothelial cell monolayer formation: effect of substrate and fluid shear stress.
Kladakis, SM; Nerem, RM,
)
0.38
" The consultants were asked to estimate the number of trabeculectomies they performed per year, how often they used 5-fluorouracil (5-FU) in primary and redo surgery, their usual method of administration of 5-FU, how often they used mitomycin (MMC) in primary and redo surgery, and their usual dosage regimen of MMC."( National survey of antimetabolite use in glaucoma surgery in the United Kingdom.
Edmunds, B; Khaw, PT; Siriwardena, D; Wormald, RP, 2004
)
0.51
" In solution dosage forms, the two conjugates had almost the same suppressive effect on tumor growth at 30 mg MMC eq."( Evaluation of antitumor and toxic side effects of mitomycin C-estradiol conjugates.
Ishiki, N; Machida, Y; Onishi, H, 2004
)
0.58
" In this study, an alternative approach was proposed and pharmaco-therapeutic agent delivery systems which will supply the suitable dosage of the agent for a certain time period were designed to solve those problems."( Bioadhesive drug carriers for postoperative chemotherapy in bladder cancer.
Denkbaş, EB; Eroğlu, M; Ozdemir, N; Oztürk, E, 2004
)
0.32
" A single injection dosage of the DSM therapy was comprised of 300-600 mg degradable starch microspheres, 30 mg ADM, and 10 mg MMC."( [Histological examination of the effect of hepatic arterial infusion of degradable starch microspheres mixed with adriamycin and mitomycin C for liver metastases of colorectal cancer--second report].
Hashimoto, D; Hoshino, T; Ishida, H; Mastumoto, Y; Miura, T; Ohsawa, T; Osada, H; Takeuchi, I; Yokoyama, M, 2004
)
0.53
" We examined whether D-Fraction could decrease the effective dosage of the chemotherapeutic agent, mitomycin-C (MMC), necessary to control carcinoma in mice."( Maitake D-Fraction enhances antitumor effects and reduces immunosuppression by mitomycin-C in tumor-bearing mice.
Asakawa, A; Hayashi, M; Inui, A; Kodama, N; Murata, Y; Nanba, H; Sakai, N, 2005
)
0.77
"d-1 was the optimal dosage of MMC because consecutive administration for 17 d resulted in antitumor effects and a survival ratio of 100% in mice bearing mammary cancer cells (MM-46)."( Maitake D-Fraction enhances antitumor effects and reduces immunosuppression by mitomycin-C in tumor-bearing mice.
Asakawa, A; Hayashi, M; Inui, A; Kodama, N; Murata, Y; Nanba, H; Sakai, N, 2005
)
0.56
"These results suggest that D-Fraction can decrease the effective dosage in tumor-bearing mice by increasing the proliferation, differentiation, and activation of immunocompetent cells and thus provide a potential clinical benefit for patients with cancer."( Maitake D-Fraction enhances antitumor effects and reduces immunosuppression by mitomycin-C in tumor-bearing mice.
Asakawa, A; Hayashi, M; Inui, A; Kodama, N; Murata, Y; Nanba, H; Sakai, N, 2005
)
0.56
"T739 mice were randomly divided into 8 groups after subcutaneous inoculation of bladder carcinoma cells, the control group (A); two mitomycin C (MMC) group, treated with MMC of routine dosage (B) and low-dosage (C) respectively; three SJZD groups, treated with SJZD of high (D), medium (E) and low-dosage (F) respectively; and two combined treatment groups, treated with SJZD of high-dosage + MMC of routine dosage(G) and SJZD of high-dosage + MMC of low-dosage(H)."( [Toxicity attenuation and efficacy potentiation effects of sijunzi decoction on bladder carcinoma treated by chemotherapy in mice].
Li, CG; Li, ML; Shu, XH, 2005
)
0.53
"Combined chemotherapy of SJZD with low dosage MMC has definite effect in inhibiting tumor growth in mice with bladder carcinoma, displaying special effects of toxicity attenuation and efficacy potentiation."( [Toxicity attenuation and efficacy potentiation effects of sijunzi decoction on bladder carcinoma treated by chemotherapy in mice].
Li, CG; Li, ML; Shu, XH, 2005
)
0.33
" Patients received CPT-11 and mitomycin-c at the dosage of 150 mg/m2 on days 1 and 15, and 8 mg/m2 on day 1, respectively, every 4 weeks."( Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106).
Battaglia, C; Colucci, G; Di Bisceglie, M; Gebbia, N; Gebbia, V; Giuliani, F; Maiello, E; Molica, S; Vinciarelli, G, 2005
)
0.92
"Micronucleus induction was studied for the DNA target clastogens mitomycin C (MMC) and 1-beta-D-arabinofuranosylcytosine (Ara-C), and also the non-DNA target aneugen colchicine (COL) in order to evaluate the dose-response relationship at very low dose levels."( Practical threshold for micronucleated reticulocyte induction observed for low doses of mitomycin C, Ara-C and colchicine.
Asano, N; Dertinger, SD; Hayashi, M; Morita, T; Tometsko, CR; Torous, DK, 2006
)
0.79
" An MMC dose-response study was carried out focusing on bleb morphology and function."( Determinants of bleb morphology in minimally invasive, clear-cornea micropenetrating glaucoma surgery with mitomycin C.
Flesner, P; Jensen, PK; Kessing, SV, 2006
)
0.55
" An MMC dose-response relation was not observed for the thin, cystic, and translucent bleb."( Determinants of bleb morphology in minimally invasive, clear-cornea micropenetrating glaucoma surgery with mitomycin C.
Flesner, P; Jensen, PK; Kessing, SV, 2006
)
0.55
"To determine the mechanism through which topical mitomycin C prevents and treats corneal haze after photorefractive keratectomy (PRK) and to examine the effects of dosage and duration of exposure."( Effect of prophylactic and therapeutic mitomycin C on corneal apoptosis, cellular proliferation, haze, and long-term keratocyte density in rabbits.
Gupta, PC; Mohan, RR; Netto, MV; Sharma, A; Sinha, S; Wilson, SE, 2006
)
0.86
"To prepare a new dosage formulation of activated carbon nanoparticles adsorbing mitomycin C (MMC-ACNP) and evaluate the beneficial effects of intraperitoneally applied MMC-ACNP as a drug delivery system for lymphatic targeting in preventing metastasis and recurrence of gastric cancer."( [Intraperitoneal chemotherapy with mitomycin C bound to activated carbon nanoparticles for nude mice bearing human gastric carcinoma].
Qu, QL; Sun, L; Yang, LZ; Zhang, YG, 2006
)
0.84
" To avoid postoperative symblepharon, ankyloblepharon, dry eye, and possible corneal neovascularization after extensive lesion excision, oral CIM at a dosage of 200 mg 4 times daily was administered for 4 months before surgery."( Oral cimetidine adjuvant therapy for recalcitrant, diffuse conjunctival papillomatosis.
Chang, SW; Huang, ZL, 2006
)
0.33
" The dose-response relationships for melphalan and irinotecan in individual samples showed great variability."( Heterogeneous activity of cytotoxic drugs in patient samples of peritoneal carcinomatosis.
Glimelius, B; Graf, W; Grundmark, B; Larsson, R; Mahteme, H; Nygren, P; Påhlman, L; Tholander, B; von Heideman, A, 2008
)
0.35
" The TACE-procedure was carried out in regular intervals using a suspension consisting of a fixed dosage of Mitomycin C (10 mg) and 10-20 ml Lipiodol."( [Transarterial chemoembolization (TACE) of the hepatocellular carcinoma (HCC) in patients with portal vein thrombosis--experiences].
Düber, C; Herber, S; Junginger, T; Kanzler, S; Kummer, I; Manzl, N; Mönch, C; Otto, G; Pitton, M; Schneider, J; Schuchmann, M, 2007
)
0.55
" Maximum Tolerated Dose (MTD) was determined by a dose-response test."( The genotoxicity study of garlic and pasipy herbal drops by peripheral blood micronucleus test.
Kalantari, H; Larki, A; Latifi, SM, 2007
)
0.34
" Performing splenectomy and CDDP dosage for HIPEC >240 mg were proven to be independent risk factors for both G3-4 hyperamylasemia and POPF."( Incidence of postoperative pancreatic fistula and hyperamylasemia after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Antonucci, A; Baratti, D; Deraco, M; Gavazzi, C; Kusamura, S; Laterza, B; Oliva, GD; Younan, R, 2007
)
0.34
" 60Co gamma-irradiation or 6MVX-ray with conventional fraction were used for radiotherapy with a total volume dosage of 55-70 Gy."( [Clinical analysis of 108 cases with adenocarcinoma Barretts's esophagus].
Han, JQ; Li, XQ; Liang, RX; Liu, Q; Qu, FS; Sun, YH; Yan, TX, 2007
)
0.34
" However, for moderate myopia and shallow depth, low dosing appears to be equally effective."( Comparison of standard (0.02%) and low dose (0.002%) mitomycin C in the prevention of corneal haze following surface ablation for myopia.
Krueger, RR; Thornton, I; Xu, M, 2008
)
0.6
" The dose-response of ethylnitrosourea-induced mutation was found to be very close to that previously established using a pedigree-based approach for ESTR mutation detection."( Single-molecule PCR analysis of germ line mutation induction by anticancer drugs in mice.
Dubrova, YE; Glen, CD; Smith, AG, 2008
)
0.35
" Many positive effects have been attributed to the topical application but there are large differences in dosage and exposure time."( [Adjuvants in operative laryngology: corticosteroids, fibrin adhesives, Mitomycin C].
Sittel, C, 2008
)
0.58
"01 mg/L, while need the dosage of MNNG reached 50-100 mg/L."( [Construction of the pUCD-recA recombinate luminescence bacterium to evaluate the genetoxicty of environment pollutants].
Cai, Q; He, M; Huang, XX; Luo, H; Shi, HC, 2009
)
0.35
" Under the diagnosis of cardiac tamponade, we treated her with pericardial drainage and systemic chemotherapy (intravenous dosage of trastuzumab and vinorelbine: VNR), and then pericardial effusion disappeared."( [A case of carcinomatous cardiac tamponade caused by breast cancer treated with instillations of OK-432 and mitomycin C].
Fujita, M; Matsuura, O; Morohashi, H; Morohashi, S; Nishimura, A; Yakoshi, Y; Yamada, K; Yonaiyama, S, 2010
)
0.57
" New findings regarding the penetration of MMC to the endothelium and into the aqueous humor may lead surgeons to reassess appropriate dosing and patient selection when the drug is used for surgery."( Use of mitomycin-C for phototherapeutic keratectomy and photorefractive keratectomy surgery.
Shah, RA; Wilson, SE, 2010
)
0.82
" The dosing volume was 20 ml."( Bladder tissue pharmacokinetics of intravesical mitomycin C and suramin in dogs.
Au, JL; Hu, L; Li, J; Wientjes, MG, 2010
)
0.62
" These data indicate that Rad21 gene dosage is critical for the ionising radiation (IR) response."( Rad21-cohesin haploinsufficiency impedes DNA repair and enhances gastrointestinal radiosensitivity in mice.
Appeldoorn, E; Balakrishnan, K; Beasley, M; Bertoncello, I; Bertonchello, I; Essers, J; Lavin, MF; Malaterre, J; McKay, MJ; Ramsay, RG; Thomaszewski, JM; Tomaszewski, JM; Vazquez, M; Verschoor, S; Xu, H; Yan, Y, 2010
)
0.36
" When MMC and VIN were dosed by different routes at the same dose levels both compounds produced positive results in all three tissues by intraperitoneal injection but not oral administration."( The rat gut micronucleus assay: a good choice for alternative in vivo genetic toxicology testing strategies.
Coffing, S; Dickinson, D; Engel, M; Schuler, M; Shutsky, T; Spellman, R; Thiffeault, C, 2011
)
0.37
" Based on the Wuerzburg bleb classification score (WBCS) for postoperative wound healing evaluation, 30 of these operations of group A (group B: n = 26) did not receive 5 FU postoperatively (controls), 67 (93) received up to 7 postoperative injections of 5 mg 5 FU (normal dosage group), and 72 (93) received more than 7 injections (high dosage group)."( [Corneal epitheliopathy following trabeculectomy with postoperative adjunctive 5-fluorouracil].
Geerling, G; Grehn, F; Klink, T; Reiter, C; Schultheiss, A; Wimmer, S, 2010
)
0.36
"In the normal dosage group the mean total dose of 5 FU was 25."( [Corneal epitheliopathy following trabeculectomy with postoperative adjunctive 5-fluorouracil].
Geerling, G; Grehn, F; Klink, T; Reiter, C; Schultheiss, A; Wimmer, S, 2010
)
0.36
"In this pilot study with a small number of subjects, short-term outcomes suggest that subconjunctival bevacizumab is equally effective in reducing intraocular pressure with a better safety profile compared with MMC in the dosing schedule studied."( Safety and efficacy of using off-label bevacizumab versus mitomycin C to prevent bleb failure in a single-site phacotrabeculectomy by a randomized controlled clinical trial.
Ravindran, RD; Sengupta, S; Venkatesh, R, 2012
)
0.62
" The optimum route of administration and dosing regimen of anti-VEGF antibodies and their positioning in comparison with 5-fluorouracil and mitomycin C are uncertain."( Anti--vascular endothelial growth factor therapy in glaucoma filtration surgery.
Barton, K; Mathew, R, 2011
)
0.57
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
"The frequency of LT1009 dosage was determined initially using an enzyme-linked immunosorbent assay assay measuring LT1009 eye tissue retention in 6 New Zealand White rabbits."( Prevention of ocular scarring after glaucoma filtering surgery using the monoclonal antibody LT1009 (Sonepcizumab) in a rabbit model.
Beattie, AR; Levine, MA; Lukowski, ZL; Meyers, CA; Min, J; Samuelson, DA; Schultz, GS; Sherwood, MB; Stoller, G, 2013
)
0.39
" Low dosage MMC was applied beneath the superficial scleral flap before dissecting the second, deep scleral flap and accessing Schlemm canal."( Canaloplasty with intraoperative low dosage mitomycin C: a retrospective case series.
Barnebey, HS, 2013
)
0.65
" Thus, appropriately dosed Cy may provide a suitable conditioning regimen for FA patients undergoing HSC gene therapy."( Cyclophosphamide promotes engraftment of gene-modified cells in a mouse model of Fanconi anemia without causing cytogenetic abnormalities.
Adair, JE; Beard, BC; Becker, PS; Chien, S; Fang, M; Kiem, HP; Taylor, JA; Trobridge, GD; Wohlfahrt, ME; Zhao, X, 2012
)
0.38
" According to the length of airway lesion, the dosage was 1 ml/cm."( [Effect of topical application with mitomycin C in the management of benign cicatricial airway stenosis].
Cui, J; Pei, YH; Wang, J; Wang, T; Xu, M; Zhang, CY; Zhang, J, 2012
)
0.65
" However, the ideal dosage has still not been determined."( Inhibitory effect of mitomycin C on proliferation of primary cultured fibroblasts from human airway granulation tissues.
Chen, N; Pei, YH; Wang, YL; Xu, M; Zhang, J, 2013
)
0.71
" The optimum dosing combination of these two agents has yet to be determined however, and in many patients it is likely that greater overall survival will be achieved by using them in successive lines rather than in combination."( New oxaliplatin-based combinations in the treatment of colorectal cancer.
Cassidy, J; Hochster, H, 2003
)
0.32
" Diffuse colorectal carcinomatosis was generated in mice prior to intraperitoneal lavage with mitomycin C (MMC) at clinically comparable dosing for variable lengths of time."( The benefit of intraperitoneal chemotherapy for the treatment of colorectal carcinomatosis.
Attwood, K; Camoriano, M; Francescutti, V; Haslinger, M; Kane, JM; Kim, M; Rivera, L; Seshadri, M; Skitzki, JJ, 2013
)
0.61
" The TNJ protective effects were concentration-dependent, indicating a dose-response correlation, that can be attributed to a powerful antioxidant and/or free radical scavenger ability of TNJ."( Antimutagenic and antirecombinagenic activities of noni fruit juice in somatic cells of Drosophila melanogaster.
Cunha, KS; De Andrade, HH; De Andrade, LR; Dihl, RR; Franchi, LP; Guimarães, NN; Lehmann, M,
)
0.13
"7 % high dose), while both TGF-β3 dosage groups showed no significant change (65."( Preliminary results of antiscarring therapy in the prevention of postendoscopic esophageal mucosectomy strictures.
Chak, A; Cipriano, C; Lash, RH; Marks, JM; Ponsky, JL; Schomisch, SJ; Wu, Y, 2014
)
0.4
" In the acute oral dose toxicity study, all rats survived during the test period and ETAS did not influence clinical appearance, body weight gain and necropsy findings at a dosage of 2000mg/kg body weight."( Toxicological assessment of enzyme-treated asparagus extract in rat acute and subchronic oral toxicity studies and genotoxicity tests.
Goto, K; Ito, T; Maeda, T; Miura, T; Nishioka, H; Ono, T; Sato, A; Wakame, K, 2014
)
0.4
" In-medium dosing with MMS produced a LOGEL of 20 µg/ml, which was very similar to the topical LOGEL when considering the total mass of MMS added."( Automation and validation of micronucleus detection in the 3D EpiDerm™ human reconstructed skin assay and correlation with 2D dose responses.
Chapman, KE; Doak, SH; Jenkins, GJ; Pfuhler, S; Thomas, AD; Wills, JW, 2014
)
0.4
" It is recognized that cellular responses to toxicants have a highly dynamic nature, and exhibit both temporal complexity and dose-response shifts."( Toxicity mechanisms identification via gene set enrichment analysis of time-series toxicogenomics data: impact of time and concentration.
Gao, C; Gou, N; Gu, AZ; Lan, J; Weisman, D, 2015
)
0.42
" Finally, we examined the ability of pulse dosing an antibiotic to eliminate persisters."( Borrelia burgdorferi, the Causative Agent of Lyme Disease, Forms Drug-Tolerant Persister Cells.
Brown, AV; Hu, LT; Lewis, K; Matluck, NE; Sharma, B, 2015
)
0.42
"A major challenge of combinatorial therapy is the unification of the pharmacokinetics and cellular uptake of various drug molecules with precise control of the dosage thereby maximizing the combined effects."( Precise Ratiometric Control of Dual Drugs through a Single Macromolecule for Combination Therapy.
Cao, Y; Gu, Y; Guo, P; He, H; Huang, X; Lei, S; Liu, M; Luo, S; Mukerabigwi, JF; Zhang, Y, 2015
)
0.42
" The results of our study indicate the feasibility and the potential benefit of a protocol including the MMC dosage at T30 after the start of HIPEC."( Mitomycin C Pharmacokinetics as Predictor of Severe Neutropenia in Hyperthermic Intraperitoneal Therapy.
Brigand, C; Brumaru, D; Kemmel, V; Lessinger, JM; Mercoli, HA; Meyer, N; Romain, B, 2015
)
1.86
" In this assay, accumulation of micronucleated hepatocytes (MNHEPs) induced by repeated dosing of genotoxic chemicals is considered to be a key factor in the detection of micronuclei induction."( Prolonged rest period enables the detection of micronucleated hepatocytes in the liver of young adult rats after a single dose of diethylnitrosamine or mitomycin C.
Miyamae, Y; Seki, J; Shimada, K; Takashima, M; Wakata, A; Yamamoto, M, 2015
)
0.62
" The areas of debate and development include the dosing and timing of MMC delivery, the role of cisplatin chemotherapy as an alternative to MMC, the replacement of the standard 96-h infusion of 5FU with oral capecitabine, the use of targeted chemotherapy agents, and the duration and dose of RT."( Advances in the Management of Anal Cancer.
Goodman, KA; Julie, DR, 2016
)
0.43
" It was nongenotoxic in an Ames assay, an in vitro micronucleus assay, and an in vivo rat micronucleus assay when dosed orally up to 2000 mg/kg."( Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
Berry, P; Campo, B; Cao, J; Ciaravino, V; Easom, EE; Erve, JCL; Freund, YR; Gamo, FJ; Guo, D; Jacobs, RT; Plattner, JJ; Rosenthal, PJ; Sanz, LM; Zhang, YK, 2017
)
0.46
"During heated intraperitoneal chemotherapy (HIPEC), neutropenia rates of 20 to 40% have been reported when mitomycin C (MMC) is dosed by weight or body surface area (BSA)."( Conflicting Data on the Incidence of Leukopenia and Neutropenia After Heated Intraperitoneal Chemotherapy with Mitomycin C.
Aycart, SN; Bhagwandin, S; Feferman, Y; Feingold, D; Kim, J; Labow, DM; Sarpel, U, 2017
)
0.88
" Furthermore, SAHA dosing did not compromise corneal endothelial phenotype, density, or function in rabbit eyes, whereas MMC application did (P < ."( Efficacy and Safety Comparison Between Suberoylanilide Hydroxamic Acid and Mitomycin C in Reducing the Risk of Corneal Haze After PRK Treatment In Vivo.
Anumanthan, G; Gupta, S; Hamm, CW; Hesemann, NP; Mohan, RR; Sharma, A; Waggoner, M, 2017
)
0.69
" However, a consensus on about appropriate dosage and treatment schedule of MMC is lacking."( Drug resistance restricts the efficacy of short term low dose Mitomycin-C treatment in UMUC-3 bladder cancer cells.
Goktas, S; Gul, M; Kars, MD; Kaynar, M, 2018
)
0.72
"We successfully created a sustained-release antifibrotic drug delivery system that delivered known dosage of the drugs at doses that are significantly lower than the current standard, and resulted in less fibrosis while maintaining a healthy bleb and equal reduction of IOP."( Effect of 2 Novel Sustained-release Drug Release Systems on Bleb Fibrosis: An In Vivo Trabeculectomy Study in a Rabbit Model.
Ayyala, RS; Blake, D; Fullerton, M; Greenberg, E; John, V; Le, C; Mancera, N; Margo, C; Muddasani, N; Satija, C; Singh, S; Swann, FB; Wall, J; Zhang, Z; Zurakowski, D, 2019
)
0.51
"Contradictory results of postoperative steroid application in photorefractive keratectomy (PRK) led to a meta-analysis of the existing data to achieve a definite conclusion on the optimum dosage and duration of corticosteroid therapy after PRK."( Duration of topical steroid application after photorefractive keratectomy with mitomycin C.
Aghamirsalim, M; Fotouhi, A; Hashemi, H; Jafarzadehpour, E; Khabazkhoob, M; Pakbin, M; Pakravan, M; Seyedian, MA, 2020
)
0.79
" Although we found that most studies could not show any correlation between MMC dosage and the surgical outcome, the success rates with the Xen® microshunt seemed to be higher when using 20 mcg of MMC than when using 10 mcg."( Learning from the past: Mitomycin C use in trabeculectomy and its application in bleb-forming minimally invasive glaucoma surgery.
Bell, K; de Padua Soares Bezerra, B; Lawlor, M; Marti, MV; Mofokeng, M; Montesano, G; Nongpiur, ME,
)
0.44
" Patients (aged ≥18 years) with primary or recurrent biopsy-proven, low-grade upper tract urothelial cancer (measuring 5-15 mm in maximum diameter) and an Eastern Cooperative Oncology Group performance status score of less than 3 (Karnofsky Performance Status score >40) were registered to receive six instillations of once-weekly UGN-101 (mitomycin 4 mg per mL; dosed according to volume of patient's renal pelvis and calyces, maximum 60 mg per instillation) via retrograde catheter to the renal pelvis and calyces."( Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial.
Adibi, M; Amin, MB; Chamie, K; Coleman, J; Godoy, G; Gore, JL; Hakim, G; Hu, B; Hubosky, S; Humphreys, MR; Kaimakliotis, H; Klein, I; Kleinmann, N; Knoedler, JJ; Konorty, M; Lerner, SP; Lifshitz, D; Linehan, J; Matin, SF; O'Donnell, M; Pak, R; Pierorazio, PM; Quek, M; Raman, JD; Rivera, M; Scherr, D; Schoenberg, M; Seltzer, E; Shabsigh, A; Smith, AB; Stern, J; Strauss-Ayali, D; Verni, M; Weight, C; Weizer, A; Woods, M, 2020
)
0.95
"This review details the current understanding of the mechanism of action and corneal effects of mitomycin C (MMC) for prophylactic prevention of stromal fibrosis after photorefractive keratectomy (PRK), and includes discussion of available information on dosage and exposure time recommended for MMC during PRK."( Biological effects of mitomycin C on late corneal haze stromal fibrosis following PRK.
Carlos de Oliveira, R; Wilson, SE, 2020
)
1.09
" The most effective drug with its optimum dosage was administered via multiple intralesional injections to a 65-year-old woman with advanced periorbital nodulo-ulcerative BCC."( Optimizing the effective doses of mitomycin C, 5-fluorouracil, and their combination on cultivated basal cell carcinoma.
Aletaha, M; Balagholi, S; Dabbaghi, R; Kanavi, MR; Karami, S; Nakhaie, PA, 2021
)
0.9
" Because MMC is the preferred agent of choice used in CRS-HIPEC, future studies should investigate optimal MMC dosing and patient selection when splenectomy is performed to balance survival benefit with hematologic toxicities."( Pancytopenia after administration of hyperthermic intraperitoneal chemotherapy with mitomycin-C: local therapy and systemic toxicity.
Chung, SY; Saif, MW; Shen, J; Wu, V, 2021
)
0.85
" Protocol variability and dosage differences limit statistical interpretation."( Nephron-sparing management of upper tract urothelial carcinoma.
Farrow, JM; Gryzinski, GM; Kern, SQ; Sundaram, CP, 2021
)
0.62
" However, PBM was not used as an organ at risk for radiotherapy planning purposes and doses to PBM were high, which may have obscured any dose-response relationships."( Sarcopenia and dosimetric parameters in relation to treatment-related leukopenia and survival in anal cancer.
Johnsson, A; Nilsson, MP; Scherman, J, 2021
)
0.62
" A 5000-patient Monte Carlo simulation was performed using various piperacillin/tazobactam dosing regimens to determine the probability of target attainment (PTA) for 50% free time above the MIC."( Piperacillin/Tazobactam Dose Optimization in the Setting of Piperacillin/Tazobactam-susceptible, Carbapenem-resistant Pseudomonas aeruginosa: Time to Reconsider Susceptible Dose Dependent.
Gill, CM; Nicolau, DP, 2023
)
0.91
" In addition, the possibility of compensation by dosage adjustments was evaluated."( Rifampicin reduces plasma concentration of linezolid in patients with infective endocarditis.
Bock, M; Bruun, NE; Bundgaard, H; Christensen, JJ; Christiansen, U; Elming, H; Fosbøl, EL; Fuursted, K; Gill, S; Helweg-Larsen, J; Høfsten, DE; Høiby, N; Ihlemann, N; Iversen, K; Køber, L; Moser, C; Povlsen, JA; Pries-Heje, MM; Rosenvinge, FS; Schwartz, F; Torp-Pedersen, C; Tønder, N; Van Hasselt, JGC; Wang, H, 2023
)
0.91
" Model-based dosing simulations showed that rifampicin cotreatment decreased the PTA of linezolid from 94."( Rifampicin reduces plasma concentration of linezolid in patients with infective endocarditis.
Bock, M; Bruun, NE; Bundgaard, H; Christensen, JJ; Christiansen, U; Elming, H; Fosbøl, EL; Fuursted, K; Gill, S; Helweg-Larsen, J; Høfsten, DE; Høiby, N; Ihlemann, N; Iversen, K; Køber, L; Moser, C; Povlsen, JA; Pries-Heje, MM; Rosenvinge, FS; Schwartz, F; Torp-Pedersen, C; Tønder, N; Van Hasselt, JGC; Wang, H, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
alkylating agentHighly reactive chemical that introduces alkyl radicals into biologically active molecules and thereby prevents their proper functioning. It could be used as an antineoplastic agent, but it might be very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. It could also be used as a component of poison gases.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
primary amineA compound formally derived from ammonia by replacing one hydrogen atom by a hydrocarbyl group.
mitomycinA family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (48)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATAD5 protein, partialHomo sapiens (human)Potency2.51190.004110.890331.5287AID504467
GLS proteinHomo sapiens (human)Potency11.22020.35487.935539.8107AID624170
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency15.84890.01789.637444.6684AID588834
transcriptional regulator ERG isoform 3Homo sapiens (human)Potency50.11870.794321.275750.1187AID624246
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency35.48130.003245.467312,589.2998AID2517
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency10.68223.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency13.33320.006038.004119,952.5996AID1159523
Fumarate hydrataseHomo sapiens (human)Potency15.84890.00308.794948.0869AID1347053
TDP1 proteinHomo sapiens (human)Potency0.33240.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency0.58630.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency13.31330.000221.22318,912.5098AID1259243; AID1259247; AID743042; AID743054
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency11.88320.013326.981070.7614AID1346978
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency18.83360.000657.913322,387.1992AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency2.96360.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency26.60320.000417.946075.1148AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency4.25130.01237.983543.2770AID1346984; AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency0.03620.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency19.12200.000214.376460.0339AID720691; AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency17.57980.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency26.32740.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency16.15020.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency13.33220.375827.485161.6524AID743217
estrogen nuclear receptor alphaHomo sapiens (human)Potency9.96240.000229.305416,493.5996AID1259244; AID1259248; AID743069; AID743078; AID743079; AID743080; AID743091
cytochrome P450 2D6Homo sapiens (human)Potency12.30180.00108.379861.1304AID1645840
polyproteinZika virusPotency15.84890.00308.794948.0869AID1347053
67.9K proteinVaccinia virusPotency3.60040.00018.4406100.0000AID720579; AID720580
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency33.48890.001024.504861.6448AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency13.33220.001019.414170.9645AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency23.91450.023723.228263.5986AID743223
caspase-3Homo sapiens (human)Potency11.88320.013326.981070.7614AID1346978
aryl hydrocarbon receptorHomo sapiens (human)Potency33.49150.000723.06741,258.9301AID743085
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency29.84930.001723.839378.1014AID743083
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency11.22020.10009.191631.6228AID1346983
Histone H2A.xCricetulus griseus (Chinese hamster)Potency19.38580.039147.5451146.8240AID1224845; AID1224896
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency3.66260.00419.984825.9290AID504444
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency1.30820.000323.4451159.6830AID743065; AID743067
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency3.98110.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency3.98110.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency3.98110.15855.287912.5893AID540303
gemininHomo sapiens (human)Potency10.32250.004611.374133.4983AID624297
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency3.75780.001557.789015,848.9004AID1259244
Cellular tumor antigen p53Homo sapiens (human)Potency2.35070.002319.595674.0614AID651631; AID720552
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency3.75780.001551.739315,848.9004AID1259244
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency20.77370.009610.525035.4813AID1479145; AID1479148
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
galanin receptor type 3Homo sapiens (human)IC50 (µMol)0.93200.00661.54317.3650AID687013
Indoleamine 2,3-dioxygenase 1Homo sapiens (human)Ki25.00000.09402.37907.0000AID734364
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (143)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of activated T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of T cell tolerance inductionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of chronic inflammatory responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of type 2 immune responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan catabolic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
inflammatory responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
female pregnancyIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan catabolic process to kynurenineIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
response to lipopolysaccharideIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of interleukin-10 productionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of interleukin-12 productionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
multicellular organismal response to stressIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
kynurenic acid biosynthetic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
swimming behaviorIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of T cell apoptotic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of T cell apoptotic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
'de novo' NAD biosynthetic process from tryptophanIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (39)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
electron transfer activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
heme bindingIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
indoleamine 2,3-dioxygenase activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
metal ion bindingIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan 2,3-dioxygenase activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (23)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
cytosolIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
smooth muscle contractile fiberIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
stereocilium bundleIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
cytoplasmIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (936)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1761354Genotoxicity in Salmonella typhimurium TA102 assessed as number of revertant by Ames spot test relative to solvent control
AID217040In vitro concentration required to kill 50% of the aerobic cells1997Journal of medicinal chemistry, Jul-18, Volume: 40, Issue:15
2-Cyclopropylindoloquinones and their analogues as bioreductively activated antitumor agents: structure-activity in vitro and efficacy in vivo.
AID138038Compound (40 mg/Kg) was evaluated in vivo for antitumor activity against MAC 16 in female NMRI mice on day 12 and ratio of tumor weight of treated to that of control was determined1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Synthesis, mechanism of action, and biological evaluation of mitosenes.
AID1061807Cytotoxicity against human prostate cancer cells assessed as growth inhibition at 10 uM by SRB assay2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Synthesis of a novel series of artemisinin dimers with potent anticancer activity involving Sonogashira cross-coupling reaction.
AID363585Clastogenic effect on C57BL mouse assessed as mitotic index in bone marrow cells at 3.5 mg/kg, ip after 24 hrs2008European journal of medicinal chemistry, Jun, Volume: 43, Issue:6
Novel N-(phosphonomethyl) glycine derivatives: Design, characterization and biological activity.
AID1254822Cytotoxicity against human MDA-MB-468 cells after 72 hrs by MTS assay2015Journal of natural products, Oct-23, Volume: 78, Issue:10
Angucyclines and Angucyclinones from Streptomyces sp. CB01913 Featuring C-Ring Cleavage and Expansion.
AID123709Ratio of the tumor weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 0.2 ml/mouse (Q2dx10) administered i.p.1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID1065294Cytotoxicity against human MG63 cells after 48 hrs by MTT assay2013European journal of medicinal chemistry, Aug, Volume: 66Diversity-oriented synthesis of α-aminophosphonates: a new class of potential anticancer agents.
AID11333350% inhibition of solid tumor growth (Sarcoma 180 cells) in mice1995Journal of medicinal chemistry, Aug-04, Volume: 38, Issue:16
Synthesis and antitumor activity of various 6-demethylmitomycins and 6-demethyl-6-halomitomycins.
AID221155in vitro inhibition of tumor cell growth in cultured HepG2 human tumor cell line2001Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
Synthesis, DNA cross-linking activity, and cytotoxicity of dimeric mitomycins.
AID98094Maximum % T/C against L-1210 leukemia cells in mice.1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Mitomycin C and porfiromycin analogues with substituted ethylamines at position 7.
AID1853133Effect on DNA damage repair in Caulobacter vibrioides expressing Gam-GFP reporter system assessed as increase in double stranded break by measuring Gam localization in cells at 0.5 ug/ml and measured after 2 hrs by fluorescence analysis2022RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12
Mechanistic insight into the repair of C8-linked pyrrolobenzodiazepine monomer-mediated DNA damage.
AID123456Anti cancer activity was tested on day 14, in mice bearing Lewis lung adenocarcinoma by injecting 0.8 mg/kg dose of compound intraperitoneally and average weight change was reported.1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Cyclopent[a]anthraquinones as DNA intercalating agents with covalent bond formation potential: synthesis and biological activity.
AID123592Evaluated for antitumor activity against B-16 melanoma in mice at a dose 4 mg/kg day, ip, on days 1, 4, and 7 against B-16 Melanoma cell1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Mitomycin C analogues with aryl substituents on the 7-amino group.
AID638416Anticancer activity against human DU145 cells assessed as growth inhibition at 50 uM after 48 hrs by SRB assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Acyl derivatives of boswellic acids as inhibitors of NF-κB and STATs.
AID133590Median survival time in days for antitumor activity against P388 Leukemia in CD2 mice at a single dose treatment of 6 mg/kg1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Synthesis, mechanism of action, and biological evaluation of mitosenes.
AID98416Minimum effective dose required for antitumor activity against L-1210 leukemia cells in mice.1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Mitomycin C and porfiromycin analogues with substituted ethylamines at position 7.
AID1454349Cytotoxicity against CHOK1 cells incubated for 24 hrs by MTT asasy2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Synthesis and biological evaluation of 5-fatty-acylamido-1, 3, 4-thiadiazole-2-thioglycosides.
AID363583Clastogenic effect on C57BL mouse assessed as number of metaphase chromosome telomere/telomeric fusion in bone marrow cells at 3.5 mg/kg, ip after 24 hrs2008European journal of medicinal chemistry, Jun, Volume: 43, Issue:6
Novel N-(phosphonomethyl) glycine derivatives: Design, characterization and biological activity.
AID133598Median survival time in days for antitumor activity against P388 Leukemia in CD2 mice at fractioned dose treatment of 3 mg/kg1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Synthesis, mechanism of action, and biological evaluation of mitosenes.
AID128415Antitumor activity against P388 mouse leukemia as maximum and average change in body weight was reported at a dose of 0.4 mg/Kg per injection.1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Synthesis and biological activity of 6-substituted mitosene analogues of the mitomycins.
AID356087Cytotoxicity against human SCL6 cells by MTT assay2003Journal of natural products, Jul, Volume: 66, Issue:7
Cytotoxic diterpenes from Scoparia dulcis.
AID228641Concentration of compound required for cross linking 50% of tyrT DNA, acid; undetectable2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Mitomycin dimers: polyfunctional cross-linkers of DNA.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID248344Inhibitory concentration againstHuman Karpas 299 Anaplastic Large Cell Lymphoma (CD30+) at 96th hour; n=392005Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5
Design, synthesis, and in vitro evaluation of dipeptide-based antibody minor groove binder conjugates.
AID1232056Antitumor activity against against mouse B16 cells implanted in mouse assessed as mouse survival at 1 mg/kg/day (Rvb = 16 days)2014MedChemComm, Jul-01, Volume: 5, Issue:7
The biology and synthesis of α-hydroxytropolones.
AID154487Minimum effective dose required for antitumor activity against P-388 murine leukemia cells in mice.1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Mitomycin C analogues with secondary amines at position 7.
AID1149655Toxicity in Escherichia coli W1709(lambda) at 0.05 ug/ml1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Comparative stereochemistry in the aziridine ring openings of N-methylmitomycin A and 7-methoxy-1,2-(N-methylaziridino)mitosene.
AID1457336Genotoxicity in human lymphocytes assessed as increase in frequency of micronucleated cells at 0.33 ug/mL after 28 hrs in absence of rat liver S9 fraction by micronucleus assay (Rvb = 0.74%)2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
AID426954Cytotoxicity against human HeLa cells after 48 hrs by SRB assay2009Journal of natural products, Jun, Volume: 72, Issue:6
Vladimuliecins A and B: cytotoxic pentacyclic pregnanols from Vladimiria muliensis.
AID397760Cytotoxicity against human CNS cancer cells2001Journal of natural products, Jul, Volume: 64, Issue:7
In vitro cytotoxicity of the protoberberine-type alkaloids.
AID229265Ratio of IC50 for Parental L1210 to that of multidrug resistant L1210.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Additional nucleotide derivatives of mitosenes. Synthesis and activity against parental and multidrug resistant L1210 leukemia.
AID154375Optimal dose required for antitumor activity against P-388 murine leukemia cells in mice.1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Mitomycin C and porfiromycin analogues with substituted ethylamines at position 7.
AID613377Binding affinity to Escherichia coli pBR322 assessed as DNA interstand cross link at 0.2 mM after 2 hrs by agarose gel electrophoresis in presence of 5 equiv of L-ditiothreitol2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Synthesis and mechanistic studies of a mitomycin dimer containing an eight-membered cyclic disulfide.
AID98096Median survival time against L1210 murine leukemia at 12 mg/kg in mice when compared with control1981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
Synthesis and antineoplastic activity of mitosene analogues of the mitomycins.
AID1243801Mutagenicity in Salmonella typhimurium TA102 assessed as mutagenicity index at 0.5 ug/plate incubated for 90 mins at 37 degC in absence of liver S9 fractions by Ames test relative to untreated control2015European journal of medicinal chemistry, Aug-28, Volume: 101Leishmanicidal, antiproteolytic, and mutagenic evaluation of alkyltriazoles and alkylphosphocholines.
AID98653Optimal dose required for antitumor activity L-1210 leukemia cells in mice.1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Mitomycin C and porfiromycin analogues with substituted ethylamines at position 7.
AID128417Antitumor activity against P388 mouse leukemia as maximum and average change in body weight was reported at a dose of 1.6 mg/kg per injection.1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Synthesis and biological activity of 6-substituted mitosene analogues of the mitomycins.
AID442342Growth inhibition of human COLO205 cells at 10 uM after 48 hrs by SRB assay2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Synthesis, anti-inflammatory and anticancer activity evaluation of some novel acridine derivatives.
AID38046Tumor free survivors on 62nd day after ip administration in B-16 melanoma in mice (dose mg/kg/day); 01983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Mitomycin C and porfiromycin analogues with substituted ethylamines at position 7.
AID123451Anti cancer activity was tested on day 7, in mice bearing Lewis lung adenocarcinoma by injecting 2.0 mg/kg dose of compound intraperitoneally and average tumor volume was calculated.1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Cyclopent[a]anthraquinones as DNA intercalating agents with covalent bond formation potential: synthesis and biological activity.
AID1302978Antibiofilm activity against Bacillus subtilis MTCC 121 after 24 hrs by crystal violet staining based assay2016European journal of medicinal chemistry, Jul-19, Volume: 117Design, synthesis and biological evaluation of diaziridinyl quinone isoxazole hybrids.
AID733316Growth inhibition of human PC3 cells at 10 uM after 48 hrs by MTT assay2013European journal of medicinal chemistry, Apr, Volume: 62Synthesis, structure activity relationship and mode of action of 3-substitutedphenyl-1-(2,2,8,8-tetramethyl-3,4,9,10-tetrahydro-2H,8H-pyrano[2,3-f]chromen-6-yl)-propenones as novel anticancer agents in human leukaemia HL-60 cells.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1149657Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as effect on median survival time at 3.2 mg/kg/day administered qd on day 1 and 5 relative to control1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Comparative stereochemistry in the aziridine ring openings of N-methylmitomycin A and 7-methoxy-1,2-(N-methylaziridino)mitosene.
AID1717204Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay2020European journal of medicinal chemistry, Jan-15, Volume: 186Novel diosgenin derivatives containing 1,3,4-oxadiazole/thiadiazole moieties as potential antitumor agents: Design, synthesis and cytotoxic evaluation.
AID1149679Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as mouse survival at 1.6 mg/kg/day administered qd on day 1 and 5 measured on day 301977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Comparative stereochemistry in the aziridine ring openings of N-methylmitomycin A and 7-methoxy-1,2-(N-methylaziridino)mitosene.
AID152272In vitro cytotoxicity of compound was measured on murine lymphocytic leukemia (P-388) cells.1998Bioorganic & medicinal chemistry letters, Dec-01, Volume: 8, Issue:23
A concise synthesis and in vitro cytotoxicity of new labdane diterpenes.
AID137385Percent T/C (total/control) for antitumor activity against P388 Leukemia in CD2 mice at a single dose treatment of 6 mg/kg1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Synthesis, mechanism of action, and biological evaluation of mitosenes.
AID98099Median survival time against L1210 murine leukemia at 3 mg/kg in mice when compared with control1981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
Synthesis and antineoplastic activity of mitosene analogues of the mitomycins.
AID109976Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 0.2 ml/mouse (Q2dx9) administered i.p.; 19.3/171999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID747039Cytotoxicity against human HCT15 cells at 1 uM after 48 hrs by SRB assay2013European journal of medicinal chemistry, May, Volume: 63Synthesis of 3-O-propargylated betulinic acid and its 1,2,3-triazoles as potential apoptotic agents.
AID128737Percentage change in body weight [(day 6 - day 1)/ day 1] for antitumor activity against P388 Leukemia in CD2 mice at fractioned dose treatment of 1 mg/kg1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Synthesis, mechanism of action, and biological evaluation of mitosenes.
AID389723Effect on cell cycle arrest in human HCT8 cells in hypoxic condition assessed as DNA fragmentation at 10 uM after 48 hrs of drug washout by flow cytometry2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Synthesis of new pyrazolo[5,1-c][1,2,4] benzotriazines, pyrazolo[5,1-c]pyrido[4,3-e][1,2,4] triazines and their open analogues as cytotoxic agents in normoxic and hypoxic conditions.
AID1256921Cytotoxicity against human A549 cells assessed as decrease in cell viability at 10 to 100 uM after 48 hrs by SRB assay2015Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23
Synthesis of natural phaeosphaeride A derivatives and an in vitro evaluation of their anti-cancer potential.
AID300327Cytotoxicity against mouse P388 cells by MTT assay2007Bioorganic & medicinal chemistry, Sep-01, Volume: 15, Issue:17
Erythrocarpines A-E, new cytotoxic limonoids from Chisocheton erythrocarpus.
AID153986Evaluation of inhibitory activity against drug sensitive P388 cells (P388/S) cells1995Journal of medicinal chemistry, Dec-22, Volume: 38, Issue:26
Novel inhibitors for multidrug resistance: 1,3,5-triazacycloheptanes.
AID111270Effect of compound on total white blood cell count in BDG1 male mice, after intraperitoneal administration at a dose of 5.63 mg/kg on day 31981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Development of new mitomycin C and porfiromycin analogues.
AID1134758Antibacterial activity against Bacillus subtilis assessed as growth inhibition at 0.2 ug/ml in 100 mm disk at pH 8.0 by single-disk method1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Mitomycin antibiotics. Synthesis of 7-methoxy-1-(N-pyrrolidino)mitosene and its methiodide.
AID103424Antiproliferative activity of compound was evaluated on MCF-7 cells from human breast adenocarcinoma2000Bioorganic & medicinal chemistry letters, Oct-02, Volume: 10, Issue:19
Synthesis and antiproliferative activity of some benzimidazole-4,7-dione derivatives.
AID718249Downregulation of uPA protein expression in human A549 cell extract at 0.05 uM after 48 hrs by ELISA (Rvb = 11.0000 +/-1.60 ng/ml)2012Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24
Synthesis and docking studies of novel antitumor benzimidazoles.
AID461534Cytotoxicity against human Hep2 cells by MTT assay2010Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5
Cytotoxic and anti-inflammatory cembranoids from the Dongsha Atoll soft coral Sarcophyton crassocaule.
AID718246Downregulation of uPA protein expression in human A549 cell extract at 0.40 uM after 48 hrs by ELISA (Rvb = 11.0000 +/-1.60 ng/ml)2012Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24
Synthesis and docking studies of novel antitumor benzimidazoles.
AID1065290Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay2013European journal of medicinal chemistry, Aug, Volume: 66Diversity-oriented synthesis of α-aminophosphonates: a new class of potential anticancer agents.
AID121516Tumor volume was calculated against sarcoma 180 cells which were inoculated intravenously to the axillary region of ddY mice; 0.28-0.461994Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12
Synthesis and antitumor activity of novel mitomycin derivatives containing functional groups at the C-6-methyl position.
AID115830Inhibitory activity against human lung adenocarcinoma xenograft LAX-83 and the ratio of the number of mice at the initial stage and the final stage of the experiment was reported at a dose of 0.2 ml/mouse (Q2dx10) administered i.p.1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1162267Cytotoxicity against human HeLa cells after 48 hrs by SRB assay2014Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19
Synthesis and evaluation of 3-salicyloylpyridine derivatives as cytotoxic mitochondrial apoptosis inducers.
AID248288Inhibitory concentration againstHuman Karpas 299 Anaplastic Large Cell Lymphoma (CD30+) at 4th hour; n=12005Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5
Design, synthesis, and in vitro evaluation of dipeptide-based antibody minor groove binder conjugates.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID442346Growth inhibition of human A549 cells at 10 uM after 48 hrs by SRB assay2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Synthesis, anti-inflammatory and anticancer activity evaluation of some novel acridine derivatives.
AID668096Cytotoxicity against human HL60 cells after 72 hrs by WST8 assay2012Journal of natural products, Apr-27, Volume: 75, Issue:4
Phenanthrene derivatives from Cymbidium Great Flower Marie Laurencin and their biological activities.
AID1446334Growth inhibition of human HCT116 cells after 72 hrs by Cell-Titer Glo assay2017Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15
Conformation-Based Design and Synthesis of Apratoxin A Mimetics Modified at the α,β-Unsaturated Thiazoline Moiety.
AID123453Anti cancer activity was tested on day10, in mice bearing Lewis lung adenocarcinoma by injecting 0.8 mg/kg dose of compound intraperitoneally and average tumor volume was calculated.1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Cyclopent[a]anthraquinones as DNA intercalating agents with covalent bond formation potential: synthesis and biological activity.
AID94812In vitro inhibitory activity against K562 leukemia cells in the presence of pd22003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Mitomycin antitumor compounds. 2. Interaction of transition metal ions with mitomycin C. Solution structure and biological activity of a Pd(2+)-MMC complex.
AID121619Activity of compound dose of 8 mg/kg/day against Murine B-16 Melanocarcinoma in mice1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Development of new mitomycin C and porfiromycin analogues.
AID38186Average weight change after ip administration of of a dose of 2 mg/kg/day in B-16 melanoma in mice1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Mitomycin C analogues with secondary amines at position 7.
AID124395Evaluated for antitumor activity against B-16 melanoma in mice at a dose 4 mg/kg day, ip, on days 1, 4, and 7 against B-16 Melanoma cell *-Tumors survivors on day 621984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Mitomycin C analogues with aryl substituents on the 7-amino group.
AID114879In vivo inhibitory activity against human lung adenocarcinoma xenograft LAX-83 in mice at a dose of 2.0 mg/kg (Q2dx10) administered i.p.1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID633104Cytotoxicity against human HeLa cells after 1 to 11 days by MTT assay2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Crassocolides N-P, three cembranoids from the Formosan soft coral Sarcophyton crassocaule.
AID1320164Cytotoxicity against CHL cells assessed as number of cells with numerical aberrations at 0.05 ug/ml preincubated for 6 hrs followed by 18 hrs incubation in fresh medium in absence of S9 fraction by Giemsa-staining-based microscopic analysis relative to co2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Phosphonate-based irreversible inhibitors of human γ-glutamyl transpeptidase (GGT). GGsTop is a non-toxic and highly selective inhibitor with critical electrostatic interaction with an active-site residue Lys562 for enhanced inhibitory activity.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1065297Cytotoxicity against human COLO320DM cells after 48 hrs by MTT assay2013European journal of medicinal chemistry, Aug, Volume: 66Diversity-oriented synthesis of α-aminophosphonates: a new class of potential anticancer agents.
AID97549Average change in weight between treated and control groups at 6 mg/kg in mice infected with L1210 leukemia cells1981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
Synthesis and antineoplastic activity of mitosene analogues of the mitomycins.
AID228640Concentration of compound required for cross linking 50% of tyrT DNA, Na2S2O42004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Mitomycin dimers: polyfunctional cross-linkers of DNA.
AID101244The compound was evaluated for survival of L1210 cells, when compound was exposed for a period of 8-9 hr 5*(10e -8)M conc1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Nucleotide derivatives of 2,7-diaminomitosene.
AID40605Median survival time (% T/C) after ip administration in B-16 melanoma in mice (dose mg/kg/day)1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Mitomycin C and porfiromycin analogues with substituted ethylamines at position 7.
AID123450Anti cancer activity was tested on day 7, in mice bearing Lewis lung adenocarcinoma by injecting 0.4 mg/kg dose of compound intraperitoneally and average tumor volume was calculated.1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Cyclopent[a]anthraquinones as DNA intercalating agents with covalent bond formation potential: synthesis and biological activity.
AID109991Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 2.0 mg/kg (Q2dx9) administered i.p.1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID1149672Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as mouse survival at 1.6 mg/kg/day administered qd on day 1 and 5 measured on day 51977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Comparative stereochemistry in the aziridine ring openings of N-methylmitomycin A and 7-methoxy-1,2-(N-methylaziridino)mitosene.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID136707Ability of intraperitoneally administered compound (2 mg/kg/day) to inhibit growth of human tumor xenograft GXF 97 was assessed on day 21 in nude mice1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Synthesis, mechanism of action, and biological evaluation of mitosenes.
AID1600374Antibacterial activity against Escherichia coli K-12 BW25113 incubated for 18 hrs by broth microdilution method2019Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
Identification of a potent small-molecule inhibitor of bacterial DNA repair that potentiates quinolone antibiotic activity in methicillin-resistant Staphylococcus aureus.
AID95330in vitro anticancer activity against cultured KB(epidermoid) human tumor cell line2001Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
Synthesis, DNA cross-linking activity, and cytotoxicity of dimeric mitomycins.
AID1254407Antiproliferative activity against human HepG2 cells after 48 hrs by resazurin reduction assay2015Bioorganic & medicinal chemistry, Dec-01, Volume: 23, Issue:23
Modification of cellular DNA by synthetic aziridinomitosenes.
AID552864Cytotoxicity against human DaOY cells after 3 days by MTT assay2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Biologically active constituents from the fruiting body of Taiwanofungus camphoratus.
AID1313930Induction of interstrand cross-linking in EcoR1-linearized Escherichia coli pBR322 plasmid DNA at 0.20 mM after 2 hrs using 5 equiv of Et3P by ethidium bromide staining based alkaline agarose gel electrophoresis2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Design, synthesis, and mode of action studies of a mitomycin tetramer inducing double activations with a single probe.
AID128421Antitumor activity against P388 mouse leukemia as maximum and average change in body weight was reported at a dose of 4.8 mg/kg per injection.1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Synthesis and biological activity of 6-substituted mitosene analogues of the mitomycins.
AID156010in vitro inhibition of tumor cell growth in cultured PC-3 human tumor cell line2001Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
Synthesis, DNA cross-linking activity, and cytotoxicity of dimeric mitomycins.
AID37916Average weight change after ip administration inB-16 melanoma in mice (dose mg/kg/day)1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Mitomycin C and porfiromycin analogues with substituted ethylamines at position 7.
AID1243489Radioprotective activity in 2-Gy gamma irradiated human PBL assessed as frequency of micronuclei at 3 uM treated for 2 to 19 hrs followed by compound washout measured after 72 hrs by cytochalasin-B-blocked micronucleus assay relative to control2015Journal of natural products, Sep-25, Volume: 78, Issue:9
Phenolic Compounds from Atriplex littoralis and Their Radiation-Mitigating Activity.
AID1869705Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay2022Journal of natural products, 07-22, Volume: 85, Issue:7
Structure Revision of Trichomide D by Total Synthesis.
AID733835Induction of recA promoter in Bacillus subtilis YB3001 using 4-methylumbelliferyl beta D-galactopyranoside as substrate incubated for 3 hrs prior to substrate addition measured after 1 hr by beta galactosidase reporter gene assay relative to control2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Atropisomeric dihydroanthracenones as inhibitors of multiresistant Staphylococcus aureus.
AID110913Degree of leukopenia produced by compound is assessed form Percent change in white cells on day 31981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Development of new mitomycin C and porfiromycin analogues.
AID8298in vitro anticancer activity against cultured A549 human tumor(lung) cell line2001Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
Synthesis, DNA cross-linking activity, and cytotoxicity of dimeric mitomycins.
AID235401Therapeutic ratio as optimal dose/minimal effective dose1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Mitomycin C and porfiromycin analogues with substituted ethylamines at position 7.
AID123717Ratio of the tumor weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 2.0 mg/kg (Q2dx10) administered i.p.1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID1313932Prodrug activation in Tris HCl methanolic solution at pH 7.4 using 5 equiv of Et3P by UV-visible spectrophotometry2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Design, synthesis, and mode of action studies of a mitomycin tetramer inducing double activations with a single probe.
AID1649636Cytotoxicity against HFF monolayers assessed as cell growth measured after 72 hrs by luciferase reporter gene assay relative to control2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Optimizing Pyrazolopyrimidine Inhibitors of Calcium Dependent Protein Kinase 1 for Treatment of Acute and Chronic Toxoplasmosis.
AID3215In vitro inhibition of 2780/S ovarian cancer cell line1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Structure-activity studies of antitumor agents based on pyrrolo[1,2-a]benzimidazoles: new reductive alkylating DNA cleaving agents.
AID150218Optimal dose required for antitumor activity against P-388 murine leukemia cells in mice.1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Mitomycin C analogues with secondary amines at position 7.
AID1134757Antibacterial activity against Bacillus subtilis assessed as growth inhibition at 0.8 ug/ml in 100 mm disk at pH 8.0 by single-disk method1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Mitomycin antibiotics. Synthesis of 7-methoxy-1-(N-pyrrolidino)mitosene and its methiodide.
AID399041Cytotoxicity against human KB cells after 3 days by methylene blue staining2005Journal of natural products, Nov, Volume: 68, Issue:11
Cytotoxic clerodane diterpenoids from Casearia membranacea.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID131333In vivo antitumor activity against lymphatic leukemia P388 cells sensitive to mitomycin C (MMC) was measured as maximal increase in life span of the treated mice at optimal dose of 1.0-6.0 mg/kg; 38-841994Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12
Synthesis and antitumor activity of novel mitomycin derivatives containing functional groups at the C-6-methyl position.
AID667184Antiproliferative activity against human Hep2 cells after 6 days by MTT assay2012Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13
A new 9,11-secosterol from the soft coral Sinularia granosa.
AID115601Antitumor activity against P-388 leukemia in mice, activity is expressed as Minimum effective dose1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Mitomycin C analogues with increased metal complexing ability.
AID152723Antitumor activity against P388/ADR (adriamycin resistant), in male BDF1 mice measured as % increase in life span (%ILS) at dose 1.0-5.0 mg/Kg/inj, ip1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
New actinomycin D analogues as superior chemotherapeutic agents against primary and advanced colon tumors and colon xenografts in nude mice.
AID466462Cytotoxicity against human KB-3-1 cells after 72 hrs by MTT assay2010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
New anti-malarial phenylpropanoid conjugated iridoids from Morinda morindoides.
AID8283Antitumor activity against A549 human lung carcinoma cell line in experiment 11989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
New 2-substituted indoloquinone mitomycin analogues.
AID90437Antitumor potency on human colon WIDR cell lines.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Structure-activity relationships for mitomycin C and mitomycin A analogues.
AID202378Antitumor activity against SW900 human lung carcinoma cell line1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
New 2-substituted indoloquinone mitomycin analogues.
AID365412Cytotoxicity against human A549 cells assessed as age growth inhibition at 10 uM after 48 hrs by sulforhodamine B assay2008Bioorganic & medicinal chemistry letters, Sep-01, Volume: 18, Issue:17
Synthesis and cytotoxic activity of some novel polycyclic gamma-butyrolactones.
AID154360Leukopenia % change in WBC at optimal dose on 3rd day.1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Mitomycin C and porfiromycin analogues with substituted ethylamines at position 7.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID459269Growth inhibition of human K562-Lucena 1 cells after 24 to 72 hrs by MTT assay2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
New pterocarpanquinones: synthesis, antineoplasic activity on cultured human malignant cell lines and TNF-alpha modulation in human PBMC cells.
AID119966Optimal dose was measured against sarcoma 180 cell in mice1995Journal of medicinal chemistry, Aug-04, Volume: 38, Issue:16
Synthesis and antitumor activity of various 6-demethylmitomycins and 6-demethyl-6-halomitomycins.
AID123457Anti cancer activity was tested on day 7, in mice bearing Lewis lung adenocarcinoma by injecting 0.4 mg/kg dose of compound intraperitoneally and average weight change was reported.1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Cyclopent[a]anthraquinones as DNA intercalating agents with covalent bond formation potential: synthesis and biological activity.
AID1302976Bactericidal activity against Micrococcus luteus MTCC 2470 after 24 hrs by serial dilution method2016European journal of medicinal chemistry, Jul-19, Volume: 117Design, synthesis and biological evaluation of diaziridinyl quinone isoxazole hybrids.
AID363582Clastogenic effect on C57BL mouse assessed as number of metaphase chromosomal centromere/centromeric fusion in bone marrow cells at 3.5 mg/kg, ip after 24 hrs2008European journal of medicinal chemistry, Jun, Volume: 43, Issue:6
Novel N-(phosphonomethyl) glycine derivatives: Design, characterization and biological activity.
AID1854156Cytotoxicity against human A549 cells2022European journal of medicinal chemistry, Aug-05, Volume: 238Cascade synthetic strategies opening access to medicinal-relevant aliphatic 3- and 4-membered N-heterocyclic scaffolds.
AID667183Antiproliferative activity against human HeLa cells after 6 days by MTT assay2012Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13
A new 9,11-secosterol from the soft coral Sinularia granosa.
AID1853122Effect on DNA damage repair in Caulobacter vibrioides lacking recA expression assessed as decrease in cell survival rate upto 1 ug/ml and measured after 2 days by agar dilution method2022RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12
Mechanistic insight into the repair of C8-linked pyrrolobenzodiazepine monomer-mediated DNA damage.
AID138044Compound (6 mg/Kg) was evaluated in vivo for antitumor activity against MAC 16 in female NMRI mice on day 4 and ratio of tumor weight of treated to that of control was determined1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Synthesis, mechanism of action, and biological evaluation of mitosenes.
AID1320152Cytotoxicity against CHL cells assessed as chromatid gap at 0.05 ug/ml after 24 hrs by Giemsa-staining-based microscopic analysis2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Phosphonate-based irreversible inhibitors of human γ-glutamyl transpeptidase (GGT). GGsTop is a non-toxic and highly selective inhibitor with critical electrostatic interaction with an active-site residue Lys562 for enhanced inhibitory activity.
AID38002Average change in weight between treated and control groups at 12 mg/kg in mice infected with L1210 leukemia cells1981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
Synthesis and antineoplastic activity of mitosene analogues of the mitomycins.
AID95054Compound was tested for antitumor activity against L-1210 Murine leukemia in BDF1 female mice at a dose of 6 mg/kg per injection1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Preparation and antitumor activity of 7-substituted 1,2-aziridinomitosenes.
AID718248Downregulation of uPA protein expression in human A549 cell extract at 0.10 uM after 48 hrs by ELISA (Rvb = 11.0000 +/-1.60 ng/ml)2012Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24
Synthesis and docking studies of novel antitumor benzimidazoles.
AID451332Antiproliferative activity against human skin fibroblast after 72 hrs by trypan blue exclusion assay2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Synthesis and evaluation of bioactive naphthoquinones from the Brazilian medicinal plant, Tabebuia avellanedae.
AID389716Cell cycle arrest in human HCT8 cells in hypoxic condition assessed as accumulation at S phase at 10 uM after 24 hrs of drug washout by flow cytometry2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Synthesis of new pyrazolo[5,1-c][1,2,4] benzotriazines, pyrazolo[5,1-c]pyrido[4,3-e][1,2,4] triazines and their open analogues as cytotoxic agents in normoxic and hypoxic conditions.
AID356957Cytotoxicity against human HEPA 59T/VGH cells after 72 hrs by methylene blue assay2002Journal of natural products, Dec, Volume: 65, Issue:12
New taxane diterpenoids from the leaves and twigs of Taxus sumatrana.
AID38185Average weight change after ip administration of of a dose of 1 mg/kg/day in B-16 melanoma in mice1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Mitomycin C analogues with secondary amines at position 7.
AID1470981Antiproliferative activity against human HT-29 cells expressing NQO1 after 72 hrs by MTT assay2017European journal of medicinal chemistry, May-26, Volume: 132Design, synthesis, and biological evaluation of NAD(P)H: Quinone oxidoreductase (NQO1)-targeted oridonin prodrugs possessing indolequinone moiety for hypoxia-selective activation.
AID389700Cell cycle arrest in human HCT8 cells in normoxic condition assessed as accumulation at G0/G1 phase at 10 uM after 24 hrs by flow cytometry2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Synthesis of new pyrazolo[5,1-c][1,2,4] benzotriazines, pyrazolo[5,1-c]pyrido[4,3-e][1,2,4] triazines and their open analogues as cytotoxic agents in normoxic and hypoxic conditions.
AID131323In vivo antitumor activity against lymphatic leukemia P388 cells resistant to mitomycin C (MMC) was measured as maximal increase in life span of the treated mice at optimal dose of 1.0-4.0 mg/kg1994Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12
Synthesis and antitumor activity of novel mitomycin derivatives containing functional groups at the C-6-methyl position.
AID1302966Antimicrobial activity against Bacillus subtilis MTCC 121 after 24 hrs by well diffusion method2016European journal of medicinal chemistry, Jul-19, Volume: 117Design, synthesis and biological evaluation of diaziridinyl quinone isoxazole hybrids.
AID124397Evaluated for antitumor activity against B-16 melanoma in mice at a dose 1 mg/kg day, ip, on days 1, 4, and 7 against B-16 Melanoma cell *-Tumors survivors on day 621984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Mitomycin C analogues with aryl substituents on the 7-amino group.
AID451335Antiproliferative activity against human IE cells after 72 hrs by trypan blue exclusion assay2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Synthesis and evaluation of bioactive naphthoquinones from the Brazilian medicinal plant, Tabebuia avellanedae.
AID552865Cytotoxicity against human Hep2 cells after 3 days by MTT assay2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Biologically active constituents from the fruiting body of Taiwanofungus camphoratus.
AID119952Compound was tested for antitumor activity against P-388 leukemia in mice, activity is expressed as Optimal dose; 3.2-4.81986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Mitomycin C analogues with increased metal complexing ability.
AID3024In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Structure-activity studies of antitumor agents based on pyrrolo[1,2-a]benzimidazoles: new reductive alkylating DNA cleaving agents.
AID1158658Cytotoxicity against human SMMC-7221 cells after 48 hrs by SRB method2014Journal of natural products, Jun-27, Volume: 77, Issue:6
Eremophilane-type sesquiterpenoids with diverse skeletons from Ligularia sagitta.
AID1134760Induction of lambda phage production in streptomycin-dependent lysogenic Escherichia coli W1709 (lambda) assessed as ratio of plaques in treated culture to control at 0.8 ug/ml1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Mitomycin antibiotics. Synthesis of 7-methoxy-1-(N-pyrrolidino)mitosene and its methiodide.
AID613374Binding affinity to Escherichia coli pBR322 assessed as DNA interstand cross link at 0.2 mM after 2 hrs by agarose gel electrophoresis in presence of 5 equiv of Et3P2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Synthesis and mechanistic studies of a mitomycin dimer containing an eight-membered cyclic disulfide.
AID40604Median survival time (% T/C) after ip administration in B-16 melanoma in mice (dose mg/kg/day)1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Mitomycin C and porfiromycin analogues with substituted ethylamines at position 7.
AID542121Induction of qnrB1 gene expression in lexA- and recA- positive Escherichia coli J53 at 0.2 ug/ml after 15 mins by quantitative PCR method relative to control2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
SOS regulation of qnrB expression.
AID123581Evaluated for antitumor activity against B-16 melanoma in mice aat a dose 1 mg/kg day, ip,on days 1, 4, and 7 against B-16 Melanoma cell1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Mitomycin C analogues with aryl substituents on the 7-amino group.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1302972Antimicrobial activity against Candida albicans MTCC 3017 after 24 hrs by well diffusion method2016European journal of medicinal chemistry, Jul-19, Volume: 117Design, synthesis and biological evaluation of diaziridinyl quinone isoxazole hybrids.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID633924Induction of mitosis in ICR mouse bone marrow cells assessed as mitotic index at 3.5 mg/kg, ip after 24 hrs2012Bioorganic & medicinal chemistry, Jan-01, Volume: 20, Issue:1
Synthesis, antiproliferative activity and genotoxicity of novel anthracene-containing aminophosphonates and a new anthracene-derived Schiff base.
AID115706Inhibitory activity against human lung adenocarcinoma xenograft A-549 and the ratio of the number of mice at the initial stage and the final stage of the experiment was reported at a dose of 0.2 ml/mouse (Q2dx9) administered i.p.; 10/101999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID1717205Cytotoxicity against human GES1 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay2020European journal of medicinal chemistry, Jan-15, Volume: 186Novel diosgenin derivatives containing 1,3,4-oxadiazole/thiadiazole moieties as potential antitumor agents: Design, synthesis and cytotoxic evaluation.
AID303273Cytotoxicity against human HT29 cells at 10 uM after 48 hrs2007Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
Cytotoxic and apoptotic activities of novel amino analogues of boswellic acids.
AID89626The compound was evaluated for the cytotoxicity against human SKOV-3 (ovarian) tumor cell lines.2000Bioorganic & medicinal chemistry letters, Feb-07, Volume: 10, Issue:3
Chemical synthesis and cytotoxicity of some azinomycin analogues devoid of the 1-azabicyclo[3.1.0]hexane subunit.
AID1853136Effect on DNA damage repair in Caulobacter vibrioides lacking recA expression and expressing Gam-GFP reporter system assessed as fold increase in double stranded break by measuring Gam localization in cells at 0.5 ug/ml and measured after 2 hrs by fluores2022RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12
Mechanistic insight into the repair of C8-linked pyrrolobenzodiazepine monomer-mediated DNA damage.
AID1303013Cytotoxicity against human A549 cells2016European journal of medicinal chemistry, Jul-19, Volume: 117Design, synthesis and biological evaluation of diaziridinyl quinone isoxazole hybrids.
AID1302975Bactericidal activity against Staphylococcus aureus MLS16 MTCC 2940 after 24 hrs by serial dilution method2016European journal of medicinal chemistry, Jul-19, Volume: 117Design, synthesis and biological evaluation of diaziridinyl quinone isoxazole hybrids.
AID109975Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 0.2 ml/mouse (Q2dx10) administered i.p.; 21.4/23.51999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID320495Cytotoxicity against human A549 cells after 72 hrs2008Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4
Synthesis, metal ion binding, and biological evaluation of new anticancer 2-(2'-hydroxyphenyl)benzoxazole analogs of UK-1.
AID1505058Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay2018Journal of natural products, 01-26, Volume: 81, Issue:1
Germacrane-Type Sesquiterpenoids with Antiproliferative Activities from Eupatorium chinense.
AID231378Ratio value, Optimal dose / Minimum effective dose1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Mitomycin C analogues with increased metal complexing ability.
AID638414Anticancer activity against human COLO205 cells assessed as growth inhibition at 50 uM after 48 hrs by SRB assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Acyl derivatives of boswellic acids as inhibitors of NF-κB and STATs.
AID775721Cytotoxicity against human HeLa cells after 48 hrs by SRB assay2013European journal of medicinal chemistry, Nov, Volume: 69β-Ionone derived chalcones as potent antiproliferative agents.
AID644104Growth inhibition of human PC3 cells at 1 uM after 48 hrs by sulpharhodamine B assay2012European journal of medicinal chemistry, Mar, Volume: 49Bakuchiol derivatives as novel and potent cytotoxic agents: a report.
AID355580Antiproliferative activity against human HT-29 cells at 1 ug after 48 hrs by two-layer agar-diffusion method
AID121615Activity of compound dose of 4 mg/kg/day against Murine B-16 Melanocarcinoma in mice1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Development of new mitomycin C and porfiromycin analogues.
AID94811In vitro inhibitory activity against K562 leukemia cells2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Mitomycin antitumor compounds. 2. Interaction of transition metal ions with mitomycin C. Solution structure and biological activity of a Pd(2+)-MMC complex.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1243849Mutagenicity in Salmonella typhimurium TA102 assessed as mutagenicity index at 0.5 ug/plate incubated for 90 mins at 37 degC in absence of liver S9 fractions by Ames test relative to control2015European journal of medicinal chemistry, Aug-28, Volume: 101Leishmanicidal, antiproteolytic, and mutagenic evaluation of alkyltriazoles and alkylphosphocholines.
AID216748Inhibitory concentration required to kill 50% of the cells was evaluated under anaerobic (N2) conditions from chinese hamster V79 cells.1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Cyclopropamitosenes, novel bioreductive anticancer agents. Synthesis, electrochemistry, and biological activity of 7-substituted cyclopropamitosenes and related indolequinones.
AID303288Cytotoxicity against human Fb cells assessed as cell viability by tryptan blue staining method2007Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
Stereoselective synthesis and cytotoxicity of a cancer chemopreventive naphthoquinone from Tabebuia avellanedae.
AID98100Median survival time against L1210 murine leukemia at 6 mg/kg in mice when compared with control1981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
Synthesis and antineoplastic activity of mitosene analogues of the mitomycins.
AID397761Cytotoxicity against human colon cancer cells2001Journal of natural products, Jul, Volume: 64, Issue:7
In vitro cytotoxicity of the protoberberine-type alkaloids.
AID1570618Mutagenicity in Salmonella typhimurium TA102 at 0.5 ug/plate preincubated for 20 mins followed by addition of top agar and measured after 48 hrs by Ames test2019Bioorganic & medicinal chemistry letters, 11-01, Volume: 29, Issue:21
Design, synthesis and evaluation of activity and pharmacokinetic profile of new derivatives of xanthone and piperazine in the central nervous system.
AID1134761Induction of lambda phage production in streptomycin-dependent lysogenic Escherichia coli W1709 (lambda) assessed as ratio of plaques in treated culture to control at 0.2 ug/ml1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Mitomycin antibiotics. Synthesis of 7-methoxy-1-(N-pyrrolidino)mitosene and its methiodide.
AID1254427Induction of DNA modifying activity in human Jurkat cells assessed as increase in DNA-protein crosslink at 100 uM under aerobic condition by K-SDS assay (Rvb = 4.5. +/- 1.5%)2015Bioorganic & medicinal chemistry, Dec-01, Volume: 23, Issue:23
Modification of cellular DNA by synthetic aziridinomitosenes.
AID153525Antitumor activity against P388/ADR cells in ip implanted CDF1 mice, qd 1-9 measured as optimal dose1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Enantiomers of 7-(2,3-epoxypropoxy)actinomycin D as dual-action DNA-acting antitumor agents.
AID667185Antiproliferative activity against human DaOY cells after 6 days by MTT assay2012Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13
A new 9,11-secosterol from the soft coral Sinularia granosa.
AID735827Antiproliferative activity against human HT1080 cells assessed as inhibition of cell proliferation after 72 hrs by CCK8 assay2013Journal of natural products, Apr-26, Volume: 76, Issue:4
Structural investigation and biological activity of sesquiterpene lactones from the traditional Chinese herb Inula racemosa.
AID1149674Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as mouse survival at 0.4 mg/kg/day administered qd on day 1 and 5 measured on day 51977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Comparative stereochemistry in the aziridine ring openings of N-methylmitomycin A and 7-methoxy-1,2-(N-methylaziridino)mitosene.
AID1134766Toxicity in streptomycin-dependent lysogenic Escherichia coli W1709 (lambda) at 0.5 ug/ml1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Mitomycin antibiotics. Synthesis of 7-methoxy-1-(N-pyrrolidino)mitosene and its methiodide.
AID210136Concentration of compound required for cross linking 50% of T-7 DNA, Na2S2O42004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Mitomycin dimers: polyfunctional cross-linkers of DNA.
AID153531Antitumor activity measured as %ILS against P388/ADR cells in ip implanted CDF1 mice, qd 1-91988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Enantiomers of 7-(2,3-epoxypropoxy)actinomycin D as dual-action DNA-acting antitumor agents.
AID1649634Cytotoxicity against MDCK cells assessed as cell growth at 20 uM measured after 72 hrs by cellTiter 96 AQueous non-radioactive cell proliferation assay relative to control2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Optimizing Pyrazolopyrimidine Inhibitors of Calcium Dependent Protein Kinase 1 for Treatment of Acute and Chronic Toxoplasmosis.
AID389718Cell cycle arrest in human HCT8 cells in hypoxic condition assessed as accumulation at G2/M phase at 10 uM after 24 hrs by flow cytometry2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Synthesis of new pyrazolo[5,1-c][1,2,4] benzotriazines, pyrazolo[5,1-c]pyrido[4,3-e][1,2,4] triazines and their open analogues as cytotoxic agents in normoxic and hypoxic conditions.
AID37914Average weight change after ip administration in B-16 melanoma in mice (dose mg/kg/day)1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Mitomycin C and porfiromycin analogues with substituted ethylamines at position 7.
AID109973Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 0.2 ml/mouse (Q2dx10) administered i.p.1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID1378414Antibacterial activity against methicillin-resistant Staphylococcus aureus subsp. aureus Rosenbach 18842017European journal of medicinal chemistry, Sep-29, Volume: 138Topological pattern for the search of new active drugs against methicillin resistant Staphylococcus aureus.
AID451336Antiproliferative activity against human Hs888Lu cells after 72 hrs by trypan blue exclusion assay2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Synthesis and evaluation of bioactive naphthoquinones from the Brazilian medicinal plant, Tabebuia avellanedae.
AID1853128Effect on DNA damage repair in Caulobacter vibrioides lacking recF expression assessed as decrease in cell survival rate upto 1 ug/ml and measured after 2 days by agar dilution method2022RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12
Mechanistic insight into the repair of C8-linked pyrrolobenzodiazepine monomer-mediated DNA damage.
AID693017Genotoxicity in human lymphocytes assessed as micronucleated binucleate cells level at 0.08 ug/mL incubated for 3 hrs measured post 21 hrs recovery in absence of rat liver S9 fraction (Rvb = 0.60%)2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
1-Aryl-4-nitro-1H-imidazoles, a new promising series for the treatment of human African trypanosomiasis.
AID101236The compound was evaluated for survival of L1210 cells, when compound was exposed for a period of 1 hr 1X (10e -5)M conc1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Nucleotide derivatives of 2,7-diaminomitosene.
AID320494Cytotoxicity against human A549 cells after 24 hrs2008Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4
Synthesis, metal ion binding, and biological evaluation of new anticancer 2-(2'-hydroxyphenyl)benzoxazole analogs of UK-1.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID459270Growth inhibition of human Raji cells after 24 to 72 hrs by MTT assay2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
New pterocarpanquinones: synthesis, antineoplasic activity on cultured human malignant cell lines and TNF-alpha modulation in human PBMC cells.
AID90128Antitumor potency on human breast MCF-7 cell lines.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Structure-activity relationships for mitomycin C and mitomycin A analogues.
AID1649663Cytotoxicity against human SH-SY5Y cells assessed as cell growth at 20 uM measured after 72 hrs by cellTiter 96 AQueous non-radioactive cell proliferation assay relative to control2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Optimizing Pyrazolopyrimidine Inhibitors of Calcium Dependent Protein Kinase 1 for Treatment of Acute and Chronic Toxoplasmosis.
AID397763Cytotoxicity against human ovarian cancer cells2001Journal of natural products, Jul, Volume: 64, Issue:7
In vitro cytotoxicity of the protoberberine-type alkaloids.
AID109988Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 2.0 mg/kg (Q2dx10) administered i.p.1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID99173Cross resistance profile versus L1210/R71 cells.1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Structure-activity relationships of antineoplastic agents in multidrug resistance.
AID1134753Antibacterial activity against Bacillus subtilis assessed as growth inhibition at 16.6 ug/ml in 100 mm disk at pH 8.0 by single-disk method1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Mitomycin antibiotics. Synthesis of 7-methoxy-1-(N-pyrrolidino)mitosene and its methiodide.
AID718400Cytotoxicity against human A549 cells after 72 hrs by alamar blue assay2012Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24
Synthesis and docking studies of novel antitumor benzimidazoles.
AID1570608Mutagenicity in Salmonella typhimurium TA100 at 0.5 ug/plate preincubated for 20 mins followed by addition of top agar and measured after 48 hrs by Ames test2019Bioorganic & medicinal chemistry letters, 11-01, Volume: 29, Issue:21
Design, synthesis and evaluation of activity and pharmacokinetic profile of new derivatives of xanthone and piperazine in the central nervous system.
AID1065303Cytotoxicity against human A549 cells after 48 hrs by MTT assay2013European journal of medicinal chemistry, Aug, Volume: 66Diversity-oriented synthesis of α-aminophosphonates: a new class of potential anticancer agents.
AID718247Downregulation of uPA protein expression in human A549 cell extract at 0.20 uM after 48 hrs by ELISA (Rvb = 11.0000 +/-1.60 ng/ml)2012Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24
Synthesis and docking studies of novel antitumor benzimidazoles.
AID359197Cytotoxicity against Aedes albopictus C6/36 cells after 24 hrs by MTT assay2001Journal of natural products, Mar, Volume: 64, Issue:3
Potent antiviral potamogetonyde and potamogetonol, new furanoid labdane diterpenes from Potamogeton malaianus.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID57470Inhibitory activity against dihydrofolate reductase (DHFR) isolated from murine L5178Y tumor cells resistant and sensitive to methotrexate1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Comparative structure-activity relationships of antifolate triazines inhibiting murine tumor cells sensitive and resistant to methotrexate.
AID97544Average change in weight between treated and control groups at 1.5 mg/kg in mice infected with L1210 leukemia cells1981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
Synthesis and antineoplastic activity of mitosene analogues of the mitomycins.
AID376601Cytotoxicity against human Hepa cells after 72 hrs2006Journal of natural products, Apr, Volume: 69, Issue:4
Xenicane-type diterpenes with cytotoxicity from Xenia florida.
AID303286Cytotoxicity against human A549 cells assessed as cell viability by tryptan blue staining method2007Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
Stereoselective synthesis and cytotoxicity of a cancer chemopreventive naphthoquinone from Tabebuia avellanedae.
AID389711Effect on cell cycle arrest in human HCT8 cells in normoxic condition assessed as DNA fragmentation at 10 uM after 48 hrs of drug washout by flow cytometry2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Synthesis of new pyrazolo[5,1-c][1,2,4] benzotriazines, pyrazolo[5,1-c]pyrido[4,3-e][1,2,4] triazines and their open analogues as cytotoxic agents in normoxic and hypoxic conditions.
AID1149667Toxicity in CDF1 mouse allografted with mouse P388 cells assessed as change in weight at 0.4 mg/kg/day administered qd on day 1 and 5 (Rvb = 3.4 g)1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Comparative stereochemistry in the aziridine ring openings of N-methylmitomycin A and 7-methoxy-1,2-(N-methylaziridino)mitosene.
AID111268Effect of compound on total white blood cell count in BDG1 male mice, after intraperitoneal administration at a dose of 5.63 mg/kg on day 51981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Development of new mitomycin C and porfiromycin analogues.
AID303272Cytotoxicity against human 502713 cells at 10 uM after 48 hrs2007Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
Cytotoxic and apoptotic activities of novel amino analogues of boswellic acids.
AID103403In vitro cytotoxicity of compound against MCF7, human breast cancer was defined by microculture tetrazolium assay2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Antitumor activity of novel deoxoartemisinin monomers, dimers, and trimer.
AID389706Cell cycle arrest in human HCT8 cells in normoxic condition assessed as accumulation at G2/M phase at 10 uM after 24 hrs by flow cytometry2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Synthesis of new pyrazolo[5,1-c][1,2,4] benzotriazines, pyrazolo[5,1-c]pyrido[4,3-e][1,2,4] triazines and their open analogues as cytotoxic agents in normoxic and hypoxic conditions.
AID101238The compound was evaluated for survival of L1210 cells, when compound was exposed for a period of 1 hr 1X (10e -7)Mconc1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Nucleotide derivatives of 2,7-diaminomitosene.
AID1869706Cytotoxicity against human HeLa S3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay2022Journal of natural products, 07-22, Volume: 85, Issue:7
Structure Revision of Trichomide D by Total Synthesis.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID459268Growth inhibition of human HL60 cells after 72 hrs by MTT assay2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
New pterocarpanquinones: synthesis, antineoplasic activity on cultured human malignant cell lines and TNF-alpha modulation in human PBMC cells.
AID95332In vitro cytotoxicity expressed as conc. that inhibits 50% of KB (human) cell proliferation2001Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22
Synthesis and cytotoxicity on sensitive and doxorubicin-resistant cell lines of new pyrrolo[2,1-c][1,4]benzodiazepines related to anthramycin.
AID1130145Antileukemic activity against mouse L1210 cells allografted in BDF1 mouse assessed as concentration required to give maximum increase in life span administered as continuous injection1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Quantitative structure-activity relationships in 2,5-bis(1-aziridinyl)-p-benzoquinone derivatives against leukemia L-1210.
AID1853127Effect on DNA damage repair in Caulobacter vibrioides assessed as fold change as increase in rifampicin resistance colonies at 2 ug/ml incubated for 0.5 hrs followed by culture in new media and treated with rifampicin and measured after 48 hrs by colony f2022RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12
Mechanistic insight into the repair of C8-linked pyrrolobenzodiazepine monomer-mediated DNA damage.
AID635955Growth inhibition of human A549 cells at 10 uM by sulforhodamine B assay2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
2-Anilinonicotinyl linked 2-aminobenzothiazoles and [1,2,4]triazolo[1,5-b] [1,2,4]benzothiadiazine conjugates as potential mitochondrial apoptotic inducers.
AID217041In vitro concentration required to kill hypoxic cells V79-379A cells1997Journal of medicinal chemistry, Jul-18, Volume: 40, Issue:15
2-Cyclopropylindoloquinones and their analogues as bioreductively activated antitumor agents: structure-activity in vitro and efficacy in vivo.
AID402671Cytotoxicity against human MCF7 cells after 3 days by SRB assay2005Journal of natural products, Jul, Volume: 68, Issue:7
Cytotoxic activity of some natural and synthetic guaianolides.
AID228639Concentration of compound required for cross linking 5% of tyrT DNA, Na2S2O42004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Mitomycin dimers: polyfunctional cross-linkers of DNA.
AID1446341Growth inhibition of human HEC6 cells after 72 hrs by Cell-Titer Glo assay2017Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15
Conformation-Based Design and Synthesis of Apratoxin A Mimetics Modified at the α,β-Unsaturated Thiazoline Moiety.
AID552867Cytotoxicity against human HeLa cells after 3 days by MTT assay2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Biologically active constituents from the fruiting body of Taiwanofungus camphoratus.
AID442567Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Cytotoxic activity of 3-(5-phenyl-3H-[1,2,4]dithiazol-3-yl)chromen-4-ones and 4-oxo-4H-chromene-3-carbothioic acid N-phenylamides.
AID101239The compound was evaluated for survival of L1210 cells, when compound was exposed for a period of 1 hr 5*(10e -5)M conc1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Nucleotide derivatives of 2,7-diaminomitosene.
AID263756Antitumor activity against human Bcap37 cell line by MTT assay2006Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8
Novel skeleton terpenes from Celastrus hypoleucus with anti-tumor activities.
AID1134763Induction of lambda phage production in streptomycin-dependent lysogenic Escherichia coli W1709 (lambda) assessed as ratio of plaques in treated culture to control at 0.0125 ug/ml1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Mitomycin antibiotics. Synthesis of 7-methoxy-1-(N-pyrrolidino)mitosene and its methiodide.
AID229557Ratio of IC50 against chinese hamster V79 cells in aerobic and anaerobic conditions1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Cyclopropamitosenes, novel bioreductive anticancer agents. Synthesis, electrochemistry, and biological activity of 7-substituted cyclopropamitosenes and related indolequinones.
AID401378Cytotoxicity against human HeLa cells after 3 days by methylene blue assay1998Journal of natural products, Jun-26, Volume: 61, Issue:6
A new taxane diterpenoid from Taxus mairei.
AID153918Maximum % T/C against P-388 murine leukemia cells in mice.1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Mitomycin C and porfiromycin analogues with substituted ethylamines at position 7.
AID229743Hypersensitivity factor (HF) of IC50 (AA8) / IC50 (UV-5) of compound for repair deffective mutants1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Hypoxia-selective antitumor agents. 2. Electronic effects of 4-substituents on the mechanisms of cytotoxicity and metabolic stability of nitracrine derivatives.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID303290Cytotoxicity against human MPC5 cells assessed as cell viability by tryptan blue staining method2007Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
Stereoselective synthesis and cytotoxicity of a cancer chemopreventive naphthoquinone from Tabebuia avellanedae.
AID1254423Induction of DNA modifying activity in human Jurkat cells assessed as tail extent moments at 10 uM under aerobic condition by alkaline comet assay in presence of 100 uM H2O22015Bioorganic & medicinal chemistry, Dec-01, Volume: 23, Issue:23
Modification of cellular DNA by synthetic aziridinomitosenes.
AID133089Minimum effective dose (MED) of compound against P388 Leukemia in mice was determined1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Conformations of complexes between mitomycins and decanucleotides. 3. Sequence specificity, binding at C-10, and mitomycin analogues.
AID1302979Antibiofilm activity against Staphylococcus aureus MTCC 96 after 24 hrs by crystal violet staining based assay2016European journal of medicinal chemistry, Jul-19, Volume: 117Design, synthesis and biological evaluation of diaziridinyl quinone isoxazole hybrids.
AID1243436Toxicity in 2-Gy gamma irradiated human PBL assessed as cytokinesis-block proliferation index at 3 uM treated for 2 to 19 hrs followed by compound washout measured after 72 hrs (Rvb = 1.6 +/- 0.1 No_unit)2015Journal of natural products, Sep-25, Volume: 78, Issue:9
Phenolic Compounds from Atriplex littoralis and Their Radiation-Mitigating Activity.
AID337077Cytotoxicity against human A549 cells2003Journal of natural products, Mar, Volume: 66, Issue:3
Three new cytotoxic sesterterpenes from a marine sponge Spongia sp.
AID1134752Antibacterial activity against Bacillus subtilis assessed as growth inhibition at 50 ug/ml in 100 mm disk at pH 8.0 by single-disk method1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Mitomycin antibiotics. Synthesis of 7-methoxy-1-(N-pyrrolidino)mitosene and its methiodide.
AID1155390Cytotoxicity against human HCT15 cells after 48 hrs by sulforhodamine B assay2014European journal of medicinal chemistry, Jul-23, Volume: 82Design and synthesis of novel 1,2,3-triazole derivatives of coronopilin as anti-cancer compounds.
AID389714Cell cycle arrest in human HCT8 cells in hypoxic condition assessed as accumulation at G0/G1 phase at 10 uM after 48 hrs of drug washout by flow cytometry2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Synthesis of new pyrazolo[5,1-c][1,2,4] benzotriazines, pyrazolo[5,1-c]pyrido[4,3-e][1,2,4] triazines and their open analogues as cytotoxic agents in normoxic and hypoxic conditions.
AID542130Induction of qnrA1 gene expression in lexA- and recA- positive Escherichia coli J53 at 0.2 ug/ml after 30 mins by quantitative PCR method relative to control2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
SOS regulation of qnrB expression.
AID775723Cytotoxicity against human PC3 cells after 48 hrs by SRB assay2013European journal of medicinal chemistry, Nov, Volume: 69β-Ionone derived chalcones as potent antiproliferative agents.
AID621742Antitumor activity against mouse EAC cells transplanted in Swiss albino mouse assessed as tumor cell inhibition in ascetic fluid at 1 mg/kg, ip administered qd for 7 days measured on 8th day2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
2,5-Disubstituted-1,3,4-oxadiazoles/thiadiazole as surface recognition moiety: design and synthesis of novel hydroxamic acid based histone deacetylase inhibitors.
AID363581Clastogenic effect on C57BL mouse assessed as number of metaphase chromosomal fragments in bone marrow cells at 3.5 mg/kg, ip after 24 hrs2008European journal of medicinal chemistry, Jun, Volume: 43, Issue:6
Novel N-(phosphonomethyl) glycine derivatives: Design, characterization and biological activity.
AID201876Antitumor activity against SW1271 human lung carcinoma cell line1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
New 2-substituted indoloquinone mitomycin analogues.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID38192Tumor free survivors on 62nd day after ip administration of a dose of 2 mg/kg/day in B-16 melanoma in mice1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Mitomycin C analogues with secondary amines at position 7.
AID1732033Induction of DNA damage in human Jurkat cells at 200 nM incubated for 48 hrs by EB staining based analysis2021European journal of medicinal chemistry, Mar-15, Volume: 214Novel diaryl-2H-azirines: Antitumor hybrids for dual-targeting tubulin and DNA.
AID389721Effect on cell cycle arrest in human HCT8 cells in hypoxic condition assessed as DNA fragmentation at 10 uM after 24 hrs by flow cytometry2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Synthesis of new pyrazolo[5,1-c][1,2,4] benzotriazines, pyrazolo[5,1-c]pyrido[4,3-e][1,2,4] triazines and their open analogues as cytotoxic agents in normoxic and hypoxic conditions.
AID120660Number of tumored survivors, 45 days after administration of compound at a dose of 1 mg/kg/day in mice1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Development of new mitomycin C and porfiromycin analogues.
AID95061Compound was tested for antitumor activity against L-1210 Murine leukemia in BDF1 female mice at a dose of 1.5 mg/kg per injection1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Preparation and antitumor activity of 7-substituted 1,2-aziridinomitosenes.
AID354542Inhibition of tubulin polymerization in rat C6 cells at 50 ug/mL to 2.5 mg/mL after 4 hrs1996Journal of natural products, Dec, Volume: 59, Issue:12
Cell-based screen for identification of inhibitors of tubulin polymerization.
AID638415Anticancer activity against human Hep2 cells assessed as growth inhibition at 50 uM after 48 hrs by SRB assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Acyl derivatives of boswellic acids as inhibitors of NF-κB and STATs.
AID137206Antitumor activity against P388 mouse leukemia as maximum and median survival time as % T/C was reported at a dose of 4.8 mg/Kg per injection.1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Synthesis and biological activity of 6-substituted mitosene analogues of the mitomycins.
AID1616075Cytotoxicity against human Caco2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay2019Journal of natural products, 09-27, Volume: 82, Issue:9
Yangpumicins F and G, Enediyne Congeners from
AID1254412Antiproliferative activity against human Jurkat T cells in hypoxic condition after 48 hrs by resazurin reduction assay2015Bioorganic & medicinal chemistry, Dec-01, Volume: 23, Issue:23
Modification of cellular DNA by synthetic aziridinomitosenes.
AID1130146Chemotherapeutic index, ratio of antileukemic activity against mouse L1210 cells allografted in BDF1 mouse assessed as concentration required to give maximum increase in life span administered as continuous injection to antileukemic activity against mouse1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Quantitative structure-activity relationships in 2,5-bis(1-aziridinyl)-p-benzoquinone derivatives against leukemia L-1210.
AID150952In vitro cytotoxicity of compound against P388, mouse fibroblast leukemia was defined by microculture tetrazolium assay2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Antitumor activity of novel deoxoartemisinin monomers, dimers, and trimer.
AID442570Growth inhibition of human Hep2 cells after 48 hrs by sulforhodamine B assay2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Cytotoxic activity of 3-(5-phenyl-3H-[1,2,4]dithiazol-3-yl)chromen-4-ones and 4-oxo-4H-chromene-3-carbothioic acid N-phenylamides.
AID459267Growth inhibition of human K562 cells after 24 to 72 hrs by MTT assay2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
New pterocarpanquinones: synthesis, antineoplasic activity on cultured human malignant cell lines and TNF-alpha modulation in human PBMC cells.
AID8284Antitumor activity against A549 human lung carcinoma cell line in experiment 21989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
New 2-substituted indoloquinone mitomycin analogues.
AID1320136Cytotoxicity against CHL cells assessed as chromatid gap at 0.05 ug/ml preincubated for 6 hrs followed by 18 hrs incubation in fresh medium in absence of S9 fraction by Giemsa-staining-based microscopic analysis2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Phosphonate-based irreversible inhibitors of human γ-glutamyl transpeptidase (GGT). GGsTop is a non-toxic and highly selective inhibitor with critical electrostatic interaction with an active-site residue Lys562 for enhanced inhibitory activity.
AID659405Cytotoxicity against human HeLa cells assessed as reduction in mean cell viability after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10
COMPARE analysis of the toxicity of an iminoquinone derivative of the imidazo[5,4-f]benzimidazoles with NAD(P)H:quinone oxidoreductase 1 (NQO1) activity and computational docking of quinones as NQO1 substrates.
AID1061801Cytotoxicity against human HeLa cells assessed as growth inhibition at 10 uM by SRB assay2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Synthesis of a novel series of artemisinin dimers with potent anticancer activity involving Sonogashira cross-coupling reaction.
AID123710Ratio of the tumor weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 0.2 ml/mouse (Q2dx10) administered i.p.; 10/101999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID1853130Effect on DNA damage repair in Caulobacter vibrioides lacking recR expression assessed as decrease in cell survival rate upto 1 ug/ml and measured after 2 days by agar dilution method2022RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12
Mechanistic insight into the repair of C8-linked pyrrolobenzodiazepine monomer-mediated DNA damage.
AID1302982Antibiofilm activity against Klebsiella planticola MTCC 530 after 24 hrs by crystal violet staining based assay2016European journal of medicinal chemistry, Jul-19, Volume: 117Design, synthesis and biological evaluation of diaziridinyl quinone isoxazole hybrids.
AID80662Inhibitory activity against H2987, human lung adenocarcinoma cell line in absence of Enterobacter cloacae bL1997Journal of medicinal chemistry, Aug-15, Volume: 40, Issue:17
Immunologically specific activation of a cephalosporin derivative of mitomycin C by monoclonal antibody beta-lactamase conjugates.
AID263757Antitumor activity against human RKO cell line by MTT assay2006Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8
Novel skeleton terpenes from Celastrus hypoleucus with anti-tumor activities.
AID363584Clastogenic effect on C57BL mouse assessed as bone marrow cells with abberation at 3.5 mg/kg, ip after 24 hrs2008European journal of medicinal chemistry, Jun, Volume: 43, Issue:6
Novel N-(phosphonomethyl) glycine derivatives: Design, characterization and biological activity.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID123449Anti cancer activity was tested on day 14, in mice bearing Lewis lung adenocarcinoma by injecting 0.8 mg/kg dose of compound intraperitoneally and average tumor volume was calculated.1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Cyclopent[a]anthraquinones as DNA intercalating agents with covalent bond formation potential: synthesis and biological activity.
AID393857Anticancer activity against mouse EAC cells xenografted in Swiss albino mouse assessed as inhibition of ascitic cell count at 1 mg/kg2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Possible anticancer agents: QSAR analogs of glutamamide: synthesis and pharmacological activity of 1,5-N,N'-disubstituted-2-(substituted benzenesulphonyl) glutamamides.
AID1254426Induction of DNA modifying activity in human Jurkat cells assessed as increase in amount of crosslink DNA at 10 uM for 1 hr under hypoxic condition by Hoechst-33342 staining based fluorescence assay2015Bioorganic & medicinal chemistry, Dec-01, Volume: 23, Issue:23
Modification of cellular DNA by synthetic aziridinomitosenes.
AID1149658Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as effect on median survival time at 1.6 mg/kg/day administered qd on day 1 and 5 relative to control1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Comparative stereochemistry in the aziridine ring openings of N-methylmitomycin A and 7-methoxy-1,2-(N-methylaziridino)mitosene.
AID1149659Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as effect on median survival time at 0.8 mg/kg/day administered qd on day 1 and 5 relative to control1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Comparative stereochemistry in the aziridine ring openings of N-methylmitomycin A and 7-methoxy-1,2-(N-methylaziridino)mitosene.
AID91260The compound was evaluated for the cytotoxicity against human A2780cisR (ovarian) tumor cell lines.2000Bioorganic & medicinal chemistry letters, Feb-07, Volume: 10, Issue:3
Chemical synthesis and cytotoxicity of some azinomycin analogues devoid of the 1-azabicyclo[3.1.0]hexane subunit.
AID123455Anti cancer activity was tested on day 14, in mice bearing Lewis lung adenocarcinoma by injecting 0.4 mg/kg dose of compound intraperitoneally and average weight change was reported.1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Cyclopent[a]anthraquinones as DNA intercalating agents with covalent bond formation potential: synthesis and biological activity.
AID389699Cytotoxicity against human HCT8 cells after 72 hrs by SRB assay2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Synthesis of new pyrazolo[5,1-c][1,2,4] benzotriazines, pyrazolo[5,1-c]pyrido[4,3-e][1,2,4] triazines and their open analogues as cytotoxic agents in normoxic and hypoxic conditions.
AID38195Tumor free survivors on 62nd day after ip administration of a dose of 4 mg/kg/day in B-16 melanoma in mice1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Mitomycin C analogues with secondary amines at position 7.
AID1254410Antiproliferative activity against human HUT78 cells after 48 hrs by resazurin reduction assay2015Bioorganic & medicinal chemistry, Dec-01, Volume: 23, Issue:23
Modification of cellular DNA by synthetic aziridinomitosenes.
AID228712E1/2 value related to the saturated calomal electrode.1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Mitomycin C analogues with secondary amines at position 7.
AID1446340Growth inhibition of human SKOV3 cells after 72 hrs by Cell-Titer Glo assay2017Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15
Conformation-Based Design and Synthesis of Apratoxin A Mimetics Modified at the α,β-Unsaturated Thiazoline Moiety.
AID1243462Radioprotective activity in 2-Gy gamma irradiated human PBL assessed as incidence of micronuclei in 1000 binucleated cells at 3 uM treated for 2 to 19 hrs followed by compound washout measured after 72 hrs by cytochalasin-B-blocked micronucleus assay (Rvb2015Journal of natural products, Sep-25, Volume: 78, Issue:9
Phenolic Compounds from Atriplex littoralis and Their Radiation-Mitigating Activity.
AID117388In vivo inhibitory activity against human lung adenocarcinoma xenograft A-549 in mice at a dose of 2.0 mg/kg (Q2dx10) administered i.p.1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID1853118Binding affinity to GC-rich 5'-fluoro and 3'-TAMRA tagged 5'-TAT-AGG-GAC-AGC-CCT-ATA-3' hairpin DNA (unknown origin) assessed as thermal stabilization by measuring change in melting temperature at 1 uM incubated for 24 hrs by FRET analysis2022RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12
Mechanistic insight into the repair of C8-linked pyrrolobenzodiazepine monomer-mediated DNA damage.
AID212880Hypoxic cytotoxic ratios of the concentration required to kill 50% of the aerobic cells and concentration required to kill hypoxic cells1997Journal of medicinal chemistry, Jul-18, Volume: 40, Issue:15
2-Cyclopropylindoloquinones and their analogues as bioreductively activated antitumor agents: structure-activity in vitro and efficacy in vivo.
AID248241Inhibitory concentration againstHuman Caki-1 Renal CellCarcinoma Cell Lines (CD70+) at 96th hour; n=142005Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5
Design, synthesis, and in vitro evaluation of dipeptide-based antibody minor groove binder conjugates.
AID123576Anti cancer activity was tested on day10, in mice bearing Lewis lung adenocarcinoma by injecting 0.8 mg/kg dose of compound intraperitoneally and average weight change was reported.1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Cyclopent[a]anthraquinones as DNA intercalating agents with covalent bond formation potential: synthesis and biological activity.
AID1454348Cytotoxicity against human DU145 cells incubated for 24 hrs by MTT asasy2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Synthesis and biological evaluation of 5-fatty-acylamido-1, 3, 4-thiadiazole-2-thioglycosides.
AID393856Anticancer activity against mouse EAC cells xenografted in Swiss albino mouse assessed as inhibition of ascitic fluid weight at 1 mg/kg2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Possible anticancer agents: QSAR analogs of glutamamide: synthesis and pharmacological activity of 1,5-N,N'-disubstituted-2-(substituted benzenesulphonyl) glutamamides.
AID678718Metabolic stability in human liver microsomes assessed as high signal/noise ratio (S/N of >100) by measuring GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID355578Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay
AID1149673Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as mouse survival at 0.8 mg/kg/day administered qd on day 1 and 5 measured on day 51977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Comparative stereochemistry in the aziridine ring openings of N-methylmitomycin A and 7-methoxy-1,2-(N-methylaziridino)mitosene.
AID128822Anti cancer activity was determined as effective dose1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Structure-activity relationships for mitomycins. Application of the distance and charge analysis method.
AID88850Antitumor potency on human ovarian 2780 cell lines.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Structure-activity relationships for mitomycin C and mitomycin A analogues.
AID364285Cytotoxicity against human HT29 cells after 72 hrs by MTT assay2008European journal of medicinal chemistry, Sep, Volume: 43, Issue:9
Synthesis and cytotoxicity evaluation of some benzimidazole-4,7-diones as bioreductive anticancer agents.
AID119960Optimal dose against sarcoma 180 tumor in ddY mice1994Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12
Synthesis and antitumor activity of novel 6-alkyl-6-demethylmitomycins.
AID26788Distribution between 1-octanol and water containing phosphate buffer at pH 7.41984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Mitomycin C analogues with aryl substituents on the 7-amino group.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID96793In vitro antitumor activity against L1210 lymphocytic leukemia tumor cell line was determined1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Synthesis, mechanism of action, and biological evaluation of mitosenes.
AID122585Activity of compound dose of 2 mg/kg/day against Murine B-16 Melanocarcinoma in mice1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Development of new mitomycin C and porfiromycin analogues.
AID1062116Cytotoxicity against human MDA-MB-231 cells overexpressing DT-diaphorase after 5 days2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
Synthesis and cytotoxicity of pyranonaphthoquinone natural product analogues under bioreductive conditions.
AID473259Anticancer activity against human PC3 cells assessed as cell growth inhibition at 10 uM after 48 hrs by SRB assay2010Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7
Solvent free synthesis, anti-inflammatory and anticancer activity evaluation of tricyclic and tetracyclic benzimidazole derivatives.
AID510379Cytotoxicity against human GM00637 cells after 72 hrs by MTT assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis and toxicity towards normal and cancer cell lines of benzimidazolequinones containing fused aromatic rings and 2-aromatic ring substituents.
AID320490Cytotoxicity against human MCF7 cells after 24 hrs2008Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4
Synthesis, metal ion binding, and biological evaluation of new anticancer 2-(2'-hydroxyphenyl)benzoxazole analogs of UK-1.
AID418211Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay2009Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5
Microwave-assisted synthesis of N-substituted cyclic imides and their evaluation for anticancer and anti-inflammatory activities.
AID1712218Cytotoxicity against Sprague-Dawley rat Cerebral cortex neuron assessed as LDH activity at 10 uM incubated for 24 hrs by LDH assay2016Bioorganic & medicinal chemistry, 07-15, Volume: 24, Issue:14
New bifunctional antioxidant/σ1 agonist ligands: Preliminary chemico-physical and biological evaluation.
AID335109Cytotoxicity against mouse P388 cells after 72 hrs by MTT assay1993Journal of natural products, Sep, Volume: 56, Issue:9
An antifungal bibenzyl from the New Zealand liverwort, Plagiochila stephensoniana. Bioactivity-directed isolation, synthesis, and analysis.
AID426952Cytotoxicity against human HL60 cells after 48 hrs by SRB assay2009Journal of natural products, Jun, Volume: 72, Issue:6
Vladimuliecins A and B: cytotoxic pentacyclic pregnanols from Vladimiria muliensis.
AID87730In vitro anticellular activity against HeLa S3 cells; 0.82-1.41994Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12
Synthesis and antitumor activity of novel mitomycin derivatives containing functional groups at the C-6-methyl position.
AID405950Cytotoxicity against BRCA2-deficient Chinese hamster V-C8 mutant cells after 3 days by WST1 cell viability assay2008Journal of natural products, Jun, Volume: 71, Issue:6
Marine natural product libraries for high-throughput screening and rapid drug discovery.
AID111420Effect of compound on total white blood cell count in BDG1 male mice, after intraperitoneal administration at a dose of 7.5 mg/kg on day 31981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Development of new mitomycin C and porfiromycin analogues.
AID1731994Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay2021European journal of medicinal chemistry, Mar-15, Volume: 214Novel diaryl-2H-azirines: Antitumor hybrids for dual-targeting tubulin and DNA.
AID1243449Radioprotective activity in 2-Gy gamma irradiated human PBL assessed as binucleated cells with micronuclei at 3 uM treated for 2 to 19 hrs followed by compound washout measured after 72 hrs by cytochalasin-B-blocked micronucleus assay (Rvb = 15.5 +/- 0.6%2015Journal of natural products, Sep-25, Volume: 78, Issue:9
Phenolic Compounds from Atriplex littoralis and Their Radiation-Mitigating Activity.
AID1162266Cytotoxicity against human PC3 cells after 48 hrs by SRB assay2014Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19
Synthesis and evaluation of 3-salicyloylpyridine derivatives as cytotoxic mitochondrial apoptosis inducers.
AID121603Activity of compound dose of 0.5 mg/kg/day against Murine B-16 Melanocarcinoma in mice1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Development of new mitomycin C and porfiromycin analogues.
AID364282Cytotoxicity against human HT29 cells after 72 hrs by MTT assay in presence of 2 uM dicoumarol2008European journal of medicinal chemistry, Sep, Volume: 43, Issue:9
Synthesis and cytotoxicity evaluation of some benzimidazole-4,7-diones as bioreductive anticancer agents.
AID635954Growth inhibition of human DU145 cells at 10 uM by sulforhodamine B assay2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
2-Anilinonicotinyl linked 2-aminobenzothiazoles and [1,2,4]triazolo[1,5-b] [1,2,4]benzothiadiazine conjugates as potential mitochondrial apoptotic inducers.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1853142Effect on DNA damage repair in Caulobacter vibrioides lacking uvrA expression and expressing Gam-GFP reporter system assessed as fold increase in double stranded break by measuring Gam localization in cells at 0.5 ug/ml and measured after 2 hrs by fluores2022RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12
Mechanistic insight into the repair of C8-linked pyrrolobenzodiazepine monomer-mediated DNA damage.
AID1254424Induction of DNA modifying activity in human Jurkat cells assessed as tail extent moments at 10 uM under hypoxic condition by alkaline comet assay in presence of 100 uM H2O22015Bioorganic & medicinal chemistry, Dec-01, Volume: 23, Issue:23
Modification of cellular DNA by synthetic aziridinomitosenes.
AID82843Inhibition of cell growth was studied in human promyelocytic leukemic (HL-60) cells.1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Cyclopent[a]anthraquinones as DNA intercalating agents with covalent bond formation potential: synthesis and biological activity.
AID1616077Cytotoxicity against human A549 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay2019Journal of natural products, 09-27, Volume: 82, Issue:9
Yangpumicins F and G, Enediyne Congeners from
AID1774826Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
AID1302973Bactericidal activity against Bacillus subtilis MTCC 121 after 24 hrs by serial dilution method2016European journal of medicinal chemistry, Jul-19, Volume: 117Design, synthesis and biological evaluation of diaziridinyl quinone isoxazole hybrids.
AID128585Body wieght treated/body weight untreated controls of compound (6 mg/kg) was evaluated in vivo for antitumor activity against MAC 16 in female NMRI mice on day 121989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Synthesis, mechanism of action, and biological evaluation of mitosenes.
AID132317Percent inhibition of compound (6 mg/kg) was evaluated in vivo for antitumor activity against MAC 13 in female NMRI mice on day 21989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Synthesis, mechanism of action, and biological evaluation of mitosenes.
AID115832Ratio of the number of mice at the initial stage and the final stage of the experiment was reported at a dose of 2.0 mg/kg (Q2dx10) administered i.p.1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID1854155Cytotoxicity against human HeLa cells2022European journal of medicinal chemistry, Aug-05, Volume: 238Cascade synthetic strategies opening access to medicinal-relevant aliphatic 3- and 4-membered N-heterocyclic scaffolds.
AID389719Cell cycle arrest in human HCT8 cells in hypoxic condition assessed as accumulation at G2/M phase at 10 uM after 24 hrs of drug washout by flow cytometry2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Synthesis of new pyrazolo[5,1-c][1,2,4] benzotriazines, pyrazolo[5,1-c]pyrido[4,3-e][1,2,4] triazines and their open analogues as cytotoxic agents in normoxic and hypoxic conditions.
AID389712Cell cycle arrest in human HCT8 cells in hypoxic condition assessed as accumulation at G0/G1 phase at 10 uM after 24 hrs by flow cytometry2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Synthesis of new pyrazolo[5,1-c][1,2,4] benzotriazines, pyrazolo[5,1-c]pyrido[4,3-e][1,2,4] triazines and their open analogues as cytotoxic agents in normoxic and hypoxic conditions.
AID459271Growth inhibition of human Jurkat cells after 24 to 72 hrs by MTT assay2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
New pterocarpanquinones: synthesis, antineoplasic activity on cultured human malignant cell lines and TNF-alpha modulation in human PBMC cells.
AID473422Anticancer activity against human SF295 cells assessed as cell growth inhibition at 10 uM after 48 hrs by SRB assay2010Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7
Solvent free synthesis, anti-inflammatory and anticancer activity evaluation of tricyclic and tetracyclic benzimidazole derivatives.
AID355583Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay
AID1267735Cytotoxicity against human PC3 cells after 72 hrs by CCK-8 assay2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
Total synthesis and cytotoxic activities of longamide B, longamide B methyl ester, hanishin, and their analogues.
AID461532Cytotoxicity against human MCF7 cells by MTT assay2010Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5
Cytotoxic and anti-inflammatory cembranoids from the Dongsha Atoll soft coral Sarcophyton crassocaule.
AID137201Antitumor activity against P388 mouse leukemia as maximum and median survival time as % T/C was reported at a dose of 0.4 mg/Kg per injection.1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Synthesis and biological activity of 6-substituted mitosene analogues of the mitomycins.
AID635956Growth inhibition of human Hep2 cells at 10 uM by sulforhodamine B assay2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
2-Anilinonicotinyl linked 2-aminobenzothiazoles and [1,2,4]triazolo[1,5-b] [1,2,4]benzothiadiazine conjugates as potential mitochondrial apoptotic inducers.
AID101212Inhibition of L1210 leukemia cells, after exposure to compound for period of 8-9 hr1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Nucleotide derivatives of 2,7-diaminomitosene.
AID1567340Cytotoxicity against CHOK1 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay2019European journal of medicinal chemistry, Sep-15, Volume: 178Synthesis and biological evaluation of 2,4,5-trisubstituted thiazoles as antituberculosis agents effective against drug-resistant tuberculosis.
AID111269Effect of compound on total white blood cell count in BDG1 male mice, after intraperitoneal administration at a dose of 5.63 mg/kg on day 71981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Development of new mitomycin C and porfiromycin analogues.
AID112767Antitumor activity against P388/ADR (adriamycin resistant tumors) in terms of % increase in life span in mice at an optimal dose of 3.0 ug/kg administered ip1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
"Reverse" and "symmetrical" analogues of actinomycin D: metabolic activation and in vitro and in vivo tumor growth inhibitory activities.
AID45745Inhibitory activity of compound for AA8 cells to reduce cell density by 50% (exposed to compound for 4 hours)1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Hypoxia-selective antitumor agents. 2. Electronic effects of 4-substituents on the mechanisms of cytotoxicity and metabolic stability of nitracrine derivatives.
AID123585Evaluated for antitumor activity against B-16 melanoma in mice at a dose 2 mg/kg day, ip, on days 1, 4, and 7 against B-16 Melanoma cell1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Mitomycin C analogues with aryl substituents on the 7-amino group.
AID1158651Cytotoxicity against human HeLa cells after 48 hrs by SRB method2014Journal of natural products, Jun-27, Volume: 77, Issue:6
Eremophilane-type sesquiterpenoids with diverse skeletons from Ligularia sagitta.
AID337076Cytotoxicity against human HeLa cells2003Journal of natural products, Mar, Volume: 66, Issue:3
Three new cytotoxic sesterterpenes from a marine sponge Spongia sp.
AID38199Median survival time (% T/C) after ip administration of a dose of 4 mg/kg/day inB-16 melanoma in mice1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Mitomycin C analogues with secondary amines at position 7.
AID633929Induction of clastogenic effect in ICR mouse bone marrow cells assessed as rearrangement in centromere to centromeric fusion at 3.5 mg/kg, ip after 24 hrs2012Bioorganic & medicinal chemistry, Jan-01, Volume: 20, Issue:1
Synthesis, antiproliferative activity and genotoxicity of novel anthracene-containing aminophosphonates and a new anthracene-derived Schiff base.
AID111110Effect of compound on total white blood cell count in BDG1 male mice, after intraperitoneal administration at a dose of 3.16 mg/kg on day 31981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Development of new mitomycin C and porfiromycin analogues.
AID137389Percent T/C (total/control) for antitumor activity against P388 Leukemia in CD2 mice at fractioned dose treatment of 1 mg/kg1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Synthesis, mechanism of action, and biological evaluation of mitosenes.
AID138973In vivo antitumor activity in mice at 1 mg/kg/day (dosing schedule Q1DX14)2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Indenopyrazoles as novel cyclin dependent kinase (CDK) inhibitors.
AID1717202Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay2020European journal of medicinal chemistry, Jan-15, Volume: 186Novel diosgenin derivatives containing 1,3,4-oxadiazole/thiadiazole moieties as potential antitumor agents: Design, synthesis and cytotoxic evaluation.
AID1470985Selectivity ratio of IC50 for NQO1 deficient human NCI-H596 cells to IC50 for human A549 cells2017European journal of medicinal chemistry, May-26, Volume: 132Design, synthesis, and biological evaluation of NAD(P)H: Quinone oxidoreductase (NQO1)-targeted oridonin prodrugs possessing indolequinone moiety for hypoxia-selective activation.
AID91259The compound was evaluated for the cytotoxicity against human A2780 (ovarian) tumor cell lines.2000Bioorganic & medicinal chemistry letters, Feb-07, Volume: 10, Issue:3
Chemical synthesis and cytotoxicity of some azinomycin analogues devoid of the 1-azabicyclo[3.1.0]hexane subunit.
AID409524Cytotoxicity against human WiDr cells by MTT assay2008Journal of natural products, Dec, Volume: 71, Issue:12
Cespihypotins Q-V, verticillene diterpenoids from Cespitularia hypotentaculata.
AID101241The compound was evaluated for survival of L1210 cells, when compound was exposed for a period of 8-9 h 1X (10e -7)M conc1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Nucleotide derivatives of 2,7-diaminomitosene.
AID337075Cytotoxicity against mouse L1210 cells2003Journal of natural products, Mar, Volume: 66, Issue:3
Three new cytotoxic sesterterpenes from a marine sponge Spongia sp.
AID112163Effective dose that gave 50 percent inhibition of sarcoma 180 tumor growth in ddY mice1994Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12
Synthesis and antitumor activity of novel 6-alkyl-6-demethylmitomycins.
AID209162Antiproliferative activity of compound was evaluated on SupT1 cells from human non-Hodgkin lymphoma2000Bioorganic & medicinal chemistry letters, Oct-02, Volume: 10, Issue:19
Synthesis and antiproliferative activity of some benzimidazole-4,7-dione derivatives.
AID735828Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by CCK8 assay2013Journal of natural products, Apr-26, Volume: 76, Issue:4
Structural investigation and biological activity of sesquiterpene lactones from the traditional Chinese herb Inula racemosa.
AID1774824Cytotoxicity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
AID635120Growth inhibition of human PC3 cells at 1 uM after 48 hrs by SRB assay2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
1,2,3-Triazole tethered β-lactam-chalcone bifunctional hybrids: synthesis and anticancer evaluation.
AID320491Cytotoxicity against human MCF7 cells after 72 hrs2008Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4
Synthesis, metal ion binding, and biological evaluation of new anticancer 2-(2'-hydroxyphenyl)benzoxazole analogs of UK-1.
AID1302967Antimicrobial activity against Staphylococcus aureus MLS16 MTCC 2940 after 24 hrs by well diffusion method2016European journal of medicinal chemistry, Jul-19, Volume: 117Design, synthesis and biological evaluation of diaziridinyl quinone isoxazole hybrids.
AID685156Growth inhibition of human MCF7 cells at 1 uM after 48 hrs by MTT assay2012European journal of medicinal chemistry, Oct, Volume: 56Synthesis, antimicrobial and cytotoxicity study of 1,3-disubstituted-1H-naphtho[1,2-e][1,3]oxazines.
AID1731992Antiproliferative activity against human A2780 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay2021European journal of medicinal chemistry, Mar-15, Volume: 214Novel diaryl-2H-azirines: Antitumor hybrids for dual-targeting tubulin and DNA.
AID1149654Toxicity in Escherichia coli W1709(lambda) at 0.2 ug/ml1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Comparative stereochemistry in the aziridine ring openings of N-methylmitomycin A and 7-methoxy-1,2-(N-methylaziridino)mitosene.
AID1853124Effect on DNA damage repair in Caulobacter vibrioides lacking DnaE2 expression assessed as decrease in cell survival rate upto 1 ug/ml and measured after 2 days by agar dilution method2022RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12
Mechanistic insight into the repair of C8-linked pyrrolobenzodiazepine monomer-mediated DNA damage.
AID111421Effect of compound on total white blood cell count in BDG1 male mice, after intraperitoneal administration at a dose of 7.5 mg/kg on day 51981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Development of new mitomycin C and porfiromycin analogues.
AID88791The compound was evaluated for the cytotoxicity against human CH1 (ovarian) tumor cell lines.2000Bioorganic & medicinal chemistry letters, Feb-07, Volume: 10, Issue:3
Chemical synthesis and cytotoxicity of some azinomycin analogues devoid of the 1-azabicyclo[3.1.0]hexane subunit.
AID373320Cytotoxicity against human MCF7 cells after 72 hrs by Alamar Blue assay2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
New transition metal ion complexes with benzimidazole-5-carboxylic acid hydrazides with antitumor activity.
AID128414Antitumor activity against P388 mouse leukemia as maximum and average change in body weight was reported at a dose of 0.2 mg/kg per injection.1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Synthesis and biological activity of 6-substituted mitosene analogues of the mitomycins.
AID1853140Effect on DNA damage repair in Caulobacter vibrioides lacking uvrA expression assessed as decrease in cell survival rate upto 1 ug/ml and measured after 2 days by agar dilution method2022RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12
Mechanistic insight into the repair of C8-linked pyrrolobenzodiazepine monomer-mediated DNA damage.
AID1616076Cytotoxicity against human Jurkat cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay2019Journal of natural products, 09-27, Volume: 82, Issue:9
Yangpumicins F and G, Enediyne Congeners from
AID674743Growth inhibition of human PC3 cells at 1 uM after 48 hrs by SRB assay2012European journal of medicinal chemistry, Sep, Volume: 55Azide-alkyne cycloaddition en route to novel 1H-1,2,3-triazole tethered isatin conjugates with in vitro cytotoxic evaluation.
AID356090Cytotoxicity against human KATO III cells by MTT assay2003Journal of natural products, Jul, Volume: 66, Issue:7
Cytotoxic diterpenes from Scoparia dulcis.
AID418216Cytotoxicity against human SK-N-SH cells after 48 hrs by SRB assay2009Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5
Microwave-assisted synthesis of N-substituted cyclic imides and their evaluation for anticancer and anti-inflammatory activities.
AID303271Cytotoxicity against human SW620 cells at 10 uM after 48 hrs2007Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
Cytotoxic and apoptotic activities of novel amino analogues of boswellic acids.
AID1374856Antiproliferative activity against human HeLa cells after 48 hrs by CCK8 assay2018Bioorganic & medicinal chemistry letters, 04-01, Volume: 28, Issue:6
Two new coumarins and a new xanthone from the leaves of Rhizophora mucronata.
AID137205Antitumor activity against P388 mouse leukemia as maximum and median survival time as % T/C was reported at a dose of 3.2 mg/Kg per injection.1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Synthesis and biological activity of 6-substituted mitosene analogues of the mitomycins.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1302974Bactericidal activity against Staphylococcus aureus MTCC 96 after 24 hrs by serial dilution method2016European journal of medicinal chemistry, Jul-19, Volume: 117Design, synthesis and biological evaluation of diaziridinyl quinone isoxazole hybrids.
AID227069Inhibition of HeLa S3 cell growth relative to mitomycin C action (ratio of IC50 values)1995Journal of medicinal chemistry, Aug-04, Volume: 38, Issue:16
Synthesis and antitumor activity of various 6-demethylmitomycins and 6-demethyl-6-halomitomycins.
AID138876Average weight change of BDF1 female mice at a dose of 12 mg/kg per injection1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Preparation and antitumor activity of 7-substituted 1,2-aziridinomitosenes.
AID134539In vivo antitumor activity in mice at 1 mg/kg/day (dosing schedule Q1DX14)2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Indenopyrazoles as novel cyclin dependent kinase (CDK) inhibitors.
AID389715Cell cycle arrest in human HCT8 cells in hypoxic condition assessed as accumulation at S phase at 10 uM after 24 hrs by flow cytometry2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Synthesis of new pyrazolo[5,1-c][1,2,4] benzotriazines, pyrazolo[5,1-c]pyrido[4,3-e][1,2,4] triazines and their open analogues as cytotoxic agents in normoxic and hypoxic conditions.
AID1061799Cytotoxicity against human MCF7 cells assessed as growth inhibition at 10 uM by SRB assay2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Synthesis of a novel series of artemisinin dimers with potent anticancer activity involving Sonogashira cross-coupling reaction.
AID1446338Growth inhibition of human MKN74 cells after 72 hrs by Cell-Titer Glo assay2017Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15
Conformation-Based Design and Synthesis of Apratoxin A Mimetics Modified at the α,β-Unsaturated Thiazoline Moiety.
AID210114In vitro cytotoxic activity against human breast cancer cell line T-47D after 72 hr of drug exposure determined by the SRB assay2004Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5
Synthesis and in vitro evaluation of 7-dialkylaminomethylbenzo[g]quinoxaline-5,10-diones.
AID104106In vitro cytotoxic activity against human breast cancer cell line MD-MB-468 after 72 hr of drug exposure determined by the SRB assay2004Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5
Synthesis and in vitro evaluation of 7-dialkylaminomethylbenzo[g]quinoxaline-5,10-diones.
AID91966In vitro anticancer activity against cultured 60 human tumor cell lines2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Mitomycin dimers: polyfunctional cross-linkers of DNA.
AID85760In vitro cytotoxicity of compound against HT29, human colorectal adenocarcinoma was defined by microculture tetrazolium assay2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Antitumor activity of novel deoxoartemisinin monomers, dimers, and trimer.
AID137200Antitumor activity against P388 mouse leukemia as maximum and median survival time as % T/C was reported at a dose of 0.2 mg/Kg per injection.1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Synthesis and biological activity of 6-substituted mitosene analogues of the mitomycins.
AID38196Median survival time (% T/C) after ip administration of a dose of 1 mg/kg/day in B-16 melanoma in mice1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Mitomycin C analogues with secondary amines at position 7.
AID1446342Growth inhibition of human 786-O cells after 72 hrs by Cell-Titer Glo assay2017Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15
Conformation-Based Design and Synthesis of Apratoxin A Mimetics Modified at the α,β-Unsaturated Thiazoline Moiety.
AID128420Antitumor activity against P388 mouse leukemia as maximum and average change in body weight was reported at a dose of 3.2 mg/kg per injection.1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Synthesis and biological activity of 6-substituted mitosene analogues of the mitomycins.
AID153919Maximum % T/C against P-388 murine leukemia cells in mice.1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Mitomycin C analogues with secondary amines at position 7.
AID288804Growth inhibition of Streptomyces 85E at 20 ug/disk by hyphae formation inhibition assay2007Journal of natural products, Jun, Volume: 70, Issue:6
Lemnalosides A-D, decalin-type bicyclic diterpene glycosides from the marine soft coral Lemnalia sp.
AID1570613Mutagenicity in Salmonella typhimurium TA98 at 0.5 ug/plate preincubated for 20 mins followed by addition of top agar and measured after 48 hrs by Ames test2019Bioorganic & medicinal chemistry letters, 11-01, Volume: 29, Issue:21
Design, synthesis and evaluation of activity and pharmacokinetic profile of new derivatives of xanthone and piperazine in the central nervous system.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID115614Minimum effective dose against P388 leukemic cells1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Mitomycin C analogues with aryl substituents on the 7-amino group.
AID365436Cytotoxicity against human DU145 cells assessed as age growth inhibition at 10 uM after 48 hrs by sulforhodamine B assay2008Bioorganic & medicinal chemistry letters, Sep-01, Volume: 18, Issue:17
Synthesis and cytotoxic activity of some novel polycyclic gamma-butyrolactones.
AID550002Cytotoxicity against human HepG2 by MTT assay2010Journal of natural products, Nov-29, Volume: 73, Issue:11
Terpenoids from the aerial parts of Parasenecio deltophylla.
AID144115Maximal percent of fibroblast cell growth inhibition using antiproliferative assay2002Journal of medicinal chemistry, Feb-28, Volume: 45, Issue:5
Synthesis, pharmacokinetics, efficacy, and rat retinal toxicity of a novel mitomycin C-triamcinolone acetonide conjugate.
AID229741Hypersensitivity factor (HF) of IC50 (AA8) / IC50 (EM-9) of compound for repair deffective mutants1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Hypoxia-selective antitumor agents. 2. Electronic effects of 4-substituents on the mechanisms of cytotoxicity and metabolic stability of nitracrine derivatives.
AID1243477Radioprotective activity in 2-Gy gamma irradiated human PBL assessed as incidence of micronuclei in binucleated cells at 3 uM treated for 2 to 19 hrs followed by compound washout measured after 72 hrs by cytochalasin-B-blocked micronucleus assay (Rvb = 1.2015Journal of natural products, Sep-25, Volume: 78, Issue:9
Phenolic Compounds from Atriplex littoralis and Their Radiation-Mitigating Activity.
AID121921Antitumor activity against P-388 murine leukemia cells in CDF1 female mice after intraperitoneal administration at the specified optimal dose of 3.2 mg/kg1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Development of new mitomycin C and porfiromycin analogues.
AID659404Cytotoxicity against human GM00637 cells assessed as reduction in mean cell viability after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10
COMPARE analysis of the toxicity of an iminoquinone derivative of the imidazo[5,4-f]benzimidazoles with NAD(P)H:quinone oxidoreductase 1 (NQO1) activity and computational docking of quinones as NQO1 substrates.
AID216610In vitro inhibition of WiDr colon cancer cell line1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Structure-activity studies of antitumor agents based on pyrrolo[1,2-a]benzimidazoles: new reductive alkylating DNA cleaving agents.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID405952Selectivity ratio for IC50 of BRCA2-deficient Chinese hamster V-C8 mutant cells to IC50 of BRCA2-proficient Chinese hamster BAC29 mutant cells2008Journal of natural products, Jun, Volume: 71, Issue:6
Marine natural product libraries for high-throughput screening and rapid drug discovery.
AID1254408Antiproliferative activity against human T47D cells after 48 hrs by resazurin reduction assay2015Bioorganic & medicinal chemistry, Dec-01, Volume: 23, Issue:23
Modification of cellular DNA by synthetic aziridinomitosenes.
AID355581Antiproliferative activity against human HT-29 cells at 0.1 ug after 48 hrs by two-layer agar-diffusion method
AID125425Antitumor activity against moser human colon carcinoma cell line1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
New 2-substituted indoloquinone mitomycin analogues.
AID1149669Toxicity in CDF1 mouse allografted with mouse P388 cells assessed as change in weight at 0.1 mg/kg/day administered qd on day 1 and 5 (Rvb = 3.4 g)1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Comparative stereochemistry in the aziridine ring openings of N-methylmitomycin A and 7-methoxy-1,2-(N-methylaziridino)mitosene.
AID1254429Induction of DNA modifying activity in human Jurkat cells assessed as DNA-protein crosslink at 100 uM under hypoxic condition by K-SDS assay2015Bioorganic & medicinal chemistry, Dec-01, Volume: 23, Issue:23
Modification of cellular DNA by synthetic aziridinomitosenes.
AID1149666Toxicity in CDF1 mouse allografted with mouse P388 cells assessed as change in weight at 0.8 mg/kg/day administered qd on day 1 and 5 (Rvb = 3.4 g)1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Comparative stereochemistry in the aziridine ring openings of N-methylmitomycin A and 7-methoxy-1,2-(N-methylaziridino)mitosene.
AID1616078Cytotoxicity against human SKBR3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay2019Journal of natural products, 09-27, Volume: 82, Issue:9
Yangpumicins F and G, Enediyne Congeners from
AID669354Cytotoxicity against human A549 cells by MTT assay2012Journal of natural products, May-25, Volume: 75, Issue:5
Antibacterial anthraquinone derivatives from a sea anemone-derived fungus Nigrospora sp.
AID1061805Cytotoxicity against human IMR32 cells assessed as growth inhibition at 10 uM by SRB assay2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Synthesis of a novel series of artemisinin dimers with potent anticancer activity involving Sonogashira cross-coupling reaction.
AID67455In vitro cytotoxicity of compound against EL4, mouse thymoma was defined by microculture tetrazolium assay2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Antitumor activity of novel deoxoartemisinin monomers, dimers, and trimer.
AID1470983Antiproliferative activity against NQO1 deficient human NCI-H596 cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, May-26, Volume: 132Design, synthesis, and biological evaluation of NAD(P)H: Quinone oxidoreductase (NQO1)-targeted oridonin prodrugs possessing indolequinone moiety for hypoxia-selective activation.
AID1470984Cytotoxicity against human LO2 cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, May-26, Volume: 132Design, synthesis, and biological evaluation of NAD(P)H: Quinone oxidoreductase (NQO1)-targeted oridonin prodrugs possessing indolequinone moiety for hypoxia-selective activation.
AID101237The compound was evaluated for survival of L1210 cells, when compound was exposed for a period of 1 hr 1X (10e -6)M conc1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Nucleotide derivatives of 2,7-diaminomitosene.
AID442341Growth inhibition of human Hep2 cells at 10 uM after 48 hrs by SRB assay2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Synthesis, anti-inflammatory and anticancer activity evaluation of some novel acridine derivatives.
AID122441Maximum percent T/C (antitumor activity) against P388 leukemia cells for the compound; 144-3251984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Mitomycin C analogues with aryl substituents on the 7-amino group.
AID40895Antitumor activity against B16-F10 murine melanoma cell line1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
New 2-substituted indoloquinone mitomycin analogues.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID123685In vivo antitumor activity (reduction of tumor volume) was determined against lewis lung carcinoma, subcutaneously in mice at a dose of 3.3 mg/kg2004Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10
New analogue of arenastatin A, a potent cytotoxic spongean depsipeptide, with anti-tumor activity.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1853115Binding affinity to AT-rich 5'-fluoro and 3'-TAMRA tagged 5'-TAT-ATA-TAG-ATA-TTT-TTT-TAT-CTA-TAT-ATA-3' hairpin DNA (unknown origin) assessed as thermal stabilization by measuring change in melting temperature at 1 uM incubated for 3 hrs by FRET analysis2022RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12
Mechanistic insight into the repair of C8-linked pyrrolobenzodiazepine monomer-mediated DNA damage.
AID38194Tumor free survivors on 62nd day after ip administration of a dose of 3 mg/kg/day in B-16 melanoma in mice1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Mitomycin C analogues with secondary amines at position 7.
AID1649660Cytotoxicity against human HepG2 cells assessed as cell growth at 20 uM measured after 72 hrs by cellTiter 96 AQueous non-radioactive cell proliferation assay relative to control2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Optimizing Pyrazolopyrimidine Inhibitors of Calcium Dependent Protein Kinase 1 for Treatment of Acute and Chronic Toxoplasmosis.
AID432751Antitumor activity against mouse S180 cells implanted in ip dosed ddY mouse assessed as tumor volume after 7 days2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Aziridine alkaloids as potential therapeutic agents.
AID1854153Cytotoxicity against human A2780 cells2022European journal of medicinal chemistry, Aug-05, Volume: 238Cascade synthetic strategies opening access to medicinal-relevant aliphatic 3- and 4-membered N-heterocyclic scaffolds.
AID537866Anticancer activity against human HL60 cells assessed as inhibition of cell growth at 5 ug/ml by MTT assay2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Design and synthesis of harzialactone analogues: promising anticancer agents.
AID451334Antiproliferative activity against human MPC5 cells after 72 hrs by trypan blue exclusion assay2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Synthesis and evaluation of bioactive naphthoquinones from the Brazilian medicinal plant, Tabebuia avellanedae.
AID1774823Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
AID1267734Cytotoxicity against human A549 cells after 72 hrs by CCK-8 assay2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
Total synthesis and cytotoxic activities of longamide B, longamide B methyl ester, hanishin, and their analogues.
AID121171Evaluated for antitumor activity against B-16 melanoma in mice at a dose 4 mg/kg day, ip, on days 1, 4, and 7 against B-16 Melanoma cell1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Mitomycin C analogues with aryl substituents on the 7-amino group.
AID78806in vitro inhibition of tumor cell growth in cultured HCT-8 human tumor cell line2001Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
Synthesis, DNA cross-linking activity, and cytotoxicity of dimeric mitomycins.
AID1134751Induction of lambda phage production in streptomycin-dependent lysogenic Escherichia coli W1709 (lambda) assessed as ratio of plaques in treated culture to control at 12.5 ug/ml1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Mitomycin antibiotics. Synthesis of 7-methoxy-1-(N-pyrrolidino)mitosene and its methiodide.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID376599Cytotoxicity against human KB cells after 72 hrs2006Journal of natural products, Apr, Volume: 69, Issue:4
Xenicane-type diterpenes with cytotoxicity from Xenia florida.
AID1731999Induction of DNA damage in human Jurkat cells assessed as increase in DNA lesion at 200 nM incubated for 48 hrs by comet assay2021European journal of medicinal chemistry, Mar-15, Volume: 214Novel diaryl-2H-azirines: Antitumor hybrids for dual-targeting tubulin and DNA.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1600376Antibacterial activity against methicillin resistant Staphylococcus aureus USA300 JE2 incubated for 18 hrs by broth microdilution method2019Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
Identification of a potent small-molecule inhibitor of bacterial DNA repair that potentiates quinolone antibiotic activity in methicillin-resistant Staphylococcus aureus.
AID123448Anti cancer activity was tested on day 14, in mice bearing Lewis lung adenocarcinoma by injecting 0.4 mg/kg dose of compound intraperitoneally and average weight change was reported.1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Cyclopent[a]anthraquinones as DNA intercalating agents with covalent bond formation potential: synthesis and biological activity.
AID625278FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of no concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID303291Cytotoxicity against human IE cells assessed as cell viability by tryptan blue staining method2007Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
Stereoselective synthesis and cytotoxicity of a cancer chemopreventive naphthoquinone from Tabebuia avellanedae.
AID418212Cytotoxicity against human SW620 cells after 48 hrs by SRB assay2009Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5
Microwave-assisted synthesis of N-substituted cyclic imides and their evaluation for anticancer and anti-inflammatory activities.
AID88954The compound was evaluated for the cytotoxicity against human HT-29 (colon) tumor cell lines.2000Bioorganic & medicinal chemistry letters, Feb-07, Volume: 10, Issue:3
Chemical synthesis and cytotoxicity of some azinomycin analogues devoid of the 1-azabicyclo[3.1.0]hexane subunit.
AID53619Inhibition of cell growth was studied in chinese hamster lung cells resistant to actinomycin D (DC-3F/AD-II).1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Cyclopent[a]anthraquinones as DNA intercalating agents with covalent bond formation potential: synthesis and biological activity.
AID773058Cytotoxicity against human SPCA1 cells after 48 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20
Five new degraded diterpenoids from Trigonostemon xyphophylloides.
AID676659Cytotoxicity against human HL60 cells after 48 hrs by SRB assay2012Journal of natural products, Jun-22, Volume: 75, Issue:6
Absolute structures of monoterpenoids with a δ-lactone-containing skeleton from Ligularia hodgsonii.
AID1149676Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as mouse survival at 0.1 mg/kg/day administered qd on day 1 and 5 measured on day 51977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Comparative stereochemistry in the aziridine ring openings of N-methylmitomycin A and 7-methoxy-1,2-(N-methylaziridino)mitosene.
AID664378Antitumor activity against mouse EAC cells allografted in Swiss albino mouse assessed as decrease in tumor cell at 1 mg/kg, ip administered from day 1 to day 7 every 24 hrs2012European journal of medicinal chemistry, Jul, Volume: 53Appraisal of GABA and PABA as linker: design and synthesis of novel benzamide based histone deacetylase inhibitors.
AID1062115Cytotoxicity against wild-type human MDA-MB-231 cells after 5 days2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
Synthesis and cytotoxicity of pyranonaphthoquinone natural product analogues under bioreductive conditions.
AID763929Growth inhibition of human MCF7 cells assessed as dead cells at 1 uM after 48 hrs by sulforhodamine-B assay relative to control2013European journal of medicinal chemistry, Aug, Volume: 66Synthesis and biological evaluation of ursolic acid-triazolyl derivatives as potential anti-cancer agents.
AID136708Ability of intraperitoneally administered compound (2 mg/kg/day) to inhibit growth of human tumor xenograft GXF 97 was assessed on day 28 in nude mice1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Synthesis, mechanism of action, and biological evaluation of mitosenes.
AID1600375Antibacterial activity against Staphylococcus aureus SH1000 incubated for 18 hrs by broth microdilution method2019Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
Identification of a potent small-molecule inhibitor of bacterial DNA repair that potentiates quinolone antibiotic activity in methicillin-resistant Staphylococcus aureus.
AID676660Cytotoxicity against human SMMC7721 cells after 48 hrs by SRB assay2012Journal of natural products, Jun-22, Volume: 75, Issue:6
Absolute structures of monoterpenoids with a δ-lactone-containing skeleton from Ligularia hodgsonii.
AID1853132Effect on DNA damage repair in Caulobacter vibrioides lacking recN expression assessed as decrease in cell survival rate upto 1 ug/ml and measured after 2 days by agar dilution method2022RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12
Mechanistic insight into the repair of C8-linked pyrrolobenzodiazepine monomer-mediated DNA damage.
AID461533Cytotoxicity against human WiDr cells by MTT assay2010Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5
Cytotoxic and anti-inflammatory cembranoids from the Dongsha Atoll soft coral Sarcophyton crassocaule.
AID730258Cytotoxicity against human PC3 cells at 1 uM after 48 hrs by sulforhodamine B assay2013Journal of natural products, Feb-22, Volume: 76, Issue:2
Tubulin inhibitors from an endophytic fungus isolated from Cedrus deodara.
AID95063Compound was tested for antitumor activity against L-1210 Murine leukemia in BDF1 female mice at a dose of 3 mg/kg per injection1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Preparation and antitumor activity of 7-substituted 1,2-aziridinomitosenes.
AID1149661Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as effect on median survival time at 0.2 mg/kg/day administered qd on day 1 and 5 relative to control1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Comparative stereochemistry in the aziridine ring openings of N-methylmitomycin A and 7-methoxy-1,2-(N-methylaziridino)mitosene.
AID409523Cytotoxicity against human Daoy cells by MTT assay2008Journal of natural products, Dec, Volume: 71, Issue:12
Cespihypotins Q-V, verticillene diterpenoids from Cespitularia hypotentaculata.
AID638413Anticancer activity against human SW620 cells assessed as growth inhibition at 50 uM after 48 hrs by SRB assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Acyl derivatives of boswellic acids as inhibitors of NF-κB and STATs.
AID1172675Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 hrs by WST8 assay2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
Synthesis and identification of α-cyano bis(indolyl)chalcones as novel anticancer agents.
AID1446343Growth inhibition of human MCF7 cells after 72 hrs by Cell-Titer Glo assay2017Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15
Conformation-Based Design and Synthesis of Apratoxin A Mimetics Modified at the α,β-Unsaturated Thiazoline Moiety.
AID1320131Cytotoxicity against CHL cells assessed as structural aberrations at 0.05 ug/ml preincubated for 6 hrs followed by 18 hrs incubation in fresh medium in absence of S9 fraction by Giemsa-staining-based microscopic analysis2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Phosphonate-based irreversible inhibitors of human γ-glutamyl transpeptidase (GGT). GGsTop is a non-toxic and highly selective inhibitor with critical electrostatic interaction with an active-site residue Lys562 for enhanced inhibitory activity.
AID633103Cytotoxicity against human KB cells after 1 to 11 days by MTT assay2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Crassocolides N-P, three cembranoids from the Formosan soft coral Sarcophyton crassocaule.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID638412Anticancer activity against human HT-29 cells assessed as growth inhibition at 50 uM after 48 hrs by SRB assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Acyl derivatives of boswellic acids as inhibitors of NF-κB and STATs.
AID357026Cytotoxicity against human HepA cells after 72 hrs by methylene blue assay2001Journal of natural products, Jul, Volume: 64, Issue:7
Taxane diterpenoids from the stem bark of Taxus mairei.
AID1446336Growth inhibition of human A549 cells after 72 hrs by Cell-Titer Glo assay2017Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15
Conformation-Based Design and Synthesis of Apratoxin A Mimetics Modified at the α,β-Unsaturated Thiazoline Moiety.
AID451337Antiproliferative activity against human SVCT-M12 cells after 72 hrs by trypan blue exclusion assay2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Synthesis and evaluation of bioactive naphthoquinones from the Brazilian medicinal plant, Tabebuia avellanedae.
AID1774828Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
AID1649662Cytotoxicity against human Caco2 cells assessed as cell growth at 20 uM measured after 72 hrs by cellTiter 96 AQueous non-radioactive cell proliferation assay relative to control2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Optimizing Pyrazolopyrimidine Inhibitors of Calcium Dependent Protein Kinase 1 for Treatment of Acute and Chronic Toxoplasmosis.
AID1731993Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay2021European journal of medicinal chemistry, Mar-15, Volume: 214Novel diaryl-2H-azirines: Antitumor hybrids for dual-targeting tubulin and DNA.
AID426845Induction of DNA interstrand cross-linking in human H1299 cells at 100 uM under aerobic condition for 1 hr followed by irradiated with 20 Gy of X-ray by modified comet assay relative to irradiated untreated control2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Potent antitumor bifunctional DNA alkylating agents, synthesis and biological activities of 3a-aza-cyclopenta[a]indenes.
AID357025Cytotoxicity against human KB cells after 72 hrs by methylene blue assay2001Journal of natural products, Jul, Volume: 64, Issue:7
Taxane diterpenoids from the stem bark of Taxus mairei.
AID303289Cytotoxicity against human Hc cells assessed as cell viability by tryptan blue staining method2007Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
Stereoselective synthesis and cytotoxicity of a cancer chemopreventive naphthoquinone from Tabebuia avellanedae.
AID101240The compound was evaluated for survival of L1210 cells, when compound was exposed for a period of 8-9 hr 1X (10e -6)M conc1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Nucleotide derivatives of 2,7-diaminomitosene.
AID1446335Growth inhibition of human BxPC3 cells after 72 hrs by Cell-Titer Glo assay2017Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15
Conformation-Based Design and Synthesis of Apratoxin A Mimetics Modified at the α,β-Unsaturated Thiazoline Moiety.
AID115705Inhibitory activity against human lung adenocarcinoma xenograft A-549 and the ratio of the number of mice at the initial stage and the final stage of the experiment was reported at a dose of 0.2 ml/mouse (Q2dx10) administered i.p.; 10/101999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID202676Inhibition of cell growth was studied in human mammary adenocarcinoma (SKBR-3).1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Cyclopent[a]anthraquinones as DNA intercalating agents with covalent bond formation potential: synthesis and biological activity.
AID442343Growth inhibition of human 502713 cells at 10 uM after 48 hrs by SRB assay2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Synthesis, anti-inflammatory and anticancer activity evaluation of some novel acridine derivatives.
AID552866Cytotoxicity against human MCF7 cells after 3 days by MTT assay2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Biologically active constituents from the fruiting body of Taiwanofungus camphoratus.
AID1254411Antiproliferative activity against human Jurkat T cells after 48 hrs by resazurin reduction assay2015Bioorganic & medicinal chemistry, Dec-01, Volume: 23, Issue:23
Modification of cellular DNA by synthetic aziridinomitosenes.
AID111252Effect of compound on total white blood cell count in BDG1 male mice, after intraperitoneal administration at a dose of 4.22 mg/kg on day 71981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Development of new mitomycin C and porfiromycin analogues.
AID111112Effect of compound on total white blood cell count in BDG1 male mice, after intraperitoneal administration at a dose of 3.16 mg/kg on day 71981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Development of new mitomycin C and porfiromycin analogues.
AID125493Antiproliferative activity of compound was evaluated on Molt3 cells from human lymphoblastic leukemia2000Bioorganic & medicinal chemistry letters, Oct-02, Volume: 10, Issue:19
Synthesis and antiproliferative activity of some benzimidazole-4,7-dione derivatives.
AID638417Anticancer activity against human PC3 cells assessed as growth inhibition at 50 uM after 48 hrs by SRB assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Acyl derivatives of boswellic acids as inhibitors of NF-κB and STATs.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID53601Inhibition of cell growth was studied in chinese hamster lung cells (DC-3F)1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Cyclopent[a]anthraquinones as DNA intercalating agents with covalent bond formation potential: synthesis and biological activity.
AID397764Cytotoxicity against human stomach cancer cells2001Journal of natural products, Jul, Volume: 64, Issue:7
In vitro cytotoxicity of the protoberberine-type alkaloids.
AID676661Cytotoxicity against human HeLa cells after 48 hrs by SRB assay2012Journal of natural products, Jun-22, Volume: 75, Issue:6
Absolute structures of monoterpenoids with a δ-lactone-containing skeleton from Ligularia hodgsonii.
AID123586Evaluated for antitumor activity against B-16 melanoma in mice at a dose 3 mg/kg day, ip, on days 1, 4, and 7 against B-16 Melanoma cell1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Mitomycin C analogues with aryl substituents on the 7-amino group.
AID235769Ratio of optimal dose (OD) and minimum effective dose (MED) required for antitumor activity in mice bearing P-388 lymphocytic leukemia1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Mitomycin C analogues with aryl substituents on the 7-amino group.
AID354543Cytotoxicity against rat C6 cells assessed as cell release at 50 ug/mL to 2.5 mg/mL after 5 hrs by MTT assay in absence of db-cAMP1996Journal of natural products, Dec, Volume: 59, Issue:12
Cell-based screen for identification of inhibitors of tubulin polymerization.
AID1853117Binding affinity to GC-rich 5'-fluoro and 3'-TAMRA tagged 5'-TAT-AGG-GAC-AGC-CCT-ATA-3' hairpin DNA (unknown origin) assessed as thermal stabilization by measuring change in melting temperature at 1 uM incubated for 3 hrs by FRET analysis2022RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12
Mechanistic insight into the repair of C8-linked pyrrolobenzodiazepine monomer-mediated DNA damage.
AID101242The compound was evaluated for survival of L1210 cells, when compound was exposed for a period of 8-9 h 1X (10e -8)Mconc1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Nucleotide derivatives of 2,7-diaminomitosene.
AID1254820Cytotoxicity against human SF539 cells after 72 hrs by MTS assay2015Journal of natural products, Oct-23, Volume: 78, Issue:10
Angucyclines and Angucyclinones from Streptomyces sp. CB01913 Featuring C-Ring Cleavage and Expansion.
AID210134Concentration of compound required for cross linking 50% T-7 DNA, Acid2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Mitomycin dimers: polyfunctional cross-linkers of DNA.
AID130503In vivo antitumor activity against P388 leukemia cells (ip)in mice and maximal increase in life span calculated as (T/C-1)*100 at the optimal dose of 4.0-6.0 mg/kg1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
New potent mitomycin derivatives: synthesis and antitumor activity of 7,7-(ethylenedioxy)mitomycins.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID451331Antiproliferative activity against human MCF7 cells after 72 hrs by trypan blue exclusion assay2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Synthesis and evaluation of bioactive naphthoquinones from the Brazilian medicinal plant, Tabebuia avellanedae.
AID376600Cytotoxicity against human WiDr cells after 72 hrs2006Journal of natural products, Apr, Volume: 69, Issue:4
Xenicane-type diterpenes with cytotoxicity from Xenia florida.
AID389703Cell cycle arrest in human HCT8 cells in normoxic condition assessed as accumulation at S phase at 10 uM after 24 hrs by flow cytometry2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Synthesis of new pyrazolo[5,1-c][1,2,4] benzotriazines, pyrazolo[5,1-c]pyrido[4,3-e][1,2,4] triazines and their open analogues as cytotoxic agents in normoxic and hypoxic conditions.
AID303287Cytotoxicity against human MCF7 cells assessed as cell viability by tryptan blue staining method2007Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
Stereoselective synthesis and cytotoxicity of a cancer chemopreventive naphthoquinone from Tabebuia avellanedae.
AID79011Antitumor activity against HCT116 human colon carcinoma cell line experiment 21989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
New 2-substituted indoloquinone mitomycin analogues.
AID103358in vitro inhibition of tumor cell growth in cultured MCF-7 human tumor cell line2001Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
Synthesis, DNA cross-linking activity, and cytotoxicity of dimeric mitomycins.
AID128416Antitumor activity against P388 mouse leukemia as maximum and average change in body weight was reported at a dose of 0.8 mg/kg per injection.1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Synthesis and biological activity of 6-substituted mitosene analogues of the mitomycins.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID355585Antiproliferative activity against mouse P388 cells at 0.1 ug after 48 hrs by two-layer agar-diffusion method
AID1712212Cytotoxicity against Sprague-Dawley rat Cerebral cortex neuron assessed as cell viability at 10 uM incubated for 24 hrs by MTT assay relative to control2016Bioorganic & medicinal chemistry, 07-15, Volume: 24, Issue:14
New bifunctional antioxidant/σ1 agonist ligands: Preliminary chemico-physical and biological evaluation.
AID401379Cytotoxicity against human Hep3B cells after 3 days by methylene blue assay1998Journal of natural products, Jun-26, Volume: 61, Issue:6
A new taxane diterpenoid from Taxus mairei.
AID1853116Binding affinity to AT-rich 5'-fluoro and 3'-TAMRA tagged 5'-TAT-ATA-TAG-ATA-TTT-TTT-TAT-CTA-TAT-ATA-3' hairpin DNA(unknown origin) assessed as thermal stabilization by measuring change in melting temperature at 1 uM incubated for 24 hrs by FRET analysis2022RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12
Mechanistic insight into the repair of C8-linked pyrrolobenzodiazepine monomer-mediated DNA damage.
AID1854154Cytotoxicity against human HCT-116 cells2022European journal of medicinal chemistry, Aug-05, Volume: 238Cascade synthetic strategies opening access to medicinal-relevant aliphatic 3- and 4-membered N-heterocyclic scaffolds.
AID664044Antitumor activity against mouse EAC cells allografted in Swiss albino mouse assessed as decrease in tumor weight at 1 mg/kg, ip administered from day 1 to day 7 every 24 hrs2012European journal of medicinal chemistry, Jul, Volume: 53Appraisal of GABA and PABA as linker: design and synthesis of novel benzamide based histone deacetylase inhibitors.
AID124399Evaluated for antitumor activity against B-16 melanoma in mice at a dose 3 mg/kg day, ip, on days 1, 4, and 7 against B-16 Melanoma cell *-Tumors survivors on day 621984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Mitomycin C analogues with aryl substituents on the 7-amino group.
AID1603955Mutagenecity against Salmonella typhimurium TA102 assessed as number of colonies in presence of Sprague-Dawley rat S9 with metabolic activation measured after 48 hrs by Ames test ( Rvb = 72 +/- 1 No_unit)2019Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17
Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID154486Minimum effective dose required for antitumor activity against P-388 murine leukemia cells1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Mitomycin C and porfiromycin analogues with substituted ethylamines at position 7.
AID1149675Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as mouse survival at 0.2 mg/kg/day administered qd on day 1 and 5 measured on day 51977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Comparative stereochemistry in the aziridine ring openings of N-methylmitomycin A and 7-methoxy-1,2-(N-methylaziridino)mitosene.
AID1853131Effect on DNA damage repair in Caulobacter vibrioides lacking addAB expression assessed as decrease in cell survival rate upto 1 ug/ml and measured after 2 days by agar dilution method2022RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12
Mechanistic insight into the repair of C8-linked pyrrolobenzodiazepine monomer-mediated DNA damage.
AID1302981Antibiofilm activity against Micrococcus luteus MTCC 2470 after 24 hrs by crystal violet staining based assay2016European journal of medicinal chemistry, Jul-19, Volume: 117Design, synthesis and biological evaluation of diaziridinyl quinone isoxazole hybrids.
AID1320172Cytotoxicity against CHL cells assessed as number of cells with numerical aberrations at 0.05 ug/ml after 24 hrs by Giemsa staining-based microscopic analysis relative to control2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Phosphonate-based irreversible inhibitors of human γ-glutamyl transpeptidase (GGT). GGsTop is a non-toxic and highly selective inhibitor with critical electrostatic interaction with an active-site residue Lys562 for enhanced inhibitory activity.
AID477295Octanol-water partition coefficient, log P of the compound2010European journal of medicinal chemistry, Apr, Volume: 45, Issue:4
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
AID44716In vitro cytotoxicity of compound against Bewo, human choriocarcinoma was defined by microculture tetrazolium assay2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Antitumor activity of novel deoxoartemisinin monomers, dimers, and trimer.
AID38049Tumor free survivors on 62nd day after ip administration in B-16 melanoma in mice (dose mg/kg/day); 6/101983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Mitomycin C and porfiromycin analogues with substituted ethylamines at position 7.
AID442553Growth inhibition of human PC3 cells at 10 uM after 48 hrs by sulforhodamine B assay2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Cytotoxic activity of 3-(5-phenyl-3H-[1,2,4]dithiazol-3-yl)chromen-4-ones and 4-oxo-4H-chromene-3-carbothioic acid N-phenylamides.
AID356088Cytotoxicity against human SCL37'6 cells by MTT assay2003Journal of natural products, Jul, Volume: 66, Issue:7
Cytotoxic diterpenes from Scoparia dulcis.
AID123711Ratio of the tumor weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 0.2 ml/mouse (Q2dx9) administered i.p.1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID685158Growth inhibition of human PC3 cells at 1 uM after 48 hrs by MTT assay2012European journal of medicinal chemistry, Oct, Volume: 56Synthesis, antimicrobial and cytotoxicity study of 1,3-disubstituted-1H-naphtho[1,2-e][1,3]oxazines.
AID442348Growth inhibition of human IMR32 cells at 10 uM after 48 hrs by SRB assay2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Synthesis, anti-inflammatory and anticancer activity evaluation of some novel acridine derivatives.
AID633925Induction of mitosis in ICR mouse bone marrow cells assessed as mitotic index at 3.5 mg/kg, ip after 48 hrs2012Bioorganic & medicinal chemistry, Jan-01, Volume: 20, Issue:1
Synthesis, antiproliferative activity and genotoxicity of novel anthracene-containing aminophosphonates and a new anthracene-derived Schiff base.
AID338961Cytotoxicity against rat XC cells assessed as inhibition of colony formation after 5 to 8 days by colony assay2002Journal of natural products, Apr, Volume: 65, Issue:4
Synthesis and structure-activity relationship study of lamellarin derivatives.
AID389709Effect on cell cycle arrest in human HCT8 cells in normoxic condition assessed as DNA fragmentation at 10 uM after 24 hrs by flow cytometry2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Synthesis of new pyrazolo[5,1-c][1,2,4] benzotriazines, pyrazolo[5,1-c]pyrido[4,3-e][1,2,4] triazines and their open analogues as cytotoxic agents in normoxic and hypoxic conditions.
AID115833Ratio of the number of mice at the initial stage and the final stage of the experiment was reported at a dose of 2.0 mg/kg (Q2dx10) administered i.p.; 10/101999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID38191Tumor free survivors on 62nd day after ip administration of a dose of 1 mg/kg/day in B-16 melanoma in mice1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Mitomycin C analogues with secondary amines at position 7.
AID1731995Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay2021European journal of medicinal chemistry, Mar-15, Volume: 214Novel diaryl-2H-azirines: Antitumor hybrids for dual-targeting tubulin and DNA.
AID1378415Bactericidal activity against methicillin-resistant Staphylococcus aureus subsp. aureus Rosenbach 18842017European journal of medicinal chemistry, Sep-29, Volume: 138Topological pattern for the search of new active drugs against methicillin resistant Staphylococcus aureus.
AID1134762Induction of lambda phage production in streptomycin-dependent lysogenic Escherichia coli W1709 (lambda) assessed as ratio of plaques in treated culture to control at 0.5 ug/ml1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Mitomycin antibiotics. Synthesis of 7-methoxy-1-(N-pyrrolidino)mitosene and its methiodide.
AID123575Anti cancer activity was tested on day10, in mice bearing Lewis lung adenocarcinoma by injecting 0.4 mg/kg dose of compound intraperitoneally and average weight change was reported.1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Cyclopent[a]anthraquinones as DNA intercalating agents with covalent bond formation potential: synthesis and biological activity.
AID442344Growth inhibition of human HCT15 cells at 10 uM after 48 hrs by SRB assay2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Synthesis, anti-inflammatory and anticancer activity evaluation of some novel acridine derivatives.
AID121172Evaluated for antitumor activity against B-16 melanoma in mice at a dose 1 mg/kg day, ip, on days 1, 4, and 7 against B-16 Melanoma cell1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Mitomycin C analogues with aryl substituents on the 7-amino group.
AID773057Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20
Five new degraded diterpenoids from Trigonostemon xyphophylloides.
AID510380Cytotoxicity against human HeLa cells after 72 hrs by MTT assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis and toxicity towards normal and cancer cell lines of benzimidazolequinones containing fused aromatic rings and 2-aromatic ring substituents.
AID1649661Cytotoxicity against human CMEC/D3 cells assessed as cell growth at 20 uM measured after 72 hrs by cellTiter 96 AQueous non-radioactive cell proliferation assay relative to control2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Optimizing Pyrazolopyrimidine Inhibitors of Calcium Dependent Protein Kinase 1 for Treatment of Acute and Chronic Toxoplasmosis.
AID228938Mean IC50 for all seven tumor cell lines was determined2001Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
Synthesis, DNA cross-linking activity, and cytotoxicity of dimeric mitomycins.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID222136Antitumor activity against human colon CX-1 tumor Xenografts in Athymic mice at a dose of 9180 micro g/kg2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Novel seco cyclopropa[c]pyrrolo[3,2-e]indole bisalkylators bearing a 3,3'-arylenebisacryloyl group as a linker.
AID1853129Effect on DNA damage repair in Caulobacter vibrioides lacking recO expression assessed as decrease in cell survival rate upto 1 ug/ml and measured after 2 days by agar dilution method2022RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12
Mechanistic insight into the repair of C8-linked pyrrolobenzodiazepine monomer-mediated DNA damage.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1254425Induction of DNA modifying activity in human Jurkat cells assessed as increase in amount of crosslink DNA at 10 uM for 1 hr under aerobic condition by Hoechst-33342 staining based fluorescence assay2015Bioorganic & medicinal chemistry, Dec-01, Volume: 23, Issue:23
Modification of cellular DNA by synthetic aziridinomitosenes.
AID67634Compound is measured for surviving fractions of EMT6 tumor cells treated in culture with (0.50 uM) concentration for 1 hr under aerobic condition.1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
2-Methylanthraquinone derivatives as potential bioreductive alkylating agents.
AID38188Average weight change after ip administration of of a dose of 4 mg/kg/day in B-16 melanoma in mice1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Mitomycin C analogues with secondary amines at position 7.
AID399043Cytotoxicity against human medulloblastoma cells after 3 days by methylene blue staining2005Journal of natural products, Nov, Volume: 68, Issue:11
Cytotoxic clerodane diterpenoids from Casearia membranacea.
AID202508In vitro cytotoxic activity against human ovarian carcinoma cell line SK-OV-3 after 72 hr of drug exposure determined by the SRB assay2004Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5
Synthesis and in vitro evaluation of 7-dialkylaminomethylbenzo[g]quinoxaline-5,10-diones.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1853120Induction of DNA damage in Caulobacter vibrioides assessed as accumulation of SOS-induced YFP at 0.5 ug/ml incubated upto 2 hrs by fluorescence microscopy2022RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12
Mechanistic insight into the repair of C8-linked pyrrolobenzodiazepine monomer-mediated DNA damage.
AID1853123Effect on DNA damage repair in Caulobacter vibrioides lacking recA, lexA and sidA expression assessed as decrease in cell survival rate upto 1 ug/ml and measured after 2 days by agar dilution method2022RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12
Mechanistic insight into the repair of C8-linked pyrrolobenzodiazepine monomer-mediated DNA damage.
AID80386Antitumor activity against HCT116 human colon carcinoma cell line1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
New 2-substituted indoloquinone mitomycin analogues.
AID1374857Antiproliferative activity against human HL60 cells after 48 hrs by CCK8 assay2018Bioorganic & medicinal chemistry letters, 04-01, Volume: 28, Issue:6
Two new coumarins and a new xanthone from the leaves of Rhizophora mucronata.
AID1505060Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay2018Journal of natural products, 01-26, Volume: 81, Issue:1
Germacrane-Type Sesquiterpenoids with Antiproliferative Activities from Eupatorium chinense.
AID542128Induction of qnrB4 gene expression in lexA- and recA- positive Escherichia coli J53 at 0.2 ug/ml after 30 mins by quantitative PCR method relative to control2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
SOS regulation of qnrB expression.
AID3026In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Structure-activity studies of antitumor agents based on pyrrolo[1,2-a]benzimidazoles: new reductive alkylating DNA cleaving agents.
AID137202Antitumor activity against P388 mouse leukemia as maximum and median survival time as % T/C was reported at a dose of 0.8 mg/Kg per injection.1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Synthesis and biological activity of 6-substituted mitosene analogues of the mitomycins.
AID121386Treated versus control value of tumor volume was measured in ddY mice1994Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12
Synthesis and antitumor activity of novel 6-alkyl-6-demethylmitomycins.
AID1774825Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
AID1166322Cytotoxicity against human A549 cells after 48 hrs by SRB assay2014European journal of medicinal chemistry, Nov-24, Volume: 87β-Ionone derived apoptosis inducing endoperoxides; Discovery of potent leads for anticancer agents.
AID97547Average change in weight between treated and control groups at 3 mg/kg in mice infected with L1210 leukemia cells1981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
Synthesis and antineoplastic activity of mitosene analogues of the mitomycins.
AID128586Body wieght treated/body weight untreated controls of compound (6 mg/kg) was evaluated in vivo for antitumor activity against MAC 16 in female NMRI mice on day 41989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Synthesis, mechanism of action, and biological evaluation of mitosenes.
AID355586Antiproliferative activity against mouse P388 cells at 0.01 ug after 48 hrs by two-layer agar-diffusion method
AID1134767In vivo antitumor activity against mouse P388 cells at 6.4 mg/kg relative to control1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Mitomycin antibiotics. Synthesis of 7-methoxy-1-(N-pyrrolidino)mitosene and its methiodide.
AID1302977Bactericidal activity against Klebsiella planticola MTCC 530 after 24 hrs by serial dilution method2016European journal of medicinal chemistry, Jul-19, Volume: 117Design, synthesis and biological evaluation of diaziridinyl quinone isoxazole hybrids.
AID115831Ratio of the number of mice at the initial stage and the final stage of the experiment was reported at a dose of 0.2 ml/mouse (Q2dx10) administered i.p.; 10/101999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID1853138Effect on DNA damage repair in Caulobacter vibrioides lacking alkB expression assessed as decrease in cell survival rate upto 1 ug/ml and measured after 2 days by agar dilution method2022RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12
Mechanistic insight into the repair of C8-linked pyrrolobenzodiazepine monomer-mediated DNA damage.
AID111251Effect of compound on total white blood cell count in BDG1 male mice, after intraperitoneal administration at a dose of 4.22 mg/kg on day 51981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Development of new mitomycin C and porfiromycin analogues.
AID139765In vivo antitumor activity in mice at 1 mg/kg/day (dosing schedule Q1DX14); 8/82001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Indenopyrazoles as novel cyclin dependent kinase (CDK) inhibitors.
AID38198Median survival time (% T/C) after ip administration of a dose of 3 mg/kg/day in B-16 melanoma in mice1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Mitomycin C analogues with secondary amines at position 7.
AID389704Cell cycle arrest in human HCT8 cells in normoxic condition assessed as accumulation at S phase at 10 uM after 24 hrs of drug washout by flow cytometry2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Synthesis of new pyrazolo[5,1-c][1,2,4] benzotriazines, pyrazolo[5,1-c]pyrido[4,3-e][1,2,4] triazines and their open analogues as cytotoxic agents in normoxic and hypoxic conditions.
AID7026In vitro inhibition of 7226/S myeloma cancer cell line1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Structure-activity studies of antitumor agents based on pyrrolo[1,2-a]benzimidazoles: new reductive alkylating DNA cleaving agents.
AID320487Cytotoxicity against human MCF7 cells by Alamar blue assay2008Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4
Synthesis, metal ion binding, and biological evaluation of new anticancer 2-(2'-hydroxyphenyl)benzoxazole analogs of UK-1.
AID23684Calculated partition coefficient for the compound (logP)1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Structure-activity relationships for mitomycin C and mitomycin A analogues.
AID138039Compound (40 mg/Kg) was evaluated in vivo for antitumor activity against MAC 16 in female NMRI mice on day 29 and ratio of tumor weight of treated to that of control was determined1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Synthesis, mechanism of action, and biological evaluation of mitosenes.
AID137393Percent T/C (total/control) for antitumor activity against P388 Leukemia in CD2 mice at fractioned dose treatment of 3 mg/kg1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Synthesis, mechanism of action, and biological evaluation of mitosenes.
AID459273Growth inhibition of phytohemagglutinin-activated human PBMC cells after 24 to 72 hrs by MTT assay2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
New pterocarpanquinones: synthesis, antineoplasic activity on cultured human malignant cell lines and TNF-alpha modulation in human PBMC cells.
AID229742Hypersensitivity factor (HF) of IC50 (AA8) / IC50 (UV-4) of compound for repair deffective mutants1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Hypoxia-selective antitumor agents. 2. Electronic effects of 4-substituents on the mechanisms of cytotoxicity and metabolic stability of nitracrine derivatives.
AID442550Growth inhibition of human COLO205 cells at 10 uM after 48 hrs by sulforhodamine B assay2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Cytotoxic activity of 3-(5-phenyl-3H-[1,2,4]dithiazol-3-yl)chromen-4-ones and 4-oxo-4H-chromene-3-carbothioic acid N-phenylamides.
AID101083Inhibitory concentration on parentral (sensitive) L1210 leukemia cells.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Additional nucleotide derivatives of mitosenes. Synthesis and activity against parental and multidrug resistant L1210 leukemia.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID120904T/C value was measured as tumor volume in the treated versus control mice.1995Journal of medicinal chemistry, Aug-04, Volume: 38, Issue:16
Synthesis and antitumor activity of various 6-demethylmitomycins and 6-demethyl-6-halomitomycins.
AID1302965Antimicrobial activity against Staphylococcus aureus MTCC 96 after 24 hrs by well diffusion method2016European journal of medicinal chemistry, Jul-19, Volume: 117Design, synthesis and biological evaluation of diaziridinyl quinone isoxazole hybrids.
AID120665Number of tumored survivors, 45 days after administration of compound at a dose of 8 mg/kg/day in mice1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Development of new mitomycin C and porfiromycin analogues.
AID451329Antiproliferative activity against human PC3 cells after 72 hrs by trypan blue exclusion assay2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Synthesis and evaluation of bioactive naphthoquinones from the Brazilian medicinal plant, Tabebuia avellanedae.
AID537869Anticancer activity against mouse P388D1 cells assessed as inhibition of cell growth at 5 ug/ml by MTT assay2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Design and synthesis of harzialactone analogues: promising anticancer agents.
AID1457327Genotoxicity in human lymphocytes assessed as increase in frequency of micronucleated cells at 0.33 ug/mL after 3 hrs in presence of rat liver S9 fraction by micronucleus assay (Rvb = 0.63%)2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
AID40892Antitumor activity against B16-BN murine melanoma cell line1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
New 2-substituted indoloquinone mitomycin analogues.
AID355582Antiproliferative activity against human HT-29 cells at 0.01 ug after 48 hrs by two-layer agar-diffusion method
AID1302980Antibiofilm activity against Staphylococcus aureus MLS16 MTCC 2940 after 24 hrs by crystal violet staining based assay2016European journal of medicinal chemistry, Jul-19, Volume: 117Design, synthesis and biological evaluation of diaziridinyl quinone isoxazole hybrids.
AID1149650Induction of lambda phage lytic activity in Escherichia coli W1709(lambda) assessed as ratio of plaques in treated culture to control at 0.0125 ug/ml preincubated for 90 mins followed by heart infusion broth and glucose addition measured after 120 mins1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Comparative stereochemistry in the aziridine ring openings of N-methylmitomycin A and 7-methoxy-1,2-(N-methylaziridino)mitosene.
AID401262Cytotoxicity against mouse P388 cells at 0.06 ug/mL2004Journal of natural products, Apr, Volume: 67, Issue:4
Ether-linked biflavonoids from Quintinia acutifolia.
AID1149681Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as mouse survival at 0.4 mg/kg/day administered qd on day 1 and 5 measured on day 301977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Comparative stereochemistry in the aziridine ring openings of N-methylmitomycin A and 7-methoxy-1,2-(N-methylaziridino)mitosene.
AID37917Average weight change after ip administration of in B-16 melanoma in mice (dose mg/kg/day)1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Mitomycin C and porfiromycin analogues with substituted ethylamines at position 7.
AID138874Average weight change of BDF1 female mice at a dose of 1.5 mg/kg per injection1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Preparation and antitumor activity of 7-substituted 1,2-aziridinomitosenes.
AID231332Ratio of toxicity in areobic conditions to hypoxic condition of EMT6 cells1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
2-Methylanthraquinone derivatives as potential bioreductive alkylating agents.
AID124403Evaluated for antitumor activity against B-16 melanoma in mice at a dose 2 mg/kg day, ip, on days 1, 4, and 7 against B-16 Melanoma cell *-Tumors survivors on day 621984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Mitomycin C analogues with aryl substituents on the 7-amino group.
AID459272Growth inhibition of human Daudi cells after 24 to 72 hrs by MTT assay2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
New pterocarpanquinones: synthesis, antineoplasic activity on cultured human malignant cell lines and TNF-alpha modulation in human PBMC cells.
AID764651Genotoxicity in human lymphocytes assessed as chromosome aberration at 0.300 u/mL relative to control2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Identification of GNE-293, a potent and selective PI3Kδ inhibitor: navigating in vitro genotoxicity while improving potency and selectivity.
AID1166324Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay2014European journal of medicinal chemistry, Nov-24, Volume: 87β-Ionone derived apoptosis inducing endoperoxides; Discovery of potent leads for anticancer agents.
AID1254406Antiproliferative activity against human HeLa cells after 48 hrs by resazurin reduction assay2015Bioorganic & medicinal chemistry, Dec-01, Volume: 23, Issue:23
Modification of cellular DNA by synthetic aziridinomitosenes.
AID303285Cytotoxicity against human PC3 cells assessed as cell viability by tryptan blue staining method2007Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
Stereoselective synthesis and cytotoxicity of a cancer chemopreventive naphthoquinone from Tabebuia avellanedae.
AID123458Anti cancer activity was tested on day 7, in mice bearing Lewis lung adenocarcinoma by injecting 2.0 mg/kg dose of compound intraperitoneally and average weight change was reported.1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Cyclopent[a]anthraquinones as DNA intercalating agents with covalent bond formation potential: synthesis and biological activity.
AID111111Effect of compound on total white blood cell count in BDG1 male mice, after intraperitoneal administration at a dose of 3.16 mg/kg on day 51981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Development of new mitomycin C and porfiromycin analogues.
AID128587Mean relative body weight change of treated / mean relative body weight change of control when compound (2 mg/kg/day) administered to inhibit growth of human tumor xenograft GXF 97 was reported at day 14 in nude mice1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Synthesis, mechanism of action, and biological evaluation of mitosenes.
AID432750Toxicity in ip dosed ddY mouse bearing mouse S180 cells2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Aziridine alkaloids as potential therapeutic agents.
AID744296Antiproliferative activity against human HCT116 cells after 48 hrs by sulforhodamine B assay2013European journal of medicinal chemistry, May, Volume: 63Synthesis and anticancer activity of novel spiro-isoxazoline and spiro-isoxazolidine derivatives of α-santonin.
AID115629Minimum effective dose that show activity against P-388 murine leukemia cells in CDF1 female mice, after intraperitoneal administration (optimal dose is 3.2 mg/kg)1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Development of new mitomycin C and porfiromycin analogues.
AID101097Inhibition of L1210 leukemia cells, after exposure to compound for period of 1 hr1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Nucleotide derivatives of 2,7-diaminomitosene.
AID1603954Mutagenecity against Salmonella typhimurium TA102 assessed as number of colonies in absence of Sprague-Dawley rat S9 with metabolic activation measured after 48 hrs by Ames test ( Rvb = 78.7 +/- 7.8 No_unit)2019Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17
Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation.
AID112165Effective dose that gave 50% inhibition of tumor growth was calculated towards sarcoma 180 cells which were inoculated subcutaneously to the axillary region of ddY mice; 1.9-3.71994Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12
Synthesis and antitumor activity of novel mitomycin derivatives containing functional groups at the C-6-methyl position.
AID389720Cell cycle arrest in human HCT8 cells in hypoxic condition assessed as accumulation at G2/M phase at 10 uM after 48 hrs of drug washout by flow cytometry2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Synthesis of new pyrazolo[5,1-c][1,2,4] benzotriazines, pyrazolo[5,1-c]pyrido[4,3-e][1,2,4] triazines and their open analogues as cytotoxic agents in normoxic and hypoxic conditions.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID356089Cytotoxicity against human SCL9 cells by MTT assay2003Journal of natural products, Jul, Volume: 66, Issue:7
Cytotoxic diterpenes from Scoparia dulcis.
AID405951Cytotoxicity against BRCA2-proficient Chinese hamster BAC29 mutant cells after 3 days by WST1 cell viability assay2008Journal of natural products, Jun, Volume: 71, Issue:6
Marine natural product libraries for high-throughput screening and rapid drug discovery.
AID38197Median survival time (% T/C) after ip administration of a dose of 2 mg/kg/day in B-16 melanoma in mice1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Mitomycin C analogues with secondary amines at position 7.
AID133594Median survival time in days for antitumor activity against P388 Leukemia in CD2 mice at fractioned dose treatment of 1 mg/kg1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Synthesis, mechanism of action, and biological evaluation of mitosenes.
AID8282Antitumor activity against A549 human lung carcinoma cell line1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
New 2-substituted indoloquinone mitomycin analogues.
AID418210Cytotoxicity against human Hep2 cells after 48 hrs by SRB assay2009Bioorganic & medicinal chemistry letters, Mar-01, Volume: 19, Issue:5
Microwave-assisted synthesis of N-substituted cyclic imides and their evaluation for anticancer and anti-inflammatory activities.
AID1254818Cytotoxicity against human SF295 cells after 72 hrs by MTS assay2015Journal of natural products, Oct-23, Volume: 78, Issue:10
Angucyclines and Angucyclinones from Streptomyces sp. CB01913 Featuring C-Ring Cleavage and Expansion.
AID1454347Cytotoxicity against human MDA-MB-231 cells incubated for 24 hrs by MTT asasy2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Synthesis and biological evaluation of 5-fatty-acylamido-1, 3, 4-thiadiazole-2-thioglycosides.
AID596548Cytotoxicity against human Hep2 cells assessed as cell growth inhibition at 1 uM after 48 hrs by sulforhodamine B assay2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Synthesis and in vitro cytotoxic evaluation of N-alkylbromo and N-alkylphthalimido-isatins.
AID397759Cytotoxicity against human breast cancer cells2001Journal of natural products, Jul, Volume: 64, Issue:7
In vitro cytotoxicity of the protoberberine-type alkaloids.
AID112764Antitumor activity against P388 (adriamycin sensitive tumors) in terms of % increase in life span in mice at an optimal dose of 3.0 ug/kg administered ip1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
"Reverse" and "symmetrical" analogues of actinomycin D: metabolic activation and in vitro and in vivo tumor growth inhibitory activities.
AID1303014Cytotoxicity against human PC3 cells2016European journal of medicinal chemistry, Jul-19, Volume: 117Design, synthesis and biological evaluation of diaziridinyl quinone isoxazole hybrids.
AID1446337Growth inhibition of human HuH7 cells after 72 hrs by Cell-Titer Glo assay2017Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15
Conformation-Based Design and Synthesis of Apratoxin A Mimetics Modified at the α,β-Unsaturated Thiazoline Moiety.
AID1454346Cytotoxicity against human HeLa cells incubated for 24 hrs by MTT asasy2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Synthesis and biological evaluation of 5-fatty-acylamido-1, 3, 4-thiadiazole-2-thioglycosides.
AID542127Induction of qnrB4 gene expression in lexA- and recA- positive Escherichia coli J53 at 0.2 ug/ml after 15 mins by quantitative PCR method relative to control2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
SOS regulation of qnrB expression.
AID1446339Growth inhibition of human U87MG cells after 72 hrs by Cell-Titer Glo assay2017Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15
Conformation-Based Design and Synthesis of Apratoxin A Mimetics Modified at the α,β-Unsaturated Thiazoline Moiety.
AID1162268Cytotoxicity against human Hep cells after 48 hrs by SRB assay2014Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19
Synthesis and evaluation of 3-salicyloylpyridine derivatives as cytotoxic mitochondrial apoptosis inducers.
AID667186Antiproliferative activity against human MCF7 cells after 6 days by MTT assay2012Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13
A new 9,11-secosterol from the soft coral Sinularia granosa.
AID1717203Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay2020European journal of medicinal chemistry, Jan-15, Volume: 186Novel diosgenin derivatives containing 1,3,4-oxadiazole/thiadiazole moieties as potential antitumor agents: Design, synthesis and cytotoxic evaluation.
AID119965Optimal dose was calculated towards sarcoma 180 cells which were inoculated subcutaneously to the axillary region of ddY mice; 4.0-6.01994Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12
Synthesis and antitumor activity of novel mitomycin derivatives containing functional groups at the C-6-methyl position.
AID774654Trypanocidal activity against Trypanosoma brucei brucei by Alamar Blue assay2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Approaches to protozoan drug discovery: phenotypic screening.
AID115834Ratio of the number of mice at the initial stage and the final stage of the experiment was reported at a dose of 2.0 mg/kg (Q2dx10) administered i.p.; 22.2/21.251999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID1505059Antiproliferative activity against human CNE2 cells after 48 hrs by MTT assay2018Journal of natural products, 01-26, Volume: 81, Issue:1
Germacrane-Type Sesquiterpenoids with Antiproliferative Activities from Eupatorium chinense.
AID132316Percent inhibition of compound (50 mg/Kg) was evaluated in vivo for antitumor activity against MAC 13 in female NMRI mice on day 291989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Synthesis, mechanism of action, and biological evaluation of mitosenes.
AID138881Average weight change of BDF1 female mice at a dose of 3 mg/kg per injection1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Preparation and antitumor activity of 7-substituted 1,2-aziridinomitosenes.
AID152724Antitumor activity against P388/S (AMD sensitive) in male BDF1 mice measured as % increase in life span (%ILS) at dose 1.0-5.0 mg/Kg/inj, ip1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
New actinomycin D analogues as superior chemotherapeutic agents against primary and advanced colon tumors and colon xenografts in nude mice.
AID109892Half-wave potential produced by the compound at their optimal dose1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Development of new mitomycin C and porfiromycin analogues.
AID117389In vivo inhibitory activity against human lung adenocarcinoma xenograft A-549 in mice at a dose of 2.0 mg/kg (Q2dx9) administered i.p.1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID1546652Cytotoxicity against CHOK1 cells assessed as reduction in cell viability after 24 hrs by MTT assay2020Journal of natural products, 01-24, Volume: 83, Issue:1
Usnic Acid Enaminone-Coupled 1,2,3-Triazoles as Antibacterial and Antitubercular Agents.
AID200824In vitro cytotoxicity of compound was measured on human gastric adenocarcinoma (SNU-1) cells.1998Bioorganic & medicinal chemistry letters, Dec-01, Volume: 8, Issue:23
A concise synthesis and in vitro cytotoxicity of new labdane diterpenes.
AID1162264Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay2014Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19
Synthesis and evaluation of 3-salicyloylpyridine derivatives as cytotoxic mitochondrial apoptosis inducers.
AID338960Cytotoxicity against human HeLa cells assessed as inhibition of colony formation after 5 to 8 days by colony assay2002Journal of natural products, Apr, Volume: 65, Issue:4
Synthesis and structure-activity relationship study of lamellarin derivatives.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID451330Antiproliferative activity against human A549 cells after 72 hrs by trypan blue exclusion assay2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Synthesis and evaluation of bioactive naphthoquinones from the Brazilian medicinal plant, Tabebuia avellanedae.
AID138043Compound (6 mg/Kg) was evaluated in vivo for antitumor activity against MAC 16 in female NMRI mice on day 2 and ratio of tumor weight of treated to that of control was determined1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Synthesis, mechanism of action, and biological evaluation of mitosenes.
AID633838Induction of clastogenic effect in ICR mouse bone marrow cells assessed as chromosomal aberration at 3.5 mg/kg, ip after 48 hrs2012Bioorganic & medicinal chemistry, Jan-01, Volume: 20, Issue:1
Synthesis, antiproliferative activity and genotoxicity of novel anthracene-containing aminophosphonates and a new anthracene-derived Schiff base.
AID123452Anti cancer activity was tested on day10, in mice bearing Lewis lung adenocarcinoma by injecting 0.4 mg/kg dose of compound intraperitoneally and average tumor volume was calculated.1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Cyclopent[a]anthraquinones as DNA intercalating agents with covalent bond formation potential: synthesis and biological activity.
AID121175Evaluated for antitumor activity against B-16 melanoma in mice at a dose 3 mg/kg day, ip, on days 1, 4, and 7 against B-16 Melanoma cell1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Mitomycin C analogues with aryl substituents on the 7-amino group.
AID51924Effect on cross resistance of chinese hamster cells resistant to Actinomycin D.1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Structure-activity relationships of antineoplastic agents in multidrug resistance.
AID234591In vivo antitumor activity (reduction of tumor volume) was determined over treated/control mice at a dose of 3.3 mg/kg2004Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10
New analogue of arenastatin A, a potent cytotoxic spongean depsipeptide, with anti-tumor activity.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID303270Cytotoxicity against human DU145 cells at 10 uM after 48 hrs2007Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
Cytotoxic and apoptotic activities of novel amino analogues of boswellic acids.
AID216747Inhibitory concentration required to kill 50% of the cells was evaluated under aerobic conditions from chinese hamster V79 cells.1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Cyclopropamitosenes, novel bioreductive anticancer agents. Synthesis, electrochemistry, and biological activity of 7-substituted cyclopropamitosenes and related indolequinones.
AID1320148Cytotoxicity against CHL cells assessed as structural aberrations at 0.05 ug/ml after 24 hrs by Giemsa-staining-based microscopic analysis2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Phosphonate-based irreversible inhibitors of human γ-glutamyl transpeptidase (GGT). GGsTop is a non-toxic and highly selective inhibitor with critical electrostatic interaction with an active-site residue Lys562 for enhanced inhibitory activity.
AID402670Cytotoxicity against human A549 cells after 3 days by SRB assay2005Journal of natural products, Jul, Volume: 68, Issue:7
Cytotoxic activity of some natural and synthetic guaianolides.
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1302971Antimicrobial activity against Pseudomonas aeruginosa MTCC 2453 after 24 hrs by well diffusion method2016European journal of medicinal chemistry, Jul-19, Volume: 117Design, synthesis and biological evaluation of diaziridinyl quinone isoxazole hybrids.
AID338962Cytotoxicity against african green monkey Vero cells assessed as inhibition of colony formation after 5 to 8 days by colony assay2002Journal of natural products, Apr, Volume: 65, Issue:4
Synthesis and structure-activity relationship study of lamellarin derivatives.
AID338963Cytotoxicity against MDCK cells assessed as inhibition of colony formation after 5 to 8 days by colony assay2002Journal of natural products, Apr, Volume: 65, Issue:4
Synthesis and structure-activity relationship study of lamellarin derivatives.
AID644119Growth inhibition of human Hep2 cells at 1 uM after 48 hrs by sulpharhodamine B assay2012European journal of medicinal chemistry, Mar, Volume: 49Bakuchiol derivatives as novel and potent cytotoxic agents: a report.
AID153920Maximum % T/C with mitomycin C against P-388 murine leukemia cells in mice.1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Mitomycin C and porfiromycin analogues with substituted ethylamines at position 7.
AID111747Percentage change in WBC at optimum dose on day 31984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Mitomycin C analogues with aryl substituents on the 7-amino group.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID633105Cytotoxicity against human DaOY cells after 1 to 11 days by MTT assay2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Crassocolides N-P, three cembranoids from the Formosan soft coral Sarcophyton crassocaule.
AID1470982Antiproliferative activity against human A549 cells expressing NQO1 after 72 hrs by MTT assay2017European journal of medicinal chemistry, May-26, Volume: 132Design, synthesis, and biological evaluation of NAD(P)H: Quinone oxidoreductase (NQO1)-targeted oridonin prodrugs possessing indolequinone moiety for hypoxia-selective activation.
AID1149682Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as mouse survival at 0.2 mg/kg/day administered qd on day 1 and 5 measured on day 301977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Comparative stereochemistry in the aziridine ring openings of N-methylmitomycin A and 7-methoxy-1,2-(N-methylaziridino)mitosene.
AID1149664Toxicity in CDF1 mouse allografted with mouse P388 cells assessed as change in weight at 3.2 mg/kg/day administered qd on day 1 and 5 (Rvb = 3.4 g)1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Comparative stereochemistry in the aziridine ring openings of N-methylmitomycin A and 7-methoxy-1,2-(N-methylaziridino)mitosene.
AID128732Percent change in body weight [(day 6 - day 1)/ day 1] when P388 Leukemic CD2 mice were treated with a compound (6 mg/Kg)1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Synthesis, mechanism of action, and biological evaluation of mitosenes.
AID402673Cytotoxicity against human KB cells after 3 days by SRB assay2005Journal of natural products, Jul, Volume: 68, Issue:7
Cytotoxic activity of some natural and synthetic guaianolides.
AID478477Antitumor activity against ip dosed mouse EAC implanted in Swiss albino mouse assessed as inhibition of ascitic cell administered daily for 7 days measured on 9th day relative to control2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis, pharmacological activity and comparative QSAR modeling of 1,5-N,N'-substituted-2-(substituted naphthalenesulphonyl) glutamamides as possible anticancer agents.
AID1149651Induction of lambda phage lytic activity in Escherichia coli W1709(lambda) assessed as ratio of plaques in treated culture to control at 0.003 ug/ml preincubated for 90 mins followed by heart infusion broth and glucose addition measured after 120 mins1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Comparative stereochemistry in the aziridine ring openings of N-methylmitomycin A and 7-methoxy-1,2-(N-methylaziridino)mitosene.
AID138887Average weight change of BDF1 female mice at a dose of 6 mg/kg per injection1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Preparation and antitumor activity of 7-substituted 1,2-aziridinomitosenes.
AID426953Cytotoxicity against human SMMC7721 cells after 48 hrs by SRB assay2009Journal of natural products, Jun, Volume: 72, Issue:6
Vladimuliecins A and B: cytotoxic pentacyclic pregnanols from Vladimiria muliensis.
AID537867Anticancer activity against human ZR-75-1 cells assessed as inhibition of cell growth at 5 ug/ml by MTT assay2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Design and synthesis of harzialactone analogues: promising anticancer agents.
AID465496Mutagenic activity in Salmonella Typhimurium TA102 assessed as increase in number of revertants at 0.002 ug/plate by Ames test absence of S9 fraction (Rvb=290+/-10)2010Journal of natural products, Feb-26, Volume: 73, Issue:2
DNA-damaging, mutagenic, and clastogenic activities of gentiopicroside isolated from Cephalaria kotschyi roots.
AID128588Mean relative body weight change of treated / mean relative body weight change of control when compound (2 mg/kg/day) administered to inhibit growth of human tumor xenograft GXF 97 was reported at day 28 in nude mice1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Synthesis, mechanism of action, and biological evaluation of mitosenes.
AID542132Induction of qnrB4 gene expression in lexA- and recA- positive Escherichia coli AB1157 at 0.2 ug/ml after 30 mins by quantitative PCR method relative to control2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
SOS regulation of qnrB expression.
AID1454345Cytotoxicity against human SKOV3 cells incubated for 24 hrs by MTT asasy2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Synthesis and biological evaluation of 5-fatty-acylamido-1, 3, 4-thiadiazole-2-thioglycosides.
AID356956Cytotoxicity against human KB cells after 72 hrs by methylene blue assay2002Journal of natural products, Dec, Volume: 65, Issue:12
New taxane diterpenoids from the leaves and twigs of Taxus sumatrana.
AID303269Cytotoxicity against human MCF7 cells at 10 uM after 48 hrs2007Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
Cytotoxic and apoptotic activities of novel amino analogues of boswellic acids.
AID763931Growth inhibition of human A549 cells assessed as dead cells at 1 uM after 48 hrs by sulforhodamine-B assay relative to control2013European journal of medicinal chemistry, Aug, Volume: 66Synthesis and biological evaluation of ursolic acid-triazolyl derivatives as potential anti-cancer agents.
AID633930Induction of clastogenic effect in ICR mouse bone marrow cells assessed as chromosomal breaks and fragmentation at 3.5 mg/kg, ip after 24 hrs2012Bioorganic & medicinal chemistry, Jan-01, Volume: 20, Issue:1
Synthesis, antiproliferative activity and genotoxicity of novel anthracene-containing aminophosphonates and a new anthracene-derived Schiff base.
AID67635Compound is measured for surviving fractions of EMT6 tumor cells treated in culture with (0.50 uM) concentration for 1 hr under hypoxic condition.1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
2-Methylanthraquinone derivatives as potential bioreductive alkylating agents.
AID399042Cytotoxicity against human DLD1 cells after 3 days by methylene blue staining2005Journal of natural products, Nov, Volume: 68, Issue:11
Cytotoxic clerodane diterpenoids from Casearia membranacea.
AID337078Cytotoxicity against human KB cells2003Journal of natural products, Mar, Volume: 66, Issue:3
Three new cytotoxic sesterterpenes from a marine sponge Spongia sp.
AID137203Antitumor activity against P388 mouse leukemia as maximum and median survival time as % T/C was reported at a dose of 1.6 mg/Kg per injection.1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Synthesis and biological activity of 6-substituted mitosene analogues of the mitomycins.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID537865Anticancer activity against human HeLa cells assessed as inhibition of cell growth at 5 ug/ml by MTT assay2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Design and synthesis of harzialactone analogues: promising anticancer agents.
AID248198Inhibitory concentration againstHuman Caki-1 Renal CellCarcinoma Cell Lines (CD70+) at 4th hour; n=12005Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5
Design, synthesis, and in vitro evaluation of dipeptide-based antibody minor groove binder conjugates.
AID1130144Antileukemic activity against mouse L1210 cells allografted in BDF1 mouse assessed as concentration required to increase 40% life span administered as continuous injection1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Quantitative structure-activity relationships in 2,5-bis(1-aziridinyl)-p-benzoquinone derivatives against leukemia L-1210.
AID1505057Antiproliferative activity against human CaSki cells after 48 hrs by MTT assay2018Journal of natural products, 01-26, Volume: 81, Issue:1
Germacrane-Type Sesquiterpenoids with Antiproliferative Activities from Eupatorium chinense.
AID613379Binding affinity to Escherichia coli pBR322 assessed as DNA interstand cross link at 0.2 mM after 2 hrs by agarose gel electrophoresis in presence of 5 equiv glutathione2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Synthesis and mechanistic studies of a mitomycin dimer containing an eight-membered cyclic disulfide.
AID214043in vitro anticancer activity against cultured U87MG (glioblastoma) human tumor cell line2001Journal of medicinal chemistry, Oct-11, Volume: 44, Issue:21
Synthesis, DNA cross-linking activity, and cytotoxicity of dimeric mitomycins.
AID9807In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Synthesis, mechanism of action, and biological evaluation of mitosenes.
AID109974Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 0.2 ml/mouse (Q2dx10) administered i.p.; 20.9/25.71999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID1149649Induction of lambda phage lytic activity in Escherichia coli W1709(lambda) assessed as ratio of plaques in treated culture to control at 0.05 ug/ml preincubated for 90 mins followed by heart infusion broth and glucose addition measured after 120 mins1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Comparative stereochemistry in the aziridine ring openings of N-methylmitomycin A and 7-methoxy-1,2-(N-methylaziridino)mitosene.
AID461535Cytotoxicity against human DaOY cells by MTT assay2010Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5
Cytotoxic and anti-inflammatory cembranoids from the Dongsha Atoll soft coral Sarcophyton crassocaule.
AID389707Cell cycle arrest in human HCT8 cells in normoxic condition assessed as accumulation at G2/M phase at 10 uM after 24 hrs of drug washout by flow cytometry2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Synthesis of new pyrazolo[5,1-c][1,2,4] benzotriazines, pyrazolo[5,1-c]pyrido[4,3-e][1,2,4] triazines and their open analogues as cytotoxic agents in normoxic and hypoxic conditions.
AID1302970Antimicrobial activity against Escherichia coli MTCC 739 after 24 hrs by well diffusion method2016European journal of medicinal chemistry, Jul-19, Volume: 117Design, synthesis and biological evaluation of diaziridinyl quinone isoxazole hybrids.
AID389713Cell cycle arrest in human HCT8 cells in hypoxic condition assessed as accumulation at G0/G1 phase at 10 uM after 24 hrs of drug washout by flow cytometry2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Synthesis of new pyrazolo[5,1-c][1,2,4] benzotriazines, pyrazolo[5,1-c]pyrido[4,3-e][1,2,4] triazines and their open analogues as cytotoxic agents in normoxic and hypoxic conditions.
AID1149665Toxicity in CDF1 mouse allografted with mouse P388 cells assessed as change in weight at 1.6 mg/kg/day administered qd on day 1 and 5 (Rvb = 3.4 g)1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Comparative stereochemistry in the aziridine ring openings of N-methylmitomycin A and 7-methoxy-1,2-(N-methylaziridino)mitosene.
AID50723Inhibitory activity against clone62, a mouse melanoma cell line in absence of Enterobacter cloacae bL1997Journal of medicinal chemistry, Aug-15, Volume: 40, Issue:17
Immunologically specific activation of a cephalosporin derivative of mitomycin C by monoclonal antibody beta-lactamase conjugates.
AID380008Cytotoxicity against mouse P388 cells at 0.06 ug/mL after 72 hrs by MTT assay2000Journal of natural products, Apr, Volume: 63, Issue:4
A cytotoxic sesquiterpene caffeate from the liverwort Bazzanianovae-zelandiae.
AID23702Partition coefficient (logP)1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Comparative structure-activity relationships of antifolate triazines inhibiting murine tumor cells sensitive and resistant to methotrexate.
AID150189Leukopenia % change in WBC at optimal dose on 3rd day.1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Mitomycin C analogues with secondary amines at position 7.
AID1134754Antibacterial activity against Bacillus subtilis assessed as growth inhibition at 12.5 ug/ml in 100 mm disk at pH 8.0 by single-disk method1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Mitomycin antibiotics. Synthesis of 7-methoxy-1-(N-pyrrolidino)mitosene and its methiodide.
AID478238Cytotoxicity against human GM00637 cells after 24 hrs by MTT assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
The influence of the aziridinyl substituent of benzimidazoles and benzimidazolequinones on toxicity towards normal and Fanconi anaemia cells.
AID234588In vivo antitumor activity (reduction of tumor volume) was determined over treated/control mice at a dose of 1.65 mg/kg2004Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10
New analogue of arenastatin A, a potent cytotoxic spongean depsipeptide, with anti-tumor activity.
AID537868Anticancer activity against human COLO205 cells assessed as inhibition of cell growth at 5 ug/ml by MTT assay2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Design and synthesis of harzialactone analogues: promising anticancer agents.
AID389705Cell cycle arrest in human HCT8 cells in normoxic condition assessed as accumulation at S phase at 10 uM after 48 hrs of drug washout by flow cytometry2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Synthesis of new pyrazolo[5,1-c][1,2,4] benzotriazines, pyrazolo[5,1-c]pyrido[4,3-e][1,2,4] triazines and their open analogues as cytotoxic agents in normoxic and hypoxic conditions.
AID550001Cytotoxicity against human HL60 by MTT assay2010Journal of natural products, Nov-29, Volume: 73, Issue:11
Terpenoids from the aerial parts of Parasenecio deltophylla.
AID153389Evaluation of inhibitory activity against multidrug resistant P388 cells (P388/ADR) cells1995Journal of medicinal chemistry, Dec-22, Volume: 38, Issue:26
Novel inhibitors for multidrug resistance: 1,3,5-triazacycloheptanes.
AID1774827Cytotoxicity against human U2OS cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
AID98095Median survival time against L1210 murine leukemia at 1.5 mg/kg in mice when compared with control1981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
Synthesis and antineoplastic activity of mitosene analogues of the mitomycins.
AID128741Percentage change in body weight [(day 6 - day 1)/ day 1] for antitumor activity against P388 Leukemia in CD2 mice at fractioned dose treatment of 3 mg/kg1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Synthesis, mechanism of action, and biological evaluation of mitosenes.
AID659406Cytotoxicity against human DU145 cells assessed as reduction in mean cell viability after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10
COMPARE analysis of the toxicity of an iminoquinone derivative of the imidazo[5,4-f]benzimidazoles with NAD(P)H:quinone oxidoreductase 1 (NQO1) activity and computational docking of quinones as NQO1 substrates.
AID87724In vitro anticellular activity against HeLa S3 cells1994Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12
Synthesis and antitumor activity of novel 6-alkyl-6-demethylmitomycins.
AID128727Mean relative body weight change of treated / mean relative body weight change of control when compound (2 mg/kg/day) administered to inhibit growth of human tumor xenograft GXF 97 was reported at day 21 in nude mice1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Synthesis, mechanism of action, and biological evaluation of mitosenes.
AID1166321Cytotoxicity against human THP1 cells after 48 hrs by SRB assay2014European journal of medicinal chemistry, Nov-24, Volume: 87β-Ionone derived apoptosis inducing endoperoxides; Discovery of potent leads for anticancer agents.
AID355584Antiproliferative activity against mouse P388 cells at 1 ug after 48 hrs by two-layer agar-diffusion method
AID354538Cytotoxicity against rat C6 cells at 50 ug/mL to 2.5 mg/mL after 3 days treated 4 hrs before db-cAMP challenge by MTT assay1996Journal of natural products, Dec, Volume: 59, Issue:12
Cell-based screen for identification of inhibitors of tubulin polymerization.
AID389702Cell cycle arrest in human HCT8 cells in normoxic condition assessed as accumulation at G0/G1 phase at 10 uM after 48 hrs of drug washout by flow cytometry2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Synthesis of new pyrazolo[5,1-c][1,2,4] benzotriazines, pyrazolo[5,1-c]pyrido[4,3-e][1,2,4] triazines and their open analogues as cytotoxic agents in normoxic and hypoxic conditions.
AID87729In vitro anticellular activity against HeLa S3 cells; 0.59-1.11994Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12
Synthesis and antitumor activity of novel mitomycin derivatives containing functional groups at the C-6-methyl position.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID111422Effect of compound on total white blood cell count in BDG1 male mice, after intraperitoneal administration at a dose of 7.5 mg/kg on day 71981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Development of new mitomycin C and porfiromycin analogues.
AID1065300Cytotoxicity against human NCI-H23 cells after 48 hrs by MTT assay2013European journal of medicinal chemistry, Aug, Volume: 66Diversity-oriented synthesis of α-aminophosphonates: a new class of potential anticancer agents.
AID8429Inhibition of cell growth was studied in human teratocarcinoma (833K).1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Cyclopent[a]anthraquinones as DNA intercalating agents with covalent bond formation potential: synthesis and biological activity.
AID120317Number of cured survivors, 45 days after administration of compound at a dose of 1 mg/kg/day in mice1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Development of new mitomycin C and porfiromycin analogues.
AID356086Cytotoxicity against human SCL cells by MTT assay2003Journal of natural products, Jul, Volume: 66, Issue:7
Cytotoxic diterpenes from Scoparia dulcis.
AID23271Partition coefficient (logD7.4)1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Structure-activity relationships of antineoplastic agents in multidrug resistance.
AID451333Antiproliferative activity against human hepatocytes after 72 hrs by trypan blue exclusion assay2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Synthesis and evaluation of bioactive naphthoquinones from the Brazilian medicinal plant, Tabebuia avellanedae.
AID389710Effect on cell cycle arrest in human HCT8 cells in normoxic condition assessed as DNA fragmentation at 10 uM after 24 hrs of drug washout by flow cytometry2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Synthesis of new pyrazolo[5,1-c][1,2,4] benzotriazines, pyrazolo[5,1-c]pyrido[4,3-e][1,2,4] triazines and their open analogues as cytotoxic agents in normoxic and hypoxic conditions.
AID1158657Cytotoxicity against human HL60 cells after 48 hrs by SRB method2014Journal of natural products, Jun-27, Volume: 77, Issue:6
Eremophilane-type sesquiterpenoids with diverse skeletons from Ligularia sagitta.
AID139404Compound (0.05 ug/mL) was evaluated in vitro for antitumor activity against human tumor xenografts in nude mice; Value expressed as active /total = 42/1041989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Synthesis, mechanism of action, and biological evaluation of mitosenes.
AID1134755Antibacterial activity against Bacillus subtilis assessed as growth inhibition at 5.5 ug/ml in 100 mm disk at pH 8.0 by single-disk method1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Mitomycin antibiotics. Synthesis of 7-methoxy-1-(N-pyrrolidino)mitosene and its methiodide.
AID120835Compound was tested for antitumor activity against P-388 leukemia in mice, activity is expressed as maximum effect (% T/C) = MST(median survival time) treated/ MST control in the presence of compound only; 132->3441986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Mitomycin C analogues with increased metal complexing ability.
AID111250Effect of compound on total white blood cell count in BDG1 male mice, after intraperitoneal administration at a dose of 4.22 mg/kg on day 31981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Development of new mitomycin C and porfiromycin analogues.
AID1134759Induction of lambda phage production in streptomycin-dependent lysogenic Escherichia coli W1709 (lambda) assessed as ratio of plaques in treated culture to control at 3.1 ug/ml1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Mitomycin antibiotics. Synthesis of 7-methoxy-1-(N-pyrrolidino)mitosene and its methiodide.
AID101082Inhibitory concentration on multidrug-resistant L1210 leukemia cells.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Additional nucleotide derivatives of mitosenes. Synthesis and activity against parental and multidrug resistant L1210 leukemia.
AID1149683Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as mouse survival at 0.1 mg/kg/day administered qd on day 1 and 5 measured on day 301977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Comparative stereochemistry in the aziridine ring openings of N-methylmitomycin A and 7-methoxy-1,2-(N-methylaziridino)mitosene.
AID1149660Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as effect on median survival time at 0.4 mg/kg/day administered qd on day 1 and 5 relative to control1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Comparative stereochemistry in the aziridine ring openings of N-methylmitomycin A and 7-methoxy-1,2-(N-methylaziridino)mitosene.
AID397762Cytotoxicity against human lung cancer cells2001Journal of natural products, Jul, Volume: 64, Issue:7
In vitro cytotoxicity of the protoberberine-type alkaloids.
AID119971Optimum dose (mg/kg) against P388 leukemic cells1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Mitomycin C analogues with aryl substituents on the 7-amino group.
AID101243The compound was evaluated for survival of L1210 cells, when compound was exposed for a period of 8-9 hr 1X (10e -9)M conc1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Nucleotide derivatives of 2,7-diaminomitosene.
AID1162265Cytotoxicity against human IMR32 cells after 48 hrs by SRB assay2014Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19
Synthesis and evaluation of 3-salicyloylpyridine derivatives as cytotoxic mitochondrial apoptosis inducers.
AID373321Cytotoxicity against human A549 cells after 72 hrs by Alamar Blue assay2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
New transition metal ion complexes with benzimidazole-5-carboxylic acid hydrazides with antitumor activity.
AID1457331Genotoxicity in human lymphocytes assessed as increase in frequency of micronucleated cells at 0.84 ug/mL after 3 hrs in absence of rat liver S9 fraction by micronucleus assay (Rvb = 0.99%)2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
AID153534Antitumor activity measured as Median survival time in days against P388/ADR cells in ip implanted CDF1 mice, qd 1-91988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Enantiomers of 7-(2,3-epoxypropoxy)actinomycin D as dual-action DNA-acting antitumor agents.
AID510381Cytotoxicity against human DU145 cells after 72 hrs by MTT assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Synthesis and toxicity towards normal and cancer cell lines of benzimidazolequinones containing fused aromatic rings and 2-aromatic ring substituents.
AID81859In vitro cytotoxic activity against human colon cancer cell line HCT15 after 72 hr of drug exposure determined by the SRB assay2004Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5
Synthesis and in vitro evaluation of 7-dialkylaminomethylbenzo[g]quinoxaline-5,10-diones.
AID1853139Effect on DNA damage repair in Caulobacter vibrioides lacking mutL expression assessed as decrease in cell survival rate upto 1 ug/ml and measured after 2 days by agar dilution method2022RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12
Mechanistic insight into the repair of C8-linked pyrrolobenzodiazepine monomer-mediated DNA damage.
AID389708Cell cycle arrest in human HCT8 cells in normoxic condition assessed as accumulation at G2/M phase at 10 uM after 48 hrs of drug washout by flow cytometry2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Synthesis of new pyrazolo[5,1-c][1,2,4] benzotriazines, pyrazolo[5,1-c]pyrido[4,3-e][1,2,4] triazines and their open analogues as cytotoxic agents in normoxic and hypoxic conditions.
AID1254821Cytotoxicity against human M14 cells after 72 hrs by MTS assay2015Journal of natural products, Oct-23, Volume: 78, Issue:10
Angucyclines and Angucyclinones from Streptomyces sp. CB01913 Featuring C-Ring Cleavage and Expansion.
AID136797Relative tumor size on day 28 was reported when compound (2 mg/kg/day) administered to inhibit growth of human tumor xenograft GXF 97 in nude mice1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Synthesis, mechanism of action, and biological evaluation of mitosenes.
AID320488Cytotoxicity against human A549 cells by Alamar blue assay2008Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4
Synthesis, metal ion binding, and biological evaluation of new anticancer 2-(2'-hydroxyphenyl)benzoxazole analogs of UK-1.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID109989Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 2.0 mg/kg (Q2dx10) administered i.p.; 21.3/21.41999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID123573In vivo antitumor activity (reduction of tumor volume) was determined against lewis lung carcinoma, subcutaneously in mice at a dose of 1.65 mg/kg2004Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10
New analogue of arenastatin A, a potent cytotoxic spongean depsipeptide, with anti-tumor activity.
AID1149662Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as effect on median survival time at 0.1 mg/kg/day administered qd on day 1 and 5 relative to control1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Comparative stereochemistry in the aziridine ring openings of N-methylmitomycin A and 7-methoxy-1,2-(N-methylaziridino)mitosene.
AID402675Cytotoxicity against human HCT8 cells after 3 days by SRB assay2005Journal of natural products, Jul, Volume: 68, Issue:7
Cytotoxic activity of some natural and synthetic guaianolides.
AID685157Growth inhibition of human A549 cells at 1 uM after 48 hrs by MTT assay2012European journal of medicinal chemistry, Oct, Volume: 56Synthesis, antimicrobial and cytotoxicity study of 1,3-disubstituted-1H-naphtho[1,2-e][1,3]oxazines.
AID153213Antitumor potency on P388 leukemia cells in culture1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Structure-activity relationships for mitomycin C and mitomycin A analogues.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1774829Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
AID633837Induction of clastogenic effect in ICR mouse bone marrow cells assessed as chromosomal aberration at 3.5 mg/kg, ip after 24 hrs2012Bioorganic & medicinal chemistry, Jan-01, Volume: 20, Issue:1
Synthesis, antiproliferative activity and genotoxicity of novel anthracene-containing aminophosphonates and a new anthracene-derived Schiff base.
AID79010Antitumor activity against HCT116 human colon carcinoma cell line experiment 11989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
New 2-substituted indoloquinone mitomycin analogues.
AID734364Uncompetitive inhibition of hexahistidyl-tagged human IDO12013Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1
Indoleamine 2,3-dioxygenase inhibitory activity of derivatives of marine alkaloid tsitsikammamine A.
AID3214In vitro inhibition of 2780/DOX ovarian cancer cell line1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Structure-activity studies of antitumor agents based on pyrrolo[1,2-a]benzimidazoles: new reductive alkylating DNA cleaving agents.
AID216602In vitro antitumor activity against WiDr colon carcinoma tumor cell line was determined1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Synthesis, mechanism of action, and biological evaluation of mitosenes.
AID542122Induction of qnrB1 gene expression in lexA- and recA- positive Escherichia coli J53 at 0.2 ug/ml after 30 mins by quantitative PCR method relative to control2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
SOS regulation of qnrB expression.
AID115835Ratio of the number of mice at the initial stage and the final stage of the experiment was reported at a dose of 2.0 mg/kg (Q2dx9) administered i.p.1999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID38190Average weight change after ip administration of of a dose of 3 mg/kg/day in B-16 melanoma in mice1983Journal of medicinal chemistry, Oct, Volume: 26, Issue:10
Mitomycin C analogues with secondary amines at position 7.
AID235400Therapeutic ratio is expressed as ratio of optimal dose and minimum effective dose1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Development of new mitomycin C and porfiromycin analogues.
AID621741Antitumor activity against mouse EAC cells transplanted in Swiss albino mouse assessed as tumor weight inhibition in ascetic fluid at 1 mg/kg, ip administered qd for 7 days measured on 8th day2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
2,5-Disubstituted-1,3,4-oxadiazoles/thiadiazole as surface recognition moiety: design and synthesis of novel hydroxamic acid based histone deacetylase inhibitors.
AID1254409Antiproliferative activity against human HL60 cells after 48 hrs by resazurin reduction assay2015Bioorganic & medicinal chemistry, Dec-01, Volume: 23, Issue:23
Modification of cellular DNA by synthetic aziridinomitosenes.
AID261768Cytotoxicity against HCT15 cell line by SRB assay2006Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5
Synthesis and biological evaluation of simplified mycothiazole analogues.
AID95051Compound was tested for antitumor activity against L-1210 Murine leukemia in BDF1 female mice at a dose of 12 mg/kg per injection1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Preparation and antitumor activity of 7-substituted 1,2-aziridinomitosenes.
AID38058Tumor free survivors on 62nd day after ip administration of in B-16 melanoma in mice (dose mg/kg/day); 01983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
Mitomycin C and porfiromycin analogues with substituted ethylamines at position 7.
AID1149668Toxicity in CDF1 mouse allografted with mouse P388 cells assessed as change in weight at 0.2 mg/kg/day administered qd on day 1 and 5 (Rvb = 3.4 g)1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Comparative stereochemistry in the aziridine ring openings of N-methylmitomycin A and 7-methoxy-1,2-(N-methylaziridino)mitosene.
AID542134Induction of qnrB4 gene expression in recA-positive lexA deficient Escherichia coli AB1157 expressing deffective lexA gene at 0.2 ug/ml after 30 mins by quantitative PCR method relative to control2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
SOS regulation of qnrB expression.
AID747042Cytotoxicity against human Hep2 cells at 1 uM after 48 hrs by SRB assay2013European journal of medicinal chemistry, May, Volume: 63Synthesis of 3-O-propargylated betulinic acid and its 1,2,3-triazoles as potential apoptotic agents.
AID263758Antitumor activity against human SMMC7721 cell line by MTT assay2006Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8
Novel skeleton terpenes from Celastrus hypoleucus with anti-tumor activities.
AID389722Effect on cell cycle arrest in human HCT8 cells in hypoxic condition assessed as DNA fragmentation at 10 uM after 24 hrs of drug washout by flow cytometry2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Synthesis of new pyrazolo[5,1-c][1,2,4] benzotriazines, pyrazolo[5,1-c]pyrido[4,3-e][1,2,4] triazines and their open analogues as cytotoxic agents in normoxic and hypoxic conditions.
AID1061804Cytotoxicity against human A549 cells assessed as growth inhibition at 10 uM by SRB assay2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Synthesis of a novel series of artemisinin dimers with potent anticancer activity involving Sonogashira cross-coupling reaction.
AID263759Antitumor activity against human K562 cell line by MTT assay2006Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8
Novel skeleton terpenes from Celastrus hypoleucus with anti-tumor activities.
AID1254819Cytotoxicity against human NCI-H226 cells after 72 hrs by MTS assay2015Journal of natural products, Oct-23, Volume: 78, Issue:10
Angucyclines and Angucyclinones from Streptomyces sp. CB01913 Featuring C-Ring Cleavage and Expansion.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID478476Antitumor activity against ip dosed mouse EAC implanted in Swiss albino mouse assessed as inhibition of ascitic fluid administered daily for 7 days measured on 9th day relative to control2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis, pharmacological activity and comparative QSAR modeling of 1,5-N,N'-substituted-2-(substituted naphthalenesulphonyl) glutamamides as possible anticancer agents.
AID136706Ability of intraperitoneally administered compound (2 mg/kg/day) to inhibit growth of human tumor xenograft GXF 97 was assessed on day 14 in nude mice1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Synthesis, mechanism of action, and biological evaluation of mitosenes.
AID1149671Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as mouse survival at 3.2 mg/kg/day administered qd on day 1 and 5 measured on day 51977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
Comparative stereochemistry in the aziridine ring openings of N-methylmitomycin A and 7-methoxy-1,2-(N-methylaziridino)mitosene.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1717201Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay2020European journal of medicinal chemistry, Jan-15, Volume: 186Novel diosgenin derivatives containing 1,3,4-oxadiazole/thiadiazole moieties as potential antitumor agents: Design, synthesis and cytotoxic evaluation.
AID363580Clastogenic effect on C57BL mouse assessed as number of metaphase chromosomal breaks in bone marrow cells at 3.5 mg/kg, ip after 24 hrs2008European journal of medicinal chemistry, Jun, Volume: 43, Issue:6
Novel N-(phosphonomethyl) glycine derivatives: Design, characterization and biological activity.
AID680289TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 uM, Mitomycin C: 20 uM) in MDR1-expressing NIH-3T3 cells2004Biochemical and biophysical research communications, Mar-19, Volume: 315, Issue:4
Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies.
AID1134756Antibacterial activity against Bacillus subtilis assessed as growth inhibition at 3.1 ug/ml in 100 mm disk at pH 8.0 by single-disk method1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Mitomycin antibiotics. Synthesis of 7-methoxy-1-(N-pyrrolidino)mitosene and its methiodide.
AID359196Cytotoxicity against Spodoptera frugiperda Sf9 cells after 24 hrs by MTT assay2001Journal of natural products, Mar, Volume: 64, Issue:3
Potent antiviral potamogetonyde and potamogetonol, new furanoid labdane diterpenes from Potamogeton malaianus.
AID1761335Genotoxicity in Salmonella typhimurium TA1535/pSK1002 assessed as DNA-damage activity by measuring beta-galactosidase activity at 1 ug/ml measured by SOS-chromotest relative to solvent control
AID542136Induction of qnrB4 gene expression in recA-positive Escherichia coli DM49 expressing protease-resistant lexA at 0.2 ug/ml after 30 mins by quantitative PCR method relative to control2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
SOS regulation of qnrB expression.
AID389717Cell cycle arrest in human HCT8 cells in hypoxic condition assessed as accumulation at S phase at 10 uM after 48 hrs of drug washout by flow cytometry2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Synthesis of new pyrazolo[5,1-c][1,2,4] benzotriazines, pyrazolo[5,1-c]pyrido[4,3-e][1,2,4] triazines and their open analogues as cytotoxic agents in normoxic and hypoxic conditions.
AID735829Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by CCK8 assay2013Journal of natural products, Apr-26, Volume: 76, Issue:4
Structural investigation and biological activity of sesquiterpene lactones from the traditional Chinese herb Inula racemosa.
AID442556Growth inhibition of human OVCAR-3 cells at 10 uM after 48 hrs by sulforhodamine B assay2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Cytotoxic activity of 3-(5-phenyl-3H-[1,2,4]dithiazol-3-yl)chromen-4-ones and 4-oxo-4H-chromene-3-carbothioic acid N-phenylamides.
AID121174Evaluated for antitumor activity against B-16 melanoma in mice at a dose 2 mg/kg day, ip, on days 1, 4, and 7 against B-16 Melanoma cell1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Mitomycin C analogues with aryl substituents on the 7-amino group.
AID134403Anti cancer activity was determined as lethal dose1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Structure-activity relationships for mitomycins. Application of the distance and charge analysis method.
AID1302969Antimicrobial activity against Klebsiella planticola MTCC 530 after 24 hrs by well diffusion method2016European journal of medicinal chemistry, Jul-19, Volume: 117Design, synthesis and biological evaluation of diaziridinyl quinone isoxazole hybrids.
AID87473In vitro anticellular activity against HeLa cells.1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
New potent mitomycin derivatives: synthesis and antitumor activity of 7,7-(ethylenedioxy)mitomycins.
AID121604Activity of compound dose of 1 mg/kg/day against Murine B-16 Melanocarcinoma in mice1981Journal of medicinal chemistry, Aug, Volume: 24, Issue:8
Development of new mitomycin C and porfiromycin analogues.
AID54621Apparent binding constant against calf thymus DNA was determined2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Mitomycin dimers: polyfunctional cross-linkers of DNA.
AID1302968Antimicrobial activity against Micrococcus luteus MTCC 2470 after 24 hrs by well diffusion method2016European journal of medicinal chemistry, Jul-19, Volume: 117Design, synthesis and biological evaluation of diaziridinyl quinone isoxazole hybrids.
AID202213In vitro inhibition of SW480 colon cancer cell line1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Structure-activity studies of antitumor agents based on pyrrolo[1,2-a]benzimidazoles: new reductive alkylating DNA cleaving agents.
AID144114Inhibition of NIH 3T3 cell growth required to induce 50% of maximum response using antiproliferative assay2002Journal of medicinal chemistry, Feb-28, Volume: 45, Issue:5
Synthesis, pharmacokinetics, efficacy, and rat retinal toxicity of a novel mitomycin C-triamcinolone acetonide conjugate.
AID389701Cell cycle arrest in human HCT8 cells in normoxic condition assessed as accumulation at G0/G1 phase at 10 uM after 24 hrs of drug washout by flow cytometry2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Synthesis of new pyrazolo[5,1-c][1,2,4] benzotriazines, pyrazolo[5,1-c]pyrido[4,3-e][1,2,4] triazines and their open analogues as cytotoxic agents in normoxic and hypoxic conditions.
AID109990Ratio of the body weight of mice at the initial stage and the final stage of the experiment was reported at a dose of 2.0 mg/kg (Q2dx10) administered i.p.; 22.2/21.251999Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18
Synthesis and antitumour activity of novel diterpenequinone salvicine and the analogs.
AID356091Cytotoxicity against human NUGC4 cells by MTT assay2003Journal of natural products, Jul, Volume: 66, Issue:7
Cytotoxic diterpenes from Scoparia dulcis.
AID1853119Induction of DNA damage in Caulobacter vibrioides assessed as increase in cell death upto 1 ug/ml and measured after 2 days by agar dilution method2022RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12
Mechanistic insight into the repair of C8-linked pyrrolobenzodiazepine monomer-mediated DNA damage.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11,913)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902776 (23.30)18.7374
1990's3062 (25.70)18.2507
2000's2991 (25.11)29.6817
2010's2402 (20.16)24.3611
2020's682 (5.72)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 77.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index77.35 (24.57)
Research Supply Index9.59 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index143.55 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (77.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials1,738 (13.48%)5.53%
Reviews0 (0.00%)6.00%
Reviews767 (5.95%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies1,218 (9.45%)4.05%
Observational0 (0.00%)0.25%
Observational48 (0.37%)0.25%
Other8 (100.00%)84.16%
Other9,122 (70.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (230)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
HYMN: A Randomized Controlled Phase III Trial Comparing Hyperthermia Plus Mitomycin to a Second Course of Bacillus Calmette-Guerin or Standard Therapy in Patients With Recurrence of Non-Muscle Invasive Bladder Cancer Following Induction or Maintenance Bac [NCT01094964]Phase 3242 participants (Anticipated)Interventional2009-10-31Recruiting
Phase II Study of Bladder-SparIng ChemoradiatioN With Durvalumab in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE) [NCT04216290]Phase 295 participants (Anticipated)Interventional2021-03-17Active, not recruiting
A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions [NCT04172675]Phase 2107 participants (Actual)Interventional2020-02-28Active, not recruiting
A Randomized, Controlled, Open-Label Study of the Efficacy, Durability, and Safety of UGN-102 With or Without TURBT in Patients With Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR NMIBC) [NCT04688931]Phase 3282 participants (Actual)Interventional2021-02-19Terminated(stopped due to Alternate approach pursued)
Single Preoperative Intravesical Instillation of Electromotive Mitomycin-c for Primary Non-muscle Invasive Bladder Cancer: a Prospective Randomized Trial. [NCT01149174]Phase 3352 participants (Actual)Interventional1994-01-31Completed
The Results of Adjunctive Intraoperative Bevacizumab Injection on Trabeculectomy Outcome: A Randomized Controlled Trial [NCT01263834]Phase 2/Phase 339 participants (Actual)Interventional2010-12-31Completed
An Open Label, Phase 2 Trial Comparing Sorafenib and 5-fluorouracil/Mitomycin in Hepatocellular Carcinoma With Pulmonary Metastasis [NCT01171482]Phase 25 participants (Actual)Interventional2015-11-30Terminated(stopped due to There were problems with national reimbursement policies.)
International Randomized Study of Transarterial Chemoembolization Versus CyberKnife for Recurrent Hepatocellular Carcinoma [NCT01327521]Phase 30 participants (Actual)Interventional2011-02-28Withdrawn(stopped due to Accrual below target levels)
REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation [NCT05902533]Phase 2/Phase 333 participants (Anticipated)Interventional2023-08-14Recruiting
Corneal Endothelial Cell Loss Following Trabeculectomy With mitomycin_c Application Before Versus After Sclera Flap Dissection [NCT01297803]Phase 20 participants Interventional2010-11-30Recruiting
A Phase II Protocol for Patients With Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent With Radiosensitizing Chemotherapy Following a Thorough Transurethral Surgical Re-Staging [NCT00981656]Phase 237 participants (Actual)Interventional2009-11-30Completed
A Randomized Phase 2 Trial of Flat Dose vs. Weight-based Dose of Intra-peritoneal (IP) Chemotherapy for Patients Undergoing Cytoreductive Surgery and Heated Intra-peritoneal Chemotherapy (CRS/HIPEC) for Advanced Gastrointestinal Malignancy [NCT04779554]Phase 2100 participants (Anticipated)Interventional2021-06-04Recruiting
Neoadjuvant Short-term Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in NMIBC [NCT03348969]Phase 4120 participants (Actual)Interventional2017-11-01Active, not recruiting
A Phase 2b, Single-Arm, Multicenter Trial to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) at Intermediate Risk of Recurrence [NCT03558503]Phase 263 participants (Actual)Interventional2018-10-15Completed
Limbal Conjunctival Autograft Versus Amniotic Membrane Graft When Combined With Mitomycin C for Recurrent Pterygium: A Randomized Trial [NCT01319721]96 participants (Actual)Interventional2010-12-31Completed
A Single Arm Phase II Trial of the Intraoperative Intravesical Instillation of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma of the Upper Urinary Tract [NCT03658304]Phase 229 participants (Actual)Interventional2018-12-05Active, not recruiting
Intraoperative Mitomycin C Application, Amniotic Membrane Transplantation and Conjunctival Autograft After Primary Pterygium Excision: A Multi-center Randomized Clinical Trial [NCT02102776]750 participants (Anticipated)Interventional2015-12-31Recruiting
A Phase 3 Multicenter Trial Evaluating the Efficacy and Safety of UGN-101 on Ablation of Upper Urinary Tract Urothelial Carcinoma [NCT02793128]Phase 371 participants (Actual)Interventional2017-04-04Completed
A Phase II Study of Cytoreduction, Gastrectomy, and Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology [NCT02891447]Phase 224 participants (Actual)Interventional2016-09-01Completed
Treatment of Ta Bladder Cancer in High Risk of Recurrence - Fluorescence Cystoscopy With Optimized Adjuvant Mitomycin-C (FinnBladder 9) [NCT01675219]Phase 3400 participants (Anticipated)Interventional2012-12-31Active, not recruiting
A Prospective Randomized Comparative Study of the Safety and Effectiveness of Ologen Collagen Matrix Versus Mitomycin-C in Trabeculectomy [NCT01174420]40 participants (Anticipated)Interventional2009-11-30Recruiting
The Effects of Sequential Mitomycin and Bacillus Calmette-Guérin Treatment Versus Bacillus Calmette-Guérin Monotherapy in Patients With High Risk Non-Muscle Invasive Bladder Cancer [NCT03790384]Phase 4140 participants (Anticipated)Interventional2019-01-15Not yet recruiting
Guidance of Adjuvant Instillation in Intermediate Risk Non-muscle Invasive Bladder Cancer by Drug Screens in Patient Derived Organoids. A Single Center, Open-label, Phase II Trial With a Feasibility Endpoint. (GAIN-INST-TRIAL) [NCT05024734]Phase 233 participants (Anticipated)Interventional2022-11-17Recruiting
Chemoembolization in Hepatocellular Carcinoma or Neuroendocrine Hepatic Metastases: A Phase II Multi-Center Trial [NCT00003907]Phase 250 participants (Actual)Interventional1999-12-15Completed
Clinical Trial to Compare Topical Interferon Alfa 2b And Mitomycin C in Conjunctival-Corneal Intraepithelial Neoplasia [NCT02199327]Phase 418 participants (Actual)Interventional2014-05-31Completed
Risk-Adapted Therapy for HIV-Associated Anal Cancer [NCT04929028]Phase 253 participants (Anticipated)Interventional2022-08-09Recruiting
Prospective, Randomized, Open, Controlled, Multicenter Stucy of Interventional Pulmonologic Treatment of Benign Central Airway Fibrotic Stricture [NCT02287389]160 participants (Anticipated)Interventional2014-12-31Not yet recruiting
The Effectiveness and Safety of Neoadjuvant Intravesical Mitomycin-C Instillation in Non-muscle Invasive Bladder Cancer Patients: Prospective, Randomized, Phase II Study [NCT03058757]Phase 271 participants (Actual)Interventional2017-02-01Completed
Intraoperative Mitomycin C Combined With Conjunctival Autograft or Limbal Conjunctival Autograft for Recurrent Pterygium: a Randomized Clinical Trial [NCT04463901]116 participants (Anticipated)Interventional2016-02-29Recruiting
Sequential Intravesical Mitomycin Plus Bacillus Calmette-Guérin for Non-Muscle Invasive Urothelial Bladder Carcinoma: Translational and Phase I Clinical Trial [NCT02311101]Phase 118 participants (Actual)Interventional2012-03-31Completed
Intravesical Mitomycin-C With Bladder Wall Hyperthermia in Intermediate and High Risk Non-muscle Invasive Bladder Cancer [NCT03694535]44 participants (Actual)Interventional2012-01-01Completed
CALIBER - A Phase II Randomised Feasibility Study of Chemoresection and Surgical Management in Low Risk Non Muscle Invasive Bladder Cancer [NCT02070120]Phase 282 participants (Actual)Interventional2014-10-31Active, not recruiting
The Ghana Primary Tube Versus Trabeculectomy Study [NCT02088528]298 participants (Anticipated)Interventional2014-03-31Recruiting
Intravesical Instillation Therapy With Bacillus Calmette-Guérin (BCG) and Sequential BCG and Electromotive Mitomycin-C (EMDA-MCC) in Patients With High-risk Non-muscle-invasive Bladder Carcinoma [NCT03664869]Phase 3300 participants (Anticipated)Interventional2018-10-26Recruiting
Multicentre, Randomized Clinical Trial to Evaluate Safety and Efficacy of Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) With Mitomycin C Used During Surgery for Treatment of Locally Advanced Colorectal Carcinoma [NCT02614534]Phase 3200 participants (Anticipated)Interventional2015-11-16Active, not recruiting
GI-108: Randomized Controlled Double-Blinded Trial Assessing the Efficacy of Topical Mitomycin C for Complex Benign Esophageal Anastomotic Strictures [NCT04037072]Phase 20 participants (Actual)Interventional2020-04-03Withdrawn(stopped due to Study was not approved for Fox Chase Cancer Center's Research Review Committee (RRC))
Decorin as an Antifibrotic Agent in Sub Scleral Trabeculectomy: A Pilot Study [NCT03924544]Phase 152 participants (Anticipated)Interventional2019-09-01Not yet recruiting
A Phase II Evaluation of Dose-Painted Intensity-Modulated Radiation Therapy (IMRT) in Combination With 5-Fluorouracil (5-FU) and Mitomycin-C for Reduction of Acute Morbidity in Carcinoma of the Anal Canal [NCT00423293]Phase 263 participants (Actual)Interventional2006-12-31Completed
Phacotrabeculectomy With Collagen Matrix Implant (Ologen®) Versus Mitomycin C Augmented Phacotrabeculectomy: Clinical Results of a Prospective Randomized Trial [NCT03506542]Phase 253 participants (Actual)Interventional2014-06-02Completed
Phase II Clinical Study of Capecitabine in Combination With Mitomycin C as First-Line Treatment in Patients With Metastatic Breast Cancer [NCT01196455]Phase 239 participants (Anticipated)Interventional2006-03-31Recruiting
Evaluation of Primary Congenital Glaucoma Management at Asyut University Hospital [NCT05205122]30 participants (Anticipated)Interventional2022-02-01Not yet recruiting
Randomised Phase III Trial of Chemoradiotherapy With or Without Paclitaxel in Patients With Squamous-cell Anal Cancer [NCT02526953]Phase 3314 participants (Anticipated)Interventional2016-01-31Enrolling by invitation
Pilot / Phase III Randomized Trial Comparing Standard Systemic Therapy to Cytoreduction + Hyperthermic Intraperitoneal Mitomycin C + Standard Systemic Therapy in Patients With Limited Peritoneal Dissemination of Colon Adenocarcinoma [NCT01167725]Phase 3340 participants (Anticipated)Interventional2010-08-31Active, not recruiting
Phase II Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer [NCT03381352]Phase 227 participants (Anticipated)Interventional2015-12-02Recruiting
Randomized Controlled Study to Evaluate Safety and Efficacy of Ologen® Collagen Matrix Versus Mitomycin-C in Patients With Juvenile-onset Open Angle Glaucoma [NCT03548805]30 participants (Actual)Interventional2018-08-16Completed
A Controlled Clinic Trial of Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen in Combination With Transcatheter Arterial Chemoembolization in Treating Patients With Advanced Hepatocellular Carcinoma [NCT02638857]Phase 1/Phase 260 participants (Anticipated)Interventional2015-09-30Recruiting
Phase II Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life [NCT02701088]Phase 271 participants (Actual)Interventional2015-12-31Active, not recruiting
The Use of Intraoperative Mitomycin-C During Photorefractive Keratectomy and Its Effect on Postoperative Topical Steroid Requirements [NCT02030990]Phase 2/Phase 3300 participants (Anticipated)Interventional2014-08-31Active, not recruiting
Preventing Intravesical Recurrence in Patients With Urothelial Carcinoma of the Upper Urinary Tract: a Pilot Randomized Trial of a Single Prophylactic Bladder Instillation of Mitomycin C After Diagnostic Ureteroscopy [NCT05979909]Phase 140 participants (Anticipated)Interventional2023-09-30Not yet recruiting
A Phase 3b, Open-Label, Single-Arm, Multicenter Study to Assess the Feasibility of Home Instillation of UGN-102 for Treatment of Patients With Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence [NCT05136898]Phase 38 participants (Actual)Interventional2021-11-30Completed
Phase II Single-Blind Randomized Trial Comparing Morbidity of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) Using Mitomycin-C Versus Melphalan for Colorectal Peritoneal Carcinomatosis [NCT03073694]Phase 2100 participants (Anticipated)Interventional2017-07-14Recruiting
Endoscopic Injection of Mitomycin C for the Treatment of Pharyngoesophageal Stenosis Refractory to Endoscopic Treatment With Dilatation in Patients With Head and Neck Cancer [NCT03540953]12 participants (Actual)Interventional2015-01-05Terminated(stopped due to adverse events was observed in all of them, with intense neck pain and ulcer evelopment)
Comparison of Conjunctival Vascularity Changes Using Optical Coherence Tomography Angiography After Trabeculectomy With Mitomycin and Ologen Implants [NCT04493073]Early Phase 1100 participants (Anticipated)Interventional2020-12-01Not yet recruiting
Intravesically Heated Thermo-chemotherapy With Mitomycin-C Prior to TURBT- Prospective Controlled Study [NCT02471547]300 participants (Anticipated)Interventional2016-01-31Recruiting
Comparing Effect of Mitomicin C Versus Placebo for Prevention of Postoperative Endoscopic Sinus Surgery Synechia and Impact on Quality of Life in Thai Patients With Chronic Rhinosinusitis [NCT02106793]Phase 3224 participants (Actual)Interventional2015-03-31Completed
BrUOG 276: A Phase I/II Evaluation of ADXS11-001, Mitomycin,5-fluorouracil (5-FU) and IMRT for Anal Cancer [NCT01671488]Phase 1/Phase 211 participants (Actual)Interventional2013-02-28Terminated(stopped due to pilot data to be used for upcoming larger trial.)
Pilot Study of Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Colorectal Cancer at High Risk for the Development of Metachronous Peritoneal Metastases [NCT02575859]Phase 1/Phase 220 participants (Actual)Interventional2006-01-31Completed
Histopathological Examination of Iris Tissue in Buphthalmos [NCT04011878]11 participants (Actual)Interventional2016-01-31Completed
Micro and Macro Arteriolar Blockade of Hepatocellular Carcinoma (HCC): Treatment With Sorafenib Before and After Hepatic Arterial Embolization (HAE) Therapy for Liver Cancer. [NCT00949182]Phase 220 participants (Actual)Interventional2009-07-31Completed
Comparative Study of Mitomycin C and Internal Nasal Septal Splint in the Treatment of Nasal Synechiae [NCT00966056]Phase 260 participants (Actual)Interventional2007-10-31Completed
Ologen Collagen Matrix Safety and Effective Comparison With Mitomycin-C(MMC) in Glaucoma Surgery [NCT00538590]Phase 420 participants (Actual)Interventional2007-07-31Completed
Chemotherapy, Irradiation, and Surgery for Function-Preserving Curative Therapy of Primary Extremity Soft Tissue Sarcomas: Initial Treatment With I-MAP and GM-CSF; Aerosol GM-CSF During Preoperative Irradiation and Postoperatively [NCT00652860]Phase 239 participants (Anticipated)Interventional2001-08-31Completed
Study of Automated Lamellar Keratectomy With a New Option in Treatment in Symptomatic Patients With Bullous Keratopathy. [NCT00654888]28 participants (Actual)Interventional2005-03-31Completed
Mitomycin and Ifosfamide (MI) as Salvage Therapy for Metastatic Pancreatic Adenocarcinoma: a Phase II Study. [NCT00967291]Phase 221 participants (Actual)Interventional2006-03-31Terminated(stopped due to lack of activity and G3-4 toxicity at interim analysis)
A Phase III Randomized, Double-Blind Trial of Chemoembolization With or Without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients With and Without Vascular Invasion [NCT01004978]Phase 3235 participants (Actual)Interventional2009-10-28Completed
A Phase 1 Study of Sorafenib Integrated With Chemoembolization for Patients With Unresectable Hepatocellular Carcinoma [NCT01042041]Phase 118 participants (Anticipated)Interventional2009-09-30Completed
A Phase 3b Multicenter Extension Trial Evaluating the Efficacy and Safety of UGN-101 (Mitomycin Gel) for Instillation on Ablation of Upper Urinary Tract Urothelial Carcinoma in Recurrent Patients From Trial TC-UT-03 [NCT04006691]Phase 30 participants (Actual)Interventional2019-10-01Withdrawn(stopped due to Due to projected low enrollment, it has decided not to move forward with the study.)
ICARuS (Intraperitoneal Chemotherapy After cytoReductive Surgery): A Multi-center, Randomized Phase II Trial of Early Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surg [NCT01815359]Phase 2292 participants (Anticipated)Interventional2013-03-31Recruiting
Pilot Study of External Hyperthermia and Intravesical Mitomycin-C To Treat Recurrent Bladder Cancer After Resection and Standard Adjuvant Therapy [NCT00734994]Early Phase 115 participants (Actual)Interventional2008-04-30Completed
[NCT00918528]Phase 1/Phase 20 participants Interventional2009-06-30Not yet recruiting
Primary Tube Versus Trabeculectomy Study [NCT00666237]Phase 4242 participants (Actual)Interventional2008-04-01Completed
Comparison of Subconjunctival 5-FU Injection and Mitomycin C for Treatment of Early Bleb Failure, a Randomized Clinical Trial [NCT00644215]40 participants (Anticipated)Interventional2007-06-30Recruiting
Adding Mitomycin to Bacillus of Calmette-Guerin (BCG) as Adjuvant Intravesical Therapy for High-risk, Non-Muscle-invasive Bladder Cancer: a Randomised Phase 3 Trial [NCT02948543]Phase 3501 participants (Actual)Interventional2013-07-31Active, not recruiting
Phase 1b/II Trial of Checkpoint Inhibitor (Pembrolizumab an Anti PD-1 Antibody) Plus Standard IMRT in HPV Induced Stage III/IV Carcinoma of Anus [NCT04046133]Phase 150 participants (Anticipated)Interventional2020-10-19Recruiting
A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent or Refractory Non-Muscle Invasive Bladder [NCT01200992]Phase 384 participants (Actual)Interventional2010-11-30Terminated(stopped due to Lack of Recruitment)
Bevacizumab Versus Mitomycin C as Trabeculectomy Adjuvant in Uncontrolled Glaucoma: A Randomized Pilot Trial. [NCT02901236]Phase 2/Phase 340 participants (Actual)Interventional2014-01-31Completed
Evaluation of the Prophylactic Use of Mitomycin C 0.02% to Inhibit Haze Formation After Photorefractive Keratectomy for High Myopia: 15 x 30 Seconds [NCT00564213]Phase 436 participants (Anticipated)Interventional2005-03-31Completed
Prophylactic Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC CO2) Versus Standard Surgery in Colorectal Carcinoma at High Risk Peritoneal Carcinomatosis. Short and Long-term Outcomes. CHECK STUDY [NCT03914820]330 participants (Anticipated)Interventional2020-06-19Recruiting
Phase II Study Evaluating Combination Chemotherapy + Radiotherapy (RT) With Avelumab in Muscle Invasive Bladder Cancer [NCT03617913]Phase 22 participants (Actual)Interventional2018-09-19Completed
Phase I Study of Transarterial Chemoembolization of Lung Metastases [NCT04200417]Phase 110 participants (Actual)Interventional2019-12-13Completed
A Single-arm Phase-I Trial for the Determination of Safety and Feasibility of the Intravenous Administration of Mitomycin C-treated Donor Peripheral Blood Mononuclear Cells (MICs) for Individualized Immunosuppression in Living Donor Kidney Transplant Reci [NCT02560220]Phase 114 participants (Actual)Interventional2015-08-05Completed
A Phase 1-2a, Multicenter, Open-Label, Multiple Dose, Safety, Tolerability, and Pharmacokinetic Study of Recombinant Human Hyaluronidase (Chemophase®) in Combination With Mitomycin in Patients With Non-Muscular-Invasive Bladder Cancer [NCT00318643]Phase 1/Phase 227 participants (Actual)Interventional2006-03-30Completed
PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study [NCT04115410]4,724 participants (Anticipated)Observational2020-07-01Not yet recruiting
A Phase III Randomized Controlled Trial of Adjuvant Chemotherapy for Advanced Gastric Adenocarcinoma [NCT00296335]Phase 3855 participants (Actual)Interventional2002-02-28Completed
Ph 2 Trial of G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan & Oxaliplatin), Followed by G-FLIP-DM (G-FLIP + Low Doses Docetaxel & MitomycinC), When Used in Combination With Vitamin C, in Patients With Advanced Pancreatic Cancer [NCT01905150]Phase 234 participants (Actual)Interventional2014-07-31Completed
Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C [NCT02040142]Phase 251 participants (Actual)Interventional2011-11-30Completed
Comparison of Canaloplasty and Trabeculectomy in Patients With Open Angle Glaucoma and Inadequate Local Eye Pressure Lowering Therapy - a Prospective, Randomized Study [NCT00854256]60 participants (Anticipated)Interventional2009-04-30Recruiting
Randomized Therapeutic Study Comparing Tumor Resection Followed Immediately by Intraperitoneal Chemotherapy and Systemic Chemotherapy VS Systemic Chemotherapy Alone for the Treatment of Colorectal Cancer Metastatic to the Peritoneum [NCT00006112]Phase 20 participants Interventional1996-01-31Active, not recruiting
Trans Retinoic Acid (Vesanoid) With Chemotherapy in Non-Small Cell Lung Cancer [NCT00005825]Phase 20 participants Interventional1998-09-30Active, not recruiting
A Phase II Study of Intra-arterial Chemotherapy With Cisplatin and Mitomycin-C [NCT00183885]Phase 276 participants (Actual)Interventional2004-10-18Active, not recruiting
Phase I Study of Daily RAD001 Administered Orally in Combination With Mitomycin C, Administered Every Three Weeks to Patients With Advanced Gastric Cancer or Cancer of the Esophagogastric Junction [NCT01042782]Phase 116 participants (Actual)Interventional2008-01-31Completed
Tube Versus Trabeculectomy (TVT) Study [NCT00306852]212 participants (Actual)Interventional1999-10-31Completed
A Feasibility Study for Individualized Treatment of Patients With Advanced Pancreatic Cancer [NCT00276744]Phase 2249 participants (Actual)Interventional2005-10-31Terminated(stopped due to Because there was no longer an active laboratory component to this study.)
A Phase II Study of Substitution of 5-FU (Fluorouracil) by Capecitabine in Scheme of Chemo-radiotherapy in Patients With Squamous Cell Carcinoma of the Anal Canal. [NCT01941966]Phase 251 participants (Anticipated)Interventional2010-11-30Completed
Intravesical Mistletoe Extract in Superficial Bladder Cancer: A Phase III Efficacy Study [NCT02106572]Phase 3546 participants (Anticipated)Interventional2015-04-30Recruiting
Phase II Study Evaluating the Efficacy of 5-fluorouracil/Mitomycin for the Patients With Pulmonary Metastasis of Hepatocellular Carcinoma Who Had Progressive Disease With Sorafenib [NCT01953406]Phase 20 participants (Actual)Interventional2015-11-30Withdrawn(stopped due to No participants were enrolled. Therefore, we stop this study, prematurely.)
Recovery After Endoscopic Dacryocystorhinostomy [NCT00571129]80 participants (Anticipated)Interventional2004-09-30Active, not recruiting
Topical vs Injection Application of Mitomycin C Trabeculectomy Trial [NCT02744690]0 participants (Actual)Interventional2015-03-01Withdrawn(stopped due to The necessary ethical approvals were not obtained in a timely manner.)
Randomized Phase IV Trial to Compare Cetuximab With Concomitant Radiation Therapy With Concomitant Mitomycin-C and 5-Fluorouracil With Radiation Therapy for Locally Advanced Squamous Cell Carcinomas of the Head and Neck [NCT02015650]Phase 44 participants (Actual)Interventional2014-04-30Terminated(stopped due to Low Recruitment rate)
Study of Second Look Surgery With or Without Chemotherapy Intraperitoneally, in the Event of Risk of Intraperitoneal Recurrence [NCT00005944]Phase 20 participants Interventional1999-07-01Terminated(stopped due to insuffisient recruitment)
An Open Label Study Evaluating Short Term Safety and Tolerability of Patients With MUSCLE INVASIVE BLADDER CANCER- for Intravesical Instillation Mitomycin c Mixed With Disposable Device Which Prevents Drug Drainage Out of the Patient's Bladder [NCT01648010]7 participants (Actual)Interventional2011-11-30Completed
Phase 2 Study of Mitomycin C Therapy for Biliary Strictures in Patients With Primary Sclerosing Cholangitis [NCT01688024]Phase 2130 participants (Anticipated)Interventional2012-09-30Recruiting
Ahmed Glaucoma Valve Alone,With Amniotic Membrane or With MMC for Treatment of Refractory Glaucoma [NCT00893490]Phase 10 participants InterventionalRecruiting
Study on the Effect of Mitomycin C 0.02% on the Corneal Endothelial After Photorefractive Keratectomy in Moderate Myopia [NCT00999973]Phase 10 participants Interventional2009-09-30Recruiting
Comparison of Efficacy Between Silicone Ahmed Glaucoma Valves and Second Trabeculectomy in Glaucoma Patients [NCT00665756]40 participants (Actual)Interventional2006-01-31Active, not recruiting
uTRACT Jelmyto Registry: A Multicenter, Prospective and Retrospective Registry to Evaluate Real World Experience and Outcomes of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto [NCT05874921]400 participants (Anticipated)Observational [Patient Registry]2023-11-17Recruiting
A Randomized, Double Blind, Placebo Controled, Multicenter Phase ⅡStudy to Evaluate the Safety and Efficacy of Tyroserleutide for Injection in Hepatocellular Carcinoma(HCC) Patients [NCT00644020]100 participants (Anticipated)Observational2007-12-31Recruiting
The Comparison of Endothelial Cell Count in Pterygium Surgery Relating to the Timing of MMC Application. [NCT02641132]Phase 462 participants (Anticipated)Interventional2015-09-30Not yet recruiting
The Clinical Efficacy of Endoscopic Postdilation Intralesional Injection of Mitomycin-C in Adults With Refractory Benign Esophageal Stricture [NCT04284826]16 participants (Actual)Interventional2013-10-01Completed
A Prospective, Open-label Randomized Clinical Trial of a Single Bladder Instillation of Mitomycin C vs. Gemcitabine vs. No Additional Treatment Immediately After Transurethral Resection of Bladder Tumor (TURBT) [NCT02695771]Phase 3101 participants (Actual)Interventional2016-04-19Completed
Comparison of Efficacy and Safety of Mitomycin and Aflibercept Used to Support Primary Trabeculectomy - a Prospective, Randomized Trial in Patients With Open-angle Glaucoma Undergoing Surgery. [NCT03766425]Early Phase 164 participants (Actual)Interventional2017-06-14Completed
Evaluation of Topical Mitomycin C as Adjuvant Drug to Endoscopic Esophageal Dilation in Children [NCT00551824]10 participants (Anticipated)Interventional2007-10-31Recruiting
Comparison Between Topical Mitomycin C and Cyclosporine After Primary Pterygium Surgery [NCT05627947]Phase 157 participants (Actual)Interventional2021-01-01Completed
A Phase I Study of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology [NCT03330028]Phase 129 participants (Actual)Interventional2017-10-27Completed
Phase Ib Clinical Trial of Sorafenib in Combination With Transarterial Chemoembolization (TACE) in Patients With Unresectable Hepatocellular Carcinoma (HCC) [NCT01011010]Phase 111 participants (Actual)Interventional2009-07-22Completed
ABT-888 as Monotherapy and in Combination With Mitomycin C in Patients With Solid Tumors With Deficiency in Homologous Recombination Repair [NCT01017640]Phase 120 participants (Actual)Interventional2009-10-31Completed
Histopathological Examination of Iris Tissue in Primary Congenital Glaucoma [NCT04079725]15 participants (Anticipated)Interventional2020-12-31Not yet recruiting
A Multicenter Phase III Trial Comparing Induction Chemotherapy Followed by Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone in Stage IV Nasopharyngeal Carcinoma (NPC) [NCT00201396]Phase 3480 participants (Actual)Interventional2003-08-31Completed
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer [NCT03775265]Phase 3475 participants (Anticipated)Interventional2019-06-03Recruiting
Comparative Study of the Safety and Effectiveness Between Ologen (OculusGen) Collagen Matrix Implant and Mitomycin-C in Glaucoma Filtering Surgery [NCT00472810]Phase 340 participants (Actual)Interventional2007-03-31Completed
A Pilot Feasibility Study of Definitive Concurrent Chemoradiation With Pencil Beam Scanning Proton Beam in Combination With 5-Fluorouracil and Mitomycin-C for Carcinoma of the Anal Canal [NCT01858025]Early Phase 125 participants (Actual)Interventional2013-07-31Active, not recruiting
Phase II Trial of Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology [NCT03092518]Phase 227 participants (Actual)Interventional2017-06-05Active, not recruiting
A Major Randomised Trial to Determine the Value of Cisplatin-Based Chemotherapy For All Patients With Non-Small Cell Lung Cancer [NCT00003240]Phase 31,800 participants (Anticipated)Interventional1995-10-31Active, not recruiting
Customized PRK With Mitomycin Versus Customized Lasik for Myopic Astigmatism [NCT00365040]40 participants Interventional2004-12-31Completed
A Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Phase III Clinical Trial to Evaluate the Safety and Efficacy of Injectable Tyroserleutide to Treat Hepatocellular Carcinoma [NCT01489566]Phase 3300 participants (Anticipated)Interventional2011-07-31Enrolling by invitation
A Pilot Trial Assessing the Feasibility of Delivering Topical MTS-01 to Reduce Dermatitis in Patients Receiving Intensity Modulated Radiation With Concurrent 5-Fluorouracil and Mitomycin-C for Stage I-III Carcinoma of the Anal Canal [NCT01324141]Phase 16 participants (Actual)Interventional2011-03-18Terminated(stopped due to Slow, insufficient accrual and failure to meet endpoints.)
Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. [NCT04230759]Phase 2180 participants (Actual)Interventional2020-01-07Active, not recruiting
A Clinical Study Comparing the Inflammatory Response of the Ex-Press Mini Glaucoma Shunt to Trabeculectomy in Subjects With Open-Angle Glaucoma [NCT00597181]Phase 440 participants (Anticipated)Interventional2007-11-30Terminated(stopped due to Patient population limited)
A RANDOMIZED TRIAL OF RADICAL RADIOTHERAPY IN pT1G3 NXM0 BLADDER CANCER [NCT00002490]Phase 30 participants Interventional1991-09-30Completed
A Phase II Trial of Infusional 5-Fluorouracil (5-FU), Calcium Leucovorin (LV), Mitomycin-C (Mito-C), and Dipyridamole (D) in Patients With Locally Advanced Unresected Pancreatic Adenocarcinoma [NCT00003018]Phase 254 participants (Actual)Interventional1997-09-30Completed
A Randomized Controlled Trial of Active Symptom Control With or Without Chemotherapy in the Treatment of Patients With Malignant Pleural Mesothelioma [NCT00075699]Phase 3840 participants (Anticipated)Interventional2003-09-30Completed
Continuous Fluorouracil Plus Mitomycin C Versus Mitomycin C Plus Cisplatin As Chemotherapy Combination In Combined Radiochemotherapy For Locally Advanced Anal Cancer. A Phase II-III Study [NCT00068744]Phase 2/Phase 388 participants (Actual)Interventional2003-07-31Terminated(stopped due to low accrual)
A Phase II Trial of Pre-operative Chemoradiotherapy Followed by Surgical Resection in Pancoast Tumors: Initial Report of Japan Clinical Oncology Group Trial (JCOG 9806) [NCT00128037]Phase 275 participants Interventional1999-05-31Completed
Intermediate Term Outcomes of Intraoperative 5-Fluorouracil Versus Mitomycin c in Trabeculectomy Surgery. [NCT00346489]Phase 470 participants Interventional2004-09-30Completed
Cytoreductive Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy for the Treatment of Peritoneal Carcinomatosis From Gastrointestinal Cancer: an Open Label, Randomized, Prospective, Phase 2 Clinical Trial [NCT00454519]Phase 260 participants (Anticipated)Interventional2007-03-31Recruiting
The Asia Primary Tube Versus Trab (TVT) Study [NCT03274024]300 participants (Anticipated)Interventional2016-09-28Recruiting
Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy. [NCT00148395]Phase 3280 participants Interventional2002-06-30Completed
Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies [NCT04847063]Phase 160 participants (Anticipated)Interventional2021-10-19Recruiting
Phase III Randomized Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) Versus Most Appropriate Therapy in Refractory Pancreatic Cancer Patients [NCT00005870]Phase 30 participants Interventional1999-03-31Active, not recruiting
Phase II Randomized Trial of Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer [NCT00201747]Phase 280 participants (Actual)Interventional2001-09-30Completed
Single Bladder Instillation With Chemotherapy Following Endoscopic Treatment for Upper Tract Urothelial Carcinoma to Reduce Bladder Recurrence [NCT06167057]264 participants (Anticipated)Interventional2023-04-17Recruiting
Anterior Stromal Changes After PRK by Using Intraoperative Mitomicin C. [NCT00599950]Phase 410 participants (Actual)Interventional2007-01-31Completed
Phototherapeutic Keratectomy With Mitomycin C in Adenoviral Infiltrates [NCT00492245]30 participants (Anticipated)Interventional2006-04-30Active, not recruiting
A Randomized Phase II Trial of Second Line Therapy in Advanced Biliary Tract Cancer: Capecitabine or Capecitabine Plus Mitomycin C [NCT01530503]Phase 252 participants (Actual)Interventional2011-11-30Completed
A Randomized Phase II Trial of Sequential Chemo-Immunotherapy Versus Immunotherapy Alone in Carcinoma in Situ of the Urinary Bladder [NCT00023842]Phase 297 participants (Actual)Interventional2001-06-30Completed
Phase II Trial Of Combined Resection, Intraperitoneal Chemotherapy, And Whole Abdominal Radiation For Treatment Of Peritoneal Mesothelioma [NCT00024271]Phase 20 participants Interventional2001-05-31Active, not recruiting
2X2 Factorial Randomized Phase III Study Comparing Standard Versus Reduced Volume Radiotherapy With and Without Synchronous Chemotherapy in Muscle Invasive Bladder Cancer [NCT00024349]Phase 3350 participants (Anticipated)Interventional2001-06-30Completed
Second UK Phase III Anal Cancer Trial: A Trial of Chemoradiation and Maintenance Therapy for Patients With Anal Cancer [NCT00025090]Phase 3600 participants (Anticipated)Interventional2001-03-31Completed
A Randomized Phase I/III Study Of Systematic Chemotherapy With Or Without Hepatic Chemoembolization For Liver-Dominant Metastatic Adenocarcinoma Of The Colon And Rectum [NCT00023868]Phase 30 participants Interventional2001-11-01Terminated(stopped due to redesign)
Randomized Feasibility Study Of Active Symptom Control With Or Without Chemotherapy In The Treatment Of Patients With Mesothelioma [NCT00030459]Phase 20 participants Interventional2000-11-30Active, not recruiting
A Phase II Evaluation of DMAP Plus GM-CSF in the Treatment of Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus [NCT00033644]Phase 20 participants Interventional2002-03-31Terminated
Chemoresection With 4 Weekly Intravesical Instillations Of Mitomycin C Versus Transurethral Resection (TUR) Followed By One Single Immediate Instillation Of Mitomycin C In Single, Small, Papillary Stage Ta, T1 Bladder Tumors: A Prospective Randomized Phas [NCT00042887]Phase 358 participants (Actual)Interventional2002-05-31Terminated(stopped due to low accrual)
A Randomized Phase II Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer [NCT00192049]Phase 290 participants Interventional2003-12-31Completed
A Prospective Pilot Study to Evaluate the Feasibility of Intensity Modulated Proton Therapy in Reducing Toxicity in Anal Cancer [NCT03018418]Phase 214 participants (Actual)Interventional2017-01-04Active, not recruiting
A Phase 1b-2 Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study [NCT03844256]Phase 1/Phase 250 participants (Anticipated)Interventional2019-01-07Recruiting
A Randomized Phase II Study De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE) [NCT04166318]Phase 2252 participants (Anticipated)Interventional2020-01-02Recruiting
Clinical Study of Curcumin in Preventing Postoperative Adhesion of Bilateral Vocal Cords [NCT05688488]Phase 1/Phase 2100 participants (Anticipated)Interventional2023-05-05Recruiting
Occlusion Prevention for Trabeculectomy Procedures Using Combination Ranibizumab and Mitomycin C (MMC) During Surgery (OCTOPUS Study) [NCT00661583]Phase 1/Phase 230 participants (Actual)Interventional2008-04-30Completed
Comparative Study on the Efficacy of Mitomycin and Lobaplatin in the Treatment of Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy [NCT04845490]Phase 2201 participants (Anticipated)Interventional2022-09-01Not yet recruiting
Phase II Study of Laparoscopic Hyperthermic Peritoneal Chemotherapy for Malignant Ascites [NCT00265863]Phase 21 participants (Actual)Interventional2004-08-31Terminated(stopped due to Withdrawn due to slow accrual)
Comparative Study of the Safety and Effectiveness of Ologen Collagen Matrix Versus Mitomycin-C in Glaucoma Filtering Surgery [NCT01440751]Phase 499 participants (Actual)Interventional2011-09-30Completed
Open, Multi-center Phase I/II Trial With Mitomycin C in Combination With 5-Fluorouracil and Folinic Acid in Pretreated Patients With Metastatic Gastrointestinal Cancer [NCT00289445]Phase 1/Phase 20 participants Interventional1999-09-30Completed
The MAX Study: A Randomised Phase II/III Study to Evaluate the Role of Mitomycin C, Avastin and Xeloda in Patients With Untreated Metastatic Colorectal Cancer [NCT00294359]Phase 2/Phase 3333 participants (Anticipated)Interventional2005-06-30Completed
Mitomycin-c Application for Photorefractive Keratectomy [NCT01504282]90 participants InterventionalCompleted
Intrahepatic and Systemic Chemotherapy Together With Antibody to Patients With Non-resectable Liver Metastases From Solid Tumors [NCT01511146]Phase 2100 participants (Anticipated)Interventional2011-07-31Recruiting
Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (>4 cm) - T4 N0-3 M0 or Any T N2-3 M0 [NCT01621217]Phase 121 participants (Anticipated)Interventional2012-06-30Completed
Phase II Individualized Therapies Selection Study for Patients With Metastatic Colorectal Carcinoma According to the Genomic Expression Profile in Tumor Samples. [NCT01703910]Phase 229 participants (Actual)Interventional2012-11-30Completed
[NCT01808495]5 participants (Anticipated)Observational2012-08-31Active, not recruiting
Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal Canal [NCT01843452]Phase 28 participants (Actual)Interventional2012-12-31Terminated(stopped due to Poor recruitment)
An Open-label, Phase 1b Study of Intravenously Administered Pegylated Liposomal Mitomycin C Lipid-based Prodrug (PROMITIL) in Combination With External Beam Radiotherapy in Patients With Advanced Cancer Requiring Palliative Radiotherapy [NCT03823989]Phase 118 participants (Actual)Interventional2019-01-03Completed
A Phase II Study of Mitomycin C, Irinotecan and Cetuximab in Patients With Previously Treated, Metastatic Colorectal Cancer [NCT00271011]Phase 213 participants (Actual)Interventional2005-12-31Terminated(stopped due to The study was discontinued due to the death of a co-investigator and a second co-investigator leaving the institution.)
An Integrated Phase II/III, Open Label, Randomized and Controlled Study of the Safety and Efficacy of CG0070 Adenovirus Vector Expressing GM-CSF in Patients With NMIBC With Carcinoma In Situ Disease Who Have Failed BCG [NCT01438112]Phase 2/Phase 322 participants (Actual)Interventional2014-03-31Terminated(stopped due to Change in study design)
Sequential Bacillus Calmette-Guérin and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin Alone for High Risk Superficial Bladder Cancer: a Prospective Randomised Study [NCT01442519]Phase 3212 participants (Actual)Interventional1994-01-31Completed
A Phase Ⅲ Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M (Docetaxel-PM) In Bacillius Calmette-Guerin Refractory Non-Muscle Invasive Bladder Cancer [NCT02982395]Phase 336 participants (Actual)Interventional2017-01-31Terminated
Combine Transcatheter Arterial Embolization and Radiofrequency Ablation Versus Transcatheter Arterial Embolization Alone for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus [NCT02301091]Phase 3240 participants (Anticipated)Interventional2014-10-31Recruiting
Comparative Study on 3 Snip Punctoplasty With and Without Mitomycine C in the Management of Punctual Stenosis or Occlusion [NCT05586620]18 participants (Actual)Interventional2021-06-01Completed
A Randomized Multi-center Phase I/II Trial of ICM (Irinotecan, Cisplatin, Mitomycin C) With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer [NCT01296763]Phase 118 participants (Actual)Interventional2011-01-31Completed
A Phase II Study of Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Gastric Carcinomatosis or Positive Cytology [NCT02092298]Phase 221 participants (Actual)Interventional2014-05-08Completed
A Pilot Study to Assess Safety and Efficacy of Intraoperative Topical Mitomycin C and Bevacizumab (Avastin) Applied to Bare Sclera in Pterygium Surgery [NCT01115517]Phase 251 participants (Actual)Interventional2010-10-31Completed
Intravesical Adjuvant Electromotive Mitomycin-C in Patients With pTa-pT1 and G1-G2 Non-muscle Invasive Bladder Cancer: a Randomized Controlled Trial [NCT01920269]Phase 2/Phase 3331 participants (Actual)Interventional1994-01-31Completed
A Prospective Study To Evaluate The Raindrop Near Vision Inlay In Presybopic or Pseudophakic Patients Treated With Mitomycin C Following Femtosecond Flap Creation. [NCT03101501]Phase 49 participants (Actual)Interventional2017-02-14Terminated(stopped due to The manufacturing company of the Raindrop Corneal Inlay has stopped distribution or sales of the product.)
A Prospective, Multicenter, Randomized Controlled Clinical Study of Blue Laser-5ALA-photodynamic Therapy (PDT) in the Prevention of Postoperative Tumor Recurrence in High-risk Non-muscle-invasive Bladder Cancer [NCT05547516]140 participants (Anticipated)Interventional2022-09-13Not yet recruiting
Safety and Efficacy of Mitomycin C-based Hyperthermic Intraperitoneal Chemotherapy After Spontaneously Ruptured Hepatocellular Carcinoma and Peritoneal Metastasis: a Randomized Controlled Trial [NCT05544253]Phase 2/Phase 368 participants (Anticipated)Interventional2022-10-01Recruiting
[NCT05494411]0 participants Expanded AccessAvailable
Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma [NCT01922154]Phase 415 participants (Actual)Interventional2009-02-28Completed
A Phase III Randomized Controlled Trial of Adjuvant Chemotherapy for Gastric Adenocarcinoma: Mitomycin and Doxifluridine Versus Intraperitoneal Chemotherapy and Mitomycin, Doxifluridine, and Cisplatin [NCT00296322]Phase 3528 participants (Actual)Interventional2001-10-31Completed
Express Implant Versus Trabeculectomy in a Fibrotic Bleb With Late Failure After Previous Trabeculectomy [NCT04417920]28 participants (Actual)Interventional2017-07-01Completed
A Phase II Trial of Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN BLADDER) [NCT02710734]Phase 278 participants (Actual)Interventional2016-02-24Active, not recruiting
A Phase 1 Study to Evaluate the Safety and Clinical Activity of Intravesicular CAVATAK (Coxsackievirus A21, CVA21) Alone and in Sequential Combination With Low Dose Mitomycin C in Patients With Non-Muscle Invasive Bladder Cancer (VLA-012 CANON) [NCT02316171]Phase 116 participants (Actual)Interventional2015-01-16Completed
A Phase III Randomized Study of 5-Fluorouracil, Mitomycin-C, and Radiotherapy Versus 5-Fluorouracil, Cisplatin, and Radiotherapy in Carcinoma of the Anal Canal [NCT00003596]Phase 3682 participants (Actual)Interventional1998-10-31Completed
Phase I and Pharmacokinetic Study of Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Solid Tumors [NCT00003710]Phase 112 participants (Actual)Interventional1998-08-31Completed
A Phase II Trial of Systemic Chemotherapy (Gemcitabine and Cisplatin) in Combination With Conventional Transarterial Chemoembolization (cTACE) in Patients With Advanced Intra-Hepatic Cholangiocarcinoma (ICC) [NCT02994251]Phase 21 participants (Actual)Interventional2017-06-21Terminated(stopped due to Study terminated due to low enrollment making it unlikely to meet recruitment goals.)
A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Three-Way Cross-over Study to Evaluate the Effect of AF-219 on Methacholine Hyper-Reactivity in Subjects With Asthma [NCT01993329]Phase 220 participants (Actual)Interventional2013-12-16Completed
RADIATION WITH MITOMYCIN C OR PORFIROMYCIN IN THE TREATMENT OF CANCER OF THE HEAD AND NECK AREA [NCT00002507]Phase 30 participants Interventional1992-11-30Completed
A Pilot Clinical Trial of Mitomycin C Modulation of Multidrug Resistance Proteins and a Phase I Evaluation of Mitomycin C and Mitoxantrone in Patients With Acute Myelogenous Leukemia [NCT00003003]Phase 129 participants (Anticipated)Interventional1996-09-30Completed
Comparing Surgical Approaches to Treat Black African and Africa-Caribbean Patients With Uncontrolled Primary Open Angle Glaucoma: A Randomised Feasibility Study [NCT02989207]60 participants (Anticipated)Interventional2016-08-31Recruiting
Evaluation of Mitomycin, Doxorubicin and Cisplatin in the Treatment of Recurrent or Advanced Uterine Sarcomas [NCT00002993]Phase 230 participants (Anticipated)Interventional1997-08-31Terminated
Randomized Trial of Surgical Resection With or Without Pre-Operative Chemotherapy in Patients With Operable Non-Small Cell Lung Cancer (NSCLC) of Any Stage [NCT00003159]Phase 3600 participants (Anticipated)Interventional1997-08-31Completed
Phase II Trial of Lung Chemoembolization [NCT05672108]Phase 230 participants (Anticipated)Interventional2023-05-12Recruiting
A Prospective Randomized Clinical Trial Comparing Three Delivery Methods of Mitomycin-C for Trabeculectomy Surgery: Preoperative Subconjunctival Injection, Intraoperative Subconjunctival Injection, and Topical Application (Conventional Use) During Trabecu [NCT03875911]Phase 465 participants (Actual)Interventional2019-03-30Terminated(stopped due to Problems unique to COVID-19, incomplete data due to a high rate of dropout to minimize non-essential appointments and difficult subject recruitment)
A Randomized Phase III Comparative Study of Paclitaxel With Carboplatin Versus Mitomycin, Ifosfamide, Cisplatin (MIC) Chemotherapy in Inoperable Advanced Stage Non-Small Cell Lung Cancer [NCT00004887]Phase 30 participants Interventional1999-01-31Active, not recruiting
A Randomized Study of MVP 3 Versus 6 Cycles in Advanced Non-Small Cell Lung Cancer [NCT00004209]Phase 30 participants Interventional1998-05-31Active, not recruiting
[NCT00371072]Phase 2/Phase 30 participants Interventional2004-03-31Completed
Subconjunctival Versus Direct Scleral Application of Mitomycin-C in Trabeculectomy [NCT04352660]Phase 4100 participants (Actual)Interventional2016-05-23Completed
Phase III Randomized Trial of Immediate Adjuvant Chemotherapy or Delayed Salvage Chemotherapy in Nasopharyngeal Carcinoma Patients With Post-radiation Detectable Plasma EBV DNA [NCT02363400]Phase 3147 participants (Anticipated)Interventional2014-11-30Enrolling by invitation
A Randomized Study of Mitomycin-C Application in the Endoscopic Surgical Treatment of Patients With Laryngotracheal Stenosis [NCT01523275]15 participants (Actual)Interventional2012-08-31Terminated(stopped due to Due to poor patient accrual, the study was closed prior to reaching the desired study size)
Randomized Trial to Evaluate Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy [NCT02369939]Phase 3118 participants (Anticipated)Interventional2014-12-31Recruiting
The Effect of Sponge Versus No-Sponge Placement of Mitomycin-C on the Outcomes of Trabeculectomy With Ex-PRESS Glaucoma Filtration Device [NCT02016898]Phase 2100 participants (Actual)Interventional2014-03-31Completed
Phase II Study of Mitomycin-C in Patients With Advanced or Recurrent Pancreatic Cancer With Mutated BRCA2 Gene [NCT00386399]Phase 20 participants (Actual)Interventional2006-10-31Withdrawn(stopped due to All consented subjects tested negative for the BRCA2 mutation, therefore, did not meet criteria to start the study, resulting in withdrawal by PI)
Intravesical Electromotive Mitomycin for High Risk Urothelial Non-muscle Invasive Bladder Cancer After Intravesical Bacillus Calmette-Guérin Failure [NCT04311580]Phase 252 participants (Actual)Interventional2000-01-01Completed
A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence [NCT05243550]Phase 3220 participants (Anticipated)Interventional2022-03-01Active, not recruiting
Lucentis Versus Mitomycin C as Adjunctive Agent During Trabeculectomy Surgery [NCT00626782]Phase 2/Phase 324 participants (Actual)Interventional2008-01-31Completed
Trial of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Primary Peritoneal Cancers and Secondary Peritoneal Cancers From Stomach, Colorectal, Appendiceal, and/or Gynecological Origins [NCT03604653]10 participants (Actual)Observational2018-05-15Completed
Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients: A Randomized Phase III Non-inferiority Trial [NCT00974818]Phase 350 participants (Actual)Interventional2009-09-30Terminated(stopped due to Lack of accrual)
A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Participants With Muscle-invasive Bladder Cancer (MIBC) (KEY [NCT04241185]Phase 3636 participants (Anticipated)Interventional2020-05-19Recruiting
A Randomized Phase III Study of Chemotherapy and Radiotherapy Versus Radiotherapy Alone as Adjuvant Treatment to Patients With Node Positive Stages IB or IIA Cervix Cancer [NCT00003209]Phase 3700 participants (Anticipated)Interventional1997-12-31Completed
Sequencing of Chemotherapy and Radiotherapy in Adjuvant Breast Cancer [NCT00003893]Phase 32,250 participants (Anticipated)Interventional1998-07-31Completed
A Multi-Center, Open-Label, Randomized Phase II Trial to Evaluate Hematologic Toxicities After HIPEC With Oxaliplatin or Mitomycin C in Patients With Appendiceal Tumors [NCT01580410]Phase 2136 participants (Actual)Interventional2009-05-31Completed
An Open Phase 1B Study for Assessment of Safety and Therapeutic Efficacy of Promitil in Combination With Oxaliplatin-based Chemotherapy in Patients With Gastro-intestinal Malignancies [NCT04729205]Phase 19 participants (Actual)Interventional2021-01-13Terminated(stopped due to Investigational drug not available)
Safety and Efficacy of Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Ovarian, Uterine, Appendiceal, Colorectal, and Gastric Cancer Patients With Peritoneal Carcinomatosis (PC) [NCT04329494]Phase 149 participants (Anticipated)Interventional2020-08-21Recruiting
Evaluation of the Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel Mixed With Mitomycin C (MMC) in Non-muscle Invasive Bladder Cancer (NMIBC) Patients [NCT02307487]Phase 214 participants (Actual)Interventional2014-12-31Completed
Feasibility Study of Adaptive Radiotherapy for the Treatment of Locally-Advanced Anal Squamous Cell Carcinoma [NCT05838391]20 participants (Anticipated)Interventional2023-05-18Recruiting
Ahmed Glaucoma Valve Surgery With Mitomycin-C [NCT02805257]Phase 2119 participants (Actual)Interventional2016-06-30Completed
A Prospective Study to Evaluate the Raindrop Near Vision Inlay in Presbyopic Patients With Treatments to Optimize the Ocular Surface Before Implantation [NCT03126877]Phase 440 participants (Anticipated)Interventional2017-04-10Recruiting
A Phase IIa Study of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and PD-L1 Expression in Gastric Cancer With Peritoneal Metastases [NCT04107077]Phase 221 participants (Anticipated)Interventional2019-11-11Recruiting
Phase II Trial of Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies [NCT02369458]Phase 248 participants (Actual)Interventional2015-04-14Active, not recruiting
A Multicenter, Single-Arm Study Evaluating the Efficacy of Synergo® Radiofrequency-Induced Thermochemotherapy Effect (RITE) With Mitomycin C (Synergo® RITE + MMC) in CIS Non-Muscle Invasive Bladder Cancer (NMIBC) Bacillus Calmette-Guérin (BCG)-Unresponsiv [NCT03335059]Phase 35 participants (Actual)Interventional2019-04-04Terminated(stopped due to poor enrollment)
PERSONALIZED MEDICINE GROUP / UCBG UC-0105/1304: SAFIR02_Breast - Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer [NCT02299999]Phase 21,460 participants (Actual)Interventional2014-04-07Active, not recruiting
A Prospective Study to Evaluate the Raindrop Near Vision Inlay in Presbyopes Treated With Mitomycin C During Surgery and Extended Steroid After Surgery [NCT03242317]Phase 440 participants (Anticipated)Interventional2017-06-16Recruiting
Evaluation of Conjunctival Autografting Augmented With Mitomycin-C Application Versus Ologen Implantation in Surgical Treatment of Recurrent Pterygium [NCT04419038]63 participants (Actual)Interventional2016-01-15Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00003907 (3) [back to overview]Tumor Response
NCT00003907 (3) [back to overview]Time to Progression
NCT00003907 (3) [back to overview]Overall Survival
NCT00276744 (1) [back to overview]6-month Overall Survival
NCT00296322 (3) [back to overview]Overall Survival
NCT00296322 (3) [back to overview]Relapse-free Survival
NCT00296322 (3) [back to overview]Toxicity Profile (According to NCI CTC Version 2.0)
NCT00296335 (3) [back to overview]Overall Survival Rate
NCT00296335 (3) [back to overview]Relapse-free Survival Rate
NCT00296335 (3) [back to overview]Number of Patients With Adverse Events
NCT00306852 (6) [back to overview]Failure Rate
NCT00306852 (6) [back to overview]Visual Acuity
NCT00306852 (6) [back to overview]Rate of Complications
NCT00306852 (6) [back to overview]Change in Intraocular Pressure
NCT00306852 (6) [back to overview]Reoperations for Glaucoma
NCT00306852 (6) [back to overview]Need for Supplemental Medical Therapy
NCT00318643 (6) [back to overview]Maximum Tolerated Dose (MTD) of Chemophase in Combination With MMC
NCT00318643 (6) [back to overview]Number of Participants Who Remained Tumor Free at the End of the Study
NCT00318643 (6) [back to overview]Number of Participants With Dose Limiting Toxicities (DLTs)
NCT00318643 (6) [back to overview]Recommended Dose of Chemophase With MMC For Future Studies
NCT00318643 (6) [back to overview]Number of Participants With a Quantifiable MMC Plasma Concentration Value
NCT00318643 (6) [back to overview]Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
NCT00423293 (12) [back to overview]Percentage of Subjects With Acute Gastrointestinal (GI) and Genitourinary (GU) Adverse Events (AE) ≥ Grade 2 as Defined by CTCAE v3.0 (Common Terminology Criteria for Adverse Events)
NCT00423293 (12) [back to overview]Clinical Complete Response Rate
NCT00423293 (12) [back to overview]Percentage of Subjects With Acute Adverse Events (AE)
NCT00423293 (12) [back to overview]Percentage of Subjects With Late Adverse Events (AE)
NCT00423293 (12) [back to overview]Five-year Rate of Disease-free Survival
NCT00423293 (12) [back to overview]Duration of Radiotherapy Treatment
NCT00423293 (12) [back to overview]Five-Year Cumulative Incidence Rate of Colostomy Failure
NCT00423293 (12) [back to overview]Five-Year Cumulative Incidence Rate of Distant Failure
NCT00423293 (12) [back to overview]Five-Year Cumulative Incidence Rate of Local-regional Failure
NCT00423293 (12) [back to overview]Five-Year Rate of Colostomy-free Survival
NCT00423293 (12) [back to overview]Five-year Rate of Overall Survival
NCT00423293 (12) [back to overview]Number of Patients With Major Radiation Planning Deviations
NCT00538590 (5) [back to overview]Complications
NCT00538590 (5) [back to overview]Postoperative Intraocular Pressure Change
NCT00538590 (5) [back to overview]Postoperative Intraocular Pressure Change
NCT00538590 (5) [back to overview]Postoperative Intraocular Pressure Change
NCT00538590 (5) [back to overview]Postoperative Intraocular Pressure Change
NCT00626782 (2) [back to overview]Post-Operative Requirement for Glaucoma Medication
NCT00626782 (2) [back to overview]Adverse Events
NCT00661583 (4) [back to overview]Mean Change in Visual Acuity
NCT00661583 (4) [back to overview]Mean Change in in Intraocular Pressure.
NCT00661583 (4) [back to overview]Percent of Subjects With a Qualified Success and Viable Bleb at 6 Months.
NCT00661583 (4) [back to overview]Assessment of Ocular Adverse Events
NCT00666237 (7) [back to overview]Reoperation for Glaucoma
NCT00666237 (7) [back to overview]Number of Glaucoma Medications
NCT00666237 (7) [back to overview]Number of Participants With Surgical Failure
NCT00666237 (7) [back to overview]Visual Acuity as Measured Using EDTRS Chart
NCT00666237 (7) [back to overview]Intraocular Pressure
NCT00666237 (7) [back to overview]Visual Acuity Using a Snellen Chart
NCT00666237 (7) [back to overview]Number of Participants With Reported Postoperative Complications
NCT00734994 (2) [back to overview]Median Recurrence Free-survival
NCT00734994 (2) [back to overview]Safety and Tolerability
NCT00974818 (1) [back to overview]Response to Treatment
NCT00981656 (6) [back to overview]Percentage of Participants Alive at 3 Years
NCT00981656 (6) [back to overview]Percentage of Participants Free From Radical Cystectomy at 3 Years
NCT00981656 (6) [back to overview]Percentage of Participants With Local Recurrence at 3 Years
NCT00981656 (6) [back to overview]American Urological Association Total Symptom Score at Baseline and at 3 Years
NCT00981656 (6) [back to overview]Distribution of Participants by Highest Grade Adverse Event
NCT00981656 (6) [back to overview]Percent of Participants With Distant Disease Progression at 3 Years
NCT01004978 (4) [back to overview]Overall Survival (OS)
NCT01004978 (4) [back to overview]Progression-free Survival (PFS) Among Patients With Intra-hepatic Progression
NCT01004978 (4) [back to overview]Progression-free Survival (PFS) Among Patients With Extra-hepatic Progression
NCT01004978 (4) [back to overview]Progression-free Survival (PFS)
NCT01115517 (3) [back to overview]Number of Participants Who Had Related Serious Adverse Events From the Time of Treatment to 1 Year
NCT01115517 (3) [back to overview]Number of Participants Who Had Complications From the Time of Treatment to Recurrence
NCT01115517 (3) [back to overview]Number of Participants Who Had Recurrence of Pterygia up to 1 Year
NCT01200992 (1) [back to overview]Comparison of Safety of EN3348 With Mitomycin C [Adverse Events (Other Than Serious Adverse Events) With Frequency Threshold of 5% or Greater].
NCT01296763 (2) [back to overview]Number of Participants Who Experienced a Dose Limiting Toxicity to Determine the Maximum Tolerated Dose (MTD)
NCT01296763 (2) [back to overview]Number of Years From Cycle 1, Day 1 On-Study to Date of Death
NCT01319721 (5) [back to overview]Eye Movement Amplitude (EMA)
NCT01319721 (5) [back to overview]Postoperative Conjunctival Inflammation
NCT01319721 (5) [back to overview]Complications
NCT01319721 (5) [back to overview]Healing Time of Corneal Epithelial Defect
NCT01319721 (5) [back to overview]Recurrence
NCT01324141 (19) [back to overview]Brief Pain Inventory Score
NCT01324141 (19) [back to overview]Mean Grade of Toxicity at Each Timepoint and Location for All Participants Who Underwent Treatment
NCT01324141 (19) [back to overview]Number of Cluster of Differentiation 4+ (CD4) Cells Per Gram of Biopsied Intestinal Tissue
NCT01324141 (19) [back to overview]Number of Cluster of Differentiation 8+ (CD8) Cells Per Gram of Biopsied Intestinal Tissue
NCT01324141 (19) [back to overview]Number of Grade 1 and Higher Adverse Events Possibly, Probably, or Definitely Related to Topical MTS-01 and 5-Fluoruracil (5-FU)/Mitomycin C (MMC)/Intensity-modulated Radiotherapy (IMRT)
NCT01324141 (19) [back to overview]Mean Percentage Pain Relief After Medication
NCT01324141 (19) [back to overview]Pain Interference
NCT01324141 (19) [back to overview]Percentage of Total Viable Cells That Were Cluster of Differentiation 3+ (CD3+) Cells in Biopsied Tissue
NCT01324141 (19) [back to overview]Peripheral Blood Mononuclear Cells (Vascular Endothelial Growth Factor (VEGF), Tumor Necrosis Factor Alpha (TNF-alpha), Interleukin-7 (IL-7), and Transforming Growth Factor Beta-1 (TGF-beta1) Cell Counts at Baseline and Course 1 Day 28
NCT01324141 (19) [back to overview]Ratio of the Number of Cluster of Differentiation 4 (CD4): Cluster of Differentiation 8 (CD8) Cells in the Circulation and Tissue Pre and Post Treatment
NCT01324141 (19) [back to overview]Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE)
NCT01324141 (19) [back to overview]Duration of Overall Response (DOR)
NCT01324141 (19) [back to overview]Number of Participants That Required a Treatment Break Relative to Hematologic Toxicity (Non-dermatologic)
NCT01324141 (19) [back to overview]Number of Participants Treated With Topical MTS-01 and 5-Fluoruracil (5-FU)/Mitomycin C (MMC)/Intensity-modulated Radiotherapy (IMRT) That Required Opiates
NCT01324141 (19) [back to overview]Number of Participants With 12 Month Disease Free Survival (DFS) Treated With 5-Fluoruracil (5-FU)/Mitomycin C (MMC)/Intensity-modulated Radiotherapy (IMRT)
NCT01324141 (19) [back to overview]Number of Participants With 12-month Progression-free Survival Treated With 5-Fluoruracil (5-FU)/Mitomycin C (MMC)/Intensity-modulated Radiotherapy (IMRT)
NCT01324141 (19) [back to overview]Number of Participants With Tumor Tissue Negative for Human Papilloma Virus (HPV)
NCT01324141 (19) [back to overview]Overall Survival
NCT01324141 (19) [back to overview]Absolute Number of Cluster of Differentiation 3+ (CD3) Cells Per Gram of Biopsied Intestinal Tissue
NCT01523275 (3) [back to overview]Time to Repeat Surgery
NCT01523275 (3) [back to overview]Peak Inspiratory Flow Measurement
NCT01523275 (3) [back to overview]Duration of Symptom Improvement
NCT01580410 (4) [back to overview]Quality of Life as Assessed by Functional Assessment of Cancer Therapy: General (FACT-G)
NCT01580410 (4) [back to overview]The Difference in the Number of Grade 3 or 4 Hematologic Toxicities (Leukopenia, Thrombocytopenia, and Neutropenia) Between the Mitomycin C and Oxaliplatin Treatments
NCT01580410 (4) [back to overview]The Difference in Percentage of Disease-free Survival Between the Two Treatment Arms up to 3 Years
NCT01580410 (4) [back to overview]The Difference in Percentage of Overall Survival Between the Two Treatment Arms up to 3 Years
NCT01671488 (3) [back to overview]To Evaluate the 6-month Clinical Complete Response Rate for Patients With Anal Cancer Treated With ADXS11-001 Mitomycin, 5-FU and IMRT.
NCT01671488 (3) [back to overview]To Evaluate the Safety of the Addition of ADXS11-001 to Standard Chemoradiation for Patients With Anal Cancer.
NCT01671488 (3) [back to overview]To Evaluate Progression-free and Overall Survival for Patients With Anal Cancer Treated With ADXS11-001, Mitomycin, 5-FU and IMRT.
NCT01993329 (2) [back to overview]Highest FEV1 After Methacholine Challenge
NCT01993329 (2) [back to overview]Provocative Concentration (PC20) After Methacholine Challenge
NCT02016898 (2) [back to overview]Change in Intraocular Pressure
NCT02016898 (2) [back to overview]Complication Rates
NCT02092298 (2) [back to overview]Overall Survival (OS) From the First Laparoscopic HIPEC
NCT02092298 (2) [back to overview]Overall Survival (OS) After Hyperthermic Intraperitoneal Chemotherapy
NCT02316171 (1) [back to overview]Incidence of Dose-limiting Toxicities Treatment-related Adverse Events.
NCT02369458 (4) [back to overview]Tumor Response Rate (TRR) for Participants Enrolled Post October 2020
NCT02369458 (4) [back to overview]Number of Participants With Grade 3/4/5 Adverse Events
NCT02369458 (4) [back to overview]Progression-free Survival (PFS)
NCT02369458 (4) [back to overview]Tumor Response Rate (TRR)
NCT02695771 (2) [back to overview]Number of Participants Without Grade ≥ 3 Adverse Event, Graded According to NCI CTCAE Version 4.03
NCT02695771 (2) [back to overview]Freedom From Bladder Stones/Dystrophic Calcification
NCT02793128 (8) [back to overview]Pharmacokinetic: The PK Profiles of the First UGN-101 Instillation in the Blood Were to be Examined for the First 6 Patients.
NCT02793128 (8) [back to overview]The Key Secondary Efficacy Endpoint Was Long-term Durability of Complete Response (CR): Number of Patients Who Maintained CR at 12 Month Post PDE Visit. This Endpoint Was Defined Only for Those Patients Who Achieved CR at the PDE Visit.
NCT02793128 (8) [back to overview]Pharmacokinetic: The PK Profiles of the First UGN-101 Instillation in the Blood Were to be Examined for the First 6 Patients.
NCT02793128 (8) [back to overview]Safety Adverse Event Outcomes: Safety Was Monitored Throughout the Study by Reviewing Adverse Events (AEs).
NCT02793128 (8) [back to overview]The Primary Efficacy Endpoint Was the Number of Patients Attaining Complete Response (CR) at the End of the Treatment Period (PDE Visit).
NCT02793128 (8) [back to overview]Pharmacokinetic: The PK Profiles of the First UGN-101 Instillation in the Blood Were to be Examined for the First 6 Patients.
NCT02793128 (8) [back to overview]Durability of Complete Response (CR) for Each Follow-up Time Point.
NCT02793128 (8) [back to overview]Clinical Benefit for Patients With Partial Response (PR) at the Primary Disease Evaluation (PDE) Visit. Clinical Benefit Endpoint Was Analyzed Using the Intent-to-Treat (ITT) Analysis Set, Including Patients Who Achieved Partial Response at PDE Visit.
NCT02805257 (8) [back to overview]Visual Acuity
NCT02805257 (8) [back to overview]Visual Acuity
NCT02805257 (8) [back to overview]Number of Participants With Postoperative Complications
NCT02805257 (8) [back to overview]Number of Participants With Intraoperative Complications
NCT02805257 (8) [back to overview]Intraocular Pressure After Surgery
NCT02805257 (8) [back to overview]Intraocular Pressure After Surgery
NCT02805257 (8) [back to overview]Number of Medications Postoperatively
NCT02805257 (8) [back to overview]Number of Medications Postoperatively
NCT03018418 (7) [back to overview]Quality of Life Changes
NCT03018418 (7) [back to overview]Complete Response Rate
NCT03018418 (7) [back to overview]Rates of Late Toxicity
NCT03018418 (7) [back to overview]Rates of Acute Toxicity
NCT03018418 (7) [back to overview]Overall Survival
NCT03018418 (7) [back to overview]Local Progression Free Survival
NCT03018418 (7) [back to overview]Distant Metastases Free Survival
NCT03558503 (10) [back to overview]Complete Response (CR) Rate for UGN-102 Treatment
NCT03558503 (10) [back to overview]Number of Participants With Treatment-emergent Adverse Events (TEAEs), Study Drug or Procedure Related TEAEs, TEAEs by Maximum Severity, TEAEs Leading to Treatment Discontinuation, and Serious TEAEs.
NCT03558503 (10) [back to overview]Number of Participants With Post-baseline Potentially Clinically Significant (PCS) Laboratory Values
NCT03558503 (10) [back to overview]Mitomycin Plasma Concentrations
NCT03558503 (10) [back to overview]Number of Participants With Post-baseline Clinically Significant (CS) Physical Examination Findings
NCT03558503 (10) [back to overview]Mitomycin Maximum Plasma Concentration (Cmax)
NCT03558503 (10) [back to overview]Number of Participants With Post-baseline PCS Vital Signs Values
NCT03558503 (10) [back to overview]Durable Complete Response (DCR) Rate
NCT03558503 (10) [back to overview]Mitomycin Area Under the Plasma Concentration-time Curve (AUC)
NCT03558503 (10) [back to overview]Number of Participants With Post-baseline CS Urology-oriented Physical Examination Findings
NCT03617913 (2) [back to overview]Progression-free Survival
NCT03617913 (2) [back to overview]Proportion of Participants With Complete Response (At 6 Months)
NCT03658304 (1) [back to overview]Bladder Tumor Recurrence Rate
NCT04352660 (5) [back to overview]Visual Acuity
NCT04352660 (5) [back to overview]Bleb Morphology
NCT04352660 (5) [back to overview]Number of Participants With Surgical Complications
NCT04352660 (5) [back to overview]Number of Participants Requiring Additional Surgery
NCT04352660 (5) [back to overview]Postoperative Interventions

Tumor Response

Clinical complete response was defined as complete disappearance of all clinically detectable malignant disease for at least 4 weeks. Partial response was defined as >= 50% decrease in tumor size for at least 4 weeks without increase in size of any area of known malignant disease of greater than 25%, or appearance of new areas of malignant disease. Tumor response was defined as complete response + partial response. (NCT00003907)
Timeframe: Assessed every 6 weeks

InterventionProportion of participants (Number)
Hepatocellular Carcinoma0
Neuroendocrine Hepatic Metastases0.17

[back to top]

Time to Progression

Time to progression was defined as time from embolization to documented disease progression. Patients without documented progression were censored at the time of the last documented disease evaluation or of the last treatment ended, whichever was more recent.Disease progression was defined as significant increase in size of lesions or appearance of new metastatic lesions. Specifically, 1) >=25% increase in the area of any malignant lesions greater than 2 cm² or in the sum of the products of the individual lesions in a given organ site; 2)>=50% increase in the size of the product of diameters if only one lesion is available for measurement and was less than or equal to 2 cm² in size at the initiation of therapy; 3)>=25% increase in the sum of the liver measurements below the costal margins and xyphoid; 4)Appearance of new malignant lesions (NCT00003907)
Timeframe: Assessed every 3 months for 2 years, then every 6 months for 3 year.

InterventionMonths (Median)
Hepatocellular Carcinoma2.3
Neuroendocrine Hepatic Metastases7.2

[back to top]

Overall Survival

Overall survival was defined as time from registration to death from any causes. (NCT00003907)
Timeframe: Assessed every 3 months for 2 years, then every 6 months for 3 year.

InterventionMonths (Median)
Hepatocellular Carcinoma12.0
Neuroendocrine Hepatic Metastases21.2

[back to top]

6-month Overall Survival

Percentage of patients survived at 6 months for patients whose tumors were xenografted and treated in the mouse when treated with the most active agent identified in that model (NCT00276744)
Timeframe: 6 months

Interventionpercentage of participants (Number)
Arm 153

[back to top]

Overall Survival

(NCT00296322)
Timeframe: 3 years

Interventionpercentage of participants (Number)
Mitomycin and Short-term Fluoropyrimidine59.6
iceMFP71.2

[back to top]

Relapse-free Survival

(NCT00296322)
Timeframe: 3 years

Interventionpercentage of participants (Number)
Mitomycin and Short-term Fluoropyrimidine50.0
iceMFP60.2

[back to top]

Toxicity Profile (According to NCI CTC Version 2.0)

Because safety profile in oncology study is evaluated for each toxicity, it is impossible to present the overall patient number. Instead, we presented the number of patients who declined study therapy due to adverse events or patient will. (NCT00296322)
Timeframe: up to 1 year

Interventionparticipants (Number)
Mitomycin and Short-term Fluoropyrimidine13
iceMFP30

[back to top]

Overall Survival Rate

Overall survival rate at 3 years was defined as the proportion of patients who were alive at 3 years after surgery. (NCT00296335)
Timeframe: 3 years

Interventionpercentage of participants (Number)
Mitomycin Plus Short-term Fluoropyrimidine76.9
Mitomycin Plus Long-term Fluoropyrimidine and Monthly Cisplati73.1

[back to top]

Relapse-free Survival Rate

"Relapse-free survival at 3 years was defined as the proportion of patients who did not show an evidence of disease recurrence after 3 years of surgery.~Relapse was defined as any new tumor lesion." (NCT00296335)
Timeframe: 3 years

Interventionpercentage of participants (Number)
Mitomycin Plus Short-term Fluoropyrimidine67.0
Mitomycin Plus Long-term Fluoropyrimidine and Monthly Cisplati64.9

[back to top]

Number of Patients With Adverse Events

Per National Cancer Institute Common Toxicity Criteria version 2.0, up to 3 years (NCT00296335)
Timeframe: Up to 3 years

,
Interventionparticipants (Number)
NeutropeniaAnemiaThrombocytopeniaFatigueDiarrheaNauseaVomiting
Mitomycin Plus Long-term Fluoropyrimidine and Monthly Cisplati387413156391288371160
Mitomycin Plus Short-term Fluoropyrimidine262393101343219293104

[back to top]

Failure Rate

Failure was prospectively defined as IOP greater than 21 mm Hg or less than 20 percent reduction below baseline on 2 consecutive follow-up visits after 3 months, IOP less than or equal to 5 mm Hg on 2 consecutive follow-up visits after 3 months, re-operation for glaucoma, or loss of light perception vision. (NCT00306852)
Timeframe: 5 years

Interventionpercentage of participants (Number)
Trabeculectomy46.9
Implant29.8

[back to top]

Visual Acuity

Visual acuity was measured by the total number of letters read (correctly) using a ETDRS eye chart (NCT00306852)
Timeframe: 5 years

,
InterventionLetters (Mean)
PATIENTS WITH COMPLICATIONSPATIENTS WITHOUT COMPLICATIONS
Implant3346
Trabeculectomy5644

[back to top]

Rate of Complications

Complications associated with both surgical procedures (NCT00306852)
Timeframe: 5 years

,
Interventionparticipants (Number)
EARLY POSTOPERATIVE COMPLICATIONSLATE POSTOPERATIVE COMPLICATIONS
Implant3336
Trabeculectomy3938

[back to top]

Change in Intraocular Pressure

The data value from the Baseline visit and 5 year follow-up visit were combined. Specifically, values were calculated by subtracting the 5 Year Intraocular Pressure from the Baseline Intraocular Pressure. (NCT00306852)
Timeframe: Baseline to 5 years

Interventionmm Hg (Mean)
Trabeculectomy12.6
Implant14.4

[back to top]

Reoperations for Glaucoma

Reoperations for glaucoma was defined as additional glaucoma surgery requiring a return to the operating room. (NCT00306852)
Timeframe: 5 years

Interventionparticipants (Number)
Trabeculectomy15
Implant20

[back to top]

Need for Supplemental Medical Therapy

The number of supplemental glaucoma medications required in the Implant Group and Trabeculectomy Group at 5 years (NCT00306852)
Timeframe: 5 years

Interventionnumber of medications (Mean)
Trabeculectomy1.2
Implant1.4

[back to top]

Maximum Tolerated Dose (MTD) of Chemophase in Combination With MMC

"The MTD was defined as the maximum dose level at which no more than two of six participants experienced dose-limiting toxicities (DLT). DLT was defined as any of the following:~Plasma MMC concentration greater than or equal to (>=) 100 nanograms (ng)/milliliter (mL)~Adverse event (AE) with a Common Toxicity Criteria (CTC) grade greater than or equal to 3~New, treatment-emergent diagnosis of bladder fibrosis." (NCT00318643)
Timeframe: 5 weeks (Week 2 to Week 6)

InterventionUnits (Number)
Cohort 5: MMC Plus Chemophase 800,000 U800000

[back to top]

Number of Participants Who Remained Tumor Free at the End of the Study

(NCT00318643)
Timeframe: Baseline up to 2 years

InterventionParticipants (Count of Participants)
Cohort 1: MMC Plus Chemophase 20,000 U2
Cohort 2: MMC Plus Chemophase 60,000 U0
Cohort 3: MMC Plus Chemophase 200,000 U2
Cohort 4: MMC Plus Chemophase 400,000 U1
Cohort 5: MMC Plus Chemophase 800,000 U6

[back to top]

Number of Participants With Dose Limiting Toxicities (DLTs)

"DLT was defined as any of the following:~Plasma MMC concentration >= 100 ng/mL~AE with a CTC grade greater than or equal to 3~New, treatment-emergent diagnosis of bladder fibrosis." (NCT00318643)
Timeframe: 5 weeks (Week 2 to Week 6)

InterventionParticipants (Count of Participants)
Cohort 1: MMC Plus Chemophase 20,000 U0
Cohort 2: MMC Plus Chemophase 60,000 U0
Cohort 3: MMC Plus Chemophase 200,000 U1
Cohort 4: MMC Plus Chemophase 400,000 U0
Cohort 5: MMC Plus Chemophase 800,000 U0

[back to top] [back to top]

Number of Participants With a Quantifiable MMC Plasma Concentration Value

A quantifiable MMC plasma concentration value was a value that was not below the quantifiable limit (BQL) of <10.0 nanogram/milliliter (ng/mL). (NCT00318643)
Timeframe: 0 (predose), 1, 2, and 3 hours postdose at Weeks 1, 2, 5, and 6

,,,,
InterventionParticipants (Count of Participants)
Week 1: PredoseWeek 1: 1 hourWeek 1: 2 hoursWeek 1: 3 hoursWeek 2: PredoseWeek 2: 1 hourWeek 2: 2 hoursWeek 2: 3 hoursWeek 5: PredoseWeek 5: 1 hourWeek 5: 2 hoursWeek 5: 3 hoursWeek 6: PredoseWeek 6: 1 hourWeek 6: 2 hoursWeek 6: 3 hours
Cohort 1: MMC Plus Chemophase 20,000 U0000000000000000
Cohort 2: MMC Plus Chemophase 60,000 U0000000000000000
Cohort 3: MMC Plus Chemophase 200,000 U0000000000110000
Cohort 4: MMC Plus Chemophase 400,000 U0000000000000110
Cohort 5: MMC Plus Chemophase 800,000 U0110000000000000

[back to top]

Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

TEAEs were defined as any AE that occurred after the first administration of the study drug and until the end of the study. AEs were defined as any untoward medical occurrence in a participant administered study drug and that did not necessarily have a causal relationship with the study drug. SAEs were defined as any AE that, in the view of either the Investigator or Sponsor, resulted in any of the following outcomes as fatal, life-threatening, required in-participant hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, a congenital anomaly/birth defect, an important medical event. A summary of all SAEs and Other AEs (nonserious) regardless of causality is located in 'Reported Adverse Events' Section. (NCT00318643)
Timeframe: Baseline up to 2 years

,,,,
InterventionParticipants (Count of Participants)
TEAEsSAEs
Cohort 1: MMC Plus Chemophase 20,000 U11
Cohort 2: MMC Plus Chemophase 60,000 U10
Cohort 3: MMC Plus Chemophase 200,000 U42
Cohort 4: MMC Plus Chemophase 400,000 U20
Cohort 5: MMC Plus Chemophase 800,000 U102

[back to top]

Percentage of Subjects With Acute Gastrointestinal (GI) and Genitourinary (GU) Adverse Events (AE) ≥ Grade 2 as Defined by CTCAE v3.0 (Common Terminology Criteria for Adverse Events)

Highest grade adverse event per subject were counted. Adverse events were graded using CTCAE v3.0. Grade refers to the severity of the AE. The CTCAE v3.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE. Acute toxicities occur within 90 days of the start of treatment. (NCT00423293)
Timeframe: From the start of treatment to 90 days

Interventionpercentage of participants (Number)
5-FU + Mitomycin + IMRT77

[back to top]

Clinical Complete Response Rate

A complete clinical response was defined as complete resolution of all palpable tumor determined by digital rectal exam and proctosigmoidoscopy supplemented with pelvic axial imaging. (NCT00423293)
Timeframe: 8 and 12 weeks after treatment completion (corresponding to 14 and 18 weeks from registration)

Interventionpercentage of participants (Number)
8 weeks after treatment12 weeks after treatment
5-FU + Mitomycin + IMRT6481

[back to top]

Percentage of Subjects With Acute Adverse Events (AE)

Highest grade adverse event per subject were counted. Adverse events were graded using CTCAE v3.0. Grade refers to the severity of the AE. The CTCAE v3.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE. Acute toxicities occur within 90 days of the start of treatment. (NCT00423293)
Timeframe: From the start of treatment to 90 days

Interventionpercentage of participants (Number)
GI Grade 2+GU Grade 2+Hematologic Grade 2+Skin Grade 2+Any Grade 2+Any Grade 3+
5-FU + Mitomycin + IMRT731573759483

[back to top]

Percentage of Subjects With Late Adverse Events (AE)

Highest grade adverse event per subject were counted. Adverse events were graded using CTCAE v3.0. Grade refers to the severity of the AE. The CTCAE v3.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE. Late toxicities occur greater than 90 days from the start of treatment. (NCT00423293)
Timeframe: From 91 days after start of study treatment to the end of follow-up. Maximum follow-up at time of analysis was 9.2 years.

Interventionpercentage of participants (Number)
GI/GU Grade 2+Non-Hematologic Grade 2+Any Grade 2+Any Grade 3+
5-FU + Mitomycin + IMRT35677520

[back to top]

Five-year Rate of Disease-free Survival

Disease-free survival time is defined as time from registration to the date of local-regional failure, the appearance of distant metastases, the appearance of a second primary failure, or date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive without failure are censored at the date of last contact. Local failure is defined as any measurable disease after 12 weeks from the completion of chemoradiation therapy. Local failure is defined as: a) For patients with no disease in pelvic and/or groin nodes, the appearance of disease in pelvic or groin nodes; b) For patients with disease in pelvic and/or groin nodes at study entry, nodal recurrence following clearance or persistent nodal disease for more than 12 weeks after completion of treatment. (NCT00423293)
Timeframe: From registration to 5 years

Interventionpercentage of participants (Number)
5-FU + Mitomycin + IMRT70

[back to top]

Duration of Radiotherapy Treatment

Number of days from radiotherapy treatment start to radiotherapy treatment end (NCT00423293)
Timeframe: From start to end of radiation therapy (6 weeks)

InterventionDays (Median)
5-FU + Mitomycin + IMRT43

[back to top]

Five-Year Cumulative Incidence Rate of Colostomy Failure

Colostomy failure time is defined as time from registration to the date of colostomy or abdominoperineal (A-P) resection and is estimated by the cumulative incidence method. Patients last known to be alive without failure are censored at the date of last contact. (NCT00423293)
Timeframe: From registration to 5 years

Interventionpercentage of participants (Number)
5-FU + Mitomycin + IMRT10

[back to top]

Five-Year Cumulative Incidence Rate of Distant Failure

Distant failure time is defined as time from registration to the appearance of distant metastases and is estimated by the cumulative incidence method. Patients last known to be alive without failure are censored at the date of last contact. (NCT00423293)
Timeframe: From registration to 5 years

Interventionpercentage of participants (Number)
5-FU + Mitomycin + IMRT16

[back to top]

Five-Year Cumulative Incidence Rate of Local-regional Failure

Local-regional failure time is defined as time from registration to date of failure and is estimated by the cumulative incidence method. Patients last known to be alive without failure are censored at the date of last contact. Local-regional failure is defined as a local or regional failure. Local failure is defined as any measurable disease after 12 weeks from the completion of chemoradiation therapy. Regional failure is defined as: a) For patients with no disease in pelvic and/or groin nodes, the appearance of disease in pelvic or groin nodes; b) For patients with disease in pelvic and/or groin nodes at study entry, nodal recurrence following clearance or persistent nodal disease for more than 12 weeks after completion of treatment. (NCT00423293)
Timeframe: From registration to 5 years

Interventionpercentage of participants (Number)
5-FU + Mitomycin + IMRT16

[back to top]

Five-Year Rate of Colostomy-free Survival

Colostomy-free survival time is defined as time from registration to date of colostomy or abdominoperineal (A-P) resection, or date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive without failure are censored at the date of last contact. (NCT00423293)
Timeframe: From registration to 5 years

Interventionpercentage of participants (Number)
5-FU + Mitomycin + IMRT74

[back to top]

Five-year Rate of Overall Survival

Overall survival time is defined as time from registration/randomization to the date of death from any cause. Overall survival rates are estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. (NCT00423293)
Timeframe: From registration to 5 years

Interventionpercentage of participants (Number)
5-FU + Mitomycin + IMRT76

[back to top]

Number of Patients With Major Radiation Planning Deviations

Deviations in intensity-modulated radiation therapy technique (IMRT) planning were determined by central review by the radiation oncology co-chairs of the study. (NCT00423293)
Timeframe: Planning occurred prior to radiation therapy

InterventionParticipants (Count of Participants)
5-FU + Mitomycin + IMRT0

[back to top]

Complications

Incidence (percentage) for complications recorded: Hyphema, early hypotony(<7days), late hypotony(>7days), shallow anterior chamber, choroidal detachment, early leak(<7days), late leak(>7days), Tenon's cysts, and revision surgery for up to 360 days. (NCT00538590)
Timeframe: 360 days

Interventionpercentage of participants (Mean)
MITOMYCIN-C15.6
Ologen (Oculusgen)15.6

[back to top]

Postoperative Intraocular Pressure Change

Postoperative intraocular pressure change at 180 days compared to baseline (preoperative) intraocular pressure measured in mmHg. Calculated as postoperative intraocular pressure minus baseline (preoperative) intraocular pressure. (NCT00538590)
Timeframe: 180 days

Interventionmm Hg (Mean)
MITOMYCIN-C-11.8
Ologen (Oculusgen)-11.8

[back to top]

Postoperative Intraocular Pressure Change

Postoperative intraocular pressure change at 30 days compared to baseline (preoperative) intraocular pressure measured in mmHg. Calculated as postoperative intraocular pressure minus baseline (preoperative) intraocular pressure. (NCT00538590)
Timeframe: 30 days

Interventionmm Hg (Mean)
MITOMYCIN-C-13.3
Ologen (Oculusgen)-12.9

[back to top]

Postoperative Intraocular Pressure Change

Postoperative intraocular pressure change at 360 days compared to baseline (preoperative) intraocular pressure measured in mmHg. Calculated as postoperative intraocular pressure minus baseline (preoperative) intraocular pressure. (NCT00538590)
Timeframe: 360 days

Interventionmm Hg (Mean)
MITOMYCIN-C-11.3
Ologen (Oculusgen)-11.6

[back to top]

Postoperative Intraocular Pressure Change

Postoperative intraocular pressure change at 90 days compared to baseline (preoperative) intraocular pressure measured in mmHg. Calculated as postoperative intraocular pressure minus baseline (preoperative) intraocular pressure. (NCT00538590)
Timeframe: 90 days

Interventionmm Hg (Mean)
MITOMYCIN-C-10.9
Ologen (Oculusgen)-14.1

[back to top]

Post-Operative Requirement for Glaucoma Medication

Mean number of glaucoma medications used by each participant over the course of one year post-operatively. (NCT00626782)
Timeframe: 1 day, 2 wks, 1, 3, 6 and 12 months

,
Interventionnumber of glaucoma medications used (Mean)
1 Day2 wks1 month3 months6 months12 months
A: Ranibizumab 0.5mg (0.05mL) Injection0.010.00.130.660.340.15
B: Mitomycin C 0.4 mg/ml Sponge0.00.010.010.080.060.06

[back to top]

Adverse Events

Percentage of participants with ocular adverse events and other adverse events as identified by eye examination, physical examination, subject reporting and changes in vital signs one year post-operatively. (NCT00626782)
Timeframe: 12 months

Interventionpercentage of participants (Number)
Treatment 1 (Ranibizumab 0.5mg)100
Treatment 2 (Mitomycin C 0.4 mg/ml)16.67

[back to top]

Mean Change in Visual Acuity

Mean change in visual acuity in logMAR. (NCT00661583)
Timeframe: 6 months

,,
InterventionlogMAR (Mean)
Month 3 minus baselineMonth 6 minus baseline
MMC Alone0.130.13
Ranibizumab Alone-0.01-0.05
Ranibizumab and MMC0.010.05

[back to top]

Mean Change in in Intraocular Pressure.

Mean change in in intraocular pressure at 3 months and at 6 months (NCT00661583)
Timeframe: 6 months

,,
InterventionmmHg (Mean)
month 3 minus baselinemonth 6 minus baseline
MMC Alone-8.35-8.00
Ranibizumab Alone-6.40-6.60
Ranibizumab and MMC-6.40-4.90

[back to top]

Percent of Subjects With a Qualified Success and Viable Bleb at 6 Months.

To determine percent of subjects with a qualified success and viable bleb at 6 months (IOP between 6mm Hg and 22 mm Hg with pressure controlled with and without adjunctive medications) (NCT00661583)
Timeframe: 6 months

Interventionpercentage of subjects (Number)
Ranibizumab Alone100
Ranibizumab and MMC100
MMC Alone100

[back to top]

Assessment of Ocular Adverse Events

To assess ocular adverse events of combination ranibizumab and MMC therapy at 6 months (NCT00661583)
Timeframe: 6 months

InterventionNumber of Reported Adverse Events (Number)
Ranibizumab Alone0
Ranibizumab and MMC0
MMC Alone0

[back to top]

Reoperation for Glaucoma

The number of participants requiring reoperation for glaucoma will be reported (NCT00666237)
Timeframe: Up to 5 years

InterventionParticipants (Count of Participants)
Tube Shunt Surgery Group21
Trabeculectomy With Mitomycin C12

[back to top]

Number of Glaucoma Medications

The need for supplemental glaucoma medications will be reported as the number of glaucoma medications used (NCT00666237)
Timeframe: At Baseline, At 1 year, At 18 months, At 2 years, At 3 years, At 4 years, At 5 years

,
Interventionglaucoma medications used (Mean)
Baseline1 year18 months2 years3 years4 years5 years
Trabeculectomy With Mitomycin C3.20.90.81.01.21.31.3
Tube Shunt Surgery Group3.12.12.12.22.12.32.2

[back to top]

Number of Participants With Surgical Failure

"Surgical failure is defined as:~Inadequate Intraocular Pressure (IOP) Reduction (IOP > 21 mmHg or reduced < 20% below baseline on 2 consecutive follow-up visits after 3 months)~Reoperation for glaucoma~Persistent hypotony (IOP ≤ 5 mmHg on 2 consecutive visits after 3 months)~Loss of light perception vision" (NCT00666237)
Timeframe: Up to 5 years

,
InterventionParticipants (Count of Participants)
Inadequate IOP reductionReoperation for GlaucomaLoss of light perception visionPersistent Hypotony
Trabeculectomy With Mitomycin C23915
Tube Shunt Surgery Group311800

[back to top]

Visual Acuity as Measured Using EDTRS Chart

Visual acuity will be reported as the number of correctly identified letters on the Early Treatment Diabetic Retinopathy Study (EDTRS) chart. Total score ranges from 0-100 with the higher score indicating better visual acuity. (NCT00666237)
Timeframe: At baseline, At 5 years

,
Interventionletters (Mean)
Baseline5 years
Trabeculectomy With Mitomycin C7366
Tube Shunt Surgery Group7369

[back to top]

Intraocular Pressure

Intraocular pressure will be reported in mmHg and measured using Goldmann applanation tonometry or a Tono-Pen. (NCT00666237)
Timeframe: At baseline, At 1 year, At 18 months, At 2 years, At 3 years, At 4 years, At 5 years

,
InterventionmmHg (Mean)
Intraocular Pressure: BaselineIntraocular Pressure: 1 yearIntraocular Pressure: 18 monthsIntraocular Pressure: 2 yearsIntraocular Pressure: 3 yearsIntraocular Pressure: 4 yearsIntraocular Pressure: 5 years
Trabeculectomy With Mitomycin C23.912.412.812.912.113.513.0
Tube Shunt Surgery Group23.313.813.513.613.913.513.4

[back to top]

Visual Acuity Using a Snellen Chart

Visual acuity will be measured using a Snellen chart on logMAR (Logarithm of Minimal Angle of Resolution) scale. Letter-by letter results calculated the visual performance score for each chart read. logMAR scores closer to zero, or below zero, indicate a better visual acuity. A logMAR visual performance score of 0.0 is equivalent to Snellen visual acuity of 20/20. (NCT00666237)
Timeframe: At Baseline, At 5 years

,
InterventionlogMAR (Mean)
Baseline5 years
Trabeculectomy With Mitomycin C0.250.42
Tube Shunt Surgery Group0.200.30

[back to top]

Number of Participants With Reported Postoperative Complications

Number of participants with early and late postoperative complications will be reported as per treating physician assessment (NCT00666237)
Timeframe: Up to 5 years

,
InterventionParticipants (Count of Participants)
Early Postoperative ComplicationsLate Postoperative Complications
Trabeculectomy With Mitomycin C4032
Tube Shunt Surgery Group2427

[back to top]

Median Recurrence Free-survival

Time to first recurrence of cancer in the bladder. (NCT00734994)
Timeframe: Median follow-up 3.18 years

InterventionMonths (Median)
Hyperthermia System, Mitomycin C15.4

[back to top]

Safety and Tolerability

Number of patient treatments stopped due to safety concerns or treatment intolerability. All events below are grade 1/2 toxicity. No grade 3-5 toxicity was observed. (NCT00734994)
Timeframe: During Treatment Phase average 6 weeks

InterventionGrade 1/2 event count (no grade 3+) (Number)
Abdominal painFatigueMyalgiaHeat intoleranceUrethral painChemical cystitisHematuriaBladder spasmWeak urinary streamVaginitisNauseaConstipationSwellingPruritisRashBruisingFlushingDizzinessConfusionAnxietyExtrapyramidal symptomsUrinary Tract InfectionHypertension
Mitomycin C With Hyperthermia52116432112143211211123

[back to top]

Response to Treatment

will be assessed by cystoscopy every 3 months (+/- 3 weeks) in the first 2 years after induction. (NCT00974818)
Timeframe: 2 years

Interventionparticipants (Number)
Mitomycin C (MMC)25
Bacillus Calmette-Guerin (BCG)25

[back to top]

Percentage of Participants Alive at 3 Years

Overall survival time is defined as time from registration to the date of death from any cause or last known follow-up (censored). Overall survival rates are estimated by the Kaplan-Meier method. (NCT00981656)
Timeframe: From registration to three years

Interventionpercentage of participants (Number)
3DCRT + CT69.2

[back to top]

Percentage of Participants Free From Radical Cystectomy at 3 Years

The number of participants who did not undergo a radical cystectomy within three years divided by the number of analyzed participants. (NCT00981656)
Timeframe: Three years from registration

Interventionpercentage of participants (Number)
3DCRT + CT88.2

[back to top]

Percentage of Participants With Local Recurrence at 3 Years

Time to local recurrence is defined as time from registration to the date of first local recurrence, last known follow-up (censored), or death without local recurrence (competing risk). Local recurrence rate is estimated using the cumulative incidence method. (NCT00981656)
Timeframe: From registration to three years

Interventionpercentage of participants (Number)
3DCRT + CT32.5

[back to top]

American Urological Association Total Symptom Score at Baseline and at 3 Years

The American Urological Association Total symptom score measures the severity of enlarged prostate symptoms. Possible scores range from 0 to 35, with higher scores indicating worse symptoms. (NCT00981656)
Timeframe: Baseline and 3 years

Interventionunits on a scale (Mean)
BaselineThree years
3DCRT + CT9.8412.00

[back to top]

Distribution of Participants by Highest Grade Adverse Event

Common Terminology Criteria for Adverse Events (CTCAE) version 4 grades adverse event severity from 1=mild to 5=death. Summary data is provided in this outcome measure; see Adverse Events Module for specific adverse event data. (NCT00981656)
Timeframe: Adverse events are evaluated 8-10 weeks after end of study treatment (approximately 7 weeks), then every 3 months for one year, every 4 months for one year, every 6 months for 3 years, then annually. Maximum follow-up at time of reporting was 8.6 years.

InterventionParticipants (Count of Participants)
Grade 1Grade 2Grade 3Grade 4Grade 5
3DCRT + CT292020

[back to top]

Percent of Participants With Distant Disease Progression at 3 Years

Distant disease progression is defined as the first appearance of disease in a non-regional lymph node, solid organ or bone. Time to distant disease progression is defined as time from registration to the date of first distant disease progression, last known follow-up (censored), or death without distant disease progression (competing risk). Distant disease progression rate is estimated using the cumulative incidence method. (NCT00981656)
Timeframe: From registration to three years

Interventionpercentage of participants (Number)
3DCRT + CT12.3

[back to top]

Overall Survival (OS)

Overall survival (OS) is defined as time from randomization to death from any cause, censoring cases who had not died at the date last known alive. (NCT01004978)
Timeframe: Assessed every 3 months for 2 years and then every 6 months for 2 years

Interventionmonths (Median)
Arm A (Sorafenib and TACE)19.8
Arm B (Placebo and TACE)19.9

[back to top]

Progression-free Survival (PFS) Among Patients With Intra-hepatic Progression

"PFS is defined to be the time from randomization to progression or death without evidence of progression.~Progression is assessed per Solid Tumor Response Criteria (RECIST) and defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum longest diameter recorded since the baseline measurements, or the appearance of one or more new lesion(s), and/or unequivocal progression of existing nontarget lesions.~For patients with progressive disease, the progression was classified as either intra- or extra-hepatic or both intra- and extra-hepatic. This analysis was performed among patients with intra-hepatic progression." (NCT01004978)
Timeframe: Assessed 4 months after first chemoembolization, 8 months after first chemoembolization, then every 8 weeks, up to 4 years

Interventionmonths (Median)
Arm A (Sorafenib and TACE)8.5
Arm B (Placebo and TACE)7.8

[back to top]

Progression-free Survival (PFS) Among Patients With Extra-hepatic Progression

"PFS is defined to be the time from randomization to progression or death without evidence of progression.~Progression is assessed per Solid Tumor Response Criteria (RECIST) and defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum longest diameter recorded since the baseline measurements, or the appearance of one or more new lesion(s), and/or unequivocal progression of existing nontarget lesions.~For patients with progressive disease, the progression was classified as either intra- or extra-hepatic or both intra- and extra-hepatic. Patients with both intra- and extra-hepatic progression were considered as having extra-hepatic progression. This analysis was performed among patients with extra-hepatic progression." (NCT01004978)
Timeframe: Assessed 4 months after first chemoembolization, 8 months after first chemoembolization, then every 8 weeks, up to 4 years

Interventionmonths (Median)
Arm A (Sorafenib and TACE)6.83
Arm B (Placebo and TACE)5.6

[back to top]

Progression-free Survival (PFS)

"PFS is defined to be the time from randomization to progression or death without evidence of progression. For cases without documentation of progression, follow-up will be censored at the date of last disease assessment without progression, unless death occurs within 4 months following the date last known progression-free, in which case the death will be counted as an event.~Progression is assessed per Solid Tumor Response Criteria (RECIST) and defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum longest diameter recorded since the baseline measurements, or the appearance of one or more new lesion(s), and/or unequivocal progression of existing nontarget lesions." (NCT01004978)
Timeframe: Assessed 4 months after first chemoembolization, 8 months after first chemoembolization, then every 8 weeks, up to 4 years

Interventionmonths (Median)
Arm A (Sorafenib and TACE)9.3
Arm B (Placebo and TACE)8.4

[back to top] [back to top]

Number of Participants Who Had Complications From the Time of Treatment to Recurrence

(NCT01115517)
Timeframe: 1 year

Interventionparticipants (Number)
Bevacizumab0
Mitomycin C0

[back to top]

Number of Participants Who Had Recurrence of Pterygia up to 1 Year

(NCT01115517)
Timeframe: 1 year

Interventionparticipants (Number)
Bevacizumab0
Mitomycin C3

[back to top]

Comparison of Safety of EN3348 With Mitomycin C [Adverse Events (Other Than Serious Adverse Events) With Frequency Threshold of 5% or Greater].

Safety endpoint displayed includes adverse events (other than serious adverse events) with a frequency threshold of 5% or greater, for each treatment arm. No statistical comparisons have been performed between the 2 treatment arms. (NCT01200992)
Timeframe: Through study early termination, approximately 23 months from first subject enrolled.

,
Interventionparticipants (Number)
DysuriaHematuriaPollakiuriaFatigueUrinary tract infectionDiarrheaBack painNausea
EN334897665322
Mitomycin C123635243

[back to top]

Number of Participants Who Experienced a Dose Limiting Toxicity to Determine the Maximum Tolerated Dose (MTD)

"1.Phase I - Assess the safety and toxicities of IC with Olaparib escalating to ICM with Olaparib in patients with locally advanced and metastatic pancreatic cancer and determine the phase 2 dose. The number of subjects who experienced a dose limiting toxicity was assessed.Dose-limiting toxicity (DLT) is defined as any of the following study drug-related events experienced during Cycle 1:~Thrombocytopenia with platelets <25,000 x106/l > 7 days. Grade 4 neutropenia lasting ≥7 days. Grade 3 or 4 febrile neutropenia. Grade 3 or greater non-haematological toxicities; excluding grade 3 diarrhoea, nausea or vomiting despite adequate treatment and grade 3 fatigue, lethargy and GGT elevation.~Delay of >2 weeks for next scheduled IC/ICM for reasons of toxicity." (NCT01296763)
Timeframe: 2 years

Interventionparticipants (Number)
Dose Level 10
Dose Level 22
Dose Level 52

[back to top]

Number of Years From Cycle 1, Day 1 On-Study to Date of Death

The overall survival of subjects with locally advanced and/or metastatic pancreatic cancer treated with Irinotecan, Cisplatin, Olaparib, with escalation to the addition of Mitomycin-C. Survival from cycle 1, day 1 on-study to date of death was assessed. (NCT01296763)
Timeframe: 5 years

Interventionyears (survival) from C1D1 to death (Mean)
Dose Level 11.43
Dose Level 20.44
Dose Level 50.60

[back to top]

Eye Movement Amplitude (EMA)

(NCT01319721)
Timeframe: One Year

,
Interventionmillimeter (Mean)
Preoperative EMAPostoperative EMAImprovement of EMA
Group AMG6.797.851.06
Group LCAG6.678.351.67

[back to top]

Postoperative Conjunctival Inflammation

The presence of conjunctival inflammation around the surgical site was assessed at 4 weeks post-operatively and graded as 0 (none), i (mild), ii (moderate), and iii (severe). (NCT01319721)
Timeframe: One month

,
Interventioneyes (Number)
Grade 0Grade iGrade iiGrade iii
Group AMG1414131
Group LCAG211790

[back to top]

Complications

(NCT01319721)
Timeframe: One year

Interventioneyes (Number)
Group LCAG9
Group AMG8

[back to top]

Healing Time of Corneal Epithelial Defect

(NCT01319721)
Timeframe: Four Weeks

Interventiondays (Mean)
Group LCAG2.78
Group AMG3.25

[back to top]

Recurrence

Recurrence was defined as the presence of fibrovascular tissue in the surgical area and invasion onto the cornea. The appearance of the surgical bed in successful cases was graded as follows: grade A was defined as the operated eye being indistinguishable from a normal eye, grade B was defined as the presence of fine episcleral vessels without fibrous tissue in the surgical area extending up to the limbus but not beyond, and grade C was defined as the presence of fibrovascular tissue in the surgical area but without invasion onto the cornea. (NCT01319721)
Timeframe: One Year

,
Interventioneyes (Number)
Grade AGrade BGrade CGrade D (recurrence)
Group AMG34323
Group LCAG46001

[back to top]

Brief Pain Inventory Score

The Brief Pain Inventory Scale is a questionnaire that asks the participant to rate their pain on a scale of 0 (no pain) to 10 (worst pain). (NCT01324141)
Timeframe: Baseline, Week 3, Week 6, 1 month follow up, and 3 months follow up

InterventionScores on a scale (Mean)
Worst pain at baselineWorst pain at treatment week 3Worst pain at treatment week 6Worst pain at 1 month follow upWorst pain at 3 months follow upLeast pain at baselineLeast pain at treatment week 3least pain at treatment week 6Least pain at 1 month follow upLeast pain at 3 months follow upAverage pain at baselineAverage pain at treatment week 3Average pain at treatment week 6Average pain at 1 month follow upAverage pain at 3 months follow upPain at time of survey at baselinePain at time of survey at treatment week 3Pain at time of survey at treatment week 6Pain at time of survey a 1 month follow upPain at time of survey at 3 months follow up
1/Chemo + Radiation4.83.57.23.12.11.41.53.61.22.81.81.95.02.03.01.61.35.42.22.2

[back to top]

Mean Grade of Toxicity at Each Timepoint and Location for All Participants Who Underwent Treatment

RTOG grade 1-5 were used to assess skin toxicity in the groin (right and left inguinal area) and gluteal cleft, as well as two control sites. Grade 0 is no skin toxicity, Grade 1 is follicular, faint or dull erythema, Grade 3 is tender or bright erythema, Grade 3 is confluent, moist desquamation, Grade 4 is ulceration, hemorrhage, or necrosis, and Grade 5 is death due to radiation toxicity. (NCT01324141)
Timeframe: baseline, weeks 1-6, follow up at 1 week, follow up at 2 weeks, and follow up at 4 weeks

,,,,
InterventionGrade (Mean)
BaselineWeek 1Week 2Week 3Week 4Week 5Week 6Follow up at 1 weekFollow up at 2 weeksFollow up at 4 weeks
Gluteal Cleft0000.40.611.21.81.20.4
Left Inguinal Area0000.20.60.81.2110.2
Left Inguinal Control (C1)0000.20.20.20.40.60.80.6
Right Inguinal Area0000.20.60.81.2110.2
Umbilical Control (C2)0000000000

[back to top]

Number of Cluster of Differentiation 4+ (CD4) Cells Per Gram of Biopsied Intestinal Tissue

Number of Cluster of Differentiation 4+ (CD4) cells per gram of biopsied intestinal tissue. The number of CD4 positive cells were analyzed with flow cytometry of cellular suspensions from biopsy tissue. (NCT01324141)
Timeframe: Baseline and 1 year follow up

InterventionCD4+cells/gm tissue(x 10^5) (Mean)
Baseline1 year follow up
1/Chemo + Radiation17.6412.72

[back to top]

Number of Cluster of Differentiation 8+ (CD8) Cells Per Gram of Biopsied Intestinal Tissue

Number of Cluster of differentiation 8+ (CD8) cells per gram of biopsied intestinal tissue. The number of CD8 positive cells were analyzed with flow cytometry of cellular suspensions from biopsy tissue. (NCT01324141)
Timeframe: Baseline and 1 year follow up

InterventionCD8+cells/gm tissue(x 10^5) (Mean)
Baseline1 year follow up
1/Chemo + Radiation4.84.0

[back to top] [back to top]

Mean Percentage Pain Relief After Medication

The Brief Pain Inventory Scale questionnaire were used to assess pain relief after medication. Participants rated pain relief on a scale of 0% (no relief) to 100% (complete relief) and a mean and full range were reported. (NCT01324141)
Timeframe: Baseline, Week 3, Week 6, 1 month follow up, and 3 months follow up

Interventionpercentage pain relief (Mean)
BaselineTreatment week 3Treatment week 61 month follow up3 months follow up
1/Chemo + Radiation90.093.844.089.083.0

[back to top]

Pain Interference

The Brief Pain Inventory Scale questionnaire were used to assess pain interference. Participants rated pain interference on a scale of 0 (does not interfere) to 10 (completely interferes). (NCT01324141)
Timeframe: Baseline, Week 3, Week 6, 1 month follow up, and 3 months follow up

InterventionScores on a scale (Mean)
Pain interference at baselinePain interference at treatment week 3Pain interference at treatment week 6Pain interference at 1 month follow upPain interference at 3 months follow up
1/Chemo + Radiation1.733.006.703.171.87

[back to top]

Percentage of Total Viable Cells That Were Cluster of Differentiation 3+ (CD3+) Cells in Biopsied Tissue

Percentage of total viable cells that were Cluster of differentiation 3+ (CD3+) cells in biopsied tissue. (NCT01324141)
Timeframe: Baseline and 1 year

Interventionpercentage of cells (Mean)
Baseline1 year
1/Chemo + Radiation7.934.40

[back to top]

Peripheral Blood Mononuclear Cells (Vascular Endothelial Growth Factor (VEGF), Tumor Necrosis Factor Alpha (TNF-alpha), Interleukin-7 (IL-7), and Transforming Growth Factor Beta-1 (TGF-beta1) Cell Counts at Baseline and Course 1 Day 28

Peripheral blood mononuclear cells (Vascular Endothelial Growth Factor (VEGF), Tumor Necrosis Factor alpha (TNF-alpha), Interleukin-7 (IL-7), and Transforming Growth Factor beta-1 (TGF-beta1) were sampled from peripheral blood from rectal associated lymphoid tissue to evaluate immune cell subsets at baseline and after treatment with MTS-0 and 15-Fluoruracil (5-FU)/Mitomycin C (MMC)/Intensity-modulated Radiotherapy (IMRT). It is unknown if a lower or higher numbers has prognostic significance. (NCT01324141)
Timeframe: Baseline and Course 1 Day 28

Interventionpg/ml (Mean)
VEGF at baselineVEGF at Course 1 Day 28TNF-alpha at baselineTNF-alpha at Course 1 Day 28IL-7 at baselineIL-7 at Course 1 Day 28TGF-beta 1 at baselineTGF-beta 1 at Course 1 Day 28
1/Chemo + Radiation151.24127.263.363.2111.3215.62144357946

[back to top]

Ratio of the Number of Cluster of Differentiation 4 (CD4): Cluster of Differentiation 8 (CD8) Cells in the Circulation and Tissue Pre and Post Treatment

Ratio of the number Cluster of Differentiation 4 (CD4): Cluster of Differentiation 8 (CD8) cells in the circulation and tissue pre and post treatment. The number of cells of CD4 are divided by the number of cells of CD8. (NCT01324141)
Timeframe: Pre-treatment and post treatment tissue (CD4), and pre-treatment and post treatment circulation (CD8)

InterventionRatio of CD4:CD8 cells (Mean)
CD4:CD8 Pre-treatment tissueCD4:CD8 post treatment tissueCD4:CD8 pre-treatment circulationCD4:CD8 post treatment circulation
1/Chemo + Radiation5.21.892.951.56

[back to top]

Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE)

Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01324141)
Timeframe: Date treatment consent signed to date off study, approximately, 36 months and 10 days.

InterventionParticipants (Count of Participants)
1/Chemo + Radiation5

[back to top]

Duration of Overall Response (DOR)

Duration of overall response is measured from the time measurement criteria are met for Complete Response until the first date that recurrent or progressive disease is objectively document. Complete Response was measured by the Response Evaluation Criteria in Solid Tumors (RECIST0 version 1.1. Complete Response is disappearance of all target lesions. (NCT01324141)
Timeframe: 12 months of follow up, approximately 14 months

Interventionmonths (Median)
1/Chemo + RadiationNA

[back to top]

Number of Participants That Required a Treatment Break Relative to Hematologic Toxicity (Non-dermatologic)

Number of participants that required a treatment break relative to hematologic (e.g. thrombocytopenia, leukopenia) toxicity (non-dermatologic). (NCT01324141)
Timeframe: From beginning until completion of radiation treatment up to 46 days

InterventionParticipants (Count of Participants)
1/Chemo + Radiation0

[back to top]

Number of Participants Treated With Topical MTS-01 and 5-Fluoruracil (5-FU)/Mitomycin C (MMC)/Intensity-modulated Radiotherapy (IMRT) That Required Opiates

Opiates are strong drugs prescribed by prescription used for maximum pain relief. (NCT01324141)
Timeframe: Completion of study, approximately 14 months after start of treatment

InterventionParticipants (Count of Participants)
1/Chemo + Radiation5

[back to top]

Number of Participants With 12 Month Disease Free Survival (DFS) Treated With 5-Fluoruracil (5-FU)/Mitomycin C (MMC)/Intensity-modulated Radiotherapy (IMRT)

DFS is defined as the duration of time from start of treatment to time of progression. Progression was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST0 version 1.1. Progression is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. And the appearance of one or more new lesions. (NCT01324141)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
1/Chemo + Radiation4

[back to top]

Number of Participants With 12-month Progression-free Survival Treated With 5-Fluoruracil (5-FU)/Mitomycin C (MMC)/Intensity-modulated Radiotherapy (IMRT)

PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. Progression was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST0 version 1.1. Progression is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. And the appearance of one or more new lesions. (NCT01324141)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
1/Chemo + Radiation4

[back to top]

Number of Participants With Tumor Tissue Negative for Human Papilloma Virus (HPV)

HPV is a sexually transmitted infection that can cause warts and cervical cancer. HPV test detects deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) of HPV in a cell sample (i.e. cervical). (NCT01324141)
Timeframe: Pretreatment

InterventionParticipants (Count of Participants)
1/Chemo + Radiation5

[back to top]

Overall Survival

OS is defined as the duration of time from start of treatment to time of death. (NCT01324141)
Timeframe: start of treatment to time of death, approximately 14 months

Interventionmonths (Median)
1/Chemo + RadiationNA

[back to top]

Absolute Number of Cluster of Differentiation 3+ (CD3) Cells Per Gram of Biopsied Intestinal Tissue

Absolute number of Cluster of differentiation 3+ (CD3) cells per gram of biopsied intestinal tissue. The number of CD3 positive cells were analyzed with flow cytometry of cellular suspensions from biopsy tissue. (NCT01324141)
Timeframe: Baseline and 1 year follow up

InterventionCD3+cells/gm tissue(x 10^5) (Mean)
Baseline1 year follow up
1/Chemo + Radiation22.9813.62

[back to top]

Time to Repeat Surgery

Length of time between surgeries for laryngotracheal stenosis during the study (NCT01523275)
Timeframe: 24 months

InterventionMonths (Mean)
Saline17.9
Mitomycin-C17.4

[back to top]

Peak Inspiratory Flow Measurement

Change in maximum inspiratory air flow from preoperative value to highest postoperative value within 3 months of surgery. Calculation details: Highest postoperative value within 3 months of surgery minus preoperative value. (NCT01523275)
Timeframe: 3 months

InterventionLiters per second (Mean)
Saline1.1
Mitomycin-C1.3

[back to top]

Duration of Symptom Improvement

Symptom improvement was measured using the Clinical COPD Questionnaire, a 10-point patient reported symptom score. Duration of symptom improvement was defined as the time from surgery to the time that symptoms to worsened beyond a CCQ score of 1 or the time to the subsequent surgery if CCQ never exceeded 1 (NCT01523275)
Timeframe: 24 months

InterventionMonths (Mean)
Saline4.1
Mitomycin-C6.0

[back to top]

Quality of Life as Assessed by Functional Assessment of Cancer Therapy: General (FACT-G)

"The FACT-G (Functional Assessment of Cancer Therapy - General) consists of 27 core items assessing patient well-being in four components: Physical (7 items), Social/Family (7 items), Emotional (6 items), and Functional (7 items). Items are rated on a five-point scale: 0-not at all, 1- a little bit, 2-somewhat, 3- quite a bit and 4-very much. The score of each component is the mean times the number of items in the component. The range of the physical, social/family, and functional components I 0-28 and the range of the emotional component is 0-24. The sum of the component scores creates the overall score which has a range of 0-108. For all component scores and overall score, the higher the score the better the QOL." (NCT01580410)
Timeframe: Throughout study completion, up to 3 years

Interventionunits on a scale (Mean)
Arm I (Mitomycin C)85.5
Arm II (Oxaliplatin)89.6

[back to top]

The Difference in the Number of Grade 3 or 4 Hematologic Toxicities (Leukopenia, Thrombocytopenia, and Neutropenia) Between the Mitomycin C and Oxaliplatin Treatments

If a patient has a grade 3 or 4 standard hematologic toxicity (leukopenia, thrombocytopenia, and neutropenia), the patient will be considered to be an event. The observed rates of the 2 treatments will be the primary outcome, and the rates will be analyzed using a 2-sided chi-square test. (NCT01580410)
Timeframe: Within 4 weeks of surgery

Interventionnumber of patients with toxicities (Number)
Arm I (Mitomycin C)8
Arm II (Oxaliplatin)5

[back to top]

The Difference in Percentage of Disease-free Survival Between the Two Treatment Arms up to 3 Years

(NCT01580410)
Timeframe: Time to first progression unless the patient's resection status is R2b or 2c, regardless of toxicity or response to study drug, assessed up to 3 years

Interventiondisease-free survival rate (%) (Mean)
Arm I (Mitomycin C)61.6
Arm II (Oxaliplatin)59.4

[back to top]

The Difference in Percentage of Overall Survival Between the Two Treatment Arms up to 3 Years

(NCT01580410)
Timeframe: Interval between surgery and death or date of last contact, assessed up to 3 years

Interventionoverall survival rate (%) (Mean)
Arm I (Mitomycin C)75.7
Arm II (Oxaliplatin)79.3

[back to top]

To Evaluate the 6-month Clinical Complete Response Rate for Patients With Anal Cancer Treated With ADXS11-001 Mitomycin, 5-FU and IMRT.

Patients to undergo tumor evaluation assessment (via sigmoidoscopy, proctoscopy, colonoscopy or anoscope) 6 months post the start of chemotherapy/radiation. (NCT01671488)
Timeframe: Tumor evaluation 6 months after coming off study

InterventionParticipants (Count of Participants)
Treatment9

[back to top]

To Evaluate the Safety of the Addition of ADXS11-001 to Standard Chemoradiation for Patients With Anal Cancer.

Evaluate maximal toxicities via CTCAE version 4.0 All adverse events, serious and non-serious, were captured from date of ICF through 4 weeks post treatment completion- regardless of causality. (NCT01671488)
Timeframe: Baseline, then prior to each ADXS11-001 and weekly during radiation. Assessments 1-2 weeks post radiation then 2-6 weeks post vaccine and off study and 30 days post treatment.

InterventionParticipants (Count of Participants)
Treatment10

[back to top]

To Evaluate Progression-free and Overall Survival for Patients With Anal Cancer Treated With ADXS11-001, Mitomycin, 5-FU and IMRT.

"Patients terminating study treatment early prior to disease recurrence will be followed every 6 months for year 1 then annually for a total of 5 years. The follow-up portion will commence once patient comes off study or post the 2-6 week post the 4th treatment time point/visit.~Assessments were tumor evaluation via sigmoidoscopy, proctoscopy, colonoscopy or anoscope and also chest/abdomen/pelvic imaging." (NCT01671488)
Timeframe: Follow up and survival status at 6 months and 1 year post coming off study and annually until patient has been off for 5 years

InterventionParticipants (Count of Participants)
Treatment8

[back to top]

Highest FEV1 After Methacholine Challenge

Serial FEV1 was measured post inhalation of methacholine challenges for 90 minutes. The highest FEV1 at 5, 15, 30, 45, 60, and 90 minutes following methacholine challenge were evaluated for each subject. The minimum highest FEV1 was derived using the first three available measures that cover the first 30 minutes after the challenge. (NCT01993329)
Timeframe: Screening (Day -21 to Day -1) and Day 3

,,,
InterventionLiters (Mean)
+ 5 minutes+15 minutes+30 minutes+45 minutes+60 minutes+90 minutesMinimum Highest FEV1
Gefapixant 3002.432.672.832.993.063.122.43
Gefapixant 502.532.722.933.023.113.152.53
Placebo2.542.772.943.033.143.182.54
Screening2.442.692.862.932.993.102.44

[back to top]

Provocative Concentration (PC20) After Methacholine Challenge

The provocative concentration (PC) of inhaled methacholine required to reduce forced expiratory volume in 1 second (FEV1) by 20% (PC20) was calculated from the methacholine challenge at screening and 2 hours (+15 minutes) post dose on Day 3 of each Treatment Period using a five-breath dosimeter method. The primary endpoint was the methacholine PC20 value normalized by means of a log (base 2) transformation, at 2 dose levels compared with placebo in participants with asthma following provocation with methacholine. (NCT01993329)
Timeframe: Screening (Day -21 to Day -1) and Day 3

Interventionlog [mg/mL] (Geometric Mean)
Gefapixant 500.91
Gefapixant 3000.84
Placebo0.82

[back to top]

Change in Intraocular Pressure

To assess final intraocular pressure lowering between patients who receive mitomycin-C using a sponge versus irrigation (NCT02016898)
Timeframe: post-operative day 1 to month 6

InterventionmmHg (millimeters of mercury) (Mean)
Sponge Placement of Mitomycin-C-8.4
Irrigation Placement of MMC-8.2

[back to top]

Complication Rates

To assess complication rates between patients who receive mitomycin-C using a sponge versus irrigation (NCT02016898)
Timeframe: post-operative day 1 to month 6

InterventionParticipants (Count of Participants)
Sponge Placement of Mitomycin-C29
Irrigation Placement of MMC28

[back to top]

Overall Survival (OS) From the First Laparoscopic HIPEC

Primary objective of study is to assess overall survival (OS) in subjects with stage IV gastric cancer representing positive cytology or imaging occult carcinomatosis after the first laparoscopic HIPEC. Patterns of tumor recurrence and survival assessed by reviewing routine surveillance CT scans. Overall survival time estimated using the Kaplan-Meier method. (NCT02092298)
Timeframe: From the day of surgery, until the last day of follow up, until death, up to 5 years

InterventionMonths (Median)
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)20.3

[back to top]

Overall Survival (OS) After Hyperthermic Intraperitoneal Chemotherapy

Primary objective of study is to assess overall survival (OS) in subjects with stage IV gastric cancer representing positive cytology or imaging occult carcinomatosis after laparoscopic hyperthermic intraperitoneal chemotherapy administration. Overall survival measured from time of laparoscopic HIPEC. Patterns of tumor recurrence and survival assessed by reviewing routine surveillance CT scans. Overall survival time estimated using the Kaplan-Meier method. (NCT02092298)
Timeframe: Between the second and sixth week after treatment, up to 5 years

InterventionMonths (Median)
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)30.2

[back to top] [back to top]

Tumor Response Rate (TRR) for Participants Enrolled Post October 2020

"TRR will be evaluated in p16+ (HPV positive) OPSCC HNSCC patients~RECIST 1.1 will be used for this outcome." (NCT02369458)
Timeframe: Approximately 6 months (median 4.0 months with full range of 0.5-12.0 months)

InterventionParticipants (Count of Participants)
Cohort A: p16+ OPSCC0

[back to top]

Number of Participants With Grade 3/4/5 Adverse Events

-Using CTCAE Version 3.0 (NCT02369458)
Timeframe: 28 days after completion of treatment (median length of follow-up was 98 days, full range of 31-463 days)

InterventionParticipants (Count of Participants)
Cohort A: p16+ OPSCC and Cohort B: p16- OPSCC26

[back to top]

Progression-free Survival (PFS)

"PFS is defined as the duration of time from start of treatment to time of first radiologic confirmation of progression or death, whichever occurs first.~Progressive disease per RECIST 1.1~Target lesions - At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.~Non-target lesions - Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase." (NCT02369458)
Timeframe: Approximately 6 months (median 5.6 months with full range of 0.1-33.7 months)

Interventionmonths (Median)
Cohort A: p16+ OPSCC2.2
Cohort B: p16- HNSCC2.1

[back to top]

Tumor Response Rate (TRR)

"TRR will be evaluated separately in p16- (HPV-unrelated) HNSCC patients and in p16+ (HPV positive) OPSCC patients using two optimal two-stage Simon designs. In both cases, the expected TRR is 10%. A TRR of 30% is considered a clinically significant increase.~RECIST 1.1 will be used for this outcome." (NCT02369458)
Timeframe: Approximately 6 months (median 5.6 months with full range of 0.1-33.7 months)

InterventionParticipants (Count of Participants)
Cohort A: p16+ OPSCC3
Cohort B: p16- HNSCC0

[back to top]

Number of Participants Without Grade ≥ 3 Adverse Event, Graded According to NCI CTCAE Version 4.03

The NCI CTCAE Version 4.03 grades adverse events as follows: grade 3 include severe but non-life-threatening consequences that result in hospitalization and/or interventions, including elective radiologic or operative interventions; grade 4 events include life-threatening consequences, such as those requiring urgent reoperation; and grade 5 events result in treatment-related death. (NCT02695771)
Timeframe: Two years

InterventionParticipants (Count of Participants)
Mitomycin C15
Gemcitabine14
No Intervention20

[back to top]

Freedom From Bladder Stones/Dystrophic Calcification

The secondary endpoint for this study will be the number of subjects who did not experience dystrophic calcification or bladder calculi measured by the number of patients with Grade 3 through Grade 5 Adverse Events that are related to study arm, graded according to NCI CTCAE Version 4.03.Version 4.03 (NCT02695771)
Timeframe: Two years

InterventionParticipants (Count of Participants)
Mitomycin C24
Gemcitabine23
No Intervention25

[back to top]

Pharmacokinetic: The PK Profiles of the First UGN-101 Instillation in the Blood Were to be Examined for the First 6 Patients.

"Half-life (t½): terminal half-life~The mean apparent t½ following instillation of mitomycin into the upper urinary tract (UUT) was 1.27 hours (76 minutes), which was longer than the true t½ of mitomycin following a 30 mg bolus injection (mean t½ value of approximately 17 minutes). The apparent t½ demonstrates that UGN-101 dissolved gradually, resulting in prolonged exposure of mitomycin following local instillation into the UUT." (NCT02793128)
Timeframe: Blood samples were collected at 0 minutes (pre-dose) and 30 minutes, 1, 2, 3, 4, 5, and 6 hours following the first instillation with UGN-101

InterventionHours (Number)
Pharmacokinetic Population1.27

[back to top]

The Key Secondary Efficacy Endpoint Was Long-term Durability of Complete Response (CR): Number of Patients Who Maintained CR at 12 Month Post PDE Visit. This Endpoint Was Defined Only for Those Patients Who Achieved CR at the PDE Visit.

"Continuously: Duration of CR or time-to-recurrence since the Primary Disease Evaluation (PDE) Visit (i.e., time in days from the visit at which CR was determined until recurrence or censoring). This endpoint served as the main long-term durability endpoint. Dichotomously: Success if CR was still present at the 12 month post-PDE Visit (at Follow-Up Visit 4), and Failure otherwise. This endpoint served as a supportive long-term durability endpoint." (NCT02793128)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
UGN-101 Mitomycin for Pyelocalyceal Solution23

[back to top]

Pharmacokinetic: The PK Profiles of the First UGN-101 Instillation in the Blood Were to be Examined for the First 6 Patients.

"Tmax: time to maximum plasma concentration~Analysis of individual plasma concentration versus time profiles showed that at 6 hours post instillation, the plasma concentrations of all 6 patients were below 2 ng/mL, with the plasma concentration of one patient dropping below the LOQ (i.e., < 0.100 ng/mL).~The mean Cmax was 6.24 ng/mL (range: 2.43 to 12.80 ng/mL), and the Tmax was 1.79 hours (range: 0.50 to 5.17 hours) after instillation. The highest individual observed Cmax value of 12.80 ng/mL was 187-fold and 40 fold lower than the observed Cmax level following an intravenous bolus dose of 30 mg or 10 mg mitomycin (2.4 μg/mL and 0.52 μg/mL, respectively) and is 31 fold lower than the threshold value of 400 ng/mL for myelosuppression observed with mitomycin." (NCT02793128)
Timeframe: Blood samples were collected at 0 minutes (pre-dose) and 30 minutes, 1, 2, 3, 4, 5, and 6 hours following the first instillation with UGN-101

InterventionHours (Mean)
Pharmacokinetic Population1.79

[back to top]

Safety Adverse Event Outcomes: Safety Was Monitored Throughout the Study by Reviewing Adverse Events (AEs).

Treatment-emergent AEs were most frequently reported from the Renal and urinary disorders system organ class (SOC), 59 (83.1%) patients, as expected, given the underlying indication of low grade (LG) Upper tract urothelial carcinoma (UTUC) in the study population, chemotherapeutic drug in a gel matrix instilled in the upper urinary tract (UUT), and the study procedure of treatment instillation via a ureteral catheter. The toxicity within the upper urinary tract was considered consistent with the disease under study and the mode of administration of UGN-101. Most events in the Renal and urinary disorders SOC were mild to moderate in severity and resolved. No new risks were identified and the overall safety profile was consistent with the known safety profile of endoscopic administration of intravesical mitomycin and of mitomycin. Overall, based on the safety and efficacy results to date, the benefit-risk profile of UGN-101 is favorable for the treatment of LG-UTUC. (NCT02793128)
Timeframe: Through study completion, an average of 15 months

InterventionParticipants (Count of Participants)
Treatment-emergent Adverse Events (TEAEs)TEAEs related to study drugTEAEs related to study procedureTEAEs related to study drug or preocedureSerious Adverse Events (SAE)SAEs related to study drug or procedure
UGN-101 Mitomycin for Pyelocalyceal Solution675255612819

[back to top]

The Primary Efficacy Endpoint Was the Number of Patients Attaining Complete Response (CR) at the End of the Treatment Period (PDE Visit).

"The primary efficacy endpoint was the number of patients attaining complete response (CR) at the end of the treatment period (Primary Disease Evaluation (PDE) visit). The CR was defined dichotomously as Success if CR was confirmed at PDE visit (or relevant follow-up), and Failure otherwise." (NCT02793128)
Timeframe: An average of 11 weeks

InterventionParticipants (Count of Participants)
UGN-101 Mitomycin for Pyelocalyceal Solution42

[back to top]

Pharmacokinetic: The PK Profiles of the First UGN-101 Instillation in the Blood Were to be Examined for the First 6 Patients.

"Cmax: maximum plasma concentration~Analysis of individual plasma concentration versus time profiles showed that at 6 hours post instillation, the plasma concentrations of all 6 patients were below 2 ng/mL, with the plasma concentration of one patient dropping below the LOQ (i.e., < 0.100 ng/mL). The mean Cmax was 6.24 ng/mL (range: 2.43 to 12.80 ng/mL). The highest individual observed Cmax value of 12.80 ng/mL was 187-fold and 40 fold lower than the observed Cmax level following an intravenous bolus dose of 30 mg or 10 mg mitomycin (2.4 μg/mL and 0.52 μg/mL, respectively) and is 31 fold lower than the threshold value of 400 ng/mL for myelosuppression observed with mitomycin." (NCT02793128)
Timeframe: Blood samples were collected at 0 minutes (pre-dose) and 30 minutes, 1, 2, 3, 4, 5, and 6 hours following the first instillation of UGN-101

Interventionng/mL (Mean)
Pharmacokinetic Population6.24

[back to top]

Durability of Complete Response (CR) for Each Follow-up Time Point.

"Durability of CR defined dichotomously as Success if CR was achieved at Primary Disease Evaluation (PDE) visit and remained at follow-up Visit 1, Visit 2 and Visit 3 (3, 6, 9 and 12 months post PDE visit), and Failure otherwise." (NCT02793128)
Timeframe: 3, 6, 9 and 12 months

InterventionParticipants (Count of Participants)
UGN-101 Patients Evaluated 3 Months Post PDE35
UGN-101 Patients Evaluated at 6 Months Post PDE33
UGN-101 Patients Evaluated at 9 Months Post PDE28
UGN-101 Patients Evaluated at 12 Months Post PDE23

[back to top]

Clinical Benefit for Patients With Partial Response (PR) at the Primary Disease Evaluation (PDE) Visit. Clinical Benefit Endpoint Was Analyzed Using the Intent-to-Treat (ITT) Analysis Set, Including Patients Who Achieved Partial Response at PDE Visit.

Clinical benefit for patients with partial response (PR) at the PDE visit. Clinical benefit endpoint was analyzed using the Intent-to-Treat (ITT) Analysis Set, including patients who achieved partial response at PDE Visit.Partial response at PDE visit will be defined dichotomously, similarly to the primary efficacy endpoint. For subjects with partial response at PDE visit, originally planned and actual treatments will be compared. (NCT02793128)
Timeframe: An average of 11 weeks

InterventionParticipants (Count of Participants)
UGN-101 Mitomycin for Pyelocalyceal Solution8

[back to top]

Visual Acuity

The Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity is tested at the one-year after surgery visit. The ETDRS Letter Score is calculated by the number of letters accurately identified at a certain distance, with the range of score being 0-100. An ETDRS letter score of 85 is considered normal vision (equivalent to visual acuity of 20/20), letter scores from 70-84 and 86-100 are considered minimal vision loss and near-normal vision, letter scores from 40-60 are considered moderate visual impairment, and letter scores 0-40 are considered severe visual impairment to total blindness. (NCT02805257)
Timeframe: 1 year

Interventionscore on a scale (Mean)
Mitomycin-C12.4
Balanced Salt Solution (BSS)16

[back to top]

Visual Acuity

The Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity is tested at the six-month after surgery visit. The ETDRS Letter Score is calculated by the number of letters accurately identified at a certain distance, with the range of score being 0-100. An ETDRS letter score of 85 is considered normal vision (equivalent to visual acuity of 20/20), letter scores from 70-84 and 86-100 are considered minimal vision loss and near-normal vision, letter scores from 40-60 are considered moderate visual impairment, and letter scores 0-40 are considered severe visual impairment to total blindness. (NCT02805257)
Timeframe: 6 months

Interventionscore on a scale (Mean)
Mitomycin-C12.81
Balanced Salt Solution (BSS)15.33

[back to top]

Number of Participants With Postoperative Complications

Postoperative complications are characterized as problems that happened after surgery but which were not intended. All complications up to the one-year after surgery visit observed were listed and analyzed. (NCT02805257)
Timeframe: 1 Year

,
Interventionparticipants (Number)
Tube occlusionChoroidal effusionSuprachoroidal hemorrhageHyphemaVitreous hemorrhageShallow Anterior ChamberCorneal edemaEndophthalmitis, cystoid macular edema, hypotony maculopathy, tube-K touch, tube erosion, diplopiaOther
Balanced Salt Solution (BSS)112729006
Mitomycin-C321619128

[back to top]

Number of Participants With Intraoperative Complications

Intraoperative complications are characterized as problems that happened during surgery but which were not intended. All complications during surgery were listed and analyzed. (NCT02805257)
Timeframe: Day of Surgery

,
Interventionparticipants (Number)
HyphemaSuprachoroidal HemorrhageOther
Balanced Salt Solution (BSS)501
Mitomycin-C300

[back to top]

Intraocular Pressure After Surgery

Goldmann applanation tonometry was used to measure intraocular pressure (IOP) at their one-year after surgery visit, however, for patients with irregular corneal astigmatism, corneal scarring, or corneal edema, which affect accurate measurement, pneumatonometer or Tonopen (Reichert Technologies, Depew, NY) was used. Two consecutive measurements were taken for the study eye. If the 2 measurements differ by 1 mm Hg or less, the IOP for the study eye was the average of the 2 readings. If the 2 measurements differ by 2 mm Hg or more, a third measurement was taken, and the IOP for the study eye was the median of the 3 readings. Efforts were made to schedule follow-up visits at similar time of the day to minimize the effect of diurnal IOP fluctuation. The average IOP and its standard deviation for each arm were calculated based on the individual IOP result obtained using the method described above. (NCT02805257)
Timeframe: 1 year

InterventionmmHg (Mean)
Mitomycin-C13.1
Balanced Salt Solution (BSS)16.2

[back to top]

Intraocular Pressure After Surgery

Goldmann applanation tonometry was used to measure intraocular pressure (IOP) at their six-month after surgery visit, however, for patients with irregular corneal astigmatism, corneal scarring, or corneal edema, which affect accurate measurement, pneumatonometer or Tonopen (Reichert Technologies, Depew, NY) was used. Two consecutive measurements were taken for the study eye. If the 2 measurements differ by 2 mm Hg or more, a third measurement was taken, and the IOP for the study eye was the median of the 3 readings. Efforts were made to schedule follow-up visits at similar time of the day to minimize the effect of diurnal IOP fluctuation. The average IOP and its standard deviation for each arm were calculated based on the individual IOP result obtained using the method described above. (NCT02805257)
Timeframe: 6 months

InterventionmmHg (Mean)
Mitomycin-C14.6
Balanced Salt Solution (BSS)16.1

[back to top]

Number of Medications Postoperatively

Counted the number of glaucoma drops at one-year after surgery visit. Glaucoma drops are characterized as topical medication used to help lower intraocular pressure. (NCT02805257)
Timeframe: 1 year

Interventionglaucoma drops (Mean)
Mitomycin-C1.2
Balanced Salt Solution (BSS)1.6

[back to top]

Number of Medications Postoperatively

Counted the number of glaucoma drops at six-month after surgery visit. Glaucoma drops are characterized as topical medication used to help lower intraocular pressure. (NCT02805257)
Timeframe: 6 months

Interventionglaucoma drops (Mean)
Mitomycin-C1.2
Balanced Salt Solution (BSS)1.6

[back to top]

Quality of Life Changes

Utilization of the Patient Reported Outcomes- Common Toxicity Criteria for Adverse Events at pretreatment and up to 12 months. This measure used the difference total score for each subject's baseline and latest PROCTCAE available. The reported statistic is the number of subjects that showed a reduction in scores between the two time points. (NCT03018418)
Timeframe: before treatment and 12 months after start of treatment

InterventionParticipants (Count of Participants)
Quality of Life Changes for 14 Subjects9

[back to top]

Complete Response Rate

Complete response was clinically determined by digital rectal examination and proctosigmoidoscopy supplemented with pelvic axial imaging. Biopsy was not required. The complete response was the absence of disease based on these evaluations. Any measurable disease at 6 months from the completion of chemoradiation will be considered a local treatment failure. Any tumor recurrence in the anus in patients who initially had a complete response will be considered a local recurrence. (NCT03018418)
Timeframe: at 6 months from the completion of chemoradiation

InterventionParticipants (Count of Participants)
Subjects With Complete Response Rate11

[back to top]

Rates of Late Toxicity

Grade 3 or greater hematologic, gastrointestinal, genitourinary, and dermatologic toxicity (NCT03018418)
Timeframe: every 6 months up to 60 months

InterventionParticipants (Count of Participants)
Grade 3+ Hematologic, Gastrointestinal, Genitourinary, and Dermatologic Toxicity6

[back to top]

Rates of Acute Toxicity

Grade 3 or greater hematologic, gastrointestinal, genitourinary, and dermatologic toxicity (NCT03018418)
Timeframe: 3 months

InterventionParticipants (Count of Participants)
Grade 3+ Hematologic, Gastrointestinal, Genitourinary, and Dermatologic Toxicity12

[back to top]

Overall Survival

This is an estimated percentage of participants that is alive at 2 years. (NCT03018418)
Timeframe: every 6 months up to 24 months

Interventionpercentage of subjects (Number)
Overall Survival for 14 Subjects76

[back to top]

Local Progression Free Survival

This is the percentage of subjects that were free of local progression. (NCT03018418)
Timeframe: every 6 months up to 60 months

InterventionParticipants (Count of Participants)
Local Progression Free Survival for 14 Subjects12

[back to top]

Distant Metastases Free Survival

This is the percentage of subjects that were free of distant metastases. (NCT03018418)
Timeframe: every 6 months up to 60 months

InterventionParticipants (Count of Participants)
Distant Metastases Free Survival for 14 Subjects13

[back to top]

Complete Response (CR) Rate for UGN-102 Treatment

To evaluate the tumor ablative effect of UGN-102 in patients with LG NMIBC. CR rate was defined as the percentage of patients with no detectable disease (NDD) as determined by cystoscopy, for cause biopsy, and urine cytology. (NCT03558503)
Timeframe: 3 months after the first instillation of UGN-102

Interventionpercentage of patients (Number)
UGN-10265.1

[back to top] [back to top]

Number of Participants With Post-baseline Potentially Clinically Significant (PCS) Laboratory Values

The number of patients who met PCS criteria for chemistry or hematology parameters post-baseline will be summarized (NCT03558503)
Timeframe: Up to 12 months

InterventionParticipants (Count of Participants)
Any PCS chemistry valueAny PCS hematology value
UGN-10284

[back to top]

Mitomycin Plasma Concentrations

Mitomycin plasma concentrations were assessed in a subset of 6 patients treated with UGN-102 (NCT03558503)
Timeframe: 0 (pre-instillation), 0.5, 1, 2, 3, 4, 5, and 6 hours after the first instillation of UGN-102

Interventionng/mL (Mean)
Pre-instillation0.5 hours post-instillation1 hour post-instillation2 hours post-instillation3 hours post-instillation4 hours post-instillation5 hours post-instillation6 hours post-instillation
UGN-10200.750.600.341.881.930.570.32

[back to top]

Number of Participants With Post-baseline Clinically Significant (CS) Physical Examination Findings

The number of patients with abnormal, CS physical examination findings post-baseline will be summarized (NCT03558503)
Timeframe: Up to 12 months

InterventionParticipants (Count of Participants)
UGN-1020

[back to top]

Mitomycin Maximum Plasma Concentration (Cmax)

Mitomycin Cmax was assessed in a subset of 6 patients treated with UGN-102 (NCT03558503)
Timeframe: 0 (pre-instillation), 0.5, 1, 2, 3, 4, 5, and 6 hours after the first instillation of UGN-102

Interventionng/mL (Mean)
UGN-1022.27

[back to top]

Number of Participants With Post-baseline PCS Vital Signs Values

The number of patients who met PCS criteria for vital signs parameters post-baseline will be summarized (NCT03558503)
Timeframe: Up to 12 months

InterventionParticipants (Count of Participants)
UGN-1028

[back to top]

Durable Complete Response (DCR) Rate

To evaluate the durability of response in patients with LG NMIBC who achieve CR. DCR rate was defined as the percentage of patients who maintained CR at the respective time point. (NCT03558503)
Timeframe: 6, 9, and 12 months after the first instillation of UGN-102

Interventionpercentage of patients (Number)
6 months (3 months after CR at the 3-month Visit)9 months (6 months after CR at the 3-month Visit)12 months (9 months after CR at the 3-month Visit)
UGN-10295.173.261.0

[back to top]

Mitomycin Area Under the Plasma Concentration-time Curve (AUC)

Mitomycin AUC was assessed in a subset of 6 patients treated with UGN-102 (NCT03558503)
Timeframe: 0 (pre-instillation) to 6 hours after the first instillation of UGN-102

Interventionng*h/mL (Mean)
UGN-1025.69

[back to top]

Number of Participants With Post-baseline CS Urology-oriented Physical Examination Findings

The number of patients with abnormal, CS urology-oriented physical examination findings post-baseline will be summarized (NCT03558503)
Timeframe: Up to 12 months

InterventionParticipants (Count of Participants)
UGN-1022

[back to top]

Progression-free Survival

Progression-free survival is defined as the time from registration to the time of progression or death. This study will not use RECIST criteria to evaluate response or progression. The patients enrolled will have non-measurable disease on imaging and response will be evaluated with biopsy or cytology. Progression is defined as progression in T stage, N stage or M stage both clinically or radiologically. Histological confirmation of metastatic disease is at the discretion of the treating provider. The median time will be estimated using the method of Kaplan-Meier. (NCT03617913)
Timeframe: From registration to time of first documentation of progression or death from any cause, assessed up to 12 months

Interventionyears (Median)
Avelumab and Cisplatin IVNA

[back to top]

Proportion of Participants With Complete Response (At 6 Months)

"Patients enrolled will have non-measurable disease based on imaging at baseline. Patients will be assessed for a response after 6 months of treatment using the results of a biopsy and cytology test. A complete response (CR) is defined as having a negative biopsy and negative urine cytology at 6 months from registration after finishing of concurrent RT and immunotherapy. Imaging of abdomen and pelvis confirming no systemic disease within 4 weeks of cystoscopy will be completed.~The proportion of patients reporting a CR is reported here with confidence intervals for the true success proportion using the binomial distribution." (NCT03617913)
Timeframe: At 6 months from registration

Interventionproportion of participants (Number)
Avelumab and Cisplatin IV0.5

[back to top]

Bladder Tumor Recurrence Rate

The bladder tumor recurrence rate will be measured by the percentage of subjects who are confirmed by bladder biopsy to have a recurrence of urothelial carcinoma in the bladder following nephroureterectomy (NCT03658304)
Timeframe: 1 year

Interventionpercentage of subjects (Number)
Mitomycin C41.37

[back to top]

Visual Acuity

Change in visual acuity from baseline (NCT04352660)
Timeframe: 6 months

InterventionlogMAR (Mean)
Injection Group0.11
Sponge Group0.03

[back to top]

Bleb Morphology

Bleb morphology at 6 months was graded using Indiana Bleb Appearance Grading Scale. Bleb height was graded on a scale of 0 to 3 (0: flat bleb without visible elevation, 1: low bleb elevation, 2: moderate bleb elevation, 3: high bleb elevation). Bleb extent was graded on a scale of 0 to 3 (0: no visible bleb extent to less than 1 clock hour, 1: extent equal to or greater than 1 clock hour but less than 2 clock hours, 2: extent equal to or greater than 2 clock hours but less than 4 clock hours, 3: extent equal to or greater than 4 clock hours). Bleb vascularity was graded on a scale of 0 to 4 (0: avascular/white, 1: avascular/cystic, 2: mild vascularity, 3: moderate vascularity, 4: extensive vascularity). Scales are descriptive and do not necessarily represent better or worse outcomes. (NCT04352660)
Timeframe: 6 months

,
Interventionscores on a scale (Mean)
HeightExtentVascularity
Injection Group1.62.21.5
Sponge Group1.72.01.5

[back to top]

Number of Participants With Surgical Complications

Number of eyes that experienced surgical complications following surgery (NCT04352660)
Timeframe: 6 months

,
Interventionparticipants (Number)
Hypotony MaculopathyChoroidal Effusions
Injection Group32
Sponge Group15

[back to top]

Number of Participants Requiring Additional Surgery

Number of eyes requiring additional surgery from each group (NCT04352660)
Timeframe: 6 months

,
Interventionparticipants (Number)
Trab RevisionGDDXenTrabectomeAny SurgeryCEIOLYAG
Injection Group8200880
Sponge Group5111751

[back to top]

Postoperative Interventions

Mean number of postoperative interventions (needling, antifibrotic injections) performed in each group (NCT04352660)
Timeframe: 6 months

,
Interventionnumber of procedures (Mean)
5FU InjectionLaser suture lysis
Injection Group3.32.0
Sponge Group3.21.6

[back to top]